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1.	Summary	
1.1	English	version	
		During	my	 Ph.D.,	 my	 research	 focused	 on	 the	 involvement	 and	 the	 role	 of	mitochondrial	 potassium	 homeostasis	 in	 the	 context	 of	 pathophysiological	processes.	 I	 have	 been	 working	 on	 three	 related	 projects,	 for	 which	 the	common	aspect	is	the	study	of	the	mitochondrial	potassium	homeostasis	and	its	 modulation	 by	 pharmacological	 tools.	 My	 thesis	 contains	 a	 general	introduction,	in	order	to	give	a	general	up-to-date	overview	covering	all	the	topics	treated	during	my	Ph.D.,	followed	by	a	collection	of	the	papers	where	I	gave	my	contribution.		Concerning	 the	 first	 project,	 my	 studies	 provided	 new	 insights	 into	 the	mechanism	 of	 action	 of	 an	 emerging	 pro-apoptotic,	 oncologically	 relevant	molecule,	namely	salinomycin.	This	molecule	was	considered	a	valinomycin-like	K+	ionophore.	Its	recent	identification	as	a	selective	inducer	of	apoptosis	in	 cancer	 stem	 cells	 (CSCs)	 and	 different	 types	 of	 non-stem	 cancer	 cells,	together	with	the	ability	to	spare	healthy	cells,	led	to	an	increased	interest	in	unravelling	 its	 mechanism	 of	 action,	 poorly	 understood	 so	 far.	 Moreover,	since	salinomycin	has	been	suggested	to	act	as	a	K+	ionophore,	it	is	expected	to	 impact	 mitochondrial	 function;	 however	 detailed	 information	 on	 its	mitochondrial	 effects	 were	 not	 available	 from	 the	 literature.	 Therefore,	 I	explored	its	early	effects	on	mitochondrial	bioenergetics.	In	order	to	do	this,	I	compared	its	activity	with	that	of	valinomycin	(K+	ionophore)	or	of	nigericin	(K+/H+	exchanger),	for	which	the	action	was	already	well	defined	by	others	in	the	past.		By	using	different	approaches,	ranging	from	classical	bioenergetic	studies	on	isolated	 mitochondria	 to	 more	 innovative	 measurement	 of	 bioenergetic	parameters	 on	 intact	 cells,	 and	 of	 course	 by	 exploiting	 different	 cellular	biology	 techniques,	 it	 has	been	 concluded	 that	 salinomycin	mediates	K+/H+	exchange	across	the	inner	mitochondrial	membrane,	similarly	to	nigericin.		It	has	been	observed	that	salinomycin	was	also	able	to	induce	cell	death	of	cells	lacking	some	crucial	actors	of	the	apoptotic	pathway		(Bax/Bak-less	double-	knockout	MEF	cells).	These	 results	were	 compatible	with	 the	 idea	of	direct	modulation	 of	 mitochondrial	 function.	 At	 this	 point,	 the	 specificity	 of	 its	action	on	pathologic	B	cells	isolated	from	patients	with	chronic	lymphocytic	leukemia	 (CLL)	 versus	 B	 cells	 from	healthy	 subjects	 has	 been	 investigated.	The	results	indicated	that	salinomycin,	when	used	above	μM	concentrations,	exerts	direct,	mitochondrial	effects,	thus	compromising	cell	survival,	even	in	non-tumoral	cells.	These	results	were	published	in	Managò	et	al.,	Cell	Death	and	Disease,	2015.			Having	 acquired	 the	 “know-how”	 to	 assess	 mitochondrial	 bioenergetic	functions,	I	also	actively	contributed	to	a	project	carried	out	in	collaboration	with	 Prof.	 Erich	 Gulbins	 from	University	 of	 Essen	 (Germany),	where	 I	 also	spent	five	months	of	my	Ph.D.	A	strict	collaboration	between	the	lab	where	I	did	 my	 Ph.D.	 and	 the	 lab	 of	 Prof.	 Gulbins	 led	 to	 the	 discovery	 of	 a	
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mitochondrial	 voltage-gated	 potassium	 channel,	 mtKv1.3	 and	 to	 the	clarification	 of	 its	 important	 role	 during	 apoptosis.	 Mechanistically,	 it	 has	been	demonstrated	that	the	pro-apoptotic	protein	Bax	directly	interacts	with	and	 inhibits	 mtKv1.3,	 via	 a	 toxin-like	 mechanism.	 The	 direct	 inhibition	 of	mtKv1.3	leads	to	hyperpolarization,	mitochondrial	ROS	production,	opening	of	the	permeability	transition	pore	(PTP),	release	of	cytochrome	c	and	finally	to	apoptosis.	 	In	accordance	to	this	model,	direct	pharmacological	inhibition	of	mtKv1.3	by	using	the	membrane-permeant	Kv1.3	inhibitors	Psora-4,	PAP-1	 and	 clofazimine	 leads	 to	 cell	 death	 in	 different	 types	 of	 cancer,	 as	demonstrated	by	our	group.	The	 starting	 point	 of	 my	 second	 project	 was	 the	 fact	 that	 pyocyanin,	 a	membrane-permeant	 toxin	 released	 by	 the	 Gram-negative	 bacterium	
Pseudomonas	 aeruginosa	 shows	 structural	 similarity	 to	 clofazimine,	 a	membrane-permeant	mtKv1.3	inhibitors.	P.	aeruginosa	causes	lung	infections	in	 immunocompromised	 patients	 and	 it	 is	 known	 that	 pyocyanin	 induces	death	of	neutrophils,	which	plays	an	important	role	in	the	host’s	early	acute	defence	 against	 pulmonary	 P.	 aeruginosa	 infections.	 However	 the	 exact	mechanism	of	action	of	pyocyanin	is	still	unknown	therefore	we	determined	whether	 its	 effect	 is	 related	 to	 Kv1.3	 expression,	 given	 the	 crucial	 role	 of	mtKv1.3	 in	apoptosis	and	 the	 structural	 similarity	of	pyocyanin	 to	mtKv1.3	inhibitors.	 	 First	 of	 all,	 it	 was	 observed	 by	 patch	 clamp	 experiments	 that	pyocyanin	is	able	to	inhibit	Kv1.3	current.	At	low	concentration	(up	to	10µM),	pyocyanin	 induced	 cell	 death	 preferentially	 in	 cells	 expressing	 Kv1.3.	However,	 in	 the	 literature	 pyocyanin	 was	 mostly	 used	 at	 higher	concentrations	 (50-100	 µM),	 since	 in	 the	 sputum	 of	 patients	 with	 P.	
aeruginosa	 infections	 it	 might	 reach	 such	 a	 high	 concentration.	 Moreover,	data	 from	 the	 literature	 suggested	 that	 pyocyanin	 might	 have	 a	mitochondrial	action	and	is	able	to	produce	high	amounts	of	reactive	oxygen	species	(ROS).	Therefore,	it	has	been	investigated	how	pyocyanin	impacts	on	mitochondrial	function	on	a	short	time	scale	when	used	at	high	concentration	(at	50µM).	Again,	intact	cells	or	isolated	mitochondria	were	used	to	assay	the	effect	 of	 this	 compound.	 It	 has	 been	 shown	 that	 pyocyanin	 determines	 an	instantaneous	 production	 of	 superoxide	 anion	 at	mitochondrial	 sites	 and	 a	rapid	 but	 incomplete	 dissipation	 of	 the	mitochondrial	membrane	potential.	Further,	 it	 has	 been	 observed	 that	 pyocyanin	 can	 replace	 the	 function	 of	complex	 III,	 while	 it	 does	 not	 directly	 alter	 the	 function	 of	 complex	 I.	Moreover,	 it	 has	 been	 shown	 that	 ROS	 production	 induced	 by	 pyocyanin	activates	 the	acid	 sphyngomyelinase,	 shown	 to	be	present	 in	mitochondria.	This	event	in	turn	leads	to	the	formation	of	ceramide,	induction	of	apoptosis	and	release	of	cytochrome	c.	Genetic	deficiency	of	acid	sphyngomyelinase	or	scavenging	of	ROS	induced	by	pyocyanin	prevented	cell	death	in	neutrophils,	meaning	 that	 pyocyanin,	 at	 high	 concentrations,	 induces	 cell	 death	 via	mitochondrial	 reactive	 oxygen	 species	 and	 mitochondrial	 acid	sphyngomyelinase,	 independently	 of	 the	 expression	 of	 the	 voltage	 gated	potassium	 channel	 Kv1.3.	 These	 results	 were	 published	 in	 Managò	 et	 al.,	Antioxidant	and	redox	signaling,	2015.			During	 the	 last	 period	 of	 my	 Ph.D,	 I	 also	 studied	 the	 effect	 of	 newly	synthesized	Psoralen	derivatives	and	clofazimine	for	the	treatment	of	cancer.	
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Concerning	 the	 first	 group,	 they	 are	 specific	 inhibitors	 of	 the	 voltage	 gated	potassium	channel	Kv1.3;	the	second	one	is	a	molecule	already	in	use	in	clinic	to	 treat	 pathologies	 like	 leprosy,	 which	 also	 inhibits	 Kv1.3	 current.	 Due	 to	their	lipophilic	structure,	they	are	all	membrane-permeant,	therefore	able	to	reach	 intracellular	 membranes,	 like	 inner	 mitochondrial	 membrane	 where	the	voltage	gated	potassium	channel	Kv1.3	 is	 also	 expressed	and	active.	As	mentioned	above,	the	specific	inhibition	of	mtKv1.3	triggers	cell	death.	It	has	previously	 been	 demonstrated	 that	 Psora-4,	 PAP-1	 (Psoralen	 derivatives)	and	 clofazimine	 are	 able	 to	 specifically	 induce	 apoptosis	 in	 cancer	 cells	 in	
vitro	 on	 many	 cancer	 cell	 lines,	 ex	 vivo	 on	 B-CLL	 (chronic	 lymphocytic	leukaemia)	 cells	 obtained	 from	 patients	 and	 in	 vivo	 on	 melanoma	 tumour	model.	 Following	 these	 promising	 results,	 in	 collaboration	 with	 Professor	Cristina	 Paradisi	 (Department	 of	 Chemical	 Sciences,	 University	 of	 Padova),	PAP-1	 and	 clofazimine	derivatives	have	been	 synthesized	 in	order	 to	make	these	 molecules	 more	 soluble	 and	 mitochondriotropic	 (i.e.:	 increased	tendency	to	target	mtKv1.3).		I	 tested	 the	 ability	 of	 these	 new	 compounds	 to	 induce	 cell	 death	 in	 cancer	cells	 first	 in	 vitro.	 Since	 the	 results	 obtained	 on	 different	 cell	 lines	 in	 vitro	were	promising	and	death	was	strictly	dependent	on	Kv1.3	expression,	it	has	been	decided	to	test	these	compounds	also	in	vivo	on	a	melanoma	model	and	on	a	pancreatic	cancer	model.	During	my	2-month	stay	at	the	end	of	the	first	year	 of	 my	 Ph.D.	 at	 the	 Institute	 for	 Experimental	 Cancer	 Research,	University	of	Kiel	 (Germany),	 I	performed	 in	vivo	 experiments,	using	PAP-1	derivatives	and	clofazimine	on	SCID	mouse	 injected	with	Colo357,	a	human	pancreas	tumour	Kv1.3	expressing	cell	line,	obtaining	a	significant	reduction	of	 the	mass	of	 the	 tumour	 (Zaccagnino,	Managò	et	al.,	 under	 submission	 to	Oncotarget).	Moreover,	PAP-1	derivatives	have	been	 tested	on	a	melanoma	model	 in	 vivo,	 obtaining	 relevant	 results	 (Leanza,	 Romio,	 Becker,	 Azzolini,	Trentin,	Managò	et	al.,	manuscript	in	preparation,	not	included	in	the	present	thesis).	 The	 treatment	 exerted	 an	 effect	 on	 cancer,	without	 significant	 side	effects	on	healthy	tissues.			Some	of	the	most	promising	clofazimine-derivatives	have	been	selected	to	be	tested	 on	 cells	 deriving	 from	 acute	 myeloid	 leukaemia	 (AML)	 patient.	 I	carried	out	these	experiments	during	my	stay	in	Germany	at	the	Department	of	 Molecular	 Biology	 University	 of	 Duisburg-Essen.	 Blood	 samples	 came	directly	 from	 the	 haematology	ward	 of	 the	 university-hospital	 in	 Essen.	 So	far,	we	obtained	preliminary	results	which	are	however	controversial,	since	different	patients	were	diagnosed	at	different	stage	of	 the	disease	(i.e.	have	different	 levels	 of	 pathological	 cells)	 and	 AML	 itself	 is	 a	 heterogeneous	disease	at	 the	molecular	and	cytogenetic	 level.	Therefore	 this	work	has	not	been	included	in	the	thesis.				Furthermore,	I	took	part	in	a	project	of	the	laboratory	of	Prof.		Holger	Kalthoff	(University	of	Kiel,	Germany),	concerning	the	study	of	the	mechanism	of	action	of	a	seaweed	extract,	for	which	I	performed	the	experiments	of	bioenergetics	(Geisen	,	Zenthoefer	,	Peipp	,	Kerber	,	Plenge	,	Managò	et	al.,	Marine	drugs,	2015).	
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Beside	the	laboratory-based	projects,	I	also	contributed	to	the	preparation	of	two	reviews,	one	concerning	 intracellular	 ion	channels	and	cancer	 (Leanza,	Biasutto,	 Managò	 et	 al.,	 Frontiers	 on	 Physiology,	 2013)	 and	 the	 other	regarding	 in	 vivo	 pharmacological	 targeting	 of	 ion	 channels	 as	 possible	therapeutic	 tool	 against	 cancer	 (Leanza,	 Managò	 et	 al.,	 BBA	 Mol.	 Cell	Research,	2015).									
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1.2	Italian	version			Durante	il	mio	dottorato,	la	mia	ricerca	si	è	concentrata	sul	coinvolgimento	e	il	 ruolo	 dell'omeostasi	 mitocondriale	 di	 potassio	 (K+)	 in	 processi	fisiopatologici.	Ho	lavorato	su	tre	progetti	correlati,	per	cui	l'aspetto	comune	è	 lo	 studio	 dell’omeostasi	 del	 potassio	mitocondriale	 e	 la	 sua	modulazione	tramite	 strumenti	 farmacologici.	 La	 mia	 tesi	 contiene	 un'introduzione	generale,	 al	 fine	 di	 dare	 una	 descrizione	 generale	 aggiornata	 di	 tutti	 gli	argomenti	trattati	durante	il	mio	dottorato	di	ricerca,	seguiti	da	una	raccolta	di	pubblicazioni	scientifiche	in	cui	ho	dato	il	mio	contributo.		Per	 quanto	 riguarda	 il	 primo	 progetto,	 i	 miei	 studi	 hanno	 fornito	 nuove	informazioni	 sul	 meccanismo	 d'azione	 di	 una	 molecola	 pro-apoptotica	emergente,	 rilevante	dal	punto	di	vista	oncologico,	nota	 come	salinomicina.	Questa	 molecola	 è	 stata	 considerata	 uno	 ionoforo	 di	 K+	 simile	 alla	valinomicina.	 La	 sua	 recente	 identificazione	 come	 induttore	 selettivo	 di	apoptosi	in	cellule	staminali	tumorali	(CSCs)	e	diversi	tipi	di	cellule	tumorali	non-staminali,	 insieme	 alla	 sua	 capacità	 di	 risparmiare	 le	 cellule	 sane,	 ha	portato	a	un	interesse	crescente	verso	la	comprensione	del	suo	meccanismo	d'azione,	 poco	 noto	 finora.	 Inoltre,	 poiché	 è	 stato	 suggerito	 che	 la	salinomicina	agisca	come	uno	ionoforo	di	K+,	ci	si	aspetta	un	suo	effetto	sulla	funzione	 mitocondriale.	 Tuttavia	 non	 erano	 disponibili	 in	 letteratura	informazioni	 dettagliate	 sugli	 effetti	 mitocondriali	 di	 questa	 molecola.	Pertanto,	 ho	 esplorato	 i	 suoi	 effetti	 istantanei	 sulla	 bioenergetica	mitocondriale.	Per	fare	questo,	ho	confrontato	la	sua	attività	con	quella	della	valinomicina	(ionoforo	di	K+)	e	della	nigericina	(scambiatore	K+/H+),	l'azione	delle	quali	era	già	stata	ben	definita	da	altri	in	passato.	Utilizzando	 diversi	 approcci,	 che	 vanno	 dagli	 studi	 bioenergetici	 classici	 su	mitocondri	isolati	alla	misurazione	di	parametri	bioenergetici	con	strumenti	più	innovativi	su	cellule	intatte,	e,	naturalmente,	sfruttando	diverse	tecniche	di	biologia	cellulare,	si	è	concluso	che	la	salinomicina	media	lo	scambio	K+/H+	attraverso	la	membrana	mitocondriale	interna	,	analogamente	alla	nigericina.	Inoltre,	è	stato	visto	che	la	salinomicina	è	stata	in	grado	di	indurre	la	morte	cellulare	 delle	 cellule	 prive	 di	 alcuni	 attori	 cruciali	 del	 processo	 apoptotico	(doppio	 knock-out	 di	 Bax/Bak	 in	 cellule	 MEF).	 Questi	 risultati	 sono	compatibili	 con	 l'idea	 di	 una	 modulazione	 diretta	 della	 funzione	mitocondriale	da	parte	della	salinomicina.	A	questo	punto,	è	stata	studiata	la	specificità	 della	 sua	 azione	 su	 cellule	 B	 patologiche	 isolate	 da	 pazienti	 con	leucemia	 linfatica	 cronica	 (CLL)	 versus	 cellule	 B	 di	 soggetti	 sani.	 I	 risultati	hanno	indicato	che	 la	salinomicina,	quando	usata	sopra	concentrazioni	mM,	esercita	 effetti	mitocondriali	diretti,	 compromettendo	così	 la	 sopravvivenza	delle	 cellule,	 anche	 di	 quelle	 non	 tumorali.	 Questi	 risultati	 sono	 stati	pubblicati	in	Managò	et	al.,	Cell	Death	and	Disease,	2015.		Avendo	 acquisito	 il	 "know-how"	 per	 valutare	 le	 funzioni	 bioenergetiche	mitocondriali,	 ho	 anche	 contribuito	 attivamente	 a	 un	progetto	 realizzato	 in	collaborazione	con	il	Prof.	Erich	Gulbins	dell'Università	di	Essen	(Germania),	
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dove	ho	anche	trascorso	cinque	mesi	del	mio	dottorato	di	ricerca.	Una	stretta	collaborazione	tra	il	 laboratorio	dove	ho	fatto	il	mio	dottorato	di	ricerca	e	il	laboratorio	 del	 Prof.	 Gulbins	 ha	 portato	 alla	 scoperta	 di	 un	 canale	 del	potassio	 voltaggio-dipendente	mitocondriale,	 mtKv1.3	 e	 al	 chiarimento	 del	suo	 importante	 ruolo	 durante	 l'apoptosi.	 Meccanicisticamente,	 è	 stato	dimostrato	che	 la	proteina	pro-apoptotica	Bax	 interagisce	direttamente	con	mtKv1.3	 e	 lo	 inibisce,	 tramite	 un	 meccanismo	 simile	 a	 quello	 di	 alcune	tossine.	 L'inibizione	 diretta	 di	 mtKv1.3	 porta	 ad	 iperpolarizzazione,	produzione	di	ROS	a	livello	mitocondriale,	apertura	del	poro	di	transizione	di	permeabilità	 (PTP),	 rilascio	 di	 citocromo	 c	 ed	 infine	 all'apoptosi.	 Secondo	questo	 modello,	 l'inibizione	 farmacologica	 diretta	 di	 mtKv1.3	 utilizzando	inibitori	di	Kv1.3	permeanti	la	membrana	come	Psora-4,	PAP-1	e	clofazimina,	porta	 alla	 morte	 cellulare	 in	 diversi	 tipi	 di	 cancro,	 come	 dimostrato	 dal	nostro	gruppo.	Il	 punto	 di	 partenza	 del	 mio	 secondo	 progetto	 è	 stato	 l’evidenza	 che	 la	piocianina,	una	tossina	permeante	la	membrana	rilasciata	dal	batterio	Gram-negativo	 Pseudomonas	 aeruginosa	 mostra	 somiglianza	 strutturale	 alla	clofazimina,	 un	 inibitore	 di	 Kv1.3	 permeante	 la	 membrana.	 P.	 aeruginosa	provoca	infezioni	polmonari	nei	pazienti	immunocompromessi	ed	è	noto	che	la	 piocianina	 induce	 morte	 cellulare	 nei	 neutrofili,	 che	 svolgono	 un	 ruolo	importante	nella	difesa	precoce	acuta	dell'ospite	contro	infezioni	polmonari	da	 P.	 aeruginosa.	 Tuttavia	 l'esatto	 meccanismo	 d'azione	 della	 piocianina	 è	ancora	sconosciuta	quindi	abbiamo	voluto	studiare	se	 il	suo	effetto	è	 legato	all'espressione	 di	 Kv1.3,	 dato	 il	 ruolo	 cruciale	 di	 mtKv1.3	 nell’apoptosi	 e	l'affinità	strutturale	della	piocianina	agli	 inibitori	di	Kv1.3.	Prima	di	 tutto,	è	stato	osservato	dagli	esperimenti	di	patch-clamp	che	la	piocianina	è	in	grado	di	 inibire	 la	 corrente	 di	 Kv1.3.	 A	 basse	 concentrazioni	 (fino	 a	 10	 µM),	 la	piocianina	 induce	 morte	 cellulare	 preferenzialmente	 in	 cellule	 esprimenti	Kv1.3.	Tuttavia,	in	letteratura	la	piocianina	è	stata	utilizzata	principalmente	a	concentrazioni	 più	 elevate	 (50-100	 µM),	 poiché	 nell'espettorato	 di	 pazienti	con	 infezioni	 da	 P.	 aeruginosa	 potrebbe	 raggiungere	 tale	 concentrazioni.	Inoltre,	diversi	dati	in	letteratura	hanno	suggerito	che	la	piocianina	potrebbe	avere	un'azione	mitocondriale	ed	è	 in	grado	di	produrre	elevate	quantità	di	specie	 reattive	 dell'ossigeno	 (ROS).	 Pertanto,	 è	 stato	 esaminato	 l'impatto	della	 piocianina	 sulla	 funzione	 mitocondriale	 con	 cinetiche	 brevi,	 quando	usata	 ad	 alta	 concentrazione	 (50	 µM).	 Ancora	 una	 volta,	 cellule	 intatte	 o	mitocondri	isolati	sono	stati	usati	per	saggiare	l'effetto	di	questo	composto.	E	'stato	 osservato	 che	 la	 piocianina	 determina	 una	 produzione	 istantanea	 di	anione	 superossido	 a	 livello	 di	 siti	mitocondriali	 e	 una	 dissipazione	 rapida	ma	 incompleta	 del	 potenziale	 di	 membrana	 mitocondriale.	 Inoltre,	 è	 stato	visto	 che	 la	 piocianina	 può	 sostituire	 la	 funzione	 del	 complesso	 III,	mentre	non	 altera	 direttamente	 la	 funzione	 del	 complesso	 I.	 Infine,	 è	 stato	dimostrato	 che	 la	 produzione	 di	 ROS	 indotta	 dalla	 piocianina	 attiva	 la	sfingomielinasi	 acida,	 presente	 anche	 in	 mitocondri.	 Questo	 evento	 a	 sua	volta	porta	alla	 formazione	di	ceramide,	 induzione	di	apoptosi	e	rilascio	del	citocromo	 c.	 La	 mancanza	 di	 espressione	 della	 sfingomielinasi	 acida	 o	 lo	
scavenging	 di	 ROS	 indotta	 dalla	 piocianina	 impedisce	 la	 morte	 cellulare	 in	neutrofili,	 che	 indicando	che	 la	piocianina,	 ad	alte	 concentrazioni,	 induce	 la	morte	 cellulare	 attraverso	 specie	 reattive	 dell'ossigeno	 mitocondriali	 e	
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sfingomielinasi	acida	mitocondriale,	indipendentemente	dall'espressione	del	canale	 del	 potassio	 voltaggio	 dipendente	 Kv1.3.	 Questi	 risultati	 sono	 stati	pubblicati	in	Managò	et	al.,	Antioxidant	and	redox	signaling,	2015.		Durante	 l'ultimo	 periodo	 del	 mio	 dottorato	 di	 ricerca,	 ho	 anche	 studiato	l'effetto	di	alcuni	derivati	di	psoraleni	di	nuova	sintesi	e	della	clofazimina	per	il	 trattamento	 del	 cancro.	 Per	 quanto	 riguarda	 il	 primo	 gruppo,	 essi	 sono	inibitori	 specifici	 del	 canale	 del	 potassio	 voltaggio	 dipendente	 Kv1.3;	 la	seconda	è	una	molecola	già	 in	uso	 in	 clinica	per	 il	 trattamento	di	patologie	come	 la	 lebbra,	 che	 agisce	 anche	 come	 inibitore	 della	 corrente	 di	 Kv1.3.	Grazie	alla	loro	struttura	lipofila,	sono	tutti	permeanti	la	membrana,	quindi	in	grado	 di	 raggiungere	 le	 membrane	 intracellulari,	 come	 la	 membrana	mitocondriale	interna	dove	il	canale	del	potassio	voltaggio	dipendente	Kv1.3	è	 espresso	 e	 attivo.	 Come	 accennato	 in	 precedenza,	 l'inibizione	 specifica	 di	mtKv1.3	innesca	la	morte	cellulare.	È	stato	dimostrato	che	Psora-4,	PAP-1	e	clofazimina	 sono	 in	 grado	 di	 indurre	 specificamente	 apoptosi	 nelle	 cellule	tumorali	in	vitro	su	molte	linee	cellulari	tumorali,	ex	vivo	su	cellule	B	ottenute	da	pazienti	con	leucemia	linfatica	cronica	e	in	vivo	su	modello	di	melanoma.	A	seguito	di	questi	risultati	promettenti,	in	collaborazione	con	la	Prof.	Cristina	Paradisi	(Dipartimento	di	Scienze	Chimiche,	Università	di	Padova),	sono	stati	sintetizzati	derivati	del	PAP-1	e	della	clofazimina	in	modo	da	rendere	queste	molecole	più	solubili	e	mitocondriotropiche		(i.e.:	indirizzate	al	mitocondrio).	Ho	 testato	 prima	 la	 capacità	 di	 questi	 nuovi	 composti	 di	 indurre	 morte	cellulare	nelle	 cellule	 tumorali	 in	vitro.	 Poiché	 i	 risultati	 ottenuti	 su	diverse	linee	 cellulari	 sono	 stati	 promettenti	 e	 l’induzione	 di	 morte	 cellulare	 era	strettamente	dipendente	dalla	espressione	Kv1.3,	si	è	deciso	di	testare	questi	composti	anche	 in	vivo	 in	un	modello	di	melanoma	e	di	tumore	pancreatico.	Durante	 il	 mio	 soggiorno	 di	 due	 mesi	 al	 termine	 del	 primo	 anno	 di	 mio	dottorato	presso	 l'Istituto	per	 la	ricerca	sperimentale	sul	cancro,	Università	di	Kiel	(Germania),	ho	eseguito	esperimenti	in	vivo,	usando	derivati	del	PAP-1	e	clofazimina	su	topi	SCID	iniettati	con	Colo357,	una	linea	di	cellule	tumorali	umane	 di	 pancreas	 esprimenti	 Kv1.3,	 ottenendo	una	 riduzione	 significativa	della	 massa	 del	 tumore	 (Zaccagnino,	 Managò	 et	 al.,	 under	 submission	 alla	rivista	 Oncotarget).	 Inoltre,	 i	 derivati	 del	 PAP-1	 sono	 stati	 testati	 su	 un	modello	 in	 vivo	 di	 melanoma,	 dando	 risultati	 rilevanti	 (Leanza,	 Romio,	Becker,	 Azzolini,	 Trentin,	 Managò	 et	 al.,	 manoscritto	 in	 preparazione,	 non	incluso	nella	presente	tesi).	Il	trattamento	ha	esercitato	un	effetto	sul	tumore,	senza	rilevanti	effetti	collaterali	sui	tessuti	sani.	Alcuni	 dei	 più	 promettenti	 derivati	 della	 clofazimina	 sono	 stati	 selezionati	per	essere	testati	su	cellule	derivanti	da	pazienti	con	leucemia	mieloide	acuta	(AML).	Ho	eseguito	questi	esperimenti	durante	il	mio	soggiorno	in	Germania	presso	 il	 Dipartimento	 di	 Biologia	 Molecolare	 dell'Università	 di	 Duisburg-Essen.	 I	 campioni	 di	 sangue	 provenivano	 direttamente	 dal	 reparto	 di	ematologia	 della	 clinica	 universitaria	 di	 Essen.	 Finora,	 abbiamo	 ottenuto	risultati	 preliminari	 che	 sono	 però	 controversi,	 poiché	 i	 pazienti	 sono	 stati	diagnosticati	 a	 diversi	 stadi	 della	 malattia	 (cioè	 hanno	 livelli	 differenti	 di	cellule	patologiche	nel	sangue)	e	poiché	la	leucemia	mieloide	acuta	è	di	per	sé	una	malattia	eterogenea	a	livello	molecolare	e	citogenetico.	Questi	studi	non	sono	stati	inclusi	nella	tesi.	
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	Inoltre,	ho	partecipato	a	un	progetto	del	laboratorio	del	Prof.	Holger	Kalthoff	(Università	di	Kiel,	Germania),	riguardante	lo	studio	del	meccanismo	d'azione	di	 un	 estratto	 di	 alghe	 marine,	 per	 il	 quale	 ho	 eseguito	 gli	 esperimenti	 di	bioenergetica	 (Geisen,	 Zenthoefer,	 Peipp,	 Kerber,	 Plenge,	 Managò	 et	 al.,	
Marine	drugs,	2015).	Oltre	 ai	 progetti	 basati	 sull’attività	 in	 laboratorio,	 ho	 anche	 contribuito	 alla	preparazione	di	due	review,	una	 in	materia	di	 canali	 ionici	 intracellulare	 in	relazione	al	cancro	(Leanza,	Biasutto,	Managò	et	al.,	Frontiers	on	Physiology,	2013)	 e	 l'altra	 riguardante	 l’utilizzo	 in	 vivo	 di	 canali	 ionici	 come	 bersaglio	farmacologico	 come	 possibile	 strumento	 terapeutico	 nella	 cura	 del	 cancro	(Leanza,	Managò	et	al.,	BBA	Mol	Cell.	Research,	2015).	
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2.	Introduction			
2.1	Mitochondrion	
2.1.1	An	overview	on	structure	and	function		Mitochondria	 derive	 from	 the	 engulfment	 of	 a	 proteobacterium	 by	 a	precursor	of	an	eukaryotic	cell	(Lane	&	Martin,	2010).	They	 are	 the	 organelles	 where	 the	 cellular	 energy	 production	 takes	 place,	due	 to	 their	 ability	 to	 synthetize	 ATP	 by	 respiration.	 This	 unique	 feature	represented	 a	 driving	 force	 in	 the	 evolution.	 	 However,	mitochondria	 have	acquired	new	functions	in	order	to	meet	the	demands	of	the	cells,	therefore	evolving	mechanisms	for	a	constant	dialogue	between	the	organelle	and	the	rest	of	the	cellular	systems,	in	many	physiological	processes.		As	 a	 consequence	 of	 their	 bacterial	 origin,	 mitochondria	 host	 a	 circular,	double	 -stranded	 genome	 (mtDNA)	 of	 16kb,	 present	 in	 multiple	 copies	 in	each	mitochondrion.	This	genome	contains	37	genes	encoding	for	ribosomal	RNAs	(2	genes),	transfer-RNAs	(22	genes)	and	protein	of	the	core	subunits	of	the	respiratory	chain	complexes	(13	genes).	The	quantity	of	genetic	material	has	drastically	became	reduced	throughout	the	evolution	and,	rapidly,	part	of	it	has	been	transferred	to	the	nucleus.				
		
Figure	1:	a):	Schematic	representation	of	mitochondria	structure;	b):	TEM	micrograph	of	a	mitochondrion	(https://commons.wikimedia.org/wiki/File:0315_Mitochondrion_new.jpg)				Mitochondria	 comprise	 over	 1000	 proteins,	 encoded	 by	 nuclear	 and	mitochondrial	 genomes.	 Therefore	 the	 ones	 deriving	 from	 mitochondrial	genome	are	 translated	 inside	 the	matrix,	where	mitochondrial	 translational	machinery	 is	 assembled.	 The	 nucleus-encoded	 protein	 are	 translated	 on	cytosolic	ribosomes	and	further	imported	and	sorted	into	mitochondrial	sub-compartments	 by	 translocase	 machines	 present	 in	 both	 the	 inner	 and	 the	outer	mitochondrial	membrane	(IMM	and	OMM).	 In	 fact,	mitochondria	own	
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an	 outer	 mitochondrial	 membrane	 and	 inner	 mitochondrial	 membrane	separated	by	the	intermembrane	space	(IMS);	inside	in	the	mitochondria,	the	matrix	is	encapsulated.	At	the	level	of	the	membranes	and	in	the	matrix,	the	actors	 of	 the	 principal	metabolic	 processes	 that	 sustain	 the	 survival	 of	 the	cell	and	of	the	entire	organism	reside	(Friedman	&	Nunnari,	2014).		Here	 I	 will	 first	 briefly	 describe	 the	 principal	 functions	 carried	 out	 by	mitochondria	or	in	which	mitochondria	take	part,	describing	in	more	details	only	mitochondrial	bioenergetics,	since	it	is	the	object	of	my	PhD	work.		Mitochondria	 regulate	 several	 key	 metabolic	 processes:	 some	 processes	entirely	 occur	 at	 the	 level	 of	 these	 organelles	 (Krebs	 cycle,	 oxidative	phosphorylation,	β-oxidation)	while	others	find	only	some	components	of	the	pathway	 residing	 at	 the	 level	 of	 mitochondria	 (e.g.:	 in	 gluconeogenesis,	glycolysis).				
		
Figure	 2:	 A	 scheme	 summarizing	 mitochondrial	 bioenergetic	 functions:	 Each	 pyruvate	molecule	produced	by	glycolysis	is	actively	transported	across	the	IMM	and	into	the	matrix	via	 the	 mitochondria	 pyruvate	 carrier	 (MPC),	 where	 it	 is	 oxidized	 and	 combined	 with	coenzyme	 A	 by	 pyruvate	 dehydrogenase	 (PDH)	 to	 form	 CO2,	 acetyl-CoA,	 and	 NADH.	 The	acetyl-CoA	 is	 the	 first	molecule	 to	enter	 the	 tricarbolixyc	acid	 (TCA)	cycle.	The	enzymes	of	the	TCA	cycle	are	 located	 in	the	mitochondrial	matrix,	except	 for	succinate	dehydrogenase,	which	 is	bound	to	the	IMM	as	part	of	complex	II.	During	the	TCA,	acetyl-CoA	is	oxidized	to	CO2,	 through	 subsequent	 step;	 three	molecules	 of	 NADH	 and	 one	molecule	 of	 FADH2	 are	generated	through	the	process.	The	redox	energy	 from	NADH	and	FADH2	 is	 transferred	to	O2	 in	 several	 steps	 via	 the	 electron	 transport	 along	 the	 respiratory	 complexes	 (i.e.:	complexes	I	to	IV	plus	ATPase).	Complex	I,	complex	III	and	complex	IV	perform	the	transfer,	and	 the	 incremental	 release	 of	 energy	 is	 used	 to	 pump	 protons	 (H+)	 into	 the	 IMS.	 As	 the	proton	concentration	 increases	 in	 the	 IMS,	a	strong	electrochemical	gradient	 is	established	across	 the	 IMM.	The	protons	 can	 return	 to	 the	matrix	 through	 the	ATP	 synthase	 complex,	and	their	potential	energy	is	used	to	synthesize	ATP	from	ADP	and	inorganic	phosphate	(Pi).	The	adenine	nucleotide	transporter	(ANT)	mediates	the	exchange	of	ATP	for	ADP.		
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αKDH:	 α-ketoglutarate	 dehydrogenase;	 Em	 :	 electrical	 field	 within	 the	 membrane;	 FH:	fumarate	 hydratase;	 IDH:	 isocitrate	 dehydrogenase;	 MDH:	 malate	 dehydrogenase;	 PDHP:	pyruvate	 dehydrogenase	 phosphatase;	 PDK:	 pyruvate	 dehydrogenase	 kinase;	 Pi:	 inorganic	phosphate;	 SCoA-S:	 succinyl-CoA	 synthase;	 SH:	 cysteine	 thiol	 (from	 Sabharwal	 and	Schumacker,	2014).					Beside	 the	 main	 contribution	 given	 by	 mitochondria	 to	 cellular	 and	organismal	 metabolism,	 they	 fulfil	 other	 functions	 in	 response	 to	 cellular	demands.	First	of	all	 they	actively	 take	part	of	cellular	calcium	homeostasis	and	 they	 behave	 as	 cytosolic	 Ca2+	 buffers.	 This	 is	 principally	 due	 to	 two	conditions:	first,	the	membrane	potential	established	at	the	level	of	the	IMM,	negatively	 charged	 inside,	 represent	 a	 huge	 driving	 force	 for	 cation	 entry;	second,	mitochondria	do	posses	Ca2+	channels	and	exchangers	that	allow	this	passage	of	charges,	among	them	MCU	plays	key	role	in	mitochondrial	calcium	signalling	 (Rizzuto,	 De	 Stefani,	 Raffaello,	 &	 Mammucari,	 2012).	 	 Moreover,	mitochondria	take	part	in	and	regulate	apoptosis,	during	which	the	opening	of	a	mitochondria	megachannel	(i.e.	the	permability	transition	pore,	PTP,	see	section	 2.3.3)	 determine	 the	 disruption	 of	 mitochondrial	 transmembrane	potential	and	the	release	of	some	IMS-located	proteins	such	as	cytochrome	c		(detailed	 description	 of	 apoptosis	will	 be	 provided	 in	 section	2.5).	 Another	important	 role	of	mitochondria	 is	 that	 they	are	a	 source	of	 reactive	oxygen	species	 (ROS);	 ROS	 are	 considered	 important	 signalling	molecules	 in	many	cellular	responses	(ROS	are	described	 in	details	 in	section	2.2).	Finally	 they	take	 part	 in	 cellular	 proliferation;	 this	 function	 is	 linked	 to	 mitochondrial	ROS	 production,	 since	 ROS	 are	 able	 to	 regulate	 the	 transcription	 of	 some	genes	 involved	 in	 proliferation,	 and	 to	 regulate	 production	 of	 other	modulators	of	gene	expression	such	as	steroid	hormones.	Subsequently,	 I	 will	 describe	 in	 details	mitochondrial	 bioenergetics,	 where	the	term	bioenergetics	indicates	the	study	of	energy	transformation	in	living	organisms	and	systems	(Nicholls	&	Ferguson	2002).		
2.1.2	The	chemiosmotic	theory	and	the	oxidative	phosphorylation		
	The	eukaryotic	cells	produce	energy	through	the	oxidative	phosphorylation.	The	chemiosmotic	 theory,	 formulated	by	Mitchell	 in	 the	1965	describes	 the	process	by	which	electrons,	deriving	from	the	oxidation	of	organic	nutrients,	pass	through	a	series	of	respiratory	enzymes	(I-IV)	embedded	in	the	IMM	in	a	precise	 order	 (i.e.	 the	 respiratory	 chain	 complexes),	 finally	 providing	 the	energy	 for	 the	 phosphorylation	 of	 ADP,	 leading	 to	 the	 production	 of	 ATP.	Electrons	 derive	 from	 reducing	 equivalents	 produced	 during	 the	 oxidation	phase	of	nutrients	such	as	glucose	or	pyruvate,	by	glycolysis	or	Krebs	cycle	respectively,	 and	are	 transferred	by	 the	 respiratory	 chain	 complexes	 to	 the	molecular	 oxygen.	 The	 passage	 of	 these	 electrons	 is	 coupled	 to	 the	generation	of	an	electrochemical	proton	gradient,	composed	of	a	membrane	potential	difference	 (ΔΨ)	and	a	cation	concentration	difference	 (ΔpH),	with	the	 ΔΨ	 representing	 the	 predominant	 component,	 because	 the	 electron	transport	 reactions	 provide	 the	 energy	 for	 pumping	 protons	 (H+)	 from	 the	matrix	 to	 the	 intermembrane	 space.	 The	 electrochemical	 proton	 gradient	
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represents	 the	 driving	 force	 for	 H+	 re-entry	 and	 this	 powers	 the	 ATP	synthase	 (complex	 V),	 which	 catalyse	 the	 synthesis	 of	 most	 cellular	 ATP	(Mitchell,	1961;	Mitchell	&	Moyle,	1967)					
		
Figure	3:	Schematic	representation	of	the	oxidative	phosphorylation,	with	principal	actors	taking	part	to	the	process	(http://www.notapositiva.com).	
	
	
	
2.1.2.1	The	respiratory	chain	complexes		The	respiratory	chain	consists	of	four	complexes	(I-IV)	and	the	ATP	synthase	(V),	 each	 composed	 by	multiple	 subunits,	 located	 in	 the	 IMM	 in	 eukaryotic	cells,	 together	with	 two	mobile	 carriers,	 i.e.	 ubiquinone	 (Q	 coenzyme,	CoQ)	and	cytochrome	c.	Further,	they	form	functionally	relevant	supercomplexes,	i.e.	structural	association	of	different	complexes,	as	demonstrated	upon	their	isolation	(Schägger,	2002).	Both	nuclear	DNA	and	mitochondrial	DNA	encode	these	complexes	(70	and	13	genes	respectively),	except	for	complex	II,	which	is	encoded	only	by	 the	nuclear	genome.	Therefore	genetic	mutation	of	both	genetic	 materials	 can	 lead	 to	 devastating	 pathologies.	 Since	 mitochondria	must	 be	 able	 to	 continuously	 re-adapt	 their	 rate	 of	 activities	 in	 order	 to	satisfy	the	needs	of	the	entire	cell,	it	is	noteworthy	to	underline	the	plasticity	in	 the	 organization	of	 the	 electron	 transport	 chain	 (Acin-Perez	&	Enriquez,	2014;	Nunnari	&	Suomalainen,	2012)		
2.1.2.1.1	Complex	I	or	NADH:ubiquinone	oxidoreductase		The	 L-shaped	 complex	 I	 constitutes	 of	 protein	 (45	 subunits,	 7	 from	mitochondrial	 DNA)	 and	 non-protein	 components	 (i.e.	 coenzymes).	 Among	the	non-protein	components	are	Q	coenzyme	(CoQ,	ubiquinone),	FMN	(flavin	mononucleotide),	clusters	Fe-S	and	phospholipid,	all	of	which	are	necessary	for	the	catalytic	activity	of	this	complex	(Carroll	et	al.,	2006).	The	reduction	of	CoQ	 is	 inhibited	 by	 rotenone.	 A	water-soluble	 arm	 and	 a	 hydrophobic	 arm	
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compose	complex	I.	The	structure	of	 the	hydrophilic	arm	of	complex	I	 from	
Thermus	 thermophilus	has	 been	 resolved	 and	 is	 likely	 to	 be	 very	 similar	 to	that	 in	mammals.	 It	 contains	 the	NADH	oxidation	site,	 the	primary	electron	acceptor	FMN	and	a	chain	of	Fe-S	centres	(Sazanov	&	Hinchliffe,	2006).	Less	is	known	about	the	hydrophobic	arm	where	the	CoQ	reduction	site	is	located.		This	respiratory	enzyme	catalyses	the	transfer	of	 two	electrons	from	NADH	to	ubiquinone,	coupling	this	reaction	to	the	vectorial	pumping	of	four	protons	from	 the	matrix	 to	 the	 IMM	 against	 electrochemical	 gradient.	 In	 detail,	 the	electrons	 are	 first	 transferred	 to	 FMN,	 the	 non-covalently	 bound	 electrons	acceptor	 of	 complex	 I.	 Subsequently,	 they	 are	 processed	 by	 the	 eight	 Fe-S	clusters	 to	 reduce	 the	 final	acceptor	ubiquinone,	now	ubiquinol	 (QH2).	The	reaction	catalysed	by	complex	I	is	the	following:		 NADH	+	H+	+	Q	+	4H+matrix	→NAD+	+	QH2	+	4H+IMS		A	3-D	high-resolution	structure	has	not	been	solved	for	complex	I,	therefore	the	 mechanism	 of	 proton	 pumping	 is	 uncertain.	 Two	 main	 models	 are	suggested	 in	 the	 literature	 and	 shared	 in	 the	 scientific	 community:	 the	coupling	 between	 electron	 transfer	 and	 proton	 translocation	 can	 be	 direct	(redox-driven)	 or	 indirect	 (conformation-driven).	 In	 the	 first	 one	 (also	defined	Q-cycle	mechanism)	 the	membrane-located	Q-binding	 sites	 and	 the	proton	translocation	component		are	in	close	contact	with	the	redox	centres	in	the	hydrophilic	arm,	therefore	they	can	directly	interact.	Contrarily,	in	the	second	 model	 the	 redox	 centres	 located	 on	 the	 water-soluble	 arm	 are	coupled	to	distal	proton-translocating	components	in	the	membrane	domain,	having	an	effect	on	 them	through	 long-range	conformational	changes	 (Holt,	Morgan,	 &	 Sazanov,	 2003).	 Further,	 in	 another	 model,	 redox-driven	conformational	 changes	 can	 affect	 directly	 the	 Q-binding	 site,	 determining	the	proton	pumping	(Ohnishi	&	Salerno,	2005).			
2.1.2.1.2	Complex	II	or	succinate:ubiquinone	oxidoreductase		Complex	 II	 or	 succinate:ubiquinone	 oxidoreductase	 (SQR),	 is	 the	 second	entry	point	for	the	electrons	to	the	respiratory	chain.	The	resolution	of	the	x-ray	 structure	 of	 the	 menaquinol	 fumarate-oxidoreductase	 (QFR)	 of	
Escherichia	coli,	an	enzyme	structurally	and	functionally	related	to	SQR,	has	provided	new	 insights	 into	 the	 function	of	 this	enzyme	(Cecchini,	Schröder,	Gunsalus,	 &	Maklashina,	 2002).	 The	 whole	 complex	 is	 encoded	 by	 nuclear	genes	 and	 it	 catalyses	 the	oxidation	of	 succinate	 to	 fumarate,	 during	which	electrons	 are	 carried	 from	 FADH2	 to	 ubiquinone.	 Its	 main	 component	 is	succinate	dehydrogenase	(SDH),	which	is	a	membrane	bound	enzyme	of	the	citric	acid	cycle.	Two	smaller	subunits	anchor	SDH	to	the	IMM,	from	the	side	of	 the	matrix,	 and	 they	 carry	 cytochrome	 b556	 and	 the	 Q-binding	 site.	 SDH	itself	shows	a	flavoprotein	subunit	and	an	iron-sulfur	protein	subunit.	Genes	encoding	 for	 this	 enzymes	 are	 considered	 housekeeping	 genes	 with	ubiquitous	expression	(van	den	Heuvel	&	Smeitink,	2001)				
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2.1.2.1.3	Complex	III	or	decylubiquinol:cytochrome	c	oxidoreductase		This	complex,	also	called	cytochrome	bc1,	catalyses	the	transfer	of	electrons	from	ubiquinol	to	cytochrome	c.	The	reaction	is	coupled	to	the	movement	of	protons	 from	 the	 matrix	 to	 the	 intermembrane	 space.	 Eleven	 components	constitute	 the	 complex	 and	 nuclear	 DNA,	 except	 for	 the	 cytochrome	 b,	encodes	them	all	(van	den	Heuvel	&	Smeitink,	2001).	Atomic	models	of	most	protein	components	of	bovine	cytochrome	bc1	have	been	provided	(Xia	et	al.,	1997),	from	which	also	the	dimeric	organization	of	complex	III	has	emerged.	Three	 of	 the	 eleven	 subunits	 carry	 a	 prosthetic	 group:	 heme	 c1	 for	cytochrome	c1,	heme	bH	and	bL	for	cytochrome	b	and	two	Fe-S	clusters	on	the	Rieske	iron-sulfur	protein.	All	these	prostetic	groups	take	part	to	the	proton	motive	 Q	 cycle,	 which	 is	 the	 overall	 accepted	 mechanism	 underlying	 the	proton	 pumping	 from	 the	matrix	 side	 to	 the	 intermembrane	 space	 carried	out	by	complex	III.			The	proton-motive	Q	 cycle	occurs	 in	 two	 steps.	 	 In	 the	 first	 step,	 ubiquinol	(QH2)	is	oxidized	at	the	Q0	site	in	a	concerted	reaction	in	which	one	electron	is	 transferred	 to	 the	 Rieske	 iron-sulfur	 protein	 to	 form	 a	 ubisemiquinone	anion	 (Q	 .-),	which	 immediately	 reduces	 the	bL	 heme.	This	process	deposits	two	 protons	 on	 the	 positive	 side	 of	 the	 membrane.	 Later,	 the	 electron	transferred	 to	 the	Fe-S	protein	Rieske,	moves	 to	cytochrome	c1	and	 then	 to	cytochrome	 c.	 The	 second	 electron	 from	 ubiquinol,	 transferred	 from	 the	heme	 bL	 to	 heme	 bH.	 The	 latter	 then	 reduces	 ubiquinone	 (Q)	 to	ubisemiquinone	anion	(Q	.-)	at	the	Qi	site.	At	this	point	only	one	electron	from	ubiquinol	has	been	 transferred	 to	cytochrome	c	and	only	 two	protons	have	been	deposited	on	the	IMS,	while	the	second	electron	from	ubiquinol		resides	on	 the	 ubisemiquinone	 anion	 at	 the	 Qi	 site.	 In	 the	 second	 step,	 a	 second	molecule	of	ubiquinol	 is	 then	oxidized	by	 the	Fe-S	protein,	 transferring	one	electron	to	cytochrome	c1,	to	reduce	a	second	molecule	of	cytochrome	c.	An	ubisemiquinone	 anion	 is	 formed	 again	 and	 two	 more	 protons	 on	 are	transferred	 on	 the	 positive	 side	 of	 the	 membrane.	 The	 Q	 .-	 reacts	 as	previously,	transferring	an	electron	from	the	heme	bL	 to	heme	bH;	the	latter	then	 reduces	 the	 previously	 formed	 ubisemiquinone	 anion	 to	 ubiquinol	 at	the	Qi	site,	consuming	two	protons	from	the	negative	side	of	the	membrane	and	completing	the	Q	cycle	(Trumpower,	1990;	Nelson	&	Cox,	2006)	The	general	reaction	catalysed	by	complex	III	is	the	following:			 QH2	+	2H+	matrix	+	2Cox	à	Q	+	4H+	IMS	+	2Cred		Where	Cox	and	Cred	indicate	cytochrome	c	oxidized	and	reduced,	respectively.	Two	 inhibitors	 of	 complex	 III	 are	 known:	 antimycin	 A	 and	 myxothiazol.	Antimycin	A	 is	a	secondary	metabolite	produced	by	strains	of	Streptomyces	bacteria,	 while	myxothiazol	 is	 a	molecule	 produced	 by	 the	myxobacterium	
Myxococcus	 fulvus.	 From	 the	 crystal	 structure,	 the	 binding	 sites	 of	 these	inhibitors	have	been	identified.	Antimycin	A	specifically	blocks	electron	flow	from	 heme	 bH	 to	 ubiquinone	 at	 the	 Qi	 site,	 while	 myxothiazol	 stops	 the	electron	flow	from	ubiquinol	to	the	iron-sulfur	center	(Xia	et	al.,	1997)			
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2.1.2.1.4	Complex	IV	or	cytochrome	c	oxidase			Complex	IV	(COX)	catalyses	the	last	step	of	the	electron	transport	respiratory	chain,	 transferring	 electrons	 from	 reduced	 cytochrome	 c	 to	 oxygen,	converting	 molecular	 oxygen	 in	 two	molecules	 of	 water;	 simultaneously	 it	moves	 protons	 across	 the	 IMM,	 contributing	 to	 the	 generation	 of	 the	electrochemical	gradient	that	drives	the	ATP	synthesis	at	the	level	of	complex	V.		Complex	 IV	 is	 composed	of	13	subunits,	of	which	 three	are	encoded	by	 the	mitochondrial	 DNA	 and	 are	 responsible	 of	 the	 protons	 transfer	 and	 the	nuclear	 DNA	 encodes	 the	 other	 10	 subunits,	 for	 which	 the	 role	 is	 not	completely	 clear	 (Grossman	 &	 Lomax,	 1997;	 van	 den	 Heuvel	 &	 Smeitink,	2001).	Two	copper	atoms	form	a	complex	with	thiol	group	of	some	cysteines	(CuA	centre)	 and,	 together	with	 two	 unique	 hemes,	 hemea	and	hemea3,	 that	together	with	 another	 cupper	 ion	 (CuB),	 they	 all	 participate	 in	 the	 electron	transport	(Nelson	&	Cox,	2006).	When	 four	 electrons	 are	 transferred	 through	 COX,	 four	 protons	 from	 the	matrix	 are	 used	 to	 reduce	molecular	 oxygen	 to	 water.	 Further,	 the	 energy	deriving	from	the	transfer	of	other	four	electrons	is	coupled	with	the	moving	of	 four	 protons	 from	 the	 matrix	 to	 the	 IMS,	 thus	 contributing	 to	 the	generation	of	the	proton	gradient	needed	to	drive	ATP	synthesis.		The	general	reaction	is	the	following:		 	4Cred	+	8H+matrix	+	O2	à	4Cox	+	4H+IMS	+	2H20		Where	Cox	and	Cred	indicate	cytochrome	c	oxidized	and	reduced,	respectively.		Complex	IV	is	inhibited	by	cyanide,	sulphide	and	azide;	they	bind	to	complex	IV	inhibiting	its	function,	most	likely	inhibiting	the	hemes	group.			
2.1.2.1.5	Complex	V	or	ATP	synthase		Complex	 V	 catalyses	 the	 addition	 of	 one	 phosphate	 to	 a	 molecule	 of	 ADP	forming	 ATP;	 the	 energy	 for	 this	 endergonic	 reaction	 is	 provided	 by	 the	influx	of	protons	from	the	mitochondrial	intermembrane	space	to	the	matrix,	because	 energy	 is	 conserved	 during	 the	 electron	 transport	 as	 a	 proton	gradient	 (negative	 from	the	matrix	side)	and	 therefore	provides	 the	energy	for	 ATP	 synthesis.	 Complex	 V	 also	 owns	 the	 ability	 to	 catalyse	 the	 reverse	reaction,	i.e.	hydrolyse	ATP	to	ADP	and	phosphate,	linking	this	process	to	the	opposite	 movement	 of	 protons,	 i.e.	 from	 the	matrix	 to	 the	 intermembrane	space.	The	structure	of	the	ATP	synthase	allows	these	processes.	 It	shows	a	feature	that	is	in	common	with	ATP	synthases	of	bacteria	and	chloroplasts;	it	consists	of	two	parts:	the	Fo	(160	kDa),	which	crosses	the	inner	mitochondrial	membrane	and	functions	as	a	proton	conduction	channel,	and	the	F1,	which	is	located	 into	 the	matrix	 and	 connected	 to	 the	 F0	by	 a	 short	 stalk;	 the	 stalk	region	is	composed	of	subunits	both	from	Fo	and	F1.	The	passage	of	protons	through	 the	 F0	 channel	 induces	 long-range	 conformational	 changes	 at	 the	level	 of	 the	 stalk	 and	 of	 the	 F1	subunit,	 allowing	 the	 formation	 of	 the	 ATP,	which	leaves	the	complex	V	from	the	matrix	side	(Nelson	&	Cox,	2006).	The	group	 of	 Walker	 identified	 in	 1994	 the	 crystal	 structure	 of	 bovine	
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mitochondrial	 F1-ATPase,	 giving	 new	 insights	 in	 the	 understanding	 of	 the	catalytic	mechanism	(Abrahams,	Leslie,	Lutter,	&	John	E.	Walker,	1994).	Five	different	proteins	constitute	the	F1-ATPase,	with	the	following	stoichiometry:	α3β3γδε.	 Each	 β	 subunit	 contains	 the	 catalytic	 site	 for	 ATP	 synthesis.	Concerning	 Fo,	 it	 results	 from	 the	 assembling	 of	 the	 subunits	 a,b	 and	 c,	forming	the	proton	channel,	with	the	following	stoichiometry:	ab2c10-12.	In	the	F1	subunit,	α	and	β	are	organized	like	orange	slices	to	create	a	sphere,	with	γ	forming	a	central	axis	(see	figure	3).	The	ATP	catalysis	is	carried	out	by	the	β	subunits.	Even	if	their	sequence	is	identical,	they	can	assume	three	different	conformations:	 β-ADP,	 binding	 ADP	 and	 Pi,	 β-ATP	 and	 β-empty.	 Switching	from	 one	 conformation	 to	 another,	 they	 catalyse	 ATP	 synthesis.	 The	conformational	changes	are	induced	by	the	passage	of	protons	through	the	Fo	subunit;	this	passage	induces	the	rotation	of	the	cylinder	structure	created	by	the	c	subunits	and	of	γ	subunit.	These	events	determine	the	conformational	changes	 affecting	 the	β	 subunits	 and	 therefore	 the	 switching	 of	 the	 affinity	for	 the	 substrate.	 For	 each	 complete	γ	 rotation,	 each	β	 subunit	 assumes	all	the	possible	conformations,	leading	to	the	formation	of	three	ATP	molecules	for	 each	 rotational	 catalytic	 cycle.	 According	 to	 this	 model,	 three	 or	 four	protons	must	 be	 driven	 from	 the	 IMS	 to	 the	matrix	 to	 synthesize	 one	 ATP	molecule	(Boyer,	1997).		Recently,	 the	 group	 of	 Bernardi	 proposed	 that	 dimers	 mitochondrial	 ATP	synthase	 form	the	permeability	 transition	pore,	a	mega-channel	of	 the	 IMM	whose	molecular	 nature	was	 not	 defined	 so	 far	 (Giorgio	 et	 al.,	 2013).	 (see	section	2.3.3)				
		
Figure	4:	Schematic	representation	of	the	FoF1	structure	of	the	ATP	synthase.	See	text	for	a	detailed	description	(http://acebiochemistry.yolasite.com/proton-gradient-and-atp-synthase.php)			
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2.2	Mitochondrial	reactive	oxygen	species	
	
2.2.1	Definition	and	roles	
	The	term	reactive	oxygen	species	(ROS)	includes	oxygen	free	radicals	such	as	superoxide	anion	(O2	.-)	and	hydroxyl	(.OH)	radicals	and	non-radical	oxidants	as	hydrogen	peroxide	(H2O2)	and	singlet	oxygen	(1O2).	ROS	are	produced	at	many	sites	within	 the	cells	 (e.g:	peroxisomes,	endoplasmic	reticulum,	Golgi,	mitochondria,	nucleus,	the	cytosol).	 In	the	context	of	this	dissertation,	I	will	take	into	account	only	mitochondrial	ROS	(mROS)	production.		Mitochondria	are	a	notable	source	of	ROS.	They	occur	as	natural	byproducts	of	 mitochondrial	 metabolism	 and	 posses	 a	 role	 in	 several	 physiological	cellular	responses,	ranging	from	regulation	of	processes	controlled	by	oxygen	concentration	such	as	adaptation	to	hypoxia	 (Bell	et	al.,	2007),	 induction	of	autophagy	 under	 starvation	 (Scherz-Shouval	 et	 al.,	 2007),	 regulation	 of	immune	 response	 to	 different	 infectious	 agents	 (Arsenijevic	 et	 al.,	 2000;	Chaudhri,	Clark,	Hunt,	Cowden,	&	Ceredig,	1986),	differentiation	of	stem	cells		(Owusu-Ansah	 &	 Banerjee,	 2009),	 aging	 (Liochev,	 2013;	 Sena	 &	 Chandel,	2012)	 and,	 finally,	 control	 of	 oxidative	 stress	 responses	 that	 ensure	 the	maintenance	of	redox	homeostasis	(Dröge,	2002).	Indeed,	redox	homeostasis	must	be	strictly	regulated,	because	the	presence	of	ROS	becomes	detrimental	for	 the	 cells,	 over	 a	 certain	 threshold;	 in	 these	 conditions	 cells	 undergo	 a	process	 called	 “oxidative	 stress”,	 in	 which	 the	 level	 of	 ROS	 in	 the	 cells	significantly	 exceed	 the	 “basal”	 level	 allowing	 the	 normal	 homeostatic	function	and	in	these	conditions	ROS	can	react	with	DNA,	proteins	and	lipids,	altering	cellular	 structures	and	 functions.	 In	effect,	 they	are	 involved	 in	 the	mitochondrial	damage	observed	in	an	extended	range	of	pathologies	such	as	cancer	(Liou	&	Storz,	2010),	diabetes	mellitus		(Nishikawa	and	Araki,	2007),	atherosclerosis	 (Hulsmans,	 Van	 Dooren,	 &	 Holvoet,	 2012),	neurodegenerative	diseases	(Uttara,	Singh,	Zamboni,	&	Mahajan,	2009)		and	ischemia/reperfusion	injury	(Di	Lisa	&	Bernardi,	2006).					
		
Figure	5:	Mitochondria-derived	ROS	level	determines	their	function	in	the	cells	(from	Sena	&	Chandel	2012)			
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Summarizing,	while	very	high	quantities	of	mROS	directly	damage	proteins,	lipids,	 and	 nucleic	 acids,	 lower	 levels	 of	 ROS	 are	 needed	 for	 normal	 cell	homeostasis	 and	 behave	 as	 signalling	 molecules	 in	 adaptation	 to	 stress	processes.	 Even	 lower	 levels	 of	 mROS	 are	 required	 for	 normal	 cell	homeostasis.		For	 all	 these	 reasons,	 the	 cells	 possess	 efficient	mechanisms	 designated	 to	balance	ROS	generation	and	ROS	scavenging	and	avoid,	in	this	way,	oxidative	stress.			
2.2.2	Mechanisms	of	redox	homeostasis	maintenance		
	Redox	 homeostasis	 maintenance	 is	 controlled	 by	 several	 mechanisms.	Among	them,	antioxidant	enzymes	play	a	major	role.					
		
Figure	 6:	 Representative	 figure	 depicting	 the	 most	 common	 mechanisms	 for	 superoxide	dismutation	within	mitochondria	(from	Sena	and	Chandel	2012).						Superoxide	 anion	 is	 the	 proximal	 mitochondrial	 ROS	 and	 the	 enzymes	superoxide	 dismutase	 (SODs)	 convert	 superoxide	 anion	 into	 hydrogen	peroxide.	 Superoxide	 can	 either	 be	 emitted	 into	 the	matrix	 either	 into	 the	intermembrane	 space;	 the	 latter,	 can	 exit	 mitochondria	 through	 VDAC	(voltage-dependent	 anion	 channel)	 present	 in	 the	 OMM.	 In	 mammals,	 the	existence	 of	 three	 different	 isoforms	 of	 SOD	 with	 different	 cellular	localization	was	 found:	 the	 Cu,Zn	 SOD	 (SOD1,	 Fridovich	 I,	 1974)	 located	 in	the	 mitochondrial	 intermembrane	 space	 and	 cytosol;	 the	 Mn	 SOD	 (SOD2,	Weisiger	RA	and	Fridovich	I,	1973),	located	in	the	mitochondrial	matrix	and	Cu,Zn	 SOD	 (ecSOD,	 SOD3,	 Marklund	 SL,	 1984)	 located	 in	 the	 extracellular	space.	Superoxide	anion	can	also	be	non-enzymatically	converted	in	the	non-radical	species	singlet	oxygen	(Steinbeck,	Khan,	&	Karnovsky,	1993).	The	fate	of	 hydrogen	 peroxide	 is	 to	 be	 converted	 into	 the	 highly	 reactive	 hydroxyl	
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radical	or,	 in	 the	best	case,	 in	water	by	the	enzymatic	reaction	catalysed	by	catalase	or	glutathione	peroxidase	 (GPX)	 (Chance,	Sies,	&	Boveris,	1979)	or	peroxiredoxins	 (PRX).	 In	 mammals	 there	 are	 6	 isoforms	 of	 PRXs	 and	 8	 of	GPXs.	Glutathione	peroxidase	determines	the	oxidation	of	glutathione	(GSH)	to	 glutathione	 disulphide	 (GSSG);	 glutathione	 reductase	 can	 catalyse	 the	reverse	 reaction,	 in	 a	 NADPH	 consuming	 process.	 PRXs	 function	 reducing	H2O2,	leading	to	the	formation	of	2H2O,	afterwards	assuming	again	it	reduced	form,	oxidizing	a	reduced	thioredoxin	molecule.		Beside	the	above	mentioned	enzymes	with	antioxidants	activities,	also	non-enzymatic	molecules	such	as	vitamin	E,	β-caroten,	glutathione	and	vitamin	C	show	antioxidant	capacities.		In	general,	antioxidants	have	been	defined	as	molecules	able	to	compete	with	other	 oxidizable	 substrates	 and,	 thus,	 to	 significantly	 delay	 or	 inhibit	 the	oxidation	of	these	substrates,	when	are	present	in	the	cells	at	relatively	low	concentrations	(Dröge,	2002).	On	the	other	hand,	molecules	with	relatively	low	specific	antioxidant	activity,	when	present	at	high	concentration	(molar	range),	strongly	contribute	to	the	overall	 ROS	 scavenging	 and	 redox	 homeostasis	 maintenance.	 For	 example,	free	 amino	 acids,	 peptides	 and	 proteins	 are	 among	 these	 low-efficiency	antioxidants,	that	need	to	be	present	at	high	concentration	within	the	cells	to	exert	a	certain	antioxidant	effect.	All	free	amino	acids	are	target	of	ROS;	they	are	present	at	high	concentration	within	the	cells	(10-1M),	therefore	they	are	important	 ROS	 scavengers.	 In	 a	 relatively	 recent	 work,	 it	 has	 been	demonstrated	 that	 the	 amino	 acid	 proline	 is	 a	 potent	 antioxidant,	 able	 to	inhibit	 programmed	 cell	 death	 induced	 by	 high	 level	 of	 ROS	 in	 a	 fungal	pathogen	 (Chen	 &	 Dickman,	 2005).	 As	 mentioned	 above,	 proteins	 are	damaged	 by	 ROS,	 which	 can	 induce	 oxidative	 modifications,	 leading	 to	changes	in	protein	function	but	also	determine	an	increased	susceptibility	to	proteasome	with	proteolysis	as	a	consequence	(Davies,	1987).	This	process	further	contributes	to	redox	homeostasis,	leading	to	the	release	of	free	amino	acids	in	the	cell.	Moreover,	redox	homeostasis	can	be	achieved	by	regulating	antioxidant	mechanisms	at	a	transcriptional	level.	A	major	mechanism	is	the	ROS-mediated	 induction	 of	 transcription	 of	 antioxidant	 enzymes.	 Redox	regulation	 of	 transcription	 is	 an	 evolutionary	 conserved	 strategy	 in	 which	alterations	in	intracellular	ROS	levels	induce	appreciable	alterations	in	gene	expression.	The	regulation	of	at	least	two	transcription	factors,	nuclear	factor	(NF)	KB	and	activator	protein	(AP)-1	depends	on	the	intracellular	redox	state	(Sen	 &	 Packer,	 1996),	 and	 more	 recently	 p53	 also	 joined	 this	 list	 (H.	 Liu,	2005).	 In	 general,	 the	 cellular	 response	 to	 an	 increase	 of	 reactive	 species	involves	the	robust	induction	of	numerous	gene	products	that	function	both	to	 inactivate	 ROS	 production	 and	 to	 restore	 homeostasis.	 Concerning	 the	mechanisms	regarding	how	ROS	 levels	 can	regulate	 transcriptional	activity,	three	 manners	 have	 been	 identified:	 direct	 oxidation	 and	 reduction	 of	transcription	factors,	changes	in	subcellular	 localization	of	the	transcription	factors	 and	 an	 alteration	 in	 ROS	 levels	 that	 can	 modulate	 the	 activity	 of	chromatin-modifying	 enzymes	 as	 a	 consequence	 of	 changes	 of	 intracellular	redox	buffers	(H.	Liu,	2005).				
	
	 20	
2.2.3		Mitochondrial	ROS	production	sites			Since	 mitochondria	 have	 been	 identified	 as	 source	 of	 ROS,	 several	 studies	have	been	conducted	 to	 investigate	 the	precise	 site	of	ROS	production.	The	first	 evidence	 that	 mitochondrial	 ROS	 production	 is	 associated	 with	 the	respiratory	 chain	 activity	 date	 back	 to	 the	 early	 ‘90s	 (Jensen,	 1996).	 Since	then,	 many	 details	 have	 been	 addressed	 and	 clarified.	 The	 two	 overall	accepted	 main	 sources	 of	 ROS	 are	 complex	 I	 and	 complex	 III,	 principally	producers	of	superoxide	anion.			
2.2.3.1	Complex	I			Complex	I	tranfers	electrons	from	NADH	to	CoQ.	According	to	a	recent	work,	two	are	the	assigned	sites	for	the	reduction	of	O2	to	superoxide	at	the	level	of	complex	 I:	 the	 NADH	 and	 the	 quinone-binding	 sites	 (Hirst,	 King,	 &	 Pryde,	2008).	 However,	 the	 role	 of	 the	 components	 of	 complex	 I	 involved	 in	superoxide	 production	 is	 still	 debated.	 Some	 consider	 FMN	 (flavin	 mono-nucleotide),	 while	 others	 identified	 iron-sulfur	 clusters	 N1a	 and	 N2,	 or	ubisemiquinone	 as	 responsible	 for	 superoxide	 generation	 in	 complex	 I	(Zorov,	 Juhaszova,	 &	 Sollott,	 2014).	 	 According	 to	 many	 scientists,	 the	isolated	complex	produces	superoxide	from	the	reaction	of	O2	with	the	fully	reduced	 FMN.	 The	 limiting	 step	 of	 the	 formation	 of	 superoxide	 is	 the	NADH/NAD+	ratio,	which	set	the	proportion	of	the	FMN	that	is	fully	reduced	(Hirst	 et	 al.,	 2008;	 Kussmaul	 &	 Hirst,	 2006).	 Therefore,	 the	 processes	determining	 the	 increase	 of	 NADH/NAD+	 ratio,	 such	 as	 respiratory	 chain	damage,	 ischemia,	 low	 ATP	 demand/low	 respiration	 rate,	 will	 lead	 to	 the	increase	 in	 O2-	 formation.	 In	 contrast,	 when	 mitochondria	 are	 respiring	normally,	 consuming	 NADH	 and	 NADH/NAD+	 ratio	 is	 relatively	 low,	 only	small	 amounts	 of	 superoxide	 are	 produced	 from	 complex	 I	 (Votyakova	 &	Reynolds,	2001).	Seo	and	colleagues	demonstrated	that	oxidative	stress	in	rat	and	human	cell	 lines	was	significantly	reduced	when	cells	were	 transfected	with	 a	 vector	 expressing	 the	 gene	of	Saccaromyces	cerevisiae	 for	 the	NADH	dehydrogenase,	 providing	 a	 clear	 evidence	 of	 the	 fundamental	 influence	 of	the	NADH/NAD+	ratio	in	ROS	production	(Seo,	Marella,	Yagi,	&	Matsuno-Yagi,	2006)	 .	 However,	 an	 interesting	 work,	 using	 submitochondrial	 particles	oxidizing	NADH,	showed	that	a	significant	amount	of	superoxide	production	occurred	 when	 micromolar	 concentrations	 of	 NADH	 were	 used	 (50	 µM),	while	in	a	millimolar	range,	 its	production	was	suppressed	(Grivennikova	&	Vinogradov,	2006).	In	the	light	of	the	fact	that	concentration	of	NADH	in	the	cells,	 in	 physiological	 condition,	 reaches	 few	 millimolar	 concentrations	(Yamada,	 Hara,	 Shibata,	 Osago,	 &	 Tsuchiya,	 2006),	 the	 contribution	 of	complex	 I	 to	 ROS	 generation	 should	 not	 be	 prevalent.	 Therefore,	 the	contribution	of	complex	I	as	source	of	ROS	in	physiological	conditions	remain	unclear.	Nevertheless,	 the	 use	 of	 the	 inhibitor	 of	 complex	 I,	 rotenone,	 results	 in	 an	increased	ROS	production;	 it	probably	diverts	electrons	onto	FMN,	blocking	the	reduction	of	ubiquinone	and	 leading	 to	production	of	superoxide.	Some	evidences	 attest	 how,	 by	 only	 the	 inhibition	 of	 complex	 I	 by	 rotenone,	 is	
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possible	 to	 trigger	 apoptotic	 cascade	 due	 to	 a	 burst	 in	 ROS	 production	 (Li,	2003).	 	 Most	 experimental	 data	 suggest	 that	 the	 complex	 I-produced	superoxide	 anions	 are	 released	 into	 the	 matrix	 space	 (Kudin,	 Debska-vielhaber,	&	Kunz,	2005).		Among	the	events	triggering	superoxide	production	by	mitochondria,	there	is	also	 the	 reverse	 electron	 transport	 (RET),	 even	 if	 the	 site	 of	 superoxide	production	 during	 RET	 is	 not	 known	 (Lambert	 &	 Brand,	 2004).	 RET	 is	 a	process	by	which,	when	ADP	 is	 absent	 and	 in	presence	of	 a	 significant	Δψ,	electrons	deriving	from	the	oxidation	of	succinate	move	from	CoQH2	toward	NAD+	reducing	it	to	NADH	(Y.	Liu,	Fiskum,	&	Schubert,	2002).	Addition	of	the	uncoupler	 carbonyl	 cyanid-4-(trifluoromethoxy)phenylhydrazone	 (FCCP)	and	ADP	to	respiring	mitochondria	 	can	inhibit	RET;	moreover	the	pathway	of	 electron	 transfer	 from	 succinate	 to	 NAD+	 is	 inhibited	 by	 Antimycin	 A,	meaning	that	it	involves	electron	carriers	up	to	antimycin	A-sensitive	site	in	complex	 III.	 Similarly,	 superoxide	 production	 by	 RET	 is	 inhibited	 by	rotenone,	confirming	that	during	RET,	an	electron	acceptor	plays	a	role	at	the	level	 of	 complex	 I.	 Interestingly,	 the	 rate	 of	 complex	 I-associated	 ROS	production	is	higher	during	RET	than	during	NADH-linked	forward	electron	transport	 (Lambert	 &	 Brand,	 2004;	 Murphy,	 2009;	 Zorov	 et	 al.,	 2014).	However,	in	presence	of	ATP,	when	inhibitors	of	the	quinine-binding	sites	of	complex	I	(e.g.	rotenone)	were	added	to	mitochondria,	leading	to	changes	in	the	 pH,	 this	 determined	 an	 increase	 in	 ROS	 production	 rate	 by	 forward	electron	flow	higher	than	the	rate	observed	wit	RET	at	the	same	pH	gradient,	meaning	that	also	pH	gradient	plays	a	role	(Lambert	&	Brand,	2004).	As	 underlined	 above,	 ROS	 generation	 supported	 by	 RET	 is	 strongly	dependent	 on	 membrane	 potential,	 since	 treatment	 of	 mitochondria	 with	increasing	 doses	 of	 an	 uncoupler	 or	 of	 ADP	 progressively	 decreases	 ROS	production,	 finally	 fully	 blocking	 it.	 On	 the	 other	 hand,	 mitochondria	respiring	 on	 glutamate-malate	 are	 less	 sensitive	 to	 changes	 of	 membrane	potential	(Votyakova	&	Reynolds,	2001).		Moreover,	the	effect	of	mitochondrial	potassium	channel	openers	(KCOs)	on	ROS	production	has	been	investigated.	When	potassium	channels	of	the	IMM	are	 activated,	 there	 is	 a	 huge	 driving	 force	 for	 potassium	 to	 enter	mitochondria.	Since	the	resting	mitochondrial	membrane	potential	is	around	180-200	mV	(negative	inside),	the	net	flux	of	potassium	ions	from	the	cytosol	into	 the	 mitochondrial	 matrix	 space	 would	 lead	 to	 a	 ‘mild	 uncoupling’,	therefore	 leading	 to	mitochondrial	membrane	 potential	 depolarization	 and	consecutive	stimulation	of	 the	respiration	rate.	This	condition	will	decrease	the	NADH/NAD+	ratio,	leading	to	a	diminished	concentration	of	FMNH2.	This	in	 turn	 would	 de-	 crease	 the	 production	 of	 reactive	 oxygen	 species	 by	respiratory	 chain	 complex	 I.	 The	 decrease	 of	 mitochondrial	 membrane	potential	 induced	 by	 treatment	 with	 KCOs	 would	 have	 the	 same	 effect	 on	complex	I	producing	ROS	by	forward	or	reverse	electron	transport,	reducing	the	 rate	 of	 superoxide	 production	 in	 both	 cases	 (Heinen	 et	 al.,	 2007;	Kulawiak,	Kudin,	Szewczyk,	&	Kunz,	2008).		Summarizing,	there	are	two	different	complex	I-linked	ways	to	produce	ROS:	when	the	ratio	NADH/NAD+	in	the	matrix	is	high,	leading	to	the	reduction	of	FMN	 site	 on	 complex	 I	 and	 the	 RET-associated	 superoxide	 production,	occurring	when	Δψ	is	high	and	ADP	is	low.	
	 22	
It	is	noteworthy	that	ROS	production	at	complex	I	depends	on	circumstances,	that	under	healthy	conditions	should	not	occur.	Consequently	 it	 seems	 that	complex	I	becomes	a	major	ROS	source	under	pathological	conditions	rather	than	being	under	resting	conditions	(Murphy,	2009;	Zorov	et	al.,	2014).			
2.2.3.2	Complex	III		Complex	 III	 transfers	 electrons	 from	 the	 reduced	 form	 of	 CoQ	 pool	 to	cytochrome	c.	This	processes	is	carried	out	through	the	Q	cycle.		Complex	III-linked	 superoxide	 formation	 is	 due	 to	 the	 reaction	 of	 O2	 with	 an	ubisemiquinone	 (Q-.)	 bound	 to	 the	 Q0	 site	 (Murphy,	 2009;	 Turrens	 et	 al.	1985;	 Cadenas	 et	 al,	 1977).	 However,	 under	 physiological	 conditions,	 the	probability	of	persistence	of	reactive	ubisemiquinone	at	the	Q0	site	together	with	the	probability	to	give	an	electron	to	the	molecular	oxygen	is	quite	low,	since	 its	 fast	 oxidation	 occurs	 during	 the	 Q	 cycle.	 But	 in	 presence	 of	antimycin	A,	an	inhibitor	of	the	Qi	site,	complex	III	produces	a	large	amount	of	ROS	 (Liu	et	 al.,	 2002).	This	 is	 apparently	due	 to	an	 increase	 in	 the	basal	level	of	ubisemiquinone,	 that	 in	 this	conditions	would	accumulate	at	 the	Q0	site	 (Zorov	 et	 al.,	 2014).	 Complex	 III-linked	 ROS	 production	 determines	release	superoxide	towards	the	IMS	(Kudin	et	al.,	2005).		.			
	
	
Figure	7:	Scheme	depicting	the	sites	of	ROS	production	at	level	of	complex	I	and	complex	III	in	mitochondria	and	the	mechanisms	of	dismutation	(from	Malinska	et	al.,	2010)				The	 addition	 of	 a	 Q0	 site	 inhibitor	 is	 able	 to	 block	 the	 production	 of	superoxide	(Ksenzenko,	Konstantinov,	Khomutov,	Tikhonov,	&	Ruuge,	1983).	In	particular,	addition	of	two	different	inhibitors	of	the	Q0	site,	causes	slightly	different	 effects:	 stigmatellin	 completely	 abolish	 superoxide	 production,	while	myxothiazol	causes	only	partial	reduction	and	when	added	alone,	can	
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even	 induce	 low	ROS	production.	 	 Indeed	 it	 is	clear	 that	 this	 two	 inhibitors	bind	to	different	portion	(i.e.	“proximal”	and	“distal”)	of	 the	Q0	site	and	this	could	 explain	 the	 different	 effects	 (Muller,	 Roberts,	 Bowman,	 &	 Kramer,	2003;	Starkov	&	Fiskum,	2001)	In	 an	 elegant	 work,	 Rottemberg	 and	 colleagues	 showed	 how	 complex	 III-linked	superoxide	production	strongly	depends	on	changes	of	mitochondrial	membrane	 potential.	 The	 rate	 of	 superoxide	 generation	 increased	exponentially	with	 the	hyperpolarization.	This	 suggests	 that	 the	membrane	potential	 slows	 down	 electron	 transfer	 from	 heme	 bL	 to	 heme	 bH	 thereby	promoting	 a	 more	 reduced	 state	 of	 heme	 bL	 which	 then	 can	 react	 with	molecular	 oxygen	 increasing	 superoxide	 generation	 (Rottenberg,	 Covian,	 &	Trumpower,	 2009).	 Contrarily,	 some	 other	 works	 attested	 an	 increasing	effect	 in	 complex	 III-linked	 ROS	 production	 upon	 addition	 of	 potassium	channel	openers,	able	to	determine	a	depolarization	(Malinska,	Mirandola,	&	Kunz,	2010).		Concluding,	 since	 complex	 III-linked	 ROS	 formation	 occurs	 only	 upon	 the	addition	of	a	drug	(antimycin	A)	having	no	analogues	in	human	physiology,	it	is	 reasonable	 to	 think	 that	 complex	 III	 contribution	 to	 the	 overall	 ROS	production	is	reduced	compared	with	that	given	by	complex	I	during	RET.	Many	 other	 sites	within	mitochondria	 are	 involved	 in	ROS	production	 (e.g:	aconitase,	monoaminoxidase,	NADPH-oxidase,	electron	transfer	flavoprotein,	p66shc),	 but	 they	 will	 not	 be	 taken	 into	 account	 in	 the	 context	 of	 this	dissertation	given	that	my	works	did	not	involve	research	in	those	directions.			
	
2.3	Ion	transport	within	mitochondria		
	
2.3.1	General	concepts	
	In	general,	any	transport	process	across	a	membrane	bilayer	can	be	classified	according	to	four	criteria:			
Ø The	transport	can	be	bilayer-mediated	or	be	protein-mediated	
Ø The	transport	can	be	passive	or	directly	coupled	to	metabolism	
Ø The	transport	can	involve	a	single	ion	(or	metabolite)	or	can	mediate	the	flux	of	two	or	more	species	that	are	directly	coupled	
Ø The	 transport	 can	 determine	 net	 charge	 transfer	 across	 the	membrane	or	be	electroneutral		The	 bilayer-mediated	 permeability	 can	 occur	 naturally	 (when	 ions	spontaneously	 move	 from	 one	 side	 of	 the	 membrane	 to	 the	 other,	 e.g.:	membrane	 leakage)	 or	 can	 be	 mediate	 by	 ionophores	 (see	 below).	 The	bilayer-mediated	 transport	 is	 always	 passive,	 while	 the	 protein-mediated	ones	 can	 be	 directly	 coupled	 to	 a	metabolite	 (very	 often	ATP).	 A	 transport	process	 involving	 one	 ion	 is	 called	 uniport	 (e.g.	 the	mitochondrial	 calcium	uniporter	 –MCU-	 in	 the	 IMM);	 when	 the	 transport	 process	 involves	 the	obligatory	 coupling	 of	 two	 or	more	 ions	 in	 parallel,	 this	 is	 called	 symport;	when	 the	 transport	 is	 coupled	 to	 the	 movement	 of	 another	 species	 in	 the	opposite	 direction,	 this	 is	 termed	 antiport.	 The	movement	 of	 ions	 across	 a	
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membrane	 can	 be	 electrical,	 e.g.:	 when	 the	 transport	 process	 creates	 an	electro-chemical	gradient	(electrogenic	transport)	or	when	the	movement	of	ions	 occurs	 as	 a	 response	 of	 a	 pre-existing	 potential	 (electrophoretic	transport).	Finally,	it	can	also	be	electroneutral,	when	no	net	charge	transfer	across	 the	 membrane	 occurs,	 e.g.:	 when	 a	 uniport	 transports	 un-charged	species	 or	 when	 a	 symport	 carries	 a	 cation	 and	 an	 anion	 or	 an	 antiporter	carries	two	species	of	equal	charge.		However,	membranes	are	very	 little	permeable	to	 ions,	since	 lipids	create	a	barrier	to	charged	species.	On	the	contrary,	uncharged	species	like	molecular	oxygen	and	CO2	can	cross	the	membranes,	and	polar	compounds	 like	water	can	 pass	 through	 the	 membranes	 thanks	 to	 the	 existence	 of	 acquaporines	(Lodish	et	al.,	2006).	At	the	level	of	mitochondria,	the	low	permeability	of	the	IMM	 is	 a	 necessary	 prerequisite	 for	 the	 energy	 conservation	 (see	 section	2.3.3).		As	already	mentioned,	ionophores	can	mediate	movement	of	ions	across	the	membranes.	 Ionophores	 are	 molecules	 able	 to	 delocalize	 or	 to	 shield	 the	charge	 of	 an	 ion,	 increasing	 its	 permeability	 across	 the	 membrane	 and	decreasing	 the	 energy	 activation	 necessary	 for	 this	 ion	 to	 insert	 into	 a	hydrophobic	 region.	 They	 are	 able	 to	 carry	 ions	 through	 the	 membranes	because	 they	 posses	 a	 hydrophobic	 outer	 component,	 to	 allow	 the	 passage	through	the	lipid	bilayer,	and	an	hydrophilic	interior	to	accommodate	the	ion.	They	 can	 function	 in	 two	manners:	 as	mobile	 carrier	 or	 forming	 a	 channel	within	 the	 membrane.	 In	 the	 first	 case	 they	 show	 high	 specificity	 among	different	ions,	instead	of	pore	forming	ionophores,	which	poorly	discriminate	the	different	ionic	species.		Channels	 and	 transporters	 are	 other	 actors	mediating	 ion	 transport	within	mitochondria.	A	detailed	description	of	ion	channels	will	follow.			
2.3.2	 Mitochondrial	 membrane	 potential,	 energy	 conservation	 and	
cation	distribution	in	mitochondria		
	As	underlined	above,	at	 the	 level	of	 the	 IMM	an	electrochemical	gradient	 is	established.	 The	 electrochemical	 gradient	 (Δµ)	 is	 constituted	 by	 two	components:	the	ΔΨm,	which	is	the	voltage	difference	between	the	two	sides	of	IMM,	and	the	ΔpH,	which	is	the	different	concentration	of	the	distribution	of	 the	 ions	 across	 the	 IMM.	 Under	 physiological	 conditions	 mitochondrial	membrane	potential	 is	 in	between	160-200	mv,	negative	on	the	matrix	side	(Szabo	&	Zoratti,	2014).	Since	in	the	IMM	the	passive	permeability	to	H+	(H+	leak),	ions	and	cations	is	very	 low,	 the	 pumping	 of	 protons	 by	 the	 respiratory	 chain	 complexes	 out	from	 the	 matrix	 results	 in	 the	 establishment	 of	 a	 ΔµH;	 therefore	 the	differential	 distribution	 of	 protons	 established	 by	 the	 respiratory	 chain	complex	activities	represents	the	major	component	of	the	ΔµH.		As	stated	by	the	 chemiosmotic	 theory,	 this	 proton	 gradient	 is	 utilized	 for	 the	 ATP	synthesis	via	the	ATP	synthase.	Intrinsically,	with	this	theory,	the	problem	of	the	 energy	 conservation	 arose.	 How	mitochondria	 avoid	 the	 dissipation	 of	the	hyperpolarization	created	by	the	respiratory	chain	complexes,	necessary	for	 energy	production?	And	do	mitochondria	 lack	any	 cation	 channel	or	do	they	 posses	 them?	 The	 existence	 and	 maintenance	 of	 an	 opposite	 charge-	
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distribution	 at	 the	 level	 of	 the	 IMM,	 negative	 inside,	 supposes	 that	mitochondrial	cation	distribution	is	regulated	somehow	(Azzone	et	al,	1977;	Azzone	et	al.,	1977;	Bernardi,	1999).	For	many	years,	the	low	permeability	of	the	IMM	to	monovalent	cation	has	been	explained	by	the	absence	of	channels	for	them	within	mitochondria.	The	evidences	that	the	electrophoretic	uptake	of	K+	and	Na+	in	isolated	mitochondria	was	very	slow	and	that	in	KCl	medium	they	 did	 not	 swell,	 unless	 the	 K+	 ionophore	 valinomycin	 was	 added,	supported	 this	 hypothesis.	 However,	 today	 we	 know	 that	 channels	 for	cations	do	exist	in	mitochondria	(Sorgato,	Keller,	&	Stühmer,	1987)	and	that	they	are	strictly	regulated	to	limit	energy	dissipation.		Concerning	energy	dissipation	and	 ions	homeostasis,	 let’s	consider	 the	case	of	potassium,	which	is	the	most	abundant	ion	within	the	cells,	in	addition	to	being	object	of	my	studies	reported	in	this	thesis.		According	 to	 the	 Nernst	 equation,	 the	 K+	electrochemical	 gradient	 through	the	membrane	is	defined	as:			 ΔµK=	zFΔΨ	+	RT	ln	[K+]i/[K+]o		where	ΔΨ	is	the	membrane	potential,	F	defines	the	Faraday	constant,	R	the	gas	 constant	 and	 T	 is	 the	 absolute	 temperature.	 At	 the	 level	 of	 the	mitochondrial	membrane,	we	 have	 that	 	 [K+]o	is	 extremely	 concentrated	 (≈	150	mM)	and	 the	ΔΨ,	as	described	before,	 is	around	180-200	mV,	negative	inside.	Therefore,	 there	would	be	a	huge	driving	 force	 for	potassium	influx;	moreover,	 to	reach	the	equilibrium	potential	 for	K+	ion,	[K+]i	should	be	very	high.	 Actually,	 in	 the	 steady	 state	 K+	 ions	 are	 not	 distributed	 at	electrochemical	equilibrium,	and	even	if	a	K+	ion	leak	does	exist,	some	system	are	 designated	 to	 regulate	 mitochondrial	 K+	 concentration	 through	 a	continuous	 equilibrium	 between	 K+	 infux	 and	 efflux,	 maintaining	 the	mitochondrial	 volume	 homeostasis	 and	 sustaining	 membrane	 potential	(Massari	 et	 al.,	 1972;	 Bernardi,	 1999;	 Leanza	 et	 al.,	 2015).	 In	 physiological	condition,	 K+	electrochemical	 gradient	 would	 favour	 continuous	 K+	uptake,	leading	to	matrix	swelling,	rupture	of	OMM,	release	of	cytochrome	c	and	loss	of	 mitochondrial	 functions.	 In	 order	 to	 maintain	 volume	 homeostasis,	exchange-specific	 carrier	 systems	 that	 couple	 the	 exchange	 of	 cations	with	the	 re-entry	 of	 protons	 in	 the	matrix	 do	 exist	 (Garlid,	 1988;	Brierley	 et	 al.,	1994).	 It	 is	 evident	 that	 if	 these	 exchangers	 solved	 the	 problem	 of	 volume	homeostasis	and	of	cation	distribution,	on	the	other	hand	their	activity	would	be	 responsible	 for	 the	 energy	 dissipation,	 because	 electrophoretic	 influx	 of	cations	 followed	 by	 their	 extrusion	 via	 an	 electroneutral	 exchanger	 (H+/K+	exchanger)	would	result	in	a	futile	cycle	dissipating	the	membrane	potential.	The	high	negative	electrical	membrane	potential	drives	an	electrophoretic	K+	influx,	 excess	 matrix	 K+	 is	 then	 exported	 by	 the	 electroneutral	 K+/H+	antiporter,	 i.e.	 potassium	cycle	 (Garlid	&	Paucek,	2003;	Leanza	et	 al.,	 2015;	Szabò	 et	 al,	 2012).	 In	 order	 to	 maintain	 constant	 the	 mitochondrial	membrane	 potential,	 the	 respiratory	 chain	 complexes	 must	 increase	 their	activity,	 pumping	 protons	 from	 the	 matrix	 to	 the	 intermembrane	 space:	when	 ΔΨm	 decreases,	 ΔpH	 undergoes	 an	 increase,	 in	 order	 to	 maintain	constant	ΔμH	.		
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Figure	 8:	Mitochondrial	potassium	cycle.	 Inner	mitochondrial	membrane	 is	not	permeable	to	 potassium	 ions	 (K+),	 but	 they	 can	 enter	 mitochondria	 exclusively	 through	 potassium	channels,	 even	 if	 a	 mild	 K+	 leakage	 does	 exist.	 A	 K+/H+	 exchanger	 exploits	 the	 proton	electrochemical	gradient	to	extrude	K+	ions	from	the	matrix,	 in	order	to	maintain	constant	mitochondrial	ion	homeostasis	(from	Leanza	et	al.,	2015).					Summarizing,	 the	 chemiosmotic	 hypothesis	 of	 the	 energy	 conservation	requests	 both	 the	 existence	 of	 cation-protons	 exchanger	 systems,	 which	work	at	 the	expense	of	 the	energy,	and	 the	 low	permeability	of	 the	 IMM	to	Na+	and	K+,	in	order	to	limit	the	energy	dissipation	due	to	the	activity	of	the	antiporters.		Despite	 the	 low	 permeability	 represents	 a	 prerequisite	 for	 mitochondrial	physiology	and	 is	 central	 for	mitochondrial	 functions,	 it	 is	also	 true	 that,	 in	precise	 conditions,	 mitochondria	 undergo	 a	 reversible	 permeability	transition.	
	
2.3.3	The	permeability	transition	and	the	permeability	transition	pore		Following	Ca2+	accumulation	in	the	mitochondrial	matrix,	a	sudden	increase	of	permeability	of	the	IMM	to	solutes	of	molecular	mass	up	to	1,5	kDa	occurs	in	 energized	 mitochondria	 (Bernardi,	 2013),	 defines	 as	 permeability	transition	 (PT).	 It	 is	 inhibited	 by	 cyclosporine	 A	 (CsA),	 a	 cyclic	immunosuppressant	peptide	(Broekemeier,	Dempsey,	&	Pfeiffer,	1989).	As	a	consequence	 of	 the	 PT,	 the	 mitochondrial	 electrochemical	 gradient	dissipates,	 ATP	 synthesis	 stops,	 and	 substrates	 of	 different	 nature	 are	 lost	from	 the	 mitochondrial	 matrix.	 Nowadays	 we	 know	 that	 PT	 is	 due	 to	 the	reversible	opening	in	the	inner	mitochondrial	membrane	of	the	permeability	transition	 pore	 (PTP),	 but	 the	 physiological	 role	 of	 PT	 remains	 an	outstanding	question.	If	PTP	opening	is	widespread	and	sustained,	 it	causes	cell	 death.	 Some	 features	 characterize	 the	 PTP,	 e.g.:	 a	 requirement	 for	 the	presence	 of	 Ca2+	 in	 the	 matrix,	 its	 inhibition	 induced	 by	 matrix	 pH	acidification,	the	voltage	dependence	(i.e.	the	PTP	opens	upon	depolarization	if	 the	 mitochondria	 have	 been	 loaded	 with	 Ca2+	 or	 other	 treatments)	 and	
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redox	 sensitivity	 (i.e.	 oxidative	 stress	 favours	 the	 PTP	 opening).	Moreover,	the	pore	is	non-selective	or	at	least	poorly	selective	(Szabo	&	Zoratti,	2014).	Until	 a	 few	years	 ago	 the	molecular	 composition	 of	 the	PTP	 comprised	 the	participation	 of	 OMM	 and	 IMM	 proteins,	 such	 as:	 the	 adenine	 nucleotide	translocator	 (ANT),	 the	 voltage-dependent	 anion	 channel	 (VDAC)	 of	 the	OMM,	 the	 mitochondrial	 benzodiazepine	 receptor	 (TSPO),	 creatine	 kinase	and	 cyclophilin	 D	 (CypD),	 a	 matrix	 peptidyl-prolyl	 cis,trans-isomerase	(PPIase)	 (Beutner,	 Rück,	 Riede,	 &	 Brdiczka,	 1998;	 Zamzami	 &	 Kroemer,	2001).	 The	 PTP	 inhibitor	 Cyclosporine	 A	 acts	 by	 binding	 CypD.	 All	 these	components,	when	 reconstructed	 in	membranes,	 lead	 to	 the	 formation	of	 a	large	pore	 (Beutner	 et	 al.,	 1998;	 Crompton,	Virji,	&	Ward,	 1998).	However,	since	genetic	evidences	did	not	support	this	molecular	composition,	for	many	years	the	real	molecular	nature	of	the	pore	has	been	investigated.		Some	recent	findings	pointed	out	the	possibility	that	the	ATP	synthase	might	form	the	PTP.	 Indeed,	 initially	 it	has	been	 found	the	CypD	 interact	with	 the	lateral	 stalk	of	 the	F0F1	ATP	 synthase	 (Giorgio	 et	 al.,	 2009)	 and	 later	 it	 has	been	demonstrated	that	dimers	of	ATP	synthase	reconstructed	in	planar	lipid	membranes	give	rise	to	ion	channel	activities	with	characteristics	that	mimic	those	of	the	PTP	(Giorgio	et	al.,	2013).	Moreover,	more	recently,	 it	has	been	shown	that	another	molecular	actor	actually	 is	essential	to	the	formation	of	the	 PTP:	mitochondrial	 SPG7	 (spastic	 paraplegia	 7).	 It	 interacts	with	 CypD	and	VDAC1	at	the	OMM/IMM	contact	sites	and	its	ablation	protect	cells	from	PTP-dependent	necrosis	(Shanmughapriya	et	al.,	2015).	As	outlined	above,	the	role	of	PT	in	pathophysiology	is	not	clear.	It	might	be	that	 brief	 opening	 of	 the	 PTP	 acts	 as	 a	 Ca2+	 release	 channel	 when	mitochondria	 need	 to	 get	 rid	 of	 the	 excess	 of	 Ca2+	 (Szabo	&	Zoratti,	 2014).	Moreover,	 the	 PT	 is	 a	 signal	 for	 induction	 of	 mitophagy	 (Kim,	 Rodriguez-Enriquez,	&	Lemasters,	2007).	Following	PT,	mitochondria	 recruit	Parkin,	a	key	 ubiquitin	 ligase	 whose	 loss-of-function	 mutations	 causes	 Parkinson’s	disease.	In	the	course	of	the	years,	it	has	emerged	that	PTP	principally	exerts	an	 effect	 in	 all	 degenerative,	 necrotic	 diseases.	 Among	 the	most	 important	pathologies	 in	which	 PT	 exert	 a	 clear	 role	 is	 ischemia/reperfusion.	 During	reperfusion,	 the	 conditions	 in	 the	 cell	 cytoplasm	 are	 nearly	 ideal	 for	 the	induction	of	PT.	Therefore,	ablation	of	CypD	or	treatment	with	PTP	inhibitors	produces	clear	protective	effects	(Di	Lisa	&	Bernardi,	2006).				
2.4	Ion	channels	in	mitochondria			Since	 my	 research	 has	 been	 focused,	 in	 general,	 on	 the	 modulation	 of	potassium	 ion	 homeostasis	 at	 the	 level	 of	 the	 IMM,	 I	 will	 describe	 only	potassium	 ion	 channels	 of	 the	 IMM,	 omitting	 any	 description	 of	 calcium,	sodium	and	anion	currents.	Literature	and	information	on	these	channels	 is	quite	vast,	but	the	detailed	description	of	all	of	them	lies	outside	the	scope	of	this	 dissertation.	 Therefore	 I	 will	 briefly	 give	 an	 up-to-date	 overview	regarding	 mitochondrial	 inner	 membrane	 potassium	 channels	 and,	 later,	 I	will	reserve	major	relevance	to	the	description	of	the	general	 feature	of	the	voltage	 gated	 potassium	 channels	 and	 in	 particular	 of	mitochondrial	 Kv1.3	(mtKv1.3).	
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As	pointed	out	in	the	previous	paragraphs,	the	IMM	has	long	been	considered	to	be	poorly	permeable	to	cations	and	anions,	since	the	strict	control	of	inner	mitochondrial	 membrane	 permeability	 is	 necessary	 for	 efficient	mitochondrial	 energy	 production.	 Given	 the	 high	 driving	 force	 for	 cation	influx,	channels	would	be	expected	to	be	under	tight	control.	 It	has	become	clear	 that	 various	 ion	 channels,	 along	with	 exchangers	 and	 uniporters,	 are	present	 in	 the	mitochondrial	 inner	membrane	 and	 that	 they	 are	present	 in	extremely	low	abundance	and	are	open	for	very	short	times	to	maintain	the	low	permeability	to	ions	required	to	exploit	the	proton-motive	force	for	ATP	generation.	There	 are	 many	 proteins	 mediating	 ion	 fluxes	 in	 the	 inner	 mitochondrial	membrane,	 as	 shown	 in	 figure	 9.	 Concerning	 potassium	 fluxes,	 proteins	known	to	mediate	potassium	ions	are,	so	far:	the	ATP-dependent	potassium	channels	 (KATP),	 the	big-conductance	 calcium-activated	potassium	 channel	(BKCa),	 the	 intermediate-conductance	 calcium-activated	 potassium	 channel	(IKCa),	 the	 small-conductance	 calcium-activated	 potassium	 channel	 (SKCa),	TASK-3	 two-pore	 potassium	 channel,	 pH-sensitive	 potassium	 channel	 and	finally	the	voltage-gated	mitochondrial	potassium	channel	Kv1.3.	The	above	listed	 mitochondrial	 potassium	 channels	 are	 expressed	 also	 in	 the	 plasma	membrane,	 in	 different	 types	 of	 tissues	 and	 cells,	 even	 if	 the	 mechanism	mediating	the	dual	targeting	needs	further	investigation.					
		
Figure	9:	Picture	showing	proteins	mediating	ion	fluxes	 in	the	IMM	(from	Szabò	&	Zoratti,	2014)				Even	 if	 the	 basic	 biophysical	 properties	 of	 IMM	 potassium	 channels	 have	been	 found	 to	 be	 similar	 to	 those	 of	 the	 corresponding	 plasma	membrane	isoforms,	 their	 roles	 in	 the	 physiology	 are	 often	 different,	 because	 of	 the	intrinsically	 unique	 nature	 of	 the	 mitochondrial	 organelle.	 In	 general,	mitochondrial	 potassium	 channels	 are	 supposed	 to	 play	 a	 role	 in	
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mitochondrial	 respiration,	 establishment	 of	 membrane	 potential,	mitochondrial	 matrix	 volume,	 regulation	 of	 energy	 demand	 of	 the	 cells,	cardioprotection,	protection	of	myocytes	during	“ischemic	preconditioning”,	cell	 death	 and	 generation	of	 reactive	 oxygen	 species,	 as	 already	mentioned	(Zoratti,	De	Marchi,	Gulbins,	&	Szabò,	2009).	Molecular,	 electrophysiological	 and	 pharmacological	 characterization	 has	made	possible	the	elucidation	of	their	pathophysiological	role.		Mitochondrial	 swelling	 assays	 and	 later	 direct	 patch-clamp	 studies	 of	mitoplasts	(which	are	mitochondria	stripped	of	their	outer	membranes)	have	identified	a	number	of	ion-conductive	pores	on	the	inner	membrane	(Zoratti	&	Szabó,	1994).		In	order	to	better	understand	how	this	channels	work,	I	will	summarize	the	general	 features	of	 ion	channels.	As	a	direct	consequence	of	being	an	“open	pore”,	the	activity	of	K+	channels	can	be	directly	measured	using	radioactive	isotopes	or	electrophysiological	techniques,	such	as	patch-clamp	and	planar	lipid	 bilayer.	 The	 electrophysiological	 techniques	 allow	 to	 describe	 the	particular	behaviour	that	distinguishes	one	channel	from	the	other:	for	each	one	 is	 possible,	 therefore,	 to	 evaluate	 conductance,	 selectivity,	 kinetics,	mechanism	of	activation	and	pharmacology,	as	already	mentioned.		
2.4.1	General	characteristic	of	ion	channels	
	In	general,	 ion	channels	are	 transmembrane	proteins	 forming	a	hydrophilic	pore	allowing	the	passage	of	ions	across	the	membrane.	They	permit	specific	inorganic	 ions	 to	 diffuse	 rapidly	 (more	 than	 one	 million	 ions	 per	 second)	down	 their	 electrochemical	 gradient	 across	 the	 lipid	 membrane	 without	energy	 consumption.	 Their	 omnipresence	 accounts	 for	 their	 fundamental	role	in	cellular	physiology	of	excitable	and	non-excitable	cells,	in	all	animals,	plants	and	microorganism,	included	in	their	intracellular	organelles.			Some	specific	characteristics	differentiate	ion	channels	from	each	other.	First	of	 all,	 the	 factors	 that	 can	 modulate	 their	 activity	 (i.e.	 the	 activation	mechanisms).	 At	 least	 three	 types	 of	 activation	 mechanism	 can	 be	distinguished:	 channels	 activated	 by	 changes	 of	 membrane	 potential	(voltage-gated),	channels	modulated	by	 ligands	(ligand-gated)	and	channels	that	open	following	a	tension	on	the	membrane	(stretch-activated).	There	are	different	 types	 of	 ligand	 (neurotransmitters,	 ions,	 nucleotides,	 G	 proteins)	that	can	exert	an	effect	on	the	channels	and	they	can	bind	the	channel	from	the	extra-cellular	side	or	the	intra-cellular	one,	or	from	one	of	the	two	sides	of	the	membrane	in	the	organelles.	Moreover,	ion	channels	are	subject	to	the	effect	of	a	set	of	substances	that	are	able	to	modulate	their	activity,	reducing	or	 increasing	 it.	 They	 are	 called	 inhibitors	 or	 activators.	 The	 term	pharmacology	 refers	 to	 the	activity	of	 these	molecules	on	 the	channels	and	they	are	used	to	modulate	channels	activity	or	even	to	identify	a	channel.		Another	 important	 characteristic	 that	 distinguish	 ion	 channels	 is	 their	selectivity,	given	by	the	molecular	properties	of	the	selectivity	filter	(see	next	section).	Indeed,	ion	channels	preferentially	carry	some	ionic	species.	Those	selective	 for	potassium,	sodium,	calcium	and	chloride	are	 the	most	studied.	Generally	 channels	 are	 not	 perfectly	 selective	 for	 a	 single	 ion	 and,	 on	 the	other	hand,	there	are	some	that	are	selective	for	diverse	cations	or	anions.		
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Therefore,	 the	 ion	selectivity,	 the	activation	mechanisms,	 the	pharmacology	together	 with	 the	 kinetic	 and	 the	 conductance,	 define	 the	 biophysical	fingerprint	of	an	ion	channel,	allowing	its	identification.	In	addition,	channel	activity	 is	 regulated	 by	 subcellular	 localization,	 post-translational	modification,	 protein-protein	 and	 protein-lipid	 interaction	 (Lodish	 et	 al.,	2006).		The	most	widely	 distributed	 types	 of	 ion	 channels	 are	 potassium	 channels	and	I	will	describe	only	voltage	gated	potassium	channels.		
2.4.2	Voltage	gated	potassium	channels			The	 structures	 of	 K+	channels	 share	 some	 features:	 a	 water-filled	 hole,	 the	pore,	 which	 allows	 K+	 ions	 to	 flow	 across	 the	 cell	 membrane,	 a	 selectivity	filter	and	a	gating	mechanism	that	serves	to	switch	between	open	and	close	channel	conformation.	A	prototypical	K+	channel	has	a	tetrameric	structure	in	which	 four	 identical	 subunits	 (α	 subunits,	which	 are	 distinct	 from	β	 and	 γ,	that	 are	 accessory	 subunits,	 that	 regulate	 α	 subunits),	 associate	 to	 form	 a	complex	arranged	around	 the	 central	 ion-conducting	pore;	however	animal	channels	consisting	of	hetero-tetramers	made	of	 similar	 subunits	exist.	The	canonical	 structure	 of	 a	 subunit	 consists	 of	 two	 TM	 α-helices	 (TM:	transmembrane	 helical	 segment)	 traditionally	 called	 TM1	 and	 TM2,	with	 a	short	amino-acid	segment	between	two	transmembrane	helices	that	dips	into	the	membrane	without	fully	crossing	it,	i.e.	the	P	loop.		The	primary	sequence	of	 the	P	 loop	of	K+	 channels	 has	 the	 signature	 sequence	Thr–Val–Gly–Tyr–Gly.	 	 This	 precise	 sequence	 at	 the	 level	 of	 the	 P-loop	 constitutes	 the	selectivity	filter.	This	structure	referred	to	as	TM1-P-TM2	structure	(2TM/P)	without	 additional	 peptide	 domains	 appears	 to	 be	 the	 minimum	 structure	necessary	for	the	permeation,	the	filtration	and	the	opening,	and	represent	a	universal	feature	of	potassium	channel	(Lu,	Klem,	&	Ramu,	2001).	The	basic	structure	 2TM/P	 domain	 includes	 an	 amino-terminal	 tetramerization	domain,	 which	 is	 conserved	 among	 voltage-gated	 K+	 channels,	 and	 a	carboxy-terminal,	 protein-interacting	 domain.	 The	 resolution	 of	 the	 crystal	structure	 of	 KCsA	 channel	 encoded	 by	 a	 bacterial	 gene	 cloned	 from	
Streptomyces	 lividans	was	 defined	 as	 shown	 in	 figure	 11,	 confirming	 how	trans-membrane	helices	and	a	short	loop	between	them	(which	is	the	P-loop)	are	 the	 principal	 characteristics	 of	 K+	 channels	 (Doyle,	 1998).	 Other	variations	 on	 the	 basic	 K+	 channel	 architecture	 include	 4TM/P	 or	 4TM/2P	channels	 and	 8TM/2P	 channels,	 which	 have	 two	 pores.	 Moreover,	 some	variants	 can	 be	 added	 to	 the	 basic	 structure.	 Further,	 four	 transmembrane	helices	(S1–S4)	precede	 the	2TM/P	 in	voltage-gated	K+	channels	 (6TM/1P),	including	the	positively	charged	S4	which	confers	to	some	of	these	channels	the	 capability	 to	 sense	 and	 respond	 to	 the	 change	 in	membrane	 potential,	instead	S5	and	S6	which	take	part	to	the	pore	formation	(see	figure	10)	This	last	 structure	 is	 called	 Shaker,	 a	 name	 due	 to	 a	 mutant	 of	 Drosophila	
melanogaster,	 which	 corresponds	 to	 the	 first	 cloned	 gene	 for	 K+	 channels	(Papazian	et	al.,	1987;	Tempel	et	al.,	1987;	Choe,	2002).		Voltage	 gated	 potassium	 channels	 (Kv)	 constitute	 the	 largest	 and	 most	diverse	family	of	potassium	channels,	comprising	40	of	the	90	genes	found	in	humans.	
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Figure	10:	The	four	main	classes	of	potassium	channels	(from	Choe	2002)				According	 to	 the	 International	 Union	 of	 Pharmacology	 (IUPHAR),	 they	 are	divided	into	12	families	(Kv1-12)	(Gutman	et	al.,	2005).	For	each	family,	the	nomenclature	 refers	 to	 the	 homologous	 gene	 found	 in	 Drosophila	
melanogaster.	The	list	of	voltage	gated	K+	channel	comprise	so	far:			
• Shaker	Kv1:	Kv1.1-Kv1.7	
• Shab	Kv2:	Kv2.1-Kv2.2	
• Shaw	Kv3:	Kv3.1-Kv3.4	
• Shal	Kv4:	Kv4.1-Kv4.3	
• KCNK/Kv7:	Kv7.1-Kv7.5	
• Eag-like:	Kv10-Kv12	
• Families	Kv5,	Kv6,	Kv8	and	Kv9	codify	non-conducting	subunits				
		
Figure	11:		Typical	structure	of	a	voltage	gated	potassium	channel	(from	Yellen	2002)	
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Beside	 the	number	of	distinct	 encoding	genes	 that	distinguish	Kv	 channels,	other	several	factors	add	diversity	among	them.		First	of	all	the	heteromultimerization;	each	gene	encode	for	a	subunit,	but	the	minimal	number	of	subunit	needed	to	create	a	functional	Kv	channel	is	four.	Kv	 channels	 can	 be	 formed	 by	 subunit	 of	 the	 same	 types	 (homotetramers)	but	also	by	subunit	of	different	type	in	the	same	families	(heterotetramers).	The	 heterotretamerization	 confers	 to	 the	 channels	 properties	 that	 are	different	from	those	of	any	hometratmer.		Another	 factor,	 which	 add	 diversity	 to	 the	 nature	 of	 the	 Kv	 channels,	 is	alternative	mRNA	splicing.	Many	Kv	channels	gene	contain	intronless	coding	regions	 that	undergo	alternate	 splicing	 (all	 the	members	of	 the	Kv1	 family,	except	for	Kv1.7,	and	Kv9.3).	On	the	other	hand	other	gene	families	(Kv3,	4,	6,	7,	 9,	 10	 and	 11)	 posses	 coding	 region	 made	 up	 of	 several	 exons	 that	 are	alternately	spliced,	providing	another	source	of	diversity.		Then,	 post-translational	 modification:	 many	 Kv	 channels	 can	 be	phosphorylated,	ubiquitinated	or	palmitoylated.		“Modifier”	 subunits	 can	 further	 increase	 functional	 diversity	 within	 Kv	families.	 Four	 Kv	 families	 (Kv5,	 6,	 8,	 and	 9)	 encode	 subunits	 that	 do	 not	generate	functional	channels	on	their	own,	but	for	heterotetramers	with	Kv2	subunits,	increasing	the	functional	Kv	features.			Finally,	accessory	proteins	can	associate	with	Kv	tetramers,	modifying	their	properties.	 Among	 them,	 are	 peptide	 like	 calmodulin	 or	 Kvβ	 subunits,	KCHIP1,	mink,	etc.,	(Gutman	et	al.,	2005).		This	 huge	 diversity	 is	 aimed	 at	 the	 precise	 regulation	 of	 potassium	 ion	channels,	 to	 fine-tune	 the	cell	homeostasis	and	 the	response	during	several	pathophysiological	processes.			
2.4.2.1	Selectivity	and	gating	mechanisms	of	voltage	gated	K+	channels			In	order	to	perform	their	 functions	 in	the	best	way,	Kv	channels	have	to	be	highly	selective	and	fast.	High	flow	rates	are	essential	in	many	physiological	processes	in	which	ion	channels	in	general	are	involved.	Therefore	they	have	to	 achieve	 a	 high	 throughput	 without	 using	 millions	 of	 proteins,	 while	maintaining	 high	 selectivity.	 How	 do	 they	 achieve	 rapid	 permeation	 and	selectivity?	 First	 of	 all,	 since	 ions	have	 an	 extremely	 favourable	 interaction	with	water	and	not	with	lipids	or	proteins,	the	channel	pores	are	filled	with	plenty	of	water,	to	make	the	ions	stable	and	facilitate	them	to	cross	the	lipid	membranes.	 The	 molecules	 of	 water,	 in	 which	 the	 unequal	 sharing	 of	electrons	between	the	hydrogen	atoms	and	the	oxygen	atom	gives	the	water	molecule	a	slight	negative	charge	near	its	oxygen	atom,	reorients	ion	like	K+	with	their	negatively	charged	end	towards	a	positively	charged.	Second,	the	K+	 channels	 achieve	 cations	 selectivity	 by	 electrostatic	 influence	 exploiting	the	fact	that	each	helix	possesses	a	negative	side,	therefore	the	intracellular	vestibule	of	K+	channels	has	the	negative	ends	of	four	helix	towards	the	pore	of	the	channel,	creating	a	negative	intracellular	vestibule.	Moreover,	the	filter	is	 characterized	 by	 the	 alignment	 of	 the	 carbonyl	 oxygens	 arranged	horizontally,	 belonging	 to	 the	 canonical	 amino	 acid	 sequence	Thr–Val–Gly–Tyr–Gly	located	in	the	S5-S6	linker,	for	each	of	the	4	subunits.	Pairs	of	these	quartets	 of	 oxygens	 partially	 surround	 K+	 ions	 with	 greater	 efficiency	
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compared	to	 the	eight	oxygens	of	hydration	of	 the	sphere	surrounding	 it	 in	aqueous	solution,	providing	an	energetically	 favorable	way	 for	de-solvation	of	 the	 ion.	This	also	explains	how	the	selectivity	 filter	shows	preference	 for	potassium	 and	 not	 for	 sodium	 ion,	 since	 it	 precisely	 matches	 the	configuration	of	oxygen	atoms	around	a	solvated	potassium	ion.	Finally,	the	long-known	feature	that	potassium	ions	cross	the	channel	in	single	file	gives	the	 high	 throughput	 (Shieh,	 Coghlan,	 Sullivan,	 &	 Gopalakrishnan,	 2000;	Yellen,	2002).			Another	 characteristic	 of	 Kv	 channels	 is	 the	 presence	 of	 a	 vestibule,	characterized	 by	 the	 presence	 of	 a	 set	 of	 negatively	 charged	 amino	 acids	which	 impart	 an	 overall	 negative	 charge	 to	 the	 vestibule	wall,	which	 helps	the	 transport	 of	 cations	 through	 the	 pore.	 These	 conserved	 residues	 can	interact	with	a	strategic	conserved	positive	amino	acid	present	in	the	peptide	toxins	of	some	venoms,	such	as	ChTx,	MgTx,	 IbTx,	ShK,	which	can	block	the	channel	(Rauer	et	al.,	1999).	The	 structural	 and	 architectural	 features	 of	 potassium	 channels	 are	 thus	perfectly	adapted	to	fit	their	function.	As	mentioned	 before,	 the	 pore	 of	 Kv	 channels	 open	 in	 response	 to	 voltage	changing.	The	S5-S6	transmembrane	domains	constitute	the	pore,	while	S1-S4	 the	 voltage	 sensor.	 In	 particular	 S4	 plays	 the	 major	 role	 in	 sensing	variation	 in	 the	 voltage,	 owing	 a	 positively	 amino	 acids-enriched	 sequence	(Papazian,	 Timpe,	 Jan,	 &	 Jan,	 1991;	 Perozo,	 Santacruz-Toloza,	 Stefani,	Bezanilla,	&	Papazian,	1994).	Membrane	depolarization	is	the	conformational	changes	inducing	factor,	 leading	to	channel	opening	and	flowing	of	the	ions.		The	 transmembrane	 segment	 S4	 displays	 a	 α-helix	 conformation	 with	 a	positively	charged	amino	acid	residue	(arginine	or	lysine)	every	three	amino	acid.	Also	the	S2	and	S3	segment	contributes	to	the	voltage	sensing,	because	they	stabilize	the	positively	charged	S4	segment	with	they	negatively	charged	amino	 acid	 (Papazian	 et	 al.,	 1995;	 Seoh,	 Sigg,	 Papazian,	&	Bezanilla,	 1996).	During	 depolarization,	 this	 stability	 decreases	 and	 this	 accounts	 for	 the	conformational	changing	occurring	 in	response	to	voltage	changing;	 indeed,	during	depolarization	S4	is	not	more	stabilized	by	S2-S3,	and	moving	into	the	lipid	membrane	it	drags	S5-S6,	via	the	S4-S5	linker,	opening	the	pore	(Choe	et	al.,	2002)			However,	 during	 sustained	 depolarization,	 Kv	 channels	 can	 undergo	inactivation,	 i.e.	 a	 closed,	 non-conducting	 state.	 Three	 types	 of	 inactivation	exist,	i.e	N-,	P-	and	C-type.	The	names	derive	from	the	distinct	domain	of	the	channel	 taking	 part	 to	 the	 process.	 	 For	 example,	 during	 the	 N-type	inactivation	(also	known	as	“ball	and	chain”	inactivation),	the	residues	of	the	N-teriminal	of	the	channel	move	into	the	channel	vestibule	to	block	the	flow	of	 ions,	occluding	 the	pore	(Hoshi	et	al.,	1990;	 Isacoff	et	al.,	1991)	This	 is	a	fast	 process,	 in	 contrast	 to	 the	 C-	 and	 P-type	 inactivation,	 in	 which	 are	necessary	specific	rearrangements	of	some	residues	in	the	pore.			
2.4.2.2	Kv1.3			The	voltage	gated	potassium	channel	Kv1.3	is	encoded	by	the	intronless	gene	KCNA3,	 located	on	 chromosome	1,	p21-p13.3	and	 its	product	 is	575	amino	acids	long	protein		(Folander	K.	et	al.,	1994).		
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The	PM-located	Kv1.3	 channel	displays	an	activation	 threshold	between	50	mV	and	60	mV,	a	single-channel	conductance	of	24	pS	in	T	lymphocytes	and,	like	 the	 other	 voltage	 gated	 potassium	 channels,	 is	 activated	 by	depolarization	(Szabo	&	Zoratti,	2014).		Interestingly,	 Kv1.3	 can	 undergo	 heterotetramerization	 with	 other	 Shaker-related	members	(Kv1.x).	For	example,	in	the	human	central	nervous	system,	it	 has	 been	 shown	 that	 in	 grey	 matter	 Kv1.3	 can	 form	 functional	heterotetramers	with	Kv1.1,	Kv1.2	and	Kv1.4,	 contrarily	 to	what	happen	 in	white	matter	or	spinal	cord	where	Kv1.3	is	not	found,	demonstrating	regional	variation	of	its	expression	(Coleman,	Newcombe,	Pryke,	&	Dolly,	1999).	Kv1.3	is	also	found	assembled	with	Kv1.6	monomers	in	some	other	cases	(Koch	et	al.,	1997;	Koschak	et	al.,	1998).				Kv1.3	is	the	main	potassium	channel	in	T-lymphocytes	were	its	function	was	first	discovered	(Chandy	et	al.,	2004),	but	it	is	expressed	also	in	other	tissues,	e.g.	 kidney	 (Yao,	 Chang,	 Boulpaep,	 Segal,	 &	 Desir,	 1996),	 central	 nervous	system	(Mourre	et	al.,	1999),	in	epithelia		(Grunnet,	Rasmussen,	Hay-Schmidt,	&	 Klaerke,	 2003)	 and	 in	 brown	 and	 white	 fat	 (Xu	 et	 al.,	 2003).	 In	 T	lymphocytes,	 during	 development	 and	 during	 activation	 of	mature	 cells	 by	mitogens,	 the	surface	density	of	K+	channels	 is	precisely	 regulated.	When	T	cells	are	immature	(thymocytes),	they	express	hundreds	of	Kv1.3	per	cell.	As	the	 developmental	 lineage	 diverges,	 Kv1.3	 are	 downregulated.	 During	activation,	 the	 abundance	 of	 Kv1.3	 increases	 once	 again.	 This	 is	 well	documented	 in	 murine	 T	 cells.	 In	 B-lymphocytes,	 stimulation	 through	 the	antigen	receptor	 increases	expression	of	Kv1.3	channels	 (George	Chandy	et	al.,	 2004).	 Moreover,	 Kv1.3	 has	 been	 implicated	 in	 the	 regulation	 of	 cell	proliferation;	for	example,	in	T-cells,	antigen	recognition	leads	to	a	molecular	cascade	which	involves	the	activation	of	tyrosine	kinases	and	phospholipase	C,	 resulting	 in	 the	 generation	 of	 inositol(1,4,5)-triphosphate	 and	diacylglycerol,	which	 induce	 the	 release	of	 calcium	 from	 the	 internal	 stores	and	 activation	 of	 protein	 kinase	 C	 (PKC).	 Depletion	 of	 internal	 Ca2+	stores	causes	 voltage-independent	 Ca2+	 release-activated	 Ca2+	 (CRAC)	 channels	 to	open,	 determining	 calcium	 influx.	 	 Coordinated	 activity	 of	 Ca2+	 and	 PKC-dependent	signalling	pathways	culminates	in	cell	proliferation	(Chandy	et	al.,	2009).	In	this	contest,	Kv1.3	regulates	Ca2+	signalling.	In	particular,	Ca2+	influx	mediated	by	CRAC	channels	 is	reduced	following	membrane	depolarization.	The	driving	 force	 for	Ca2+	entry	 is	restored	by	membrane	hyperpolarization	brought	 about	 by	 the	 opening	 of	 Kv1.3	 potassium	 channels	 in	 the	 plasma	membrane	in	response	to	membrane	depolarization.	Accordingly,	 inhibitors	of	Kv1.3	potently	suppress	effector	memory	T	cell	proliferation,	making	these	blockers	 a	 promising	 tool	 for	 the	 therapy	 of	 autoimmune	diseases,	 such	 as	multiple	sclerosis	(Beeton	et	al.,	2001).	In	addition,	Kv1.3	together	with	other	types	 of	 potassium	 channel	 participate	 to	 neurotransmitter	 release	 at	 the	presynaptic	nerve	endings	in	different	neuronal	cells	(Shoudai	et	al.,	2007).		Furthermore,	Kv1.3	channels	are	involved	in	volume	regulatory	mechanisms	during	 apoptosis;	 following	 the	 induction	 of	 apoptosis	 by	 triggering	 of	 the	CD95	receptor,	activation	of	the	cell	volume	regulatory	anion	channel	ORCC	occurs,	 but	 on	 the	 other	 hand	 this	 event	 is	 paralleled	 by	 inhibition	 of	potassium	channel	Kvl.3,	which	exert	a	control	on	cell	volume	regulation	as	well.	 This	 latter	 event	 leads	 to	 shrinkage	 of	 the	 cell,	 which	 is	 one	 of	 the	
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principal	hallmarks	of	apoptosis	(Lang	et	al.,	2004).	A	 central	 role	 of	 Kv1.3	 in	 cell	 death	was	 also	 highlighted	 by	 other	 studies.	Cells	 genetically	 deficient	 for	 Kv1.3	 expression	 did	 not	 undergo	 cell	 death	when	 stimulated	 with	 cytostatic	 drugs	 like	 actinomycin	 D.	 Transfection	 of	these	 cells	with	 an	 expression	 vector	 for	Kv1.3	 rendered	 them	 sensitive	 to	actinomycin	 D	 effects,	 and	 apoptotic	 hallmarks	 like	 DNA	 fragmentation,	release	of	cytochrome	C	and	loss	of	mitochondrial	membrane	potential	(Δψm)	were	observed	(Bock,	Szabó,	Jekle,	&	Gulbins,	2002).	In	light	of	the	fact	that	the	 lack	 of	 Kv1.3	 determines	 resistance	 to	 apoptosis	 induced	 by	 cytostatic	drugs	 and	 mitochondria-related	 apoptotic	 events	 are	 impaired,	 the	subcellular	 localization	of	Kv1.3	was	investigated.	 Interestingly,	 functionally	active	 Kv	 channels	 have	 been	 identified	 in	 the	 IMM	 of	 T	 lymphocytes	(mtKv1.3)	(Szabò	et	al.,	2005).	First,	its	expression	at	the	mitochondrial	level	was	 detected	 through	 immunogold	 electron	microscopy	 on	 isolated	 human	blood	lymphocytes.	Activity	was	observed	with	patch	clamp	experiments	on	mitochondria	 from	 human	 Jurkat	 leukemic	 T	 cells.	 To	 unambiguously	identify	mitoKv1.3,	patch	clamp	experiments	were	performed	on	mitoplasts	(mitochondria	 deprived	 of	 the	 OMM)	 isolated	 from	 cells	 lacking	 Kv1.3	expression	 and	 in	 parallel	 on	 the	 same	 cells	 stably	 transfected	 with	 an	expression	 vector	 for	 Kv1.3.	 This	 allowed	 identifying	 precisely	 mitoKv1.3	current.	Moreover	mitoKv1.3	current	colocalized	with	PTP	current.	The	level	of	expression	in	lymphocytes	was	analyzed	also	by	Western	blot.		Subsequently,	 localization	 of	 Kv1.3	 in	 the	 IMM	 has	 been	 demonstrated	 in	other	cell	 types	beside	 lymphocytes	by	combining	multiple	 techniques	such	as	patch	clamp,	Western	blot,	 in	which	 isolated	purified	mitochondria	were	used	 with	 attention	 to	 different	 markers	 to	 assess	 contamination	 by	 ER	and/or	PM,	and	immunogold	transmission	electron	microscopy.		For	example	in	macrophages	(Vicente	et	al.,	2006),	 in	postsynaptic	medial	nucleus	of	the	trapezoid	 body	 (MNTB)	 neurons	 (Gazula,	 Strumbos,	 &	 Mei,	 2010),	hippocampal	 neurons	 (Bednarczyk	 et	 al.,	 2010)	 and	 also	 in	 caner	 cells	 like	PC-3	 prostate	 cancer,	MCF-7	 breast	 adenocarcinoma,	 SAOS-2	 osteosarcoma	and	 B16F10	 melanoma	 cells	 (Szabo	 &	 Zoratti,	 2014),	 for	 all	 the	 cases	revealed	in	genetically	non-manipulated	cell	lines.	The	 channel	 is	 active	 at	 the	 resting	 negative	 mitochondrial	 potential,	contrary	to	the	plasma	membrane	Kv1.3	that	do	not	mediate	abundant	flux	at	the	 resting	 potential.	 The	 functional	 expression	 of	 mtKv1.3	 at	 the	mitochondrial	 resting	potential	 (-180,	 -200mV)	 is	 indicated	by	 the	 fact	 that	addition	 of	 specific	 Kv1.3	 inhibitors	 to	 isolated	 mitochondria	 lead	 to	hyperpolarization	(Szabò	et	al.,	2005).	In	fact,	at	resting	condition	potassium	channel	of	the	IMM	are	expected	to	drive	an	electrophoretic	inward	current	since	 the	 entry	 of	 cation	 is	 thermodynamically	 favoured	 according	 to	 the	electrochemical	 gradient	 established	 by	 the	 respiratory	 chin	 activity.	 As	stressed	 in	 the	 previous	 paragraphs,	 entry	 of	 potassium	 must	 be	compensated,	 otherwise	 this	 would	 lead	 to	 energy	 dissipation,	 volume	changes	 and	 mitochondria	 depolarization;	 this	 job	 is	 carried	 out	 by	 the	activity	of	 the	electroneutral	K+/H+	antiporter	 and	by	 the	 respiratory	 chain	complexes.		
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If	mtKv1.3	mediates	the	influx	of	K+	across	the	IMM,	plasma	membrane	Kv1.3	mediates	the	efflux	of	potassium	ions	from	the	cytoplasm,	where	K+	ions	are	more	concentrated	towards	the	extracellular	space,	where	K+	ions	is	lower.		The	mitochondria-located	channel	is	a	product	of	the	Kv1.3	gene,	since	stable	transfection	 of	 CTLL-2	 lymphocytes	 (lacking	 Kv1.3	 expression)	 with	 the	Kv1.3	 coding	 gene	 gave	 rise	 to	 active	 channel	 both	 in	 PM	 and	 in	 IMM,	suggesting	that	the	same	gene	generates	the	different	located	Kv1.3	channels.	However,	 much	 less	 is	 known	 about	 the	 dual	 targeting	 of	 this	 channel.		Alternative	splicing	or,	more	likely,	posttranslational	modifications	could	be	possibilities.			
2.4.2.2.1	Pharmacological	features	of	Kv1.3		As	 mentioned	 above	 PM-located	 Kv1.3	 opens	 in	 response	 to	 membrane	depolarization	 at	 a	 voltage	 around	 50-60	 mV,	 instead	 of	 mtKv1.3,	 which	results	 active	 at	 the	 extremely	 negative	 mitochondrial	 resting	 membrane	potential.		Kv1.3	 electrophysiological	 characteristics	have	been	 investigated	mainly	by	exploiting	 the	 pharmacological	 features	 of	 kv1.3	 channels.	 Kv1.3	pharmacology	includes	organic	compounds	or	peptide	inhibitors.	Among	the	non-peptide	 inhibitors	 are	 general	 potassium	 channel	 blockers	 such	 as	quinidine,	tetraethylammonium	(TEA),	4-aminopyridine	(4-AP)	(Grissmer	et	al.,	 1994),	 benzamide	 (Miao	 et	 al.,	 2003);	 but	 peptide	 inhibitors	 such	 as	natural	venoms	appear	as	 the	most	effective	 inhibitors	and	have	been	used	for	 the	 electrophysiological	 characterization	 of	 this	 channel	 (Chandy	 et	 al.,	2004).	 For	 example	 Margatoxin	 (MgTx)	 from	 the	 scorpion	 Centuroides	
margaritatus,	exhibits	 an	 EC50	 in	 the	 picomolar	 range;	 Charybdotoxin	 from	
Leiurius	 quinquestriatus	 (Quintero-Hernández,	 Jiménez-Vargas,	 Gurrola,	Valdivia,	 &	 Possani,	 2013)	 is	 also	 a	 scorpion	 venom	 effectively	 blocking	Kv1.3.	 ShK,	 from	 the	 anemone	 Stichodactyla	 helianthus,	 block	 Kv1.3	 at	nanomolar	 concentration	 although	 some	 effect	 on	 Kv1.1,	 Kv1.4	 and	 Kv1.6	have	 been	 described.	 The	 structure	 of	 the	 sea	 anemone	 toxin	 Shk	 is	 well	characterized;	 it	 is	 a	 35	 amino-acid	peptide.	 It	 has	been	demonstrated	 that	Shk	 interacts	 with	 Kv1.3	 by	 using	 positive	 residues	 (i.e.	 His19,	 Ser20,	 Lys22	Tyr23)	 interacting	with	negative-charged	residues	(i.e.	Asp386)	 located	at	the	level	of	the	channel	pore	vestibule.	The	substitution	of	the	critical	Shk-Lys22	with	 neutral	 residues	 substantially	 reduce	 the	 affinity	 of	 the	 toxin	 for	 the	channel,	 indicating	 that	 other	 residues	 are	 not	 binding	 efficiently	 to	 the	channel	 pore	 vestibule	 (Rauer,	 Pennington,	 Cahalan,	 &	 Chandy,	 1999).	 It	binds	 to	 the	 channel	 with	 high	 affinity	 (Kd	=	 11pM)	 and	 shows	 1000-fold	higher	selectivity	with	respect	to	other	Kv	and	IK	channels.	All	 the	 inhibitors	 described	 above	 are	 non	 permeable	 to	 the	 plasma	membrane.	However,	a	class	of	permeable	Kv1.3	blockers	also	exists.	These	types	of	Kv1.3	 inhibitors	are	able	 to	enter	 the	cytoplasm	across	 the	plasma	membrane	and	to	produce	effects	on	mitochondrial	K+	channels.	This	class	of	Kv1.3	 inhibitors	 includes	 Psora-4,	 PAP-1	 and	 Clofazimine.	 Psora-4,	 a	 small	molecule	Kv1.3	blocker,	is	the	most	potent	inhibitor	(Chandy	et	al.,	2004).	It	belongs	 to	 the	 family	of	natural	products,	 called	psoralens.	Psoralens	occur	naturally	 in	 the	 seeds	 of	 Psoralea	 corylifolia.	 Psoralens	 are	 photosensitive	
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molecules	 used	 in	 the	 treatment	 of	 some	 skin	 disease	 like	 psoriasis.	 It	 has	been	 shown	 that	 Psora-4	 inhibits	 Kv1.3	 (IC50	 =	 3	 nM)	 (Vennekamp	 et	 al.,	2004),	but	 it	 inhibits	 to	 the	same	extent	also	Kv1.5	 .	For	 these	 reasons,	 the	Wulff’s	 group	 synthesized	 a	 derived	 inhibitor	 with	 the	 same	 potency	 but	more	 selective	 called	 PAP-1	 (IC50	 =	 2	 nM)	 (Schmitz	 &	 Sankaranarayanan,	2005).	 Patch	 clamp	 experiments,	 however,	 demonstrated	 that	 both	compounds,	used	at	 significantly	higher	 concentration	determine	 inhibition	of	other	Kv	family	members	as	well.	Clofazimine	 (IC50=	 300nM),	 a	 fat-soluble	 riminophenazine	 compound,	 is	currently	used	in	the	treatment	of	multi-bacillary	leprosy.	Moreover,	 its	use	in	 several	 infectious	 or	 non-infectious	 diseases,	 like	 antibiotic	 resistant	tuberculosis,	 is	 under	 investigation.	 Clofazimine	 appears	 to	 preferentially	bind	 to	 mycobacterial	 DNA,	 leading	 to	 disruption	 of	 the	 cell	 cycle	 and	eventually	 kills	 the	 bacterium.	 It	 may	 also	 bind	 to	 bacterial	 potassium	transporters,	thereby	inhibiting	their	function	(Ren	et	al.,	2008).		In	 the	 IMM,	 the	 roles	 played	 by	 mtKv1.3	 are	 multiple,	 ranging	 from	regulation	 of	 mitochondrial	 membrane	 potential,	 volume,	 ROS	 production.	Interestingly,	a	crucial	role	for	this	channel	in	apoptosis	became	evident,	first	in	lymphocytes	and	later	in	other	systems	as	well.			
2.5	Apoptosis		Apoptosis,	 also	 known	 as	 programmed	 cell	 death,	 is	 a	 complex	 and	evolutionarily	 conserved	 physiological	 process.	 Programmed	 cell	 death	allows	the	organism	to	tightly	control	cell	number	and	tissue	size,	therefore	to	 maintain	 tissue	 homeostasis	 and	 to	 remove	 cells	 that	 are	 in	 excess	 or	potentially	dangerous.	It	also	plays	an	important	role	in	the	development	and	organogenesis.	 To	 this	 end,	 cells	 use	 a	 dedicated	 molecular	 program	 to	regulate	the	destruction	of	the	cell.		Mitochondria	 play	 an	 important	 role	 during	 apoptosis.	 In	 most	 pathways	leading	to	apoptosis,	permeability	transition	of	the	IMM	and	the	consequence	rapture	of	the	OMM	are	critical.		I	will	describe	 the	general	aspects	of	 this	process,	 in	order	 to	contextualize	the	role	of	mitochondria			
2.5.1	Pathways	leading	to	apoptosis	and	molecular	players		Programmed	 cell	 death	 was	 defined	 apoptosis	 and	 described	 for	 the	 first	time	 in	 the	early	 ‘70s	(Kerr,	Wyllie,	&	Currie,	1972).	Nowadays	we	know	in	details	the	complex		“death	machinery”	responsible	for	the	execution	of	this	“suicide”,	acting	in	a	coordinated	manner	to	regulate	cell	death.		There	are	two	main	pathways	to	induce	apoptosis:	the	extrinsic	pathway	and	the	intrinsic	one.	Both	pathways	converge	on	mitochondria.	The	 extrinsic	 pathway,	 or	 death	 receptor	 pathway,	 is	 triggered	 by	transmembrane	 receptors-mediated	 interactions.	 The	 death	 receptors	 (DR)	are	 member	 of	 the	 tumour	 necrosis	 factors	 (TNF)	 receptors	 gene	superfamily.	A	cysteine-rich	extracellular	domain	and	a	cytoplasmic	domain	(the	“death	domain”)	characterize	these	receptors	(Ashkenazi,	1998).	One	of	the	 best-characterized	 ligands/receptors	 mechanisms	 is	 that	 involving	
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FasL/FasR.	 Binding	 of	 extrinsic	 ligands,	 such	 as	 CD95	 ligand	 (also	 called	FasL)	to	CD95	receptor	(FasR),	induces	receptor	clustering	and	formation	of	death	 inducing	 signalling	 complex	 (DISC).	 This	 complex	 recruits,	 via	 the	adaptor	 molecule	 FADD	 (Fas-associated	 death	 domain	 protein)	 multiple	procaspase-8	 molecules,	 resulting	 in	 caspase-8	 activation	 (Wajant,	 2002).	Following,	other	intracellular	signals	ultimately	lead	to	the	destruction	of	the	cell.	Other	well-characterized	death	receptor	ligands	are	TRAIL	and	TNF-α.		The	 intrinsic	 pathway,	 or	 mitochondrial	 pathway	 is	 extensively	 used	 in	response	 to	 extracellular	 signals	 and	 internal	 insults.	 These	 stimuli	 that	initiate	 the	 intrinsic	 apoptotic	 pathway	 can	 be	 positive	 or	 negative.	 The	absence	 of	 certain	 growth	 factors,	 hormones	 and	 cytokines	 are	 considered	negative	stimuli	 that	 lead	to	apoptosis.	On	the	other	hand,	radiation,	 toxins,	hypoxia,	 hyperthermia,	 viral	 infections,	 free	 radicals	 and	 many	 others	 are	stimuli	 that	act	 in	a	positive	 fashion,	 leading	to	 induction	apoptosis	as	well.	All	 of	 these	 stimuli	 affect	 mitochondria,	 causing	 changes	 in	 the	 inner	mitochondrial	 membrane	 that	 results	 in	 an	 opening	 of	 the	 mitochondrial	permeability	transition	pore	(PTP),	loss	of	the	mitochondrial	transmembrane	potential	and	release	of	pro-apoptotic	factors	that	reside	in	the	mitochondrial	intermembrane	space.	Pro-	and	anti-apoptotic	Bcl-2	 family	proteins	control	the	release	of	these	factors	from	mitochondria	(Saelens	et	al.,	2004).		In	 some	 cases,	 the	 extrinsic	 and	 the	 intrinsic	 pathway	 can	 intersect,	 at	 the	level	 of	 the	 caspase-8	 mediated	 cleavage	 of	 the	 pro-apoptotic	 BH3-only	protein	 Bid,	 member	 of	 the	 Bcl-2	 family.	 After	 cleavage	 of	 the	 C-terminal	portion,	 the	 truncated	 form	 of	 Bid	 (t-Bid)	 moves	 to	 mitochondria	 and	determines	the	inhibition	of	the	anti-apoptotic	protein	Bcl-2,	determining	the	de-repression	of	pro-apoptotic	proteins	as	Bax	and	Bak.	These	events	lead	to	the	 permeabilization	 of	 the	 outer	mitochondrial	membrane	 (OMM),	 via	 the	opening	of	 the	permeability	 transition	pore	(PTP)	and/or	 the	pores	 formed	by	the	oligomerization	of	pro-apoptotic	proteins	(Wei	et	al.,	2000).	Once	the	OMM	 has	 been	 permeabilized,	 soluble	 protein	 diffuse	 from	 the	 inter-membrane	space	to	the	cytosol	where	they	promote	activation	of	the	effector	caspases	caspase-3,	-6,	-7	and	the	capsase-9,	by	the	formation	of	apoptosome	(Cain,	Brown,	Langlais,	&	Cohen,	1999;	Hengartner,	1997).	Cytochrome	c	 is	released	 from	 mitochondria,	 as	 well	 as	 the	 protein	 Smac/Diablo	 which	antagonize	 the	 action	 of	 the	 inhibitor	 of	 apoptosis	 proteins	 (IAPs).	 The	release	of	cytochrome	c	is	considered	the	non-return	point	of	apoptosis.		
2.5.1.1	The	Bcl-2	family	
	The	 Bcl-2	 family	 proteins	 (B-cell	 lymphoma-2,	 that	 are	 B-cells	 follicular	lymphoma	where	 the	 Bcl-2	 gene	was	 discovered)	 have	 either	 pro-	 or	 anti-apoptotic	activity.	These	proteins	are	important	not	only	in	the	regulation	of	apoptosis,	 but	 also	 in	 tumorigenesis	 and	 in	 the	 cellular	 responses	 to	 anti-cancer	therapy.	Bcl-2	 family	 members	 have	 been	 grouped	 in	 three	 classes:	 pro-survival	family	 members	 (e.g.	 Bcl-2,	 Bcl-xL),	 the	 pro-apoptotic	 Bax/Bak	 family	members	and	pro-apoptotic	BH3-only	proteins	(e.g.	Bim,	Bid,	PUMA,	NOXA).	The	 role	 of	 the	 anti-apoptotic	members	 of	 this	 family	 is	 to	 inhibit	 the	 pro-apoptotic	 Bax/Bak	 family	 members.	 The	 BH3-only	 proteins,	 through	 their	
	 39	
BH3	 conserved	 domain,	 bind	 and	 regulate	 the	 anti-apoptotic	 proteins,	inhibiting	their	action	and	promoting	apoptosis	(Youle	&	Strasser,	2008).		The	multi	BH	(Bcl-2	homology)	domain	Bcl-2	family	members	and	the	BH3-only	 proteins	 have	 conserved	 region	 of	 sequence	 homology.	 All	 members	share	at	least	one	BH	domain.	Anti-apoptotic	proteins	like	Bcl-2,	Bcl-xL,	Mcl-1,	possess	 four	BH	domains.	Members	of	 the	Bax	pro-apoptotic	 family	have	sequences	 that	are	 similar	 to	 those	 in	Bcl-2,	 especially	BH1,	BH2,	BH3.	The	other	pro-apoptotic	proteins	share	only	the	BH3	domain.	The	pro-survival	family	members,	in	addition	to	their	four	BH	domains,	also	have	an	hydrophobic	carboxy-terminal	domain,	which	helps	to	target	them	to	the	 cytoplasmic	 face	 of	 three	 intracellular	 membranes:	 the	 outer	mitochondrial	 membrane,	 the	 endoplasmic	 reticulum	 and	 the	 nuclear	envelope.	Bcl-2	is	an	integral	membrane	protein	even	in	healthy	cells,	while	other	members	 like	Bcl-xL	and	Bcl-w	become	associated	 to	 the	membranes	only	 after	 a	 cytotoxic	 signal.	 The	 three	 dimensional	 structure	 is	 well	conserved	among	the	members	of	 this	group	of	proteins.	 It	 is	characterized	by	 a	 globular	 bundle	 of	 five	 amphipathic	 α-helices	 located	 around	 two	hydrophobic	 α-helices.	 Residues	 from	 BH1	 to	 BH3	 create	 a	 hydrophobic	groove,	 which	 can	 bind	 the	 BH3	 α-helix	 of	 a	 BH3-only	 relative.	 Every	nucleated	cell	requires	at	least	one	Bcl-2	homologue	because	these	proteins	are	 “guardians”	 and	 are	 important	 in	 the	 regulation	 of	 tissue	 homeostasis	(Cory	&	Adams,	2002).	Bax	 and	 Bak	 are	 the	 most	 abundant	 and	 widely	 distributed	 pro-apoptotic	proteins.	The	absence	of	both	these	proteins	dramatically	impairs	apoptosis.	Bax	 is	 a	 cytosolic	 monomer	 in	 healthy	 cells,	 but	 its	 localization	 and	conformation	 changes	 during	 apoptosis	 and	 it	 integrates	 into	 the	 outer	mitochondrial	 membrane	 and	 it	 oligomerizes	 (Annis	 et	 al.,	 2005).	 On	 the	contrary,	Bak	is	located	in	the	outer	mitochondria	membrane	even	in	healthy	cells,	but	apoptotic	 stimuli	determine	a	 conformational	 change	also	 for	 this	protein	and	 the	 formation	of	aggregates.	Bax	and	Bak	oligomers	are	widely	believed	 to	provoke	or	 contribute	 to	 the	permeabilization	of	 the	OMM.	The	three-dimensional	 structure	 of	 Bax	 resembles	 that	 of	 its	 anti-apoptotic	relatives.		The	BH3	only	proteins	are	subdivided	 in	 two	subgroups,	according	 to	 their	mechanism	of	action.	There	are	the	“activators”	(i.e.	Bid,	Bim,	Puma),	which	directly	 engage	 Bax	 or	 Bak.	 The	 other	 subset	 of	 proteins	 is	 called	 the	“sensitizers”	 (i.e.	 Bad	 and	 Noxa),	 which	 act	 only	 by	 displacing	 the	 pro-survival	 proteins,	 allowing	 to	 Bak	 and	 Bax	 to	 act.	 Thus,	 the	 apoptosis	 is	triggered	when	BH3-only	proteins	engage	the	multiple	pro-survival	relatives,	which	normally	 inhibit	Bax	and	Bak.	Hence,	 the	presence	of	Bax	and	Bak	 is	however	essential	(Willis	et	al.,	2007).	The	 precise	 way	 in	 which	 the	 anti-apoptotic	 Bcl-2	 members	 prevent	 cell	death	is	still	debated.	The	widespread	view	is	that	the	only	function	of	Bcl-2	protein	 is	 to	guard	mitochondrial	 integrity,	keeping	enclosed,	 in	 this	way,	a	number	of	factors	involved	in	the	induction	of	apoptosis.	Despite	this	view,	a	central	role	for	mitochondria	destruction	is	difficult	to	reconcile	with	the	lack	of	involvement	of	cytochrome	C	in	cell	death	in	other	model	organisms	like	C.	
elegans	and	Drosophila	(Cory	&	Adams,	2002).			
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Figure	 12.	 Bcl-2	 family	 proteins	 regulate	 caspases	 activation	 both	 blocking	 or	 activating	their	functions	(	from	Cory	and	Adams,	2002).					At	 the	 molecular	 level,	 Bcl-2	 pro	 survival	 protein,	 acting	 at	 the	mitochondrion,	 the	 endoplasmic	 reticulum	 and	 nuclear	membrane,	 control	the	 activation	 of	 several	 upstream	 initiator	 caspases,	 perhaps	 by	sequestering	 their	 activators.	 Then,	 initiator	 caspases	 process	 proteins,	 for	example	 Bid,	 those	 activate	 Bax	 and	 Bak.	 Bax	 and	 Bak	 form	 oligomers	produce	 damage	 to	 the	 organelles	 and	 this	 event	 amplifies	 the	 proteolytic	cascade.	 Furthermore,	 Bcl-2	 might	 control	 apoptosis	 from	 the	 ER.	 The	process	is	shown	in	Figure	12.	Alteration	 at	 the	 level	 of	 the	 Bcl-2	 family	 repertoire	 of	 a	 cell	 has	 a	determining	 role	 in	 tumorigenesis.	 Impaired	 apoptosis	 is	 one	 of	 the	 main	characteristics	 in	 cancer	 development.	 In	 this	 scenario,	 all	 the	 Bcl-2	 pro-survival	family	members	are	likely	to	be	oncogenes.	By	contrast,	members	of	both	 pro-apoptotic	 subfamilies	 are	 tumor	 suppressors.	 Both	 control	 of	 cell	death	 and	 cell	 proliferation	 are	 important	 during	 cell	 cycle:	 in	 fact,	cooperation	 between	mutations	 those	 enforce	 proliferation	 and	 those	 that	inhibit	apoptosis	has	been	observed	in	different	type	of	cancers.		
2.5.1.2	Caspases		Caspases,	a	 large	protein	 family,	are	a	set	of	cysteine	proteases	activated	 in	apoptotic	 cells,	 which	 determine	 most	 of	 the	 morphological	 changes	observed	during	apoptosis.	Caspases	 are	 subdivided	 in	 two	 groups,	 according	 to	 their	 action:	 initiator	caspases	(2,	8,	9,	10)	and	effector	caspases	(3,	6,	7)	(Alnemri	et	al.,	1996).	
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All	 known	 caspases	 possess	 an	 active-site	 cysteine	 and	 cleave	 substrate	specifically	 after	 an	 aspartic	 acid	 residues.	 The	 substrate	 specificity	 of	caspases	 is	determined	by	the	four	residues	amino-terminal	to	the	cleavage	site.	 Therefore,	 caspases	 cleave	 a	 restricted	 set	 of	 target	 proteins	(Thornberry	et	al.,	1997).	Proteolytic	cleavage	by	caspases	not	always	lead	to	protein	destruction	and,	hence,	 inactivation.	 The	 different	 results	 depend	 on	 the	 nature	 of	 the	substrate.	 The	 simplest	 outcome	 is	 the	 loss	 of	 biological	 activity;	 in	 other	case,	 cleavage	by	 caspases	 can	 result	 in	 gain	of	biological	 activity;	 again,	 in	other	 cases,	 cleavage	 of	 inhibitory	 domains	 lead	 to	 increased	 biological	activity.	Caspases	 are	 synthesized	 as	 pro-enzymes,	 or	 zymogens.	 These	 inert	 pro-enzymes	are	constituted	by	an	N-terminal	pro-domain	and	by	p10	and	p20	domains.	Therefore,	caspases	have	to	be	activated	by	a	proteolytic	cleavage,	which	 generally	 occurs	 between	 the	 p10	 and	 p20	 domains	 or	 between	 the	pro-domain	 and	 the	 p20.	 These	 cleavage	 sites	 occur	 at	 Asp-X	 domain,	suggesting	the	possibility	of	an	autocatalytic	activation	(Hengartner,	2000).	Caspase-8	 is	 the	 key	 initiator	 caspase	 in	 the	 dead	 receptor	 pathway.	 The	interaction	 between	 the	 CD95	 ligand	 and	 CD95	 receptor	 determine	 the	recruitment	 of	 several	 procaspase-8	 molecules.	 The	 low	 intrinsic	 protease	activity	of	procaspase-8	 is	 sufficient	 to	 allow	 the	pro-enzyme	 to	 cleave	and	activate	each	other.	This	mechanism	is	also	called	 induced	proximity	model	(Muzio,	 Stockwell,	 Stennicke,	 Salvesen,	&	Dixit,	 1998).	 In	 the	 simplest	 case,	caspases	are	activated	by	the	proteolytic	cleavage	operated	by	an	upstream-activated	caspase.	This	is	the	case	of	caspase-3,	an	effector	caspase.	The	 most	 complex	 mechanism	 described	 so	 far	 is	 that	 of	 activation	 of	caspase-9.	This	event	requires	the	association	with	the	protein	cofactor	Apaf-1,	 which	 is	 not	 only	 necessary	 for	 caspase-9	 activation,	 but	 also	 for	 its	regulation.	 Together	 with	 other	 molecules,	 Apaf-1	 and	 caspase-9	 form	 a	holoenzyme,	 called	 apoptosome.	 The	 ATP-dependent	 oligomerization	 of	Apaf-1	allows	 the	 recruitment	of	procaspase-9	 in	 the	apoptosome	complex,	determining	its	activation.	In	 summary,	 effector	 caspase	 are	 usually	 activated	 proteolytically	 by	 an	upstream	 caspase,	while	 initiator	 caspases	 are	 activated	 through	 regulated	protein-protein	interaction	(Youle	&	Strasser,	2008).		
2.5.2	Kv1.3	in	apoptosis		It	is	widely	accepted	that	mitochondria	have	a	central	role	in	apoptosis	since	the	release	of	cytochrome	c	and	other	proteins	 from	the	mitochondrial	 IMS	and	matrix	mark	the	point	of	no	return.		In	 cells	 lacking	 the	 expression	 of	 the	 potassium	 channel	 Kv1.3	 (CTLL-2	lymphocytes),	 the	expression	of	mitochondria-targeted	Kv1.3	was	sufficient	to	 restore	 the	 response	 of	 these	 cells	 to	 several	 apoptotic	 stimuli.	 The	mechanisms	 underlying	 these	 events	 have	 been	 completely	 elucidated.	Indeed,	mtKv1.3	has	been	identified	as	a	target	of	the	pro-apoptotic	protein	Bax,	 a	 member	 of	 the	 Bcl-2	 family	 (details	 in	 the	 next	 section).	 Bax	 and	mtKv1.3	 physical	 interaction,	 occurring	 only	 upon	 induction	 of	 apoptosis,	was	demonstrated	by	co-immunoprecipitation	experiments,	confirmed	both	
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in	mouse	 and	 human	 cells.	Moreover,	 incubation	 of	 isolated	 Kv1.3-positive	mitochondria	 with	 recombinant	 Bax	 or	 toxins	 triggered	 hyperpolarization,	due	 to	 the	 inhibition	 of	 the	 influx	 of	 positive	 charges	 mediated	 by	 Kv1.3,	followed	 by	 a	 depolarization	 due	 to	 the	 opening	 of	 the	 PTP,	 formation	 of	reactive	 oxygen	 species	 and	 release	 of	 cytochrome	 c,	while	 deficient-Kv1.3	mitochondria	were	resistant	(Szabó	et	al.,	2008).	A	model	of	the	structure	of	the	membrane-integrated	Bax	monomer	 indicates	 that	 at	 least	 amino	 acids	127	and	128,	 located	between	the	5th	and	6th	helices	of	Bax,	protrude	from	the	outer	mitochondrial	membrane	into	the	inter-membrane	space	(Annis	et	al.,	 2005).	 The	 amino	 acid	 in	 position	 128	 is	 a	 highly	 conserved,	 positively	charged	 lysine,	 which	 mimics	 the	 action	 of	 the	 critical	 lysine	 in	 Kv1.3-blocking	 toxins	 by	 binding	 to	 the	 negative	 residues	 at	 the	 pore	 channel	vestibule,	which	 face	 the	 inter-membrane	 space	 in	mitochondria.	All	 toxins	contained	a	positive	residue,	which	 is	critical	 for	 interaction	with	Kv1.3.	By	contrast,	 anti-apoptotic	 proteins	 contain	 a	 negative	 charge	 in	 the	corresponding	 position	 (Glu158	 in	 Bcl-xL).	 Mutation	 of	 Bax	 at	 lysine	 128	(K128E)	 abrogated	 its	 effects	 on	 Kv1.3	 and	 the	 induction	 of	 apoptotic	changes	 in	mitochondria,	 while	mutation	 of	 Bcl-xL	 at	 glutamic	 acid	 158	 to	Lysine	(E158K)	rendered	Bcl-xL	pro-apoptotic	when	expressed	in	Bax/Bak-less	MEF	cells	(	Szabò	et	al,		2011).	In	the	light	of	this,	the	mechanism	of	the	inhibition	 exerted	 by	 Bax	 became	 delineated:	 Bax,	 after	 inserting	 as	monomer,	inhibits	Kv1.3	via	lysine	128	by	interacting	with	the	channel	pore	vestibule,	 inducing	 an	 increase	 of	 the	 electrochemical	 gradient	 (i.e.	hyperpolarization)	 because	 of	 the	 block	 of	 the	 positive	 influx	mediated	 by	Kv1.3.	 Hyperpolarization	 interferes	 with	 respiration	 and	 triggers	 ROS	release,	 favouring	 detachment	 of	 cytochrome	 c;	 ROS	 are	 also	 expected	 to	prompt	Bax	migration	to	mitochondria	(Ahmad,	Iskandar,	Hirpara,	Clement,	&	Pervaiz,	2004);	subsequent	exit	of	cytochrome	c	through	Bax	oligomers	in	the	 outer	 membrane	 can	 occur.	 Activation	 of	 the	 PTP	might	 be	 caused	 by	oxidation	 of	 cysteine	 residues	 (Orrenius,	 Gogvadze,	 &	 Zhivotovsky,	 2007).	PTP	 opening	 determines	 membrane	 depolarization,	 and	 rupture	 of	 OMM,	ultimately	contributing	to	cytochrome	C	release.					
		
Figure	13:	Mechanism	of	action	of	mtKv1.3	during	apoptosis	(from	Szabò	et	al.,	2008)	
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2.6	Potassium	channels	as	therapeutic	target	in	cancer	
	The	involvement	of	 ion	channels	in	several	cellular	events	and	the	evidence	that	many	ion	channel-related	processes	are	altered	in	tumour	biology	makes	them	 candidates	 as	 pharmacological	 target.	 In	 general,	 ion	 channels	 are	virtually	 involved	 in	 all	 basic	 cellular	 processes,	 among	 them	 some	 of	 the	most	decisive	such	as	proliferation	and	cell	death	(Lang	et	al.,	2005).	It	dates	back	to	the	early	80s	the	first	evidence	that	voltage	gated	potassium	channels	could	 have	 a	 role	 in	 mitogenesis	 	 (DeCoursey	 et	 al.,	 1984).	 Later,	 the	oncogenic	potential	of	EAG,	a	voltage	gated	potassium	channel,	was	proved	by	the	fact	that	transfection	of	EAG	into	mammalian	cell	 led	to	transformed	phenotype	(Pardo	et	al	1999).	Rapidly,	the	number	of	ion	channels	involved	in	 tumorigenesis	 and	 progression	 of	 aggressive	 and	 metastatic	 cancers	increased.	 Today	we	 know	 that	 the	 vast	 group	 of	 ion	 channels	 involved	 in	tumour	 biology	 includes	 plasma	 membrane	 ion	 channels	 (Prevarskaya,	Skryma,	&	Shuba,	2010)	and	intracellular	ion	channels	(	Leanza	et	al.,	2013),	and	 that	 the	 pharmacological	 targeting	 in	vivo	 for	 the	 treatment	 of	 tumour	could	be	worthy	of	consideration	(Leanza,	Managò,	Zoratti,	Gulbins,	&	Szabo,	2015).							
		
Figure	14:	Acquired	capabilities	of	cancer	(from	Hanahan	and		Weinberg,	2011).				In	2000,	Hanahan	and	Weinberg	 (Hanahan	&	Weinberg,	2000)	enumerated	the	 typical	 features	 shared	 among	 all	 different	 types	 of	 cancer.	 Genome	instability	 accounts	 for	 the	 impairment	 of	 tissues	 homeostasis	 and	inflammation	favours	and	sustains	these	altered	functions.		These	hallmarks	are	 six	 capabilities,	 acquired	 during	 the	 development	 of	 a	 tumour:	 1)	 self-
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sufficiency	 in	 growth	 signals,	 2)	 insensitivity	 to	 growth-inhibitory	(antigrowth)	 signals,	 3)	 evasion	 of	 programmed	 cell	 death	 (apoptosis),	 4)	limitless	 replicative	 potential,	 5)	 sustained	 angiogenesis,	 and	 6)	 tissue	invasion	 and	 metastasis	 (Hanahan	 et	 al.,	 2000).	 After	 a	 decade,	 the	 same	authors	added	to	the	list	two	emerging	hallmarks:	reprogramming	of	energy	metabolism	and	evading	 immune	destruction.	Further,	 they	stressed	on	 the	role	of	normal	cells,	which	contribute	to	the	development	of	hallmarks	trait	by	creating	the		‘‘tumor	microenvironment.’’	(Hanahan	&	Weinberg,	2011).		As	stated	above,	since	ion	channels	define	cell	volume,	cellular	proliferation	rate,	 cell	 membrane	 potential	 and	 intra-cellular	 signalling	 events,	 it	 is	predictable	 that	genes	encoding	 ion	channels	are	affected	during	malignant	transformation.	 Therefore	 the	 altered	 expression	 of	 different	 ion	 channels	could	account	for	one	or	more	pathophysiological	features	that	characterize	malignant	growth.		In	the	next	figure	are	summarized	the	ion	channels	taking	part	to	each	cancer	hallmarks.	 In	 2008,	 the	 first	 international	meeting	 of	 scientists,	 oncologists	and	representatives	of	the	pharmaceutical	industry	interested	made	possible	an	up-to-date	overview	on	 the	role	of	 ion	channels	 in	 the	development	and	progression	 of	 cancer	 and	 the	 possibility	 of	 their	 exploitation	 for	 cancer	diagnosis	and	treatment	(Fraser	&	Pardo,	2008).		Among	 all	 ion	 channels,	 potassium	 channels	 represent	 the	 most	heterogeneous	 group	 whit	 its	 huge	 structural	 and	 functional	 diversity.	Moreover,	 potassium	 channels	 show	 the	 highest	 altered	 expression	 in	tumours.	 As	 already	 mentioned	 and	 shown	 in	 figure	 16,	 cell	 cycle	 and	proliferation,	cell	migration,	invasion	and	apoptosis	are	all	processes	that	can	be	modified	by	the	expression	of	potassium	channels.	They	exert	an	effect	on	these	 processes	 by	 	 permeation-dependent	 and	 permeation-independent	mechanisms.	 Potassium	 channels	 show	 cells	 and	 tissue	 specific	 expression;	their	activity	can	be	modified	by	using	synthetic	blockers	or	natural	peptides	and	 this	 strategy	 is	 already	 in	 use	 in	 clinic	 for	 other	 pathologies	 such	 as	cardiac	diseases.	For	all	these	reasons	targeting	potassium	channels	in	cancer	therapy	could	give	successful	strategy	(Pardo	&	Stühmer,	2013).		From	 the	 vast	 literature	 reporting	 dysregulated	 potassium	 channel	expression	 in	 cancer,	 it	 is	 mostly	 about	 overexpression	 and	 potassium	channels	 implicated	 in	 oncological	 processes	 belonging	 to	 all	 four	 main	classes	of	potassium	channels,	i.e.:	2TM/P,	6TM/P,	8TM/2P,	4TM/2P.	In	the	vast	majority	of	 cases,	 the	 abnormally	 expressed	 channel	 is	wild	 type	 (Huang	&	Jan,	2014).	Changes	in	the	expression	levels	of	K+	channels	can	occur	in	different	ways:		at	 the	 genomic	 level,	 at	 the	 transcriptional	 level,	 at	 the	 post-translational	level	or	epigenetic	 levels,	 and	 in	 some	cases	an	 increase	 in	 channel	activity	can	be	explained	by	upstream	changes	such	as	interaction	with	non-channel	molecules,	often	membrane	proteins	(such	as		 	β1	integrin)	(Hofmann	et	al.,	2001)	or	soluble	ones	(such	as	β-catenin)	(Munoz	et	al.,	2012).	Concerning	 the	 voltage	 gated	 potassium	 channel	 Kv1.3,	 epigenetic	mechanisms	regarding	its	gene	KCNA3,	such	as	DNA	methylation,	have	been	implicated	 in	 the	 altered	 expression	 of	 this	 channel	 in	 pancreatic	 (Brevet,	Fucks,	 et	 al.,	 2009)	and	breast	 (Brevet,	Haren,	 Sevestre,	Merviel,	&	Ouadid-Ahidouch,	2009)	cancer.	Even	if	most	of	the	mechanisms	that	lead	to	a	loss	of	
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controlled	 expression	 of	 potassium	 channels	 in	 tumours	 are	 not	 well	understood,	it	is	reasonable	to	think	that	the	sustained	expression	of	such	a	channels	 during	 tumour	 progression	 could	 give	 a	 selective	 advantage	 to	cancer	cells	(Pardo	&	Stühmer,	2013).					
		
Figure	 15:	 Ion	 channels	 linked	 to	 the	 six	 hallmarks	 of	 cancer	 proposed	 by	 Hanahan	 and	Weinberg	(from	Fraser	and	Pardo,	2008)				Altogether,	these	observation	led	to	the	hypothesis	that	ion	channel	blockers,	especially	 for	 potassium	 channels	 could	 impair	 tumour	 progression,	especially	 in	 those	 cases	 where	 a	 different	 pattern	 of	 expression	 of	 ion	channels	in	cancer	with	respect	to	healthy	cells	is	found	(Pardo	2004).	From	a	pharmacological	point	of	view,	 ion	channels	offer	several	 important	benefits;	for	example,	in	the	case	of	plasma	membrane	ion	channels,	they	can	be	 often	 accessed	 from	 the	 extracellular	 space,	 which	 allows	 reaching	 the	range	 of	 concentration	 acting	 in	vitro	 and	 the	 therapeutic	 doses	 in	 plasma.	Another	 advantage	 of	 ion	 channels	 compared	 to	 other	 types	 of	pharmaceutical	targets	is	that	by	using	patch-clamp	techniques	it	is	possible	to	 elucidate	 the	 mechanism	 of	 drug	 action	 in	 a	 relatively	 easy	 manner	because	 of	 the	 high	 sensitivity	 and	 kinetic	 insight	 offered	 by	 this	 method;	with	 the	 same	 technique,	 the	 effect	 of	 newly	 synthetized	 compounds	 or	derivatives	 of	 precursors	 of	 ion	 channels	 inhibitors	 can	be	 studied	 and	 the	electrophysiological	 properties	 can	 be	 defined	 in	 living	 cells.	 On	 the	 other	hand,	 the	 fact	 that	many	potassium	ion	channels	are	expressed	above	all	 in	excitable	 cells,	 carrying	 out	 fundamental	 function	 in	 the	 central	 nervous	system	(CNS),	renders	the	use	of	 ion	channel	blockers	harmful	 for	excitable	tissue.	 An	 option	 to	 avoid	 side	 effect	 in	 central	 nervous	 system	 is	 to	 use	molecules	 that	 are	 unable	 to	 cross	 the	 blood-brain	 barrier	 or	 limit	 the	
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therapeutic	 concentrations	 in	 order	 to	 limit	 the	 diffusion	 into	 the	cerebrospinal	 fluid.	 However,	 emerging	 evidences	 suggest	 that	 the	 risk	 of	causing	side	effect	in	peripheral	tissues,	e.g.	inducing	cardiotoxicity,	is	higher	than	that	for	the	CNS	(A.	Arcangeli	&	Becchetti,	2015).					
		
Figure	16:	Summary	of	the	process	in	which	K+	channels	are	involved	in	oncology.	Changes	in	 their	 expression	 level	 can	 influence	precise	 steps	of	 tumour	progression	 (from	Pardo	&	Stühmer,	2014)				There	 are	 several	 mechanisms	 by	 which	 an	 inhibitor	 can	 affect	 channel	activity.		The	 simplest	 is	 by	 directly	 blocking	 the	 pore	 or	 preventing	 the	 agonist	binding	by	occupying	its	binding	site.	Another	way	is	by	allosteric	regulation;	they	 can	 modify	 the	 conformational	 state	 of	 the	 channel	 interacting	 with	allosteric	sites.	Composition	and	physical	state	of	the	plasma	membrane	also	exert	 an	 effect	 on	 channel	 proteins.	 Several	 drugs	 can	 modify	 plasma	membrane	 characteristics.	 Finally,	 ion	 channels	 form	 complexes	 with	 a	variety	 of	membrane	 proteins	 (e.g.	 the	mentioned	 above	 β1	 integrin	 and	 β	catenin,	 and	 many	 others),	 which	 offers	 other	 possible	 ways	 for	 altering	channel	function	(Andersen,	2008;	A.	Arcangeli	&	Becchetti,	2010).		The	detailed	understanding	of	the	molecular	mechanisms	of	the	action	of	the	drug	and	of	 its	 interaction	with	the	channels	allow	to	reach	an	high	level	of	specificity,	 i.e.	attack	targeted	cell	 types,	without	causing	toxic	effects	 in	the	healthy	 tissues.	 	An	example	 is	exploiting	 the	 fact	 that	cells	not	only	have	a	different	 pattern	 of	 channels	 expression	 but	 also	 different	 proportion	 of	channel	 in	 different	 states.	 The	 ion	 channel	 function	 is	 characterized	 by	continuous	 transitions	 between	 three	 conformational	 states,	 such	 as	 open	(active),	 closed	 (deactivated)	 and	 inactivated	 (or	 desensitized,	 in	 ligand-gated	 channels).	 If	 in	 pathological	 cells	 channels	 preferentially	 assume	 a	precise	conformational	state,	specificity	can	be	obtained	by	using	drugs	that	preferentially	 have	 more	 affinity	 for	 those	 states	 (Kaczorowski,	 McManus,	
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Priest,	 &	 Garcia,	 2008).	 	 Indeed,	 membrane	 potential	 (and	 actually	 also	organellar	 membrane	 potential)	 varies	 between	 healthy	 and	 pathological	cells.	Indeed,	a	specific	conformational	state	of	a	voltage-dependent	channel	could	 predominate	 in	 a	 cancer	 type	 as	 compared	 to	 the	 normal	 tissue	because	of	their	different	voltage	dynamics	(in	the	case	of	voltage-dependent	channels)	 or	 different	 patterns	 of	 extracellular	 activators	 (for	 ligand-gated	channels)	of	the	different	cell	types.				
2.6.1	Kv1.3	as	oncological	target		At	this	point,	it	is	important	to	remind	the	crucial	role	of	mtKV1.3	potassium	channel	in	apoptosis.	It	is	a	direct	target	of	the	pro-apoptotic	protein	Bax	and	the	inhibition	exerted	by	this	latter	mimic	the	molecular	mechanisms	exerted	by	the	toxins	known	to	 inhibit	Kv1.3	currents	(see	above).	 	 	The	absence	of	Kv1.3	makes	cells	resistant	to	apoptotic	stimuli	of	various	nature	(e.g.:	TNFα,	CD95,	 sphyngomielinase,	 staurosporine),	 underlining	 its	 crucial	 importance	in	programmed	cell	death.		Moreover,	Kv1.3	has	been	shown	to	be	expressed	in	 several	 tissues,	 such	 as	 brain,	 lung,	 thymus,	 spleen,	 lymph	 node,	fibroblasts,	 lymphocytes	 (Szabò	et	 al.,	 2005),	 tonsils,	macrophages	 (Leanza,	Zoratti,	 Gulbins,	 &	 Szabo,	 2012),	 central	 nervous	 system	 (Mourre	 et	 al.,	1999),	 brown	 and	 white	 fat,	 microglia,	 oligodendrocytes,	 osteoclasts,	platelets,	liver,	skeletal	muscle,	in	hippocampal	neurons,	astrocytes	(Gutman	et	al.,	2005).	Interestingly,	Kv1.3	was	shown	to	be	expressed	in	various	types	of	cancer.	In	B-cells	of	lymphoma	(Alizadeh	et	al.,	2000),	in	melanoma	cells	in	close	 proximity	 of	 β1	 integrin	 molecules	 (Artym	 &	 Petty,	 2002),	 in	 human	glioma	together	with	Kv1.5	(Preußat	et	al.,	2003)	,	in	colon	cancer	(Abdul	et	al.	2002),	in	breast	cancer	(Abdul,	Santo,	&	Hoosein,	2003;	Jang,	Kang,	Ryu,	&	Lee,	2009)	and	gastric	cancer	(Lan	&	Shi,	2005).	Moreover	for	some	of	these	cancers,	mitochondrial	expression	of	Kv1.3	has	been	proven	(Gulbins,	Sassi,	Grassmè,	 Zoratti,	 &	 Szabò,	 2010;	 Leanza	 et	 al.,	 2013;	 Leanza	 et	 al.,	 2012).	Moreover	a	slight	increase	of	the	transcripts	of	Kv1.3	has	been	highlighted	in	transformed	 hematopoietic	 cells	 (Smith	 et	 al.,	 2002),	 as	 well	 as	 its	 altered	expression	 in	 various	 tumor	 cell	 lines	 was	 observed,	 such	 as	 in	 B-cells	lymphoma,	T-cell	lymphoma,	acute	myeloid	leukemia,	breast	cancer,	prostate	cancer	and	colon	cancer	 (	Arcangeli	et	al.,	2009).	Since	Kv1.3	 is	 involved	 in	cell	proliferation,	its	altered	expression	confers	an	advantage	to	cancer	cells.		On	the	other	hand,	mtKv1.3	is	involved	in	apoptosis,	leading	its	inhibition	by	Bax	 to	 a	 cascade	 of	 events	 culminating	 with	 cell	 death.	 As	 a	 consequence,	exploiting	 its	 expression	 in	 cancer	 cells,	 sometimes	 even	 altered	 towards	over-expression,	mtKv1.3	became	an	oncological	target	of	great	interest.		In	fact,	 in	the	light	of	the	above-mentioned	model	(figure	13),	by	mimicking	the	action	of	the	pro-apoptotic	protein	Bax	it	is	possible	to	trigger	cell	death.	Inhibition	 of	mtKv1.3	 is	 possible	 by	 using	membrane	 permeant	molecules,	that	are	able	to	cross	plasma	membrane.	As	mentioned	above,	Psora-4,	PAP-1	and	 clofazimine	 are	 selective	 membrane-permeant	 Kv1.3	 inhibitors,	representing	potential	therapeutic	drugs.	Actually,	their	ability	to	induce	cell	death	 in	 different	 types	 of	 cancer	 cells	 has	 been	 already	 demonstrated	 in	vitro,	in	multiple	human	and	mouse	cancer	cell	lines,	in	vivo,	in	a	melanoma	mouse	 model	 and	 ex	 vivo	 on	 B-leukemic	 cells	 deriving	 from	 cronic	
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lymphocytic	leukemia	(CLL)	patient	(Leanza	et	al.,	2013;	Leanza	et	al.,	2012).	In	 order	 to	 prove	 the	 specificity	 of	 the	 action	 of	 the	 three	 inhibitors,	experiments	 were	 carried	 out	 using	 a	 genetic	 model	 in	 which	 CTLL-2	lymphocytes,	which	 normally	 lack	 Kv1.3	 expression,	were	 transfected	with	either	 an	 expression	 vector	 for	 Kv1.3	 cells,	 (pJK-Kv1.3)	 (cells	 designated	CTLL-2/Kv1.3),	 or	 control	 vector	 (pJK)	 (cells	 designated	 CTLL-2/pJK).	 It	represents	 the	 same	genetic	model	used	 to	 test	 the	physiological	processes	linked	 to	 the	 activity	 of	 Kv1.3	 (Szabó	 et	 al.,	 2008;	 Szabò	 et	 al.,	 2005).	 The	experiments	 proved	 that	 only	 cells	 expressing	Kv1.3	 underwent	 cell	 death.	To	provide	another	 level	of	specificity	and	clarify	the	contribute	of	mtKv1.3	to	the	whole	process,	cells	were	also	treated	with	some	non-permeant	Kv1.3	inhibitors	 (e.g.	 MgTx).	 The	 results	 showed	 how	 membrane-impermeant	Kv1.3	 inhibitors	 did	 not	 affect	 cell	 viability,	 indicating	 that	 inhibition	 of	mitochondrial	 but	 not	 plasma	membrane	 Kv1.3	 is	 necessary	 to	 induce	 cell	death.		It	 is	 worth	 to	 underline	 that	 the	 inhibition	 of	 mtKv1.3	 with	 membrane	permeant	 inhibitors	 lead	 to	 apoptosis	 and	 not	 to	 other	 unspecific	 forms	 of	necrosis.	In	fact,	caspase-9	and	caspase-3	activity	was	increased	25-	and	30-	fold	respectively,	 in	 the	Kv1.3	expressing	cells	upon	12	h	of	 treatment	with	the	 three	 membrane	 permeant	 Kv1.3	 inhibitors,	 while	 the	 drugs	 were	without	effect	in	CTLL-2/pJK	cells.	Moreover,	Psora-4,	PAP-1	and	clofazimine	induced	 poly	 (ADP-ribose)	 polymerase	 (PARP)	 cleavage,	 an	 event	downstream	of	cytochrome	C	release	and	caspase-3	activation,	only	 in	cells	expressing	 Kv1.3.	 PARP	 cleavage	was	more	 pronounced	when	 these	 drugs	were	 used	 in	 combination	 with	 multi-drug	 resistance	 pumps	 inhibitors	(MDRi),	 since	 a	 typical	 feature	 of	 cancer	 cells	 is	 to	 extrude	 applied	 drugs.	Mitochondrial	cytochrome	c	release	was	also	tested.	It	was	observed	only	in	Kv1.3-positive	 cells,	 upon	 treatment	with	 the	 drugs.	 In	 contrast,	MgTx	 and	Shk	did	not	 induce	caspase-9	or	caspase-3	activation,	cytochrome	c	release,	mitochondrial	 depolarization	 or	 PARP	 cleavage	 neither	 in	 Kv1.3	 negative	cells	nor	in	Kv1.3	positive	ones	(Leanza	et	al.,	2012).	Two	 characteristic	 mitochondrial	 events	 occurring	 during	 cell	 death	 were	observed	after	 treatment	CTLL-2	cells	with	Psora-4,	PAP-1	and	clofazimine:	the	 increase	 of	 ROS	 production	 and	 the	 mitochondrial	 membrane	depolarization.	 Both	 events	 were	 observed	 only	 in	 CTLL-2/Kv1.3	 cells	 but	not	 in	 CTLL-2/pJK	 cells,	 indicating	 that	 the	 three	 drugs	 did	 not	 induced	oxidative	stress	per	se	and	that	ROS	production	is	downstream	of	Kv1.3.	The	 molecular	 mechanism	 by	 which	 Kv1.3	 induce	 apoptosis	 suggests	 that	membrane	 permeant	 Kv1.3	 inhibitors	 are	 able	 to	 induce	 cell	 death	independently	from	Bax	and	Bak.	This	was	demonstrated	in	Bax/Bak-double	deficient	 human	 Jurkat	 leukemic	 T	 cells,	 where	 the	 three	 membrane	permeant	 Kv1.3	 inhibitors	 efficiently	 induced	 apoptosis.	 As	 expected,	Bax/Bak	deficient	cells	were	resistant	to	staurosporine.	Further,	 the	 specificity	 of	 the	 action	 of	 the	 three	 membrane	 permeant	inhibitors	was	proved	by	suppressing	the	Kv1.3	expression	in	human	Jurkat	leukemic	T	cells	by	transient	transfection	of	siRNA	targeting	Kv1.3,	which	is	the	only	potassium	channel	of	 the	Kv	 family	expressed	 in	 these	cells	and	 is	active	also	in	mitochondria	(Szabò	et	al.,	2005).	Apoptosis	induced	by	Psora-4,	 PAP	 1	 and	 clofazimine	 was	 significantly	 decreased	 in	 human	 Jurkat	
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leukemic	 T	 cells	 upon	 reduction	 of	 channel	 expression	 by	 siRNA.	 Cells	transfected	with	control	siRNA	still	underwent	apoptosis	to	an	extent	similar	to	that	observed	in	non-transfected	cells.					
		
Figure	17:	Structure	of	the	three	membrane-permeant	Kv1.3	inhibitors	Psora-4,	PAP-1	and	clofazimine				Altogether,	 the	 results	 suggested	 that	 the	 cytotoxic	effect	of	Psora-4,	PAP-1	and	clofazimine	was	due	to	a	specific	action	on	mitoKv1.3.	The	 same	 results	 were	 obtained	 also	 in	 a	 variety	 of	 tumor	 cell	 lines	 by	targeting	 mitoKv1.3,	 for	 example	 in	 B16F10	 cells,	 which	 normally	 express	Kv1.3.	 Transfection	 with	 siRNA	 prevent	 cell	 death	 upon	 treatment	 with	Psora-4	PAP-1	and	clofazimine.	Furthermore,	 the	 specificity	 of	 these	 compounds	 on	 mitoKv1.3	 was	demonstrated	 testing	 cell	 survival	 by	 the	MTT	assay	on	 a	 variety	of	 cancer	cell	 lines.	 Psora-4,	 PAP-1	 and	 clofazimine	 induced	 apoptosis	 only	 in	Kv1.3-	expressing	 cell	 lines,	 but	not	 either	 in	HEK293	cells,	 known	 to	 express	 low	level	 of	 Kv	 potassium	 current	 (Yu	 &	 Kerchner,	 1998),	 or	 in	 K562	 human	chronic	myelogenous	leukemia	cell	line,	shown	to	lack	Kv1.3	expression	and	current	 (Smith	 et	 al.,	 2002).	 Again,	 the	 non-permeant	 inhibitors,	MgTx	 and	Shk,	did	not	have	any	effect	both	on	expressing	and	not	expressing	Kv1.3	cell	lines.	These	 results	 confirmed	 that	 cell	 death	 can	 be	 induced	 by	 these	 Kv1.3	membrane-permeant	inhibitors	downstream	of	Bax	and	Bak,	offering	in	this	way,	 novel	 treatment	 for	 chemotherapeutic	 drug-resistance	 malignancies,	often	expressing	low	level	of	these	two	pro-apoptotic	proteins.	
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The	 significance	 of	 Kv1.3	 inhibition	mediated	 apoptosis	 was	 also	 tested	 in	
vivo,	 through	 the	 establishment	 of	 a	 melanoma	 model	 using	 B16F10	melanoma	 cells	 injected	 subcutaneously	 in	 a	 mouse.	 The	 tumor,	 after	establishment	 and	 growth,	 was	 treated	 with	 intra-peritoneally	 injected	clofazimine	 (at	 days	 5,	 7,	 9	 and	 11	 post	 cells	 injection).	 The	 tumors	 were	removed	 and	 analyzed	 after	 16	 days:	 a	 90%	 reduction	 of	 the	 volume	was	observed	after	treatment	with	clofazimine	compare	to	the	untreated	(figure	19).					
		
Figure	 18:	 Scheme	 representing	 the	 events	 triggered	 by	 the	 use	 of	 membrane-permeant	inhibitors	 Psora-4,	 PAP-1	 and	 clofazimine	 ,	 leading	 to	 apoptotic	 cascade	 (from	 Szabò	 and	Zoratti	2014)				Moreover,	 no	 side	 effects	 were	 present	 in	 treated	 mice,	 as	 revealed	 by	cytological	analysis	of	the	other	tissues	(Leanza	et	al.,	2012).	The	data	by	Leanza	et	 al.	 provide	a	novel	 approach	 for	 the	development	of	drugs	 that	 can	 induce	 apoptosis	 independently	 of	 Bax	 and	 Bak.	 The	identification	of	molecules	that	mediate	the	death	of	cancer	cells	independent	of	Bax	and	Bak	is	a	clinical	challenge,	because	of	the	resistance	of	tumors	to	chemotherapy.		As	already	mentioned,	the	ability	of	membrane	permeant	Kv1.3	inhibitors	to	kill	cancer	cells	was	also	demonstrated	in	an	ex-vivo	model.		Psora-4,	PAP-1	and	clofazimine	were	used	against	cancer	cells	deriving	from	chronic	lymphocytic	leukemia	(CLL)	patients.		B-CLL	 is	 a	 pathology	 characterized	 by	 a	 clonal	 accumulation	 of	 apoptosis-resistant	mature	neoplastic	B-cells.		It	 has	 been	 demonstrated	 that	 cells	 from	 B-CLL	 patients	 show	 high	expression	 and	 activity	 of	 Kv1.3	 potassium	 channel	 compared	 with	 cells	deriving	 from	 healthy	 subject	 (Leanza	 et	 al.,	 2013).	 Healthy	 B	 cells	 or	pathologic	B	cells	were	purified	from	peripheral	blood	lymphocytes.	By	using	FITC-labeled	anti-Kv1.3,	it	was	possible	to	assess	the	level	of	Kv1.3	proteins	
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in	the	two	types	of	cells	by	fluorescence-activated	cell	sorting.	Cells	from	B-CLL	 patients	 expressed	 higher	 levels	 of	 Kv1.3	 than	 cells	 deriving	 from	healthy	 subject.	 These	 results,	 together	with	 the	 fact	 that	 Kv1.3	 potassium	channels	 are	not	only	expressed	but	also	active	 in	 these	 cells,	were	 further	confirmed	 by	 patch	 clamp	 experiments.	 Patch	 clamp	 experiments	 in	 the	whole-cell	configuration	confirmed	higher	expression	of	functional	Kv1.3:	the	peak	current	measured	at	+70mV	was	significantly	higher	in	the	B-CLL	than	in	 control	 B	 cells.	 Shk,	 a	 membrane-impermeant	 specific	 inhibitor,	 and	clofazimine	blocked	Kv1.3	 current	 (Szabo,	Trentin,	 Trimarco,	 Semenzato,	&	Leanza,	 2015).	 Moreover,	 biochemical	 assays	 revealed	 that	 subcellular	fractions	from	B-CLL	cells	express	Kv1.3	also	in	their	mitochondria.				
				
Figure	 19:	 	A)	 Average	 and	 SD	 of	 the	 volume	 of	 the	 melanoma	 tumors	 after	 16	 days	 of	growth	in	untreated	and	clofazimine	treated	mice.	B)	Representative	tumors	from	untreated	and	clofazimine	treated	mice	(Leanza	et	al.,	2012).				Given	 the	 fact	 that	 B-CLL	 cells	 expressed	 mtKv1.3,	 membrane	 permeant	inhibitors	 activity	 was	 tested	 very	 efficiently	 induced	 apoptosis	 of	 B-CLL	cells,	 in	 particular	 if	 administered	 in	 combination	 with	 inhibitors	 of	 the	multidrug	 resistance	pumps	 (MDRi).	 In	 contrast,	 the	 cells	were	 resistant	 to	the	 membrane-impermeant	 inhibitor	 ShK,	 clearly	 indicating	 that	 the	 PM-located	 Kv1.3	 itself	 is	 not	 responsible	 for	 the	 apoptotic	 response.	Interestingly,	 B	 or	 T	 cells	 isolated	 from	 healthy	 subjects	 were	 resistant	 to	these	stimuli.	The	same	mechanisms	observed	from	the	in	vitro	experiments	on	cancer	cells	treated	with	the	three	membrane	permeant	Kv1.3	inhibitors	were	observed:	an	increased	mtROS	production	and	a	marked	depolarization	in	 B-CLL	 cells	 after	 treatment	with	 the	 drugs.	Most	 importantly,	 residual	 T	lymphocytes	 cells	 taken	 from	 a	 B-CLL	 patient	 did	 not	 undergo	 apoptosis	when	 treated	 with	 Psora-4,	 PAP-1	 and	 clofazimine;	 treatment	 induced	
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apoptosis	only	 in	the	pathologic	B	cells,	sparing	the	residual	normal	T	cells.	However,	T	 lymphocytes	 from	two	B-CLL	patients	expressed	relatively	high	levels	of	Kv1.3	but	were	resistant	to	treatment.	This	finding	clearly	suggested	that	 specificity	 of	 the	 drugs	 towards	 pathologic	 cells	 is	 not	 merely	 due	 to	higher	 expression	 of	 Kv1.3.	 A	 possibility	 could	 be	 the	 increase	 in	mitochondrial	 ROS	 production,	 proposed	 to	 be	 involved	 in	 genesis	 and	development	 of	 cancer	 (Ralph,	 Rodríguez-Enríquez,	 Neuzil,	 &	 Moreno-Sánchez,	 2010).	 Indeed,	 a	 mild	 mitochondrial	 oxidative	 stress	 rendered	healthy	cells	that	express	less	Kv1.3	sensitive	to	permeant	channel	inhibitor-induced	 oxidative	 stress	 and	 death.	 Pre-incubation	 with	 a	 pro-oxidant	stimulated	 mtROS	 production,	 but	 alone	 did	 not	 induce	 apoptosis.	 The	subsequent	 addition	 of	 Kv1.3	 inhibitors	 induced	 a	 rapid	 and	 significant	increase	 in	 mtROS	 and	 subsequent	 apoptosis.	 On	 the	 other	 hand,	 pre-treatment	 of	 pathologic	 B	 cells	 with	 membrane-permeant	 catalase	 and	superoxide	 dismutase	 abolished	 the	 apoptosis-inducing	 effect	 of	 Kv1.3	inhibitors.	 The	 same	 results	 were	 obtained	 also	 with	 residual	 T	 cells	 and	pathologic	B	cells	of	the	same	patient.		These	 are	 clear	 evidences	 that	mtKv1.3	 inhibitors	 are	 potent	 and	 selective	inducers	of	intrinsic	apoptosis	pathways	in	leukemic	cells.	Importantly,	they	kill	 B-CLL	 cells	while	 sparing	 the	 residual	T	 cells	 even	of	 the	 same	patient,	and	 act	 on	 B-CLL	 cells	 independently	 of	 current	 prognostic	 factors.	 The	selective	 effect	 seems	 to	 be	 given	 by	 the	 synergistic	 action	 of	 Kv1.3	expression	level	and	of	altered	redox	state	in	the	malignant	B-CLL	cells.			
2.7	Melanoma		Melanoma	 is	a	 cancer	 that	develops	 from	 the	oncological	 transformation	of	melanocytes,	 the	pigment-producing	cells	of	 the	skin;	however	melanocytes	are	also	found	iris	and	rectum,	where	they	can	give	rise	to	tumour	as	well.	In	the	Western	world,	the	majority	of	deaths	related	to	skin	cancer	is	caused	by	melanoma	(Schadendorf	&	Hauschild,	2014).	In	physiological	conditions,	melanocytes	produce	pigment	that	protects	cells	from	sun-induced	damages.	However,	sun	exposure	is	the	major	risk	factor.	In	 fact,	UV-light	has	a	direct	mutagenic	 role	 in	melanoma	pathogenesis	and	the	 mutational	 signature	 of	 UV-light	 induced	 mutation	 is	 cytosine	 to	thymidine	(C	>	T)	transitions	(induced	by	UVB)	and	guanine	to	thymidine	(G	>	T)	 transitions	 (induced	by	UVA).	 Some	mutations	 causing	melanoma	 lack	the	 typical	 UV	 signature;	 despite	 a	 causative	 role	 for	 UV-light	 cannot	 be	excluded	in	these	tumours.	Also	free	radicals	induced	by	UV-exposure	can	act	as	 secondary	 mutagens	 (Hodis	 et	 al.,	 2012).	 However,	 like	 in	 all	 types	 of	cancer,	the	transformation	of	melanocytes	in	malignant	cells	that	give	rise	to	melanoma	is	a	set	of	exogenous	and	endogenous	events.		A	low	percentage	represents	the	familiar	cases	of	melanoma	tumour	(~	8%).	In	most	of	these	cases	(40%),	mutation	in	cyclin-dependent	kinase	inhibitor	2A	(CDKN2A)	locus	accounts	for	this	familial	predisposition	(FitzGerald	et	al.,	1996;	 Sheppard	&	McArthur,	 2013).	 Inactivating	mutations	 of	 the	 CDKN2A	gene	 determine	 the	 loss	 of	 two	 important	 oncogenes:	 p53	 and	retinoblastoma	 associated	 protein	 (RB).	 In	 fact,	 this	 gene	 encodes	 two	
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distinct	tumour	suppressors	p16INK4A	and	p14ARF.	The	first	one	maintains	cell-cycle	 control	 by	 inhibiting	 inactivation	 of	 RB,	 while	 the	 second	 one	prevents	degradation	of	cellular	tumour	antigen	p53.	Thus	the	consequences	of	CDKN2A	inactivating	mutations	lead	to	uncontrolled	cell	proliferation.	p53	 is	 the	most	commonly	mutated	gene	 in	human	cancers	 (Kandoth	et	al.,	2013).	The	p53	protein	plays	a	central	role	in	modulating	cellular	responses	to	 diverse	 cellular	 stress	 signals	 (such	 as	 DNA	 damage,	 hypoxia	 and	oncogenes	 activation)	 and	 contribute	 to	 cell-cycle	 arrest,	 senescence	 and	apoptosis	 and	 other	 processes.	 Therefore,	 mutational	 loss	 of	 p53	 function	during	 carcinogenesis	 can	 lead	 to	 inappropriate	 cell	 growth,	 increased	 cell	survival,	and	genetic	instability	(Bieging,	Mello,	&	Attardi,	2014).		The	higher	percentage	of	melanomas	(~90%)	consists	of	sporadic	cases.	The	genes	 responsible	 for	 these	 cases	 are	 several	 and	 their	 penetrance	 is	 a	spectrum,	 ranging	 from	 high-risk	 allele	 to	 moderate	 risk	 alleles.	 The	moderate	 risk	 alleles	 are	 more	 widespread	 in	 the	 population	 with	 mild	effects	 while	 the	 high-risk	 alleles	 are	 less	 common	 but	 their	 effects	 arise	almost	always	(Ward,	Lazovich,	&	Hordinsky,	2012).	Common	mutation	giving	rise	 to	 sporadic	melanoma	are	 those	occurring	at	the	level	of	genes	such	as	BRAF	(encoding	for	the	proto-oncogene	B-Raf)	and	NRAS	 (neuroblastoma	 RAS	 viral	 oncogene	 homologue,	 encoding	 for	 an	enzyme).		The	 BRAF	 gene	 encodes	 a	 serine/threonine	 kinase	 implicated	 in	 the	regulation	 of	 the	 signaling	 cascade	 and	 controlling	 cell	 proliferation,	differentiation,	migration	 and	 survival.	 NRAS	 is	 a	member	 of	 the	RAS	 gene	family;	they	have	GTPase	activity	and	they	are	involved	in	the	control	of	cell	proliferation	 and	 cell	 growth.	 Other	 genes	 affected	 in	melanoma	 are	 PTEN	(encoding	for	the	protein	phosphatase	and	tensin	homologue)	and	AKT	(also	known	as	protein	kinase	B)	(Schadendorf	&	Hauschild,	2014).	In	 melanoma,	 metastatic	 progressions	 are	 also	 frequent,	 causing	 death	 in	most	 cases.	Metastasis	 can	occur	at	 late	 stage	of	 the	disease	or	be	 initiated	already	 earlier	 (this	 last	 case	 is	 also	 called	 “parallel	 progression”).	 The	mutational	 events	 described	 above	 (BRAF,	 NRAS	 etc.)	 are	 determinant	 not	only	 for	 the	driving	 the	onset	of	melanoma	but	also	 for	 the	development	of	metastases.	 Like	 in	 other	 types	 of	 cancers,	 metastatic	 events	 depend	 on	secondary	 factors	 such	 as	 host	 defence,	 microenvironmental	 factors	 and	survival	 of	 circulating	 cancer	 cells.	 It	 is	 still	 object	 of	 debate	 whether	metastatic	events	depend	on	a	population	of	cells	deriving	 from	a	stem	cell	precursor.	 On	 the	 other	 hand	 it	 is	 clear	 that	 selected	 melanoma	 cell	subpopulations	 are	 able	 to	 survive	 upon	 drug	 treatment	 and	 in	 adverse	condition,	 accounting	 for	 the	 recurrence	of	 cancer	and	 for	 its	 spread	 in	 the	body	(Roesch	et	al.,	2011).		Another	 feature	 conferring	 resistance	 to	 chemotherapeutic	 approaches	 and	disease	progression	 is	 the	overexpression	of	anti-apoptotic	proteins,	 like	 in	several	 types	 of	 tumour.	 	 	 Moreover,	 melanoma	 cells	 probably	 use	developmental	 programmes	 such	 as	 Notch	 or	 WNT	 signalling	 during	metastasis	to	actively	maintain	their	high	mesenchymal	cell-like	plasticity.		The	molecular	understanding	of	genetic	events	 leading	to	melanoma	cancer	and	metastases,	 rapidly	 allowed	 the	 development	 of	 drugs	 targeting	 those	protein	 involved	 in	 tumour	 progression.	 BRAF-inhibitors	 vemurafenib	 and	
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dabrafenib	 were	 used	 in	 clinical	 trials,	 determining	 survival	 benefit	 in	patients	 and	 significantly	 improving	 prognosis	 for	 patients	with	 advanced-stage	metastatic	disease.			
2.8	Pancreatic	ductal	adenocarcinoma	(PDAC)		Pancreatic	 ductal	 adenocarcinoma	 (PDAC)	 is	 the	 most	 common	 type	 of	pancreatic	cancer	(90%	of	all	pancreatic	malignancies)	and	one	of	 the	most	aggressive	types	of	tumour.		It	is	relatively	rare	(about	2%	of	all	cancer	cases)	and	it	is	the	fourth	leading	cause	 of	 cancer	mortality	 in	men	 and	women.	 Life	 expectancy	 for	 patients	affected	by	PDAC	is	at	most	five	years	after	diagnosis,	even	if	most	of	patients	die	within	one	year	 following	cancer	detection	(Hariharan,	Saied,	&	Kocher,	2008;	 Siegel,	Miller,	 &	 Jemal,	 2015).	 Due	 to	 the	 poor	 prognostic	 factor	 and	due	to	the	fact	that	pancreatic	cancer	usually	has	no	symptoms,	patients	are	diagnosed	at	late	stage	disease.	Several	 environmental	 factors	 account	 for	 the	 increase	 in	predisposition	 to	pancreatic	 cancer;	 among	 them	 smoking,	 obesity,	 chronic	 pancreatitis,	diabetes	mellitus	and	intake	of	alcohol	have	been	reported.		In	patients	with	a	PDAC	family	history	genetic	defects	rather	than	environmental	ones	are	the	major	cause.	Some	studies	have	shown	an	increased	incidence	of	pancreatic	cancer	among	patients	with	genetic	mutations	in	BRCA2,	CDKN2A,	PRSS1	and	some	other	genes	(Hidalgo,	2010).	Usually	PDAC	arises	 in	 the	head	of	 the	pancreas,	 rapidly	disseminating	 into	surrounding	tissues	like	spleen	and	peritoneal	cavity	and	with	metastasis	to	the	 liver	 and	 lungs.	 It	 evolves	 from	precursors	 lesions	present	 in	pancreas.	Precursors	 lesions	 mainly	 responsible	 for	 PDAC	 are	 three:	 pancreatic	intraepithelial	 neoplasms	 (PanINs),	mucinous	 cystic	 neoplasms	 (MCN),	 and	intraductal	papillary	mucinous	neoplasms	 (IPMN)	 (Hruban,	Maitra,	Kern,	&	Goggins,	 2007).	 PanINs	 are	 the	 most	 common	 and	 well-characterized	precursors.		The	 genetic	 causes	 leading	 to	 progression	 from	 precursors	 lesion	 to	 PDAC	are	several.	Like	in	other	types	of	cancer	gene	mutation,	oncogene	activation,	inhibition	 of	 tumor	 suppressors	 and	 alteration	 in	 gene	 expression	 play	 a	crucial	 role.	 Like	 in	 melanoma,	 the	 p16INK4A/CDKN2A	 gene	 show	inactivating	mutation	very	often	(Caldas	et	al.,	1994),	as	well	as	p53	(Kandoth	et	al.,	2013).		Loss	 of	 function	mutations	 have	 been	 identified	 also	 in	 p21,	 an	 important	player	in	the	control	of	cell	cycle.		On	the	other	hand,	the	activation/overexpression	of	oncogenes	also	accounts	for	tumor	progression	in	PDAC.	Among	them,	the	member	of	the	RAS	family	KRAS	(V-Ki-ras2	Kirsten	rat	sarcoma	viral	oncogene	homolog),	represent	the	most	 frequent	mutated	oncogene	 in	PDAC.	Also	BRAF	 is	often	expressed	 in	PDAC,	like	in	melanoma	(see	above)	(Witkiewicz	et	al.,	2015).		Moreover,	 several	 growth	 factor	 and	 the	 relative	 receptors	 have	 been	reported	 to	 be	 overexpressed	 in	 PDAC,	 such	 as	 EGF	 (epidermal	 growth	factors),	 IGF-I	 (insulin	 growth	 factor	 I),	 FGF	 (fibroblast	 growth	 factor)	 and	
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VEGF	 (vascular	 endothelial	 growth	 factor),	 together	 with	 their	 receptors	(Ozawa,	Friess,	Tempia-Caliera,	Kleeff,	&	Büchler,	2001).	Therapeutic	 options	 for	 pancreatic	 cancer	 are:	 surgery,	 chemotherapy,	radiation	therapy,	targeted	therapy,	immune	therapy,	palliative	therapy	and	personalized	therapy.	In	order	to	choose	which	kind	of	therapy	is	the	best	for	patients,	 the	 stage	 of	 pancreatic	 cancer	 is	 the	 most	 important	 factor.	Unfortunately,	only	20%	of	patients	are	candidates	for	surgery.		Concerning	 chemotherapy,	 it	 is	 the	 main	 treatment	 for	 metastatic	unresectable	 pancreatic	 tumours.	 Chemotherapy	 is	 used	 as	 a	 neoadjuvant	(before	surgery)	or	as	adjuvant	(following	surgery),	but	also	when	surgery	is	not	 an	option.	 For	 about	20	years,	 the	only	option	 considered	valid	 for	 the	treatment	 of	 PDAC	 has	 been	 5-fluorouracile	 (5-FU).	 Nowadays,	 the	 most	diffused	 chemotherapy	 drug	 in	 clinical	 use	 is	 gemcitabine,	 administered	alone	 or	 in	 combination	 with	 other	 chemotherapy	 such	 as	 5-fluorouracile,	capecitabine,	 platinum	 analogues	 and	 texane	 (Herreros-Villanueva,	 2012).	For	all	these	molecules,	the	mechanism	of	action	by	which	the	cytotoxic	effect	is	 exerted	 is	 the	 block	 of	 DNA	 synthesis;	 therefore	 a	 lot	 of	 side	 effects	 are	caused	in	the	healthy	tissues	by	these	therapies.		We	assessed	whether	PDAC	cells	express	Kv1.3	and	since	it	was	the	case,	we	addressed	 the	 effect	 of	 clofazimine	 in	 vitro	 and	 then	 in	 vivo	 (Zaccagnino,	Managò	et	al,	under	submission,	see	attached	manuscript).			
2.9	Mitochondrial	potassium	homeostasis	perturbing	drug	as	
antineoplastic	agent:	salinomycin			Salinomycin	 is	 a	 monocarboxyl	 polyether	 antibiotic	 obtained	 by	 isolation	from	 fermentation	 products	 of	 Streptomyces	 albus.	 It	 is	 used	 commercially	against	 coccidioisis,	 a	 gastrointestinal	 infection	 caused	 by	 a	 protozoan	parasite,	 in	 poultry	 and	 as	 growth	 promoter	 for	 ruminants.	 In	 general,	polyether	antibiotic,	also	known	as	carboxyl	ionophores,	are	broad	spectrum	antibiotics.	 They	 are	 active	 against	 a	 wide	 range	 of	 biological	 targets:	bacterial,	fungal,	protozoan,	viral,	neoplastic,	cardiovascular,	immune	system	(Kevin	II,	Meujo,	&	Hamann,	2009)	(a	general	description	of	ionophores	can	be	 found	 in	 section	2.3.1).	They	are	effective	even	against	many	multi-drug	resistant	 (MDR)	 pathological	 agents.	 Despite	 these	 characteristics	 and	 the	fact	that	they	are	used	at	low	doses	in	veterinary	medicine,	they	have	no	use	as	 clinical	 antibacterial	 agents	 in	 humans,	 due	 to	 their	 toxicity.	 The	 toxic	effect	in	mammals	is	still	not	fully	understood	and	it	varies	depending	on	the	species,	e.g.	 they	are	relatively	 less	 toxic	 for	poultry,	while	horses	and	dogs	are	particularly	sensitive	to	ionophores	(Huczynski,	2012).		As	 well	 as	 other	 known	 carboxyl	 ionophores,	 salinomycin	 shows	 a	 typical	structure	 characterized	 by	 a	 lipophilic	 outer	 part	 and	 an	 hydrophilic	 inner	cavity;	 this	 latter	 contains	 oxygen	 atoms	 and	 carboxylic	 group	which	make	possible	 the	 allocation	 of	 monovalent	 positively	 charged	 ions.	 Salinomycin	shows	preference	 for	potassium	ions	but	also	Na+	and	H+	can	be	carried	by	this	ionophore.	Obviously,	this	structure	allows	salinomycin	to	exert	an	effect	at	 the	 plasma	 membrane	 and	 at	 the	 inner	 mitochondrial	 membrane	whenever	a	K+	gradient	is	present.	The	conformation	of	the	ionophore-metal	
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complex	between	salinomycin	and	sodium	was	determined	both	by	2D-NMR	spectroscopy	in	crystal	structure,	in	organic	solvent	(Paulus,	Kurz,	Matter,	&	Vértesy,	 1998)	 	 and	 in	 bicelles	 mimicking	 the	 membrane	 environment	(Matsumori,	Morooka,	&	Murata,	2007).					
		
Figure	 20:	 Model	 representing	 ion	 transport	 across	 lipid	 bilayer	 by	 salinomycin	 (from	Matsumori	et	al.,		2007)				Matsumori	and	colleagues	proposed	a	working	model	of	ion	transport	across	biological	 membranes	 for	 salinomycin,	 on	 the	 basis	 of	 their	 work	 and	 of	previous	reports	(Shown	in	figure	20).	According	to	this	model,	salinomycin	changes	 its	 conformation	 during	 its	 “trip”	 across	 biological	 lipid	 bilayers,	assuming	 an	 open	 conformation	 in	 the	 polar	 region	 of	 the	 membrane,	 a	closed	 conformation	 while	 diffusing	 into	 the	 hydrophobic	 region	 and	 then	again	an	open	 conformation	when	 it	 is	 on	 the	other	 side	of	 the	membrane.	The	open	conformation	favours	the	association/dissociation	of	the	ion,	which	in	these	conditions	is	weakly	bound.	Then	the	closed	conformation	ensures	a	strong	bond	of	the	ion	to	salinomycin	and	it	is	completely	shielded	from	the	non-polar	lipid	environment	and	can	easily	diffuse	across	the	bilayer.	As	described	 in	 the	previous	paragraphs	 ions	are	distributed	 in	 the	 cells	 at	the	 steady	 state	 at	 precise	 concentrations	 in	 order	 to	 maintain	 cell	homeostasis.	The	principal	actors	of	this	maintenance	are	ion	channels.	But,	as	explained	above,	other	organic	molecules	(e.g.	ionophores)	can	modify	cell	permeability.	 When	 this	 ion	 homeostasis	 is	 disrupted,	 cells	 activate	 some	defence	mechanisms	(e.g.:	apoptosis,	necrosis).	It	is	well	known	for	example	
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that	 induction	 of	 volume	 loss	 in	 the	 cells	 (shrinkage)	 due	 for	 example	 to	 a	massive	 efflux	 of	 potassium	 from	 the	 cytosol,	 where	 its	 concentration	 is	higher	 than	 the	 extracellular	 space,	 leads	 to	 apoptosis;	 this	 event	 likely	induces	activation	of	caspases	and	endonucleases.	On	the	contrary,	apoptosis	is	prevented	when	potassium	efflux	is	inhibited	somehow	(Bortner,	Hughes,	Cidlowski,	&	Carolina,	1997;	Yu	&	Choi,	2000).		Salinomycin	exhibits	several	pharmacological	 effects	 acting	 on	 the	 alteration	 of	 ions	 balance	 across	 cell	membranes,	 finally	 leading	 to	 cell	 death.	 Given	 its	 lipophilic	 structure,	 it	 is	able	to	act	also	on	intracellular	membranes,	disturbing	also	intracellular	ion	balance.		In	2009,	the	group	of	Weinberg	announced	that	salinomycin,	 is	a	100	times	more	 effective	 killer	 of	 breast	 cancer	 stem-like	 cells	 than	 paclitaxel,	 a	chemotherapeutic	 drug	 currently	 used	 to	 treat	 breast	 cancer.	 Salinomycin	was	 selected	 following	 a	 screening	 of	 a	 library	 of	 16000	 natural	 and	commercial	chemical	compounds	for	their	ability	to	kill	drug-resistant	stem-like	 breast	 cancer	 cells.	 They	 found	 that	 only	 a	 small	 subset,	 including	salinomycin	and	nigericin	(known	to	be	a	H+/K+	exchanger),	targeted	cancer	stem	cells	(CSCs)	(Gupta	et	al.,	2009).	Nigericin,	similarly	to	monensin,	acts	as	an	 ionophore	with	 a	 preference	 for	 potassium	 and	mediates	 electroneutral	exchange	 of	 potassium	 ions	with	 protons	 at	 the	 level	 of	 the	 IMM.	 Notably,	nigericin	and	monensin	have	been	shown	to	induce	apoptosis	in	human	lung	cancer	 and	 lymphoma	 cells(Andersson,	 Janson,	 Behnam-Motlagh,	Henriksson,	&	Grankvist,	2006;	Park,	Kim,	Kim,	&	Lee,	2003)	suggesting	that	the	 common	 mechanism	 of	 polyether	 ionophore	 antibiotics	 to	 altering	potassium	homeostasis	in	the	cytoplasm	and	mitochondria	contributes	to	the	induction	of	apoptosis	in	cancer	cells.	The	work	of	Gupta	and	colleagues	was	really	 challenging	 since	 CSCs,	 integral	 to	 the	 development	 of	 tumour	 and	responsible	for	the	recurrence	of	cancer	after	remission,	are	very	rare	to	find	in	a	tumour	cell	population	and	is	difficult	to	maintain	them	in	culture.	In	this	work,	 salinomycin	 was	 also	 administrated	 to	 mice	 and	 it	 was	 shown	 to	decrease	mammary	tumour	growth	in	vivo.		After	the	publication	of	this	work,	the	interest	around	salinomycin	has	been	growing.	Indeed,	its	toxic	effect	towards	cancer	cells	has	been	proved	in	vitro	and	 in	 vivo	 also	 on	 various	 non-stem	 cancer	 cells	 like	 chronic	 lymphocytic	leukemia	(CLL)	cells,	colorectal	cancer,	hepatocellular	carcinoma,	lymphoma,	human	colon,	breast,	prostate,	and	lung	(Kopp	et	al.,	2014;	D.	Lu	et	al.,	2011;	Naujokat	&	Steinhart,	2012;	Sánchez-Tilló	et	al.,	2014;	Verdoodt	et	al.,	2012;	Wang	et	al.,	2012;	Zhou	et	al.,	2013).	On	the	other	hand,	the	use	of	animal	models	revealed	that	salinomycin	has	a	narrow	therapeutic	index.	Daily	salinomycin	injection	for	4	weeks	at	doses	of	5mg/kg	 body	weight	was	well	 tolerated,	 and	 no	 alterations	 on	 tissues	 and	blood	 were	 revealed,	 but	 salinomycin	 induced	 neuropathy	 in	 vivo	 even	 at	relatively	 low	 doses,	 such	 as	 sensory	 polyneuropathy	with	mechanical	 and	cold	allodynia,	decreased	sensory	nerve	action	potential	amplitudes,	and	loss	of	myelinated	fibers	in	the	sciatic	nerve.	However	the	treatment	did	not	give	rise	to	systemic	toxicity	Interestingly,	it	has	been	observed	that	inhibition	of	the	mitochondrial	Na+/Ca2+	 exchanger	partially	prevented	 the	development	of	 salinomycin-induced	neuropathy	 in	vivo,	without	 reducing	 antineoplastic	
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efficacy	 of	 salinomycin	 (Boehmerle,	 Muenzfeld,	 Springer,	 Huehnchen,	 &	Endres,	2014).		Extensive	research	has	been	undertaken	to	clarify	the	general	mechanism(s)	by	which	salinomycin	induces	apoptosis	and	blocks	tumour	growth.	Several	independent	ways	 of	 action	 have	 been	 proposed	 to	 account	 for	 the	 cancer	cell-killing	 ability	 of	 salinomycin.	 For	 example,	 it	 has	 been	 shown	 that	salinomycin	 is	 able	 to	 inhibit	 proximal	 signalling;	 the	 Wnt/β-catenin	transduction	 pathway	 plays	 a	 central	 role	 in	 the	 physiology	 of	 CSCs	 and	undergoes	 aberrant	 activation	 during	 tumour	 development.	 It	 has	 been	proposed	 that	 salinomycin	 acts	 blocking	 the	 phosphorylation	 of	 the	 Wnt	coreceptor,	 lipoprotein	 receptor	 related	 protein	 6	 (LRP6),	 inducing	 its	degradation.	 With	 the	 same	 mechanism	 nigericin	 exerts	 similar	 effects	 on	CSCs	 (Lu	 et	 al.,	 2011).	 	 Another	 proposed	mechanism	 is	 the	 induction	 of	 a	marked	increase	in	the	expression	of	the	pro-apoptotic	protein	NAG-1	upon	salinomycin	 treatment	 (Arafat	 et	 al.,	 2013).	 Recent	 results	 point	 to	salinomycin	as	a	strong	mTORC1	signaling	antagonist,	beside	Wnt/β-catenin	pathway	inhibitor,	 in	breast	and	prostate	cancer	cells,	where	mTORC1	is	an	essential	 effector	 in	driving	 cell	proliferation	and	oncogenic	 transformation	(Lu	&	 Li,	 2014).	 Some	 opposing	 effects	 on	 autophagy	 have	 been	 proposed:	salinomycin	 can	 be	 an	 initiator	 of	 autophagy	 in	 tumour	 cells	 (Reddy	 et	 al.,	2013;	Verdoodt	et	al.,	2012),	however	it	is	also	able	to	suppress	late	stages	of	autophagy,	 leading	 to	 accumulation	 of	 dysfunctional	 mitochondria	 with	increased	production	of	reactive	oxygen	species	(ROS)	(Klose	et	al.,	2014).			Most	 important,	 salinomycin	 is	 expected	 to	 impact	 mitochondrial	 function	thanks	 to	 its	 ability	 to	 act	 as	 an	 ionophore,	 but	 only	 few	 early	 studies	addressed	the	direct	effect	of	salinomycin	on	isolated	mitochondria	(Mitani,	Yamanishi,	Miyazaki,	&	Otake,	1976).	However,	 later	works	 generally	 interpreted	mitochondria-related	 effects	 of	salinomycin	 in	 intact	 cells	 presuming	 that	 salinomycin	 acts	 similarly	 to	valinomycin,	 a	 potassium	 selective	 ionophore	 mediating	 potassium	 influx	into	 the	 mitochondria	 according	 to	 the	 electrochemical	 driving	 force.	 For	example,	effects	like	salinomycin-induced	mitochondrial	membrane	potential	depolarization	and	mitochondrial	ROS	production	have	been	proposed	to	be	compatible	 with	 influx	 of	 positively	 charged	 potassium	 ions	 (J.	 Kim,	 Choi,	Kim,	Kim,	&	Yoon,	2013;	Verdoodt	et	al.,	2012;	Zhu	et	al.,	2013).	The	chemical	structure	of	salinomycin	is	however	more	similar	to	nigericin	rather	than	to	valinomycin;	 in	 fact,	 salinomycin	 structure	 shows	 a	 carboxyl	 group,	 which	can	act	as	the	H+	carrier.		The	mitochondrial	effects	of	salinomycin	have	generally	been	addressed	12–48	 h	 following	 addition	 of	 the	 drug,	 even	 though	 it	 is	 expected	 to	 reach	quickly	the	IMM,	as	valinomycin	and	nigericin	do	when	added	to	intact	cells.	For	all	these	reasons	we	decided	to	study	the	early	effects	of	salinomycin	on	mitochondrial	 function	 as	 compared	 with	 valinomycin	 and	 nigericin,	 in	primary	 human	 healthy	 cells,	 in	 cancer	 stem	 cell-like	 immortalized	 human	mammary	 epithelial	 cells	 and	 in	 cancer	 cells.	 Our	 results	 reveal	 the	 short-term	 effects	 of	 salinomycin	 on	 mitochondrial	 function,	 contributing	 to	 the	elucidation	of	its	mechanism	of	action.	The	results	indicate	that	salinomycin,	when	 used	 above	 μM	 concentrations,	 exerts	 direct,	 mitochondrial	 effects,	thus	compromising	cell	survival	(Managò	et	al.,	2015).	
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2.10	A	bacterial	derived	redox	active	compound	as	inducer	of	
cell	death		I	previously	described	the	principal	features	of	apoptosis.	The	stimuli	able	to	induce	cell	death	are	numerous	and	different	and	they	can	derive	from	inside	the	 cells	 or	 be	 external.	 Many	 toxins	 existing	 in	 nature,	 clinically	 relevant	because	 strongly	 pathogenic,	 lead	 to	 the	 induction	 of	 cell	 death	when	 they	come	in	contact	with	the	host	cells,	 therefore	it	 is	 interesting	to	understand	the	mechanisms	underlying	these	events	in	order	to	increase	the	therapeutic	options.		One	 example	 is	 pyocyanin,	 a	membrane-permeable	 pigment	 toxin	 released	by	 the	 Gram-negative	 bacterium	 Pseudomonas	 aeruginosa.	 This	 bacterium	has	 a	 ubiquitous	 nature	 and	 show	 ability	 to	 easily	 develop	 resistance	 to	antibiotic.	 It	 is	 an	 important	 pathogen	 causing	 a	 wide	 range	 of	 acute	 and	chronic	infections,	especially	at	the	respiratory	airways.	P.	aeruginosa	rarely	causes	 infection	 in	 the	 normal	 host,	 but	 its	 infections	 are	 clinically	 very	serious	 for	 patients	 who	 are	 mechanically	 ventilated,	 immunosuppressed	patients	and	for	those	with	pneumonia,	sepsis,	or	cystic	fibrosis	(Caldwell	et	al.,	2009;	Sadikot,	Blackwell,	Christman,	&	Prince,	2005).		It	 is	therefore	very	important	to	define	the	first-line	defence	mechanisms	of	the	immune	system	and	their	interaction	with	the	pathogen.		A	 variety	 of	 factors	 accounts	 for	 the	 virulence	 of	 P.	 aeruginosa,	 including	exoenzyme	 U	 (Exo	 U),	 a	 phospholipase	 A2,	 able	 to	 inhibit	 inflammasome	activation	 by	 P.	 aeruginosa;	 pyocyanin,	 a	 heterocyclic	 nitrogen-containing	phenazine,	and	rhamnolipid,	another	secreted	small	molecule,	able	to	induce	neutrophil	necrosis;	all	these	factors	attack	immune	system	cells	and	aim	to	establish	a	long-term	lung	infection	(Lavoie,	Wangdi,	&	Kazmierczak,	2012).		Pyocyanin	 is	 a	 redox-active	 compound	 capable	 of	 accepting	 and	 donating	electrons.	 It	 was	 determined	 that	 in	 the	 sputum	 of	 patients	 with	 cystic	fibrosis	it	is	detected	at	concentrations	till	100	µM	(Wilson	et	al.,	1988).	In	an	
in	vivo	model	were	mice	were	chronically	exposed	to	pyocyanin	 it	has	been	shown	 how	 it	 strongly	 contributes	 to	 oxidative	 stress	 and	immunomodulation	and	how	bacteria	lacking	pyocyanin	are	less	pathogenic,	a	 finding	 indicating	 that	 this	 factor	 plays	 an	 important	 role	 in	 in	 vivo	infection.	 Moreover	 the	 solely	 chronic	 exposure	 to	 pyocyanin	 in	 mice	 can	mimic	the	pulmonary	pathophysiological	phenotype	observed	in	CF	patients	(Caldwell	et	al.,	2009).	Due	 to	 its	 lipophilic	 structure,	 pyocyanin	 is	 able	 to	 cross	 biological	membranes	and	this	feature	accounts	for	its	role	as	a	mobile	electron	carrier	for	 P.	 aeruginosa.	 Under	 aerobic	 conditions,	 pyocyanin	 directly	 oxidizes	reduced	nicotinamide	adenine	dinucleotide	phosphate	 (NADPH)	 in	 the	host	cell	 cytoplasm	 and	 donates	 accepted	 electrons	 to	 oxygen	 molecules	 to	produce	 superoxide	 anions	 and	 reactive	 oxygen	 species	 (ROS).	 When	pyocyanin	is	in	its	reduced	state	it	is	colourless;	in	this	condition,	it	donates	one	 electron	 to	 molecular	 oxygen	 thereby	 creating	 superoxide	 anion	 and	turning	into	the	blue,	oxidized	form	(Rada,	Lekstrom,	Damian,	Dupuy,	&	Leto,	2008).		Basically,	pyocyanin	shows	to	 induce	short-term	effect	and	 long-term	effect	when	 coming	 in	 contact	 with	 the	 respiratory	 epithelium.	 As	 soon	 as	
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pyocyanin	 is	 secreted	 by	 P.aeruginosa,	 it	 enters	 the	 cytosol	 of	 airway	epithelial	 cells	 immediately	 determining	 production	 of	 oxygen	 species	because	 of	 its	 direct	 interaction	with	NAD(P)H	pool	 and	molecular	 oxygen.	Catalase,	 the	 enzyme	 responsible	 for	 the	 dismutation	 of	 superoxide	 to	hydrogen	peroxide,	is	inhibited	by	pyocyanin.	These	events	in	turn	determine	reduction	of	the	level	of	reduced	glutathione	(GSH)	and	the	level	of	ATP.	The	reduction	of	ATP	levels	has	some	consequence	on	energy	metabolism	of	the	cells,	 inhibiting	for	example	ciliary	beat	 frequency	and	CFTR	(cystic	 fibrosis	transmembrane	conductance	regulator)	channel	 functions.	Reduced	NADPH	levels	 inhibit	antibacterial	 functions	exerted	by	 the	enzymes	dual	oxidase	1	and	2	(Duox1	and	Duox2),	i.e.	NADPH	oxidases	releasing	hydrogen	peroxide	into	 the	 airway	 surface	 liquid,	 responsible	 for	 bacterial	 killing.	 Long-term	effects	 of	 PYO	 manifest	 in	 transcriptional	 changes.	 Indeed,	 pyocyanin	determines	the	inhibition	of	the	transcription	of	genes	acting	as	antioxidants	and	 antimicrobial	 and	 enhances	 the	 transcription	 of	 the	 pro-inflammatory	ones	(Rada	&	Leto,	2013).				
		
Figure	 21:	 Model	 summarizing	 the	 several	 effects	 induced	 by	 pyocyanin	 produces	 by	
Pseudomonas	aeruginosa	 in	 the	 respiratory	 epithelium	 (see	 text	 for	details)(modified	 from	Rada	&	Leto,	2013)	Abbreviations:	 CFTR,	 cystic	 fibrosis	 transmembrane	 conductance	 regulator;	 CXCL,	chemokine	(C-X-C	motif)	ligand;	Duox,	dual	oxidase;	Eredox,	redox	potential;	EGFR,	epidermal	growth	 factor	 receptor;	 IL,	 interleukin;	 LPO,	 lactoperoxidase;	MPO,	myeloperoxidase;	 GSH,	reduced	glutathione;	GSSG,	oxidized	glutathione				Given	 the	 fact	 that	 pyocyanin	 shows	 the	 ability	 to	 move	 electrons	 and	 to	cross	 the	 biological	 membranes,	 it	 could	 have	 an	 effect	 also	 directly	 on	intracellular	component,	for	example	mitochondria.	Mitochondria	are	crucial	for	 the	 production	 of	 ATP,	 the	 regulation	 of	 intracellular	 Ca2+	 homeostasis,	
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and	the	production	of	ROS.	They	are	also	key	participants	in	the	regulation	of	cell	 death	 Indeed,	 it	 has	 been	 shown	 that	 pyocyanin	 determines	mitochondrial	ultra-structural	changes,	O2-	and	H2O2	formation	at	the	level	of	mitochondria,	 time	 and	 concentration-dependent	 ATP	 cellular	 depletion	upon	 treatment	 of	 the	 cells	 with	 pyocyanin	 and	 finally,	 to	 decease	mitochondrial	membrane	potential,	a	 finding	suggesting	a	direct	 interaction	between	pyocyanin	and	mitochondria.	Confocal	microscopy	studies	indicated	that	 extracellularly	 administered	pyocyanin	 reaches	mitochondria,	where	 it	may	 enhance	 the	 production	 of	ROS	 and	 alter	mitochondrial	 ultrastructure	by	 mechanisms	 that	 are	 still	 poorly	 defined	 (O’Malley	 et	 al.,	 2003).	 	 One	possibility	could	be	that	pyocyanin	can	directly	interact	with	the	respiratory	chain	complexes.	 Interestingly,	Rho0	yeast	mutants,	which	are	devoid	of	the	mitochondrial	 respiratory	 chain,	 have	 been	 reported	 to	 be	 almost	 entirely	resistant	 to	 pyocyanin	 under	 aerobic	 conditions	 (Barakat,	 Goubet,	 Manon,	Berges,	 &	 Rosenfeld,	 2014).	 Thus,	 elucidation	 of	 the	 mechanism	 by	 which	pyocyanin	affects	mitochondrial	functions	in	intact	cells	 is	an	important	but	still	largely	unexplored	topic.		The	primary	response	of	the	lung	during	P.aeruginosa	infection	is	carried	out	by	macrophages	and	lymphocytes	are	involved	in	the	primary	response,	but	neutrophils	 are	 most	 important	 and	 absolutely	 necessary	 for	 the	 host’s	defence	against	 the	bacteria.	This	 is	also	confirmed	by	 the	 fact	 that	 in	vivo,	when	 mice	 are	 deprived	 of	 neutrophils	 (i.e.	 neutropenia),	 their	 lung	 are	greatly	 sensitized	 to	pulmonary	P.	aeruginosa	 infection,	 and	 the	application	of	 even	 very	 low	 numbers	 of	 bacteria	 to	 the	 lung	 is	 lethal	 for	 them	 (Koh,	Priebe,	Ray,	Van	Rooijen,	&	Pier,	2009).	 	On	 the	other	hand,	when	mice	are	depleted	 of	 lymphocytes	 their	 mortality	 upon	 infection	 with	 P.	 aeruginosa	increases	only	slightly	(Dunkley,	Clancy,	Cripps,	&	Medicine,	1994),	underling	the	 critical	 role	 of	 neutrophils	 in	 the	 immune	 response	 against	 this	bacterium.	 Therefore	 it	 is	 important	 to	 define	 the	 mechanism	 by	 which	pyocyanin	interacts	with	neutrophils	of	the	host.	Recently,	new	insights	have	been	 addressed,	 clarifying	 the	 effects	 of	 pyocyanin	 on	 mitochondria	 and	identifying	other	molecular	player	involved	in	pyocyanin	toxicity	(Managò	et	al.,	2015).										
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Several types of channels play a role in the maintenance of ion homeostasis in
subcellular organelles including endoplasmatic reticulum, nucleus, lysosome, endosome,
and mitochondria. Here we give a brief overview of the contribution of various
mitochondrial and other organellar channels to cancer cell proliferation or death. Much
attention is focused on channels involved in intracellular calcium signaling and on ion fluxes
in the ATP-producing organelle mitochondria. Mitochondrial K+ channels (Ca2+-dependent
BKCa and IKCa, ATP-dependent KATP, Kv1.3, two-pore TWIK-related Acid-Sensitive K+
channel-3 (TASK-3)), Ca2+ uniporter MCU,Mg2+-permeable Mrs2, anion channels (voltage-
dependent chloride channel VDAC, intracellular chloride channel CLIC) and the Permeability
Transition Pore (MPTP) contribute importantly to the regulation of function in this organelle.
Since mitochondria play a central role in apoptosis, modulation of their ion channels by
pharmacological means may lead to death of cancer cells. The nuclear potassium channel
Kv10.1 and the nuclear chloride channel CLIC4 as well as the endoplasmatic reticulum
(ER)-located inositol 1,4,5-trisphosphate (IP ) receptor, the ER-located Ca23 + depletion
sensor STIM1 (stromal interaction molecule 1), a component of the store-operated Ca2+
channel and the ER-resident TRPM8 are also mentioned. Furthermore, pharmacological
tools affecting organellar channels and modulating cancer cell survival are discussed.
The channels described in this review are summarized on Figure 1. Overall, the view
is emerging that intracellular ion channels may represent a promising target for cancer
treatment.
Keywords: cancer, organelles, ion channel, apoptosis, pharmacology
MITOCHONDRIA
The “impermeable” mitochondrial inner membrane (IMM)
allows the formation of an electrochemical proton gradient which
drives the aerobic synthesis of ATP. The “semipermeable” outer
membrane (OMM) encloses a periplasmic space where proteins
with fundamental roles in cell death are stored until a sufficiently
strong pro-apoptotic signal arrives. Mitochondria have assumed
a peculiar role in cancer cell physiology (Ralph and Neuzil, 2009).
They are crucial for the control of intracellular Ca2+ homeostasis,
and produce reactive oxygen species (ROS). ROS are involved in
the regulation of physiological processes, but may also be harm-
ful if produced excessively. Mitochondria are the checkpoint of
the intrinsic pathway of apoptosis: the release of caspase cofac-
tors, such as cytochrome c (cyt c) and SMAC/Diablo, results in
the assembly of the apoptosome and in commitment of the cell
to apoptosis. In cancer cells mitochondrial metabolism is deregu-
lated to optimize the production of glycolytic intermediates for
anabolic reactions. Much effort has been devoted to discover
drugs inducing cancer cell death by targeting tumor-specific alter-
ations of mitochondrial metabolism or by stimulating OMM
permeabilization and thus, allowing the release of apoptotic co-
factors (Fulda et al., 2010). Mitochondrial ion channels play a
role in this process by influencing organellar membrane poten-
tial, ROS production, volume, calcium homeostasis, and possibly
morphology. The mitochondrial channels characterized over the
last two decades include outer membrane-located VDAC and
MAC in the IMM, potassium channels mtKATP, mtBKCa, mtIKCa,
mtKv1.3, TASK-3, the non-selective permeability transition pore
PTP, chloride channels, and the calcium uniporter (e.g., Zoratti
et al., 2009; Shoshan-Barmatz et al., 2010; Rizzuto et al., 2012;
Szabò et al., 2012).
CHANNELS OF THE OUTERMITOCHONDRIAL MEMBRANE INVOLVED
IN APOPTOSIS/CANCER
Mitochondrial apoptosis-induced channel (MAC)
OMM permeabilization has been proposed to involve oligomers
of pro-apoptotic Bax, which display ion channel activity in phos-
pholipid bilayers (e.g., Tait and Green, 2010). However, the
hypothesis that Bax alone is sufficient to induce cyt c release
has been challenged, given that a single point mutant of Bax did
not mediate cell death in Bax/Bak-less mouse embryonic fibrob-
lasts despite forming channels with properties similar to WT Bax
(Brustovetsky et al., 2010; Szabò et al., 2011). A pore (mito-
chondrial apoptosis-induced channel, MAC) with an estimated
diameter sufficient to allow the passage of cyt c was detected by
patch clamp (Martinez-Caballero et al., 2009). The timing of cyt c
release in apoptotic cells correlated with the onset of MAC activity
and with the translocation of Bax to mitochondrial membranes.
MAC, whose formation requires Bim-induced activation of Bax
and a still unidentified protein, is considered as a target for novel
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FIGURE 1 | Ion channels involved in regulation of apoptosis and/or
tumorigenesis are shown in different organelles. Channels for whose
crucial role pharmacological and/or genetic in vivo evidence is available are
shown in red.
cancer therapies (Peixoto et al., 2012) but specific MAC activators
are not available yet. The BH3mimetic ABT-737, an efficient anti-
cancer agent in vivo, activates MAC by disrupting Bcl-2/Bax/Bim
complexes (Dejean et al., 2010).
Mitochondrial voltage dependent anion channel (VDAC)
The major protein of the OMM, porin or VDAC is deeply
involved in apoptosis. The role of VDAC1 and of the other iso-
forms VDAC2 and VDAC3 in cell death is multi-faceted and com-
plex (e.g., McCommis and Baines, 2012; Shoshan-Barmatz and
Golan, 2012; Shoshan-Barmatz and Mizrachi, 2012). Formation
of a large pore comprising VDAC and Bax/Bak was proposed to
account for cyt c release (Tsujimoto and Shimizu, 2000; but see
Martinez-Caballero et al., 2009). Alternatively, dimers and higher
oligomers of VDAC1 might form the conduit for the efflux of
cyt c (Shoshan-Barmatz et al., 2010). Binding of anti-apoptotic
Bcl-2 and BclxL to VDAC1 (with resulting inhibition of porin)
(Shimizu et al., 2000) has an anti-apoptotic action (e.g., Arbel
et al., 2012). In contrast, block of VDAC1 by the phosphoroth-
ioate oligonucleotide G3139 (Tan, 2012) or by avicins (plant
saponins with anticancer activity) is pro-apoptotic, presumably
by reducing flux of metabolites across the OMM (Haridas et al.,
2007). VDAC2 inhibits Bak activation and apoptosis (Cheng et al.,
2003), and Bak reportedly relocates from the OMM to the ER in
the absence of VDAC2 (Raghavan et al., 2012). In contrast, Bax-
induced cyt c release from mitochondria isolated from WT or
VDAC1−, VDAC3− and VDAC1/VDAC3-null cells was reported
to be the same (Baines et al., 2007).
VDAC may inhibit apoptosis and promote tumorigenesis
through specific interactions with enzymes favoring glycolysis. It
is being examined as a cancer-specific target since tumor cells have
elevated glycolysis and increased expression of VDACs (Grills
et al., 2011). Overexpression of Hexokinase-2 (HK2) and its asso-
ciation with VDAC are key features of glycolytic cancers (e.g.,
Wolf et al., 2011). HK2 binding to the conduit channeling ATP
out of mitochondria provides a metabolic benefit to cancer cells
(Warburg effect) and it antagonizes cell death via inhibition of
Bax-induced cyt c release (Pastorino et al., 2002; Gall et al., 2011)
and/or inhibition of the Mitochondrial Permeability Transition
(MPT) (Chiara et al., 2008). HK detachment seems to favor
cell death by disruption of aerobic glycolysis and of the energy
balance of the cell, regulation of ROS production, altered inter-
action of Bcl2 family proteins with mitochondria, facilitation of
VDAC oligomer formation (e.g., Shoshan-Barmatz et al., 2010;
Shoshan-Barmatz and Golan, 2012). Therefore, a major oncolog-
ical target is the HK-VDAC complex (e.g., Galluzzi et al., 2008;
Simamura et al., 2008; Fulda et al., 2010; Mathupala and Pedersen,
2010). HK2 can be dissociated from mitochondria by peptides
interfering with HK-VDAC association, by erastin (Yagoda et al.,
2007) and by 3-bromopyruvate (e.g., Cardaci et al., 2012; Ko
et al., 2012; Pedersen, 2012; Shoshan, 2012). Antifungal drugs
clotrimazole and bifonazole and the plant hormone methyl jas-
monate (MJ) are also effective. MJ is particularly promising since
it has selective anticancer activity in preclinical studies (Fulda
et al., 2010). Finally, the anti-cancer agent furanonaphthoquinone
(FNQ) induces caspase-dependent apoptosis via the production
of ROS, which is enhanced by VDAC1 overexpression (Simamura
et al., 2008). A systematic search for compounds acting at the level
of VDAC to antagonize cancer remains to be performed.
ION CHANNELS OF THE INNER MITOCHONDRIAL MEMBRANE
INVOLVED IN APOPTOSIS/CANCER
Permeability transition pore (MPTP)
When the IMM becomes freely permeable to solutes, the conse-
quences for the cell can be catastrophic. Thus, the selective induc-
tion of IMM permeabilization in cancer cells is a strategy worth
pursuing in oncotherapy. A number of cellular stresses and cyto-
toxic agents trigger the prime example of such a catastrophe, i.e.,
the mitochondrial permeability transition (MPT), considered as
a final common pathway of cell death (Brenner andGrimm, 2006;
Bernardi, 2013). The MPT is caused by the opening of a large
Ca2+- and oxidative stress-activated pore [the mitochondrial
megachannel, MMC, with a conductance of up to 1.5 nS (Szabó
and Zoratti, 1991)] which makes the IMM permeable to ions and
solutes up to about 1500Da MW, leading to matrix swelling.
MPT is considered to bear substantial responsibilities in the
tissue damage caused by, e.g., ischemia/reperfusion and oxidative
stress. In cancer cells, instead, signaling pathways are activated
which desensitize the mitochondria to MPT induction (Rasola
et al., 2010; Matassa et al., 2012; Traba et al., 2012), while
chemotherapeutic agents causing oxidative stress may activate sig-
nals causing death via the MPT (Chiara et al., 2012). Cyclosporin
A (CSA), a cyclic endecapeptide, is a powerful inhibitor of the
MPTP (Fournier et al., 1987; Crompton et al., 1988; Broekemeier
et al., 1989) (and also of calcineurin and thus is a widely used
immunosuppressant). CSA inhibits the MPTP via its binding to
matrix cyclophilin (CyP) D, a peptidyl-prolyl cis-trans isomerase
(PPIase). Patients treated with CSA to prevent transplant rejec-
tion have a high incidence of cancer not only because of the drug’s
immunosuppressive action, but also because CSA inhibits the
MPTP (Norman et al., 2010). The molecular nature of the MPTP
is being finally delineated: the dimeric form of ATP synthase and
CypD as regulator are currently proposed as components (Baines
et al., 2005; Bernardi, 2013; Giorgio et al., 2013).
For oncological applications MPT inducers are relevant,
despite the likelihood of noxious side-effects, for example on
the nervous system. A large number of compounds, often used
at relatively high concentrations, have been shown to induce
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the MPT in cultured cells, often as a consequence of oxidative
stress and/or disruption of Ca2+ homeostasis. Some MPTP-
targeting molecules such as 4-(N-(S-glutathionylacetyl) amino)
phenylarsenoxide are currently being evaluated in clinical trials
for cancer treatment of refractory tumors (Brenner and Moulin,
2012; Elliott et al., 2012).
Signaling pathways which modulate occurrence of the MPT
have been elucidated, a key component being GSK3α/β whose
activation, e.g., by induction of oxidative stress by gold com-
plex AUL12, favors MPTP opening (Chiara and Rasola, 2013).
A large portion of MPTP openers are natural compounds like
jasmonates (e.g., Raviv et al., 2013), betulinic acid, the synthetic
retinoid CD437 (Lena et al., 2009; Javadov et al., 2011), berberine
(Pereira et al., 2007, 2008), honokiol (Li et al., 2007), α-bisabolol
(Cavalieri et al., 2009) and shikonin (Han et al., 2007), just to
name a few. Data on in vivo anti-tumor activities are available
for all these compounds (Fulda et al., 2010). Mitochondria-
penetrating peptides, such as mastoparan-like sequences, pep-
tides of the innate immunity systems, or the molecules developed
by Kelley’s group (e.g., Risso et al., 2002; Jones et al., 2008; Horton
et al., 2012) also induce MPT. Some MPTP-targeting molecules
such as 4-(N-(S-glutathionylacetyl) amino) phenylarsenoxide are
currently being evaluated in clinical trials for cancer treatment of
refractory tumors (Brenner andMoulin, 2012; Elliott et al., 2012).
IMM potassium channels Kv1.3, BKca, IKca, and TASK-3 in the
regulation of apoptosis/cancer
A functional mitochondrial counterpart of the potassium chan-
nel Kv1.3 has been identified in the IMM of several cell types
(mtKv1.3) (Szabò et al., 2005; Gulbins et al., 2010). It is
expected to participate in regulation of mitochondrial mem-
brane potential, volume, and ROS production. A crucial role
of mtKv1.3 in apoptosis became evident since expression of a
mitochondria-targeted Kv1.3 construct was sufficient to sensi-
tize apoptosis-resistant CTLL-2 T lymphocytes, which lack Kv
channels. MtKv1.3 has been identified as a target of Bax and
physical interaction between the two proteins in apoptotic cells
has been demonstrated (Szabó et al., 2008; Szabò et al., 2011).
Incubating Kv1.3-positive isolated mitochondria with Bax trig-
gered apoptotic events including membrane potential changes
(hyperpolarization followed by depolarization due to the opening
of MPTP), ROS production and cyt c release, whereas Kv1.3-
deficient mitochondria were resistant. Highly conserved Bax
lysine 128 protrudes into the intermembrane space (Annis et al.,
2005) and mimics a crucial lysine in Kv1.3-blocking peptide tox-
ins. Mutation of Bax at K128 (BaxK128E) abrogated its effects on
Kv1.3 andmitochondria, as well as in Bax/Bak-less double knock-
out (DKO) mouse embryonic fibroblasts, indicating a toxin-like
action of Bax on Kv1.3 to trigger mitochondrial phenomena.
Psora-4, PAP-1 and clofazimine, three membrane-permeant
inhibitors of Kv1.3, can induce death by directly targeting
the mitochondrial channel, while membrane-impermeant Kv1.3
inhibitors ShK or Margatoxin did not induce apoptosis (Leanza
et al., 2012a,b). Importantly, the membrane-permeant drugs
killed cells also in the absence of Bax and Bak, in agreement
with the above model. Genetic deficiency or siRNA-mediated
downregulation of Kv1.3 abrogated the effects of the drugs.
Intraperitoneal injection of clofazimine reduced tumor size by
90% in an orthotopic melanoma B16F10 mouse model in vivo,
while no adverse effects were observed in several healthy tissues.
Similar results were obtained with primary human cancer cells
from patients with chronic lymphocytic leukemia (Leanza et al.,
2013). The selective action of these drugs on tumor cells is related
to a synergistic effect of a higher expression of Kv1.3 and of an
altered redox state of cancer cells. The fact that clofazimine is
already used in the clinic for the treatment of e.g., leprosis (Ren
et al., 2008) and shows an excellent safety profile supports the
feasibility of targeting mtKv1.3 for therapy.
The large conductance calcium- and voltage-activated K+
channel BKCa (KCa1.1) has been revealed also in intracellular
membranes, including nuclear membrane, ER, Golgi and mito-
chondria (Xu et al., 2002; O’Rourke, 2007; Singh et al., 2012).
Patch clamp experiments with recombinant Bax showed an inhi-
bition of BKCa, which might contribute to opening of the MPTP
during cell death (Cheng et al., 2011).
The intermediate conductance potassium channel (IKCa;
KCa3.1), selectively inhibited by clotrimazole and TRAM-34,
has been recorded from the inner mitochondrial membranes of
human cancer cells (De Marchi et al., 2009; Sassi et al., 2010).
TRAM-34 used alone did not induce apoptosis (Sassi et al., 2010;
Quast et al., 2012), but it synergistically increased sensitivity to
the death receptor ligand TRAIL in melanoma cells (Quast et al.,
2012). Given that both TRAM-34 and TRAIL have a relatively
good safety profile, co-administration of the two drugs might be
exploited for melanoma treatment.
Recently TASK-3 (KCNK9), a two-pore potassium channel,
was identified in mitochondria of melanoma and keratinocyte
(Rusznák et al., 2008) as well as healthy intestinal epithelial cells
(Kovács et al., 2005). Reduced expression of TASK-3 resulted in
compromised mitochondrial function and cell survival in WM35
melanoma cells (Kosztka et al., 2011). Whether TASK-3 protein
gives rise to a functional channel in the IMM and whether it will
become an oncological target remain to be determined.
OTHER IMM CHANNELS LINKED TO TUMORIGENESIS: UNCOUPLING
PROTEIN UCP, Mg2+ CHANNELMrs-2 AND CALCIUM UNIPORTERMCU
Uncoupling protein-2 (UCP-2), which mediates proton leak
(Cannon and Nedergaard, 2004; Fedorenko et al., 2012), has
been proposed to regulate cell survival by decreasing mito-
chondrial ROS, since a depolarizing proton leak is expected to
diminish superoxide production (Baffy et al., 2011). UCP2 over-
expression reportedly prevents oxidative injury, thereby possibly
contributing to a higher apoptotic threshold assisting survival
of cancer cells. Over-expression of UCP2 was found in numer-
ous types of tumors and has been shown to protect cells from
oxidative stress (Arsenijevic et al., 2000; Zhang et al., 2007)
and even to abolish chemotherapeutic agent- induced apopto-
sis (Derdak et al., 2008). Ectopic expression of UCP2 in MCF7
breast cancer cells leads to a decreased mitochondrial mem-
brane potential and increased tumorigenic properties as mea-
sured by cell migration, in vitro invasion, and anchorage inde-
pendent growth. Interestingly, UCP2 over-expression has also
been proposed to directly contribute to the Warburg pheno-
type (Samudio et al., 2008) and to development of tumors in
an orthotopic model of breast cancer (Ayyasamy et al., 2011).
Cisplatin downregulated the expression of UCP2 in colon cancer
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cells (Santandreu et al., 2010), suggesting that UCP2 over-
expression is involved in the development of a variety of cancers.
UCP2 can be considered as a promising oncological target.
Mitochondria accumulate Mg2+ via Mrs2, a Mg2+–selective
channel of the IMM (Kolisek et al., 2003). An early increase in
cytosolic Mg2+ occurs during apoptosis (Chien et al., 1999) and
this ion seems to be required for cytochrome c release (Kim
et al., 2000). Long-lasting knock-down of Mrs2 caused cell death
by inducing loss of respiratory complex I and mitochondrial
membrane depolarization (Piskacek et al., 2009). A subtrac-
tive hybridization method applied on vincristine or adriamycin
resistant and parental human gastric adenocarcinoma cell lines
highlighted upregulation of Mrs2 (Chen et al., 2009), suggesting
that high expression of Mrs2 may protect against death (Wolf and
Trapani, 2009).
The molecular identification of the mitochondrial Ca2+ “uni-
porter” (MCU), responsible for the low-affinity uptake of calcium
into the mitochondrial matrix (Kirichok et al., 2004), has recently
been achieved (Baughman et al., 2011; De Stefani et al., 2011).
MCU participates in the control of Ca2+ signaling in the whole
cell, and may thus be a very useful tool to influence the myr-
iad cellular calcium-dependent processes, including cell death
(Rizzuto et al., 2012). Subthreshold apoptotic signals were shown
to synergize with cytosolic Ca2+ waves (Pinton et al., 2001)
resulting in opening of MPTP. Cells overexpressing MCU under-
went more pronounced apoptosis upon challenging with H2O2
and C2-ceramide (De Stefani et al., 2011). Overexpression of an
MCU-targeting microRNA, miR-25, in colon cancer cells resulted
in MCU downregulation, impaired calcium uptake and increased
resistance to apoptosis (Marchi et al., 2013). Thus, MCU seems to
be a crucial protein for tumorigenesis and its specific pharmaco-
logical activators, if identified, might become useful tools.
ION CHANNELS IN OTHER ORGANELLESWITH A ROLE IN
APOPTOSIS/TUMORIGENESIS
The intracellular chloride channel CLIC4/mtCLIC has both a sol-
uble and a membrane-inserted form and can be localized to the
mitochondrial inner membrane (Fernández-Salas et al., 1999),
cytoplasm, ER membrane, and the nucleus. CLIC4 overexpres-
sion induced apoptosis associated with loss of mitochondrial
membrane potential, cytochrome c release, and caspase activation
(Fernández-Salas et al., 2002). On the other hand, inhibition of
CLIC4 expression triggered mitochondrial apoptosis under star-
vation and enhanced autophagy in glioma cells (Zhong et al.,
2012). Marked changes in expression and subcellular localiza-
tion of CLIC4 occur early in tumorigenesis. In particular, reduced
CLIC4 expression and nuclear localization in cancer cells is asso-
ciated with the altered redox state and CLIC4 acts as an important
suppressor of squamous tumor development and progression
(Suh et al., 2012).
A functional “oncogenic” potassium channel, Kv10.1 has been
described in the nuclear inner membrane (Chen et al., 2011)
where it might participate in setting nuclear [K+] thereby affect-
ing gene expression. The PM Kv10.1 is also rapidly internal-
ized to lysosomes (Kohl et al., 2011), whose patch clamping
has been achieved (Wang et al., 2012). The possible influ-
ence of these channels on cancer cell survival remains to be
determined.
Finally, we should briefly mention other intracellular chan-
nels involved in Ca2+ signaling, (Ca2+ permeable channels are
discussed in detail by other contributions in this special issue).
For example the calcium-permeable ion channel TRPM8, overex-
pressed in several tumors, has been located to the ER (Zhang and
Barritt, 2004), resulting in decreased ER [Ca2+] and increased
resistance to apoptosis (Bidaux et al., 2007). Patients suffering
of breast cancers with high ER-located STIM1 levels have signifi-
cantly reduced survival (McAndrew et al., 2011). The PM-located
other component, ORAi1 contributes to altered calcium home-
ostasis as well (Monteith et al., 2012). Expression of ER-resident
IP3 receptors acting as Ca2+ store release channels is altered in
glioblastoma (Kang et al., 2010). Repression of IP3- mediated
Ca2+ elevation by Bcl-2 has been proposed to contribute to the
pathophysiology of chronic lymphocytic leukemia (Zhong et al.,
2011).
In summary, while considerable further work is required to
clarify the mechanisms by which intracellular channels contribute
to tumorigenesis and tumor progression, or intervene in cell
death, a few in vivo studies targeting these channels underline the
importance of pursuing this line of research.
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Pseudomonas aeruginosa Pyocyanin Induces Neutrophil
Death via Mitochondrial Reactive Oxygen Species
and Mitochondrial Acid Sphingomyelinase
Antonella Manago`,1,* Katrin Anne Becker,2,* Alexander Carpinteiro,2 Barbara Wilker,2 Matthias Soddemann,2
Aaron P. Seitz,3 Michael J. Edwards,3 Heike Grassme´,2 Ildiko Szabo`,1,{ and Erich Gulbins2,3,{
Abstract
Aims: Pulmonary infections with Pseudomonas aeruginosa are a serious clinical problem and are often lethal.
Because many strains of P. aeruginosa are resistant to antibiotics, therapeutic options are limited. Neutrophils play an
important role in the host’s early acute defense against pulmonary P. aeruginosa. Therefore, it is important to define
the mechanisms by which P. aeruginosa interacts with host cells, particularly neutrophils. Results: Here, we report
that pyocyanin, a membrane-permeable pigment and toxin released by P. aeruginosa, induces the death of wild-type
neutrophils; its interaction with the mitochondrial respiratory chain results in the release of reactive oxygen species
(ROS), the activation of mitochondrial acid sphingomyelinase, the formation of mitochondrial ceramide, and the
release of cytochrome c from mitochondria. A genetic deficiency in acid sphingomyelinase prevents both the
activation of this pathway and pyocyanin-induced neutrophil death. This reduced death, on the other hand, is
associated with an increase in the release of interleukin-8 from pyocyanin-activated acid sphingomyelinase-deficient
neutrophils but not from wild-type cells. Innovation: These studies identified the mechanisms by which pyocyanin
induces the release of mitochondrial ROS and by which ROS induce neutrophil death via mitochondrial acid
sphingomyelinase. Conclusion: These findings demonstrate a novel mechanism of pyocyanin-induced death of
neutrophils and show how this apoptosis balances innate immune reactions. Antioxid. Redox Signal. 22, 1097–1110.
Introduction
Pseudomonas aeruginosa infections are clinicallyvery serious for immunosuppressed patients and for
those with trauma, burn wounds, ventilator-associated
pneumonia, sepsis, or cystic fibrosis (30). It is therefore very
important to define the first-line defense mechanisms of the
immune system and their interaction with the pathogen.
Previous studies have shown that macrophages and lym-
phocytes are involved in the primary response of the lung to
P. aeruginosa, but neutrophils are most important and are
absolutely necessary for the host’s defense against the
bacteria (5, 16). It has been reported that mortality rates of
mice depleted of lymphocytes increase only slightly (5) and,
surprisingly, that the depletion of macrophages does not
affect mortality rates at all (16). In marked contrast, neu-
tropenia or the inhibition of neutrophil migration to the lung
greatly sensitizes mice to pulmonary P. aeruginosa infec-
tion, and the application of even very low numbers of bac-
teria to the lung is lethal for neutropenic mice (5, 16).
Although the induction of proinflammatory mediators and
the activation of neutrophils are required for an efficient
innate immune response to pathogens, this activation must
be carefully balanced and turned off, because overshooting
immune activation may result in a cytokine storm and a
lethal shock syndrome.
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We have previously shown that a deficiency in acid sphin-
gomyelinase (human protein, ASM; EC 3.1.4.12, sphingo-
myelin phosphodiesterase; optimal pH 5.0; murine protein,
Asm; gene symbol, Smpd1) overshoots the activation of the
immune system after pulmonary infection with P. aeruginosa
(9). At present, the mechanisms by which a deficiency in Asm
disturbs the balance of innate immune activation are unknown.
Asm is ubiquitously expressed and releases ceramide from
sphingomyelin, predominantly not only in lysosomes but also
in secretory lysosomes and on the plasma membrane (7, 13,
25). The ceramidemolecules generated byAsm spontaneously
associate to form ceramide-enriched membrane domains that
serve to trap and cluster receptor and signaling molecules (8,
11, 12, 25). This spatial organization of receptors and signaling
molecules seems to mediate many of the signaling effects of
Asm and ceramide (11). This general function in the organi-
zation of cellular signaling explains the involvement of Asm in
many forms of cellular stress.
ASM is also present in mitochondria (21). However, its
physiological function and significance in these organelles
are unknown.
P. aeruginosa can induce neutrophil death by a variety of
factors, including exoenzyme U (Exo U), a phospholipase A2;
pyocyanin, a phenazine; and rhamnolipids (17, 26). Bacteria that
lack pyocyanin are less pathogenic in vivo (3), a finding indi-
cating that this factor plays an important role in in vivo infection.
Pyocyanin is a redox-active compound capable of ac-
cepting and donating electrons. It has been detected at con-
centrations till 100 lM in the sputum of patients with cystic
fibrosis (36). Because pyocyanin can cross biological mem-
branes, it serves as a mobile electron carrier for P. aeruginosa
(29). Under aerobic conditions, pyocyanin directly oxidizes
reduced nicotinamide adenine dinucleotide phosphate
(NADPH) in the host cell cytoplasm and donates accepted
electrons to oxygen molecules to produce superoxide anions
and reactive oxygen species (ROS) (29). Pyocyanin, how-
ever, has been also shown to decrease both cellular adenosine
trisphosphate (ATP) levels and the mitochondrial membrane
potential (MMP), a finding suggesting a direct interaction
between pyocyanin and mitochondria (15, 22). Mitochondria
are crucial for the production of ATP, the regulation of in-
tracellular Ca2 + homeostasis, and the production of ROS.
They are also key participants in the regulation of cell death.
Confocal microscopy studies indicate that extracellu-
larly administered pyocyanin reaches mitochondria, where it
may enhance the production of ROS and alter mitochondrial
ultrastructure by mechanisms that are still poorly defined
(22). Rho0 cells, which are devoid of the mitochondrial re-
spiratory chain, have been reported to be almost entirely re-
sistant to pyocyanin under aerobic conditions (1). Thus,
elucidation of the mechanism by which pyocyanin affects
mitochondrial functions in intact cells is an important but still
largely unexplored topic.
The studies reported here focused on the molecular mech-
anisms that determine the balance between the proinflam-
matory and proapoptotic effects of pyocyanin in neutrophils. In
particular, we investigated a possible effect of pyocyanin on
mitochondria. Indeed, not only mitochondria are the check-
point for the release of procaspases and caspase cofactors such
as cytochrome c during cell death (6), but also they coordinate
the inflammasome and inflammatory pathways (38).
We found that bacterial pyocyanin interferes with mito-
chondrial respiration and that this interference results in the
formation of ROS and in the loss of MMP within a few
minutes, even in intact cells. ROS then activate mitochon-
drial Asm, trigger the release of mitochondrial ceramide and
the release of cytochrome c from mitochondria, and induce
cell death. A deficiency in Asm prevents the pyocyanin-
induced release of cytochrome c from isolated mitochondria,
thereby preventing cell death. This reduced cell death, on the
other hand, is associated with an increase in the release of
interleukin-8 (IL-8) from pyocyanin-activated cystic fibrosis
neutrophils but not from wild-type cells.
Results
Pseudomonas aeruginosa induces the death
of neutrophils via acid sphingomyelinase
Neutrophils not only are key cells of the innate immune
system but also play an important role in cystic fibrosis and its
associated lung changes. To define the molecular mecha-
nisms of the interaction between neutrophils and P. aerugi-
nosa, we tested whether the P. aeruginosa strain ATCC
27853 induces the death of cultured and ex vivo neutrophils.
We stimulated HL-60 cells with retinoic acid to induce their
maturation to neutrophils and then determined cell death 8 h
after infection with P. aeruginosa by staining the cells with
Cy3-labeled annexin V and analyzing them by fluorescence-
activated cell sorting (FACS). Furthermore, we isolated
peritoneal neutrophils from wild-type and Asm-deficient
mice and infected them with P. aeruginosa. The results
showed that neutrophils lacking Asm are resistant to
P. aeruginosa-induced death, whereas wild-type neutrophils
rapidly undergo apoptosis after infection with P. aeruginosa
strain ATCC 27853 (Fig. 1A). Similar findings were obtained
with a second P. aeruginosa strain, 762 (not shown).
P. aeruginosa releases soluble toxins that are very im-
portant for the infection of mammalian hosts. To gain insight
into the mechanism of P. aeruginosa-induced cell death, we
incubated the pathogen directly with isolated mitochondria,
key organelles in many forms of cell death. We determined
cytochrome c release as a measurement for apoptotic changes
in isolated mitochondria. Because it has been previously
shown that Asm is present in the mitochondrial intermem-
brane space and that it associates with procaspase 3 and ni-
trous oxide (NO) synthases (21), we also tested the effect of
P. aeruginosa on Asm-deficient mitochondria. The results
Innovation
The studies described here identified the mechanisms of
mitochondrial reactive oxygen species (ROS) release by
Pseudomonas aeruginosa pyocyanin. The Asm/ceramide
system is functional in mitochondria and is activated by
ROS. Mitochondrial Asm mediates both cytochrome c
release from mitochondria and cell death. Induction of
cell death not only is a part of the method by which
P. aeruginosa attack the host, but it also prevents an
overshooting inflammatory reaction, which is observed in
Asm-deficient cells. The results of these studies may be
important for understanding sepsis and the often-lethal
cytokine storm, as well as for defining molecular events
involved in the interaction between pyocyanin and neu-
trophils in P. aeruginosa infections.
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showed that incubating isolated mitochondria from wild-type
neutrophils with P. aeruginosa strains 762 or ATCC 27853
results in the release of cytochrome c, an effect that is ab-
rogated by a deficiency of Asm in mitochondria isolated
from Asm-deficient neutrophils (Fig. 1B). Control studies
confirmed that the mitochondrial preparations did not con-
tain lysosome-associated membrane protein 2 (LAMP-2)
and cathepsin D but were very highly enriched in cyto-
chrome c and in Tim and Tom proteins, findings that ex-
clude contamination with lysosomes that also contain Asm
(not shown).
To gain insight into the mechanisms by which P. aerugi-
nosa kill neutrophils, we determined whether the bacterial
product, pyocyanin, is involved in this process and whether
pyocyanin acts in mitochondria by stimulating mitochondrial
Asm and releasing ceramide.
Pyocyanin induces ROS in mitochondria
To gain in-depth insight into the possible interaction be-
tween pyocyanin and mitochondria, we first determined the
short-term effects of pyocyanin on mitochondrial function in
intact cells. The addition of 50 lM pyocyanin, a concentra-
tion that has been measured in the sputum of patients (36)
and, thus, is pathophysiologically relevant, to Jurkat lym-
phocytes or neutrophils resulted in an immediate increase in
superoxide anion production at the level of the mitochondria
(Fig. 2A, B). This increase was assessed with MitoSOX Red,
a mitochondria-targeted fluorogenic dye that can directly
measure the superoxide generated in the mitochondria of live
cells. Superoxide anion (O2
- !), the product of reducing ox-
ygen by one electron (produced by various respiratory
complexes that leak electrons to oxygen, producing primarily
superoxide anions), is the precursor of most ROS. We used
antimycin A, an inhibitor of complex III activity, as a positive
control to force electrons to leak outside of the tight single-
electron transfer mechanism, causing the production of su-
peroxide anions. Dismutation of O2
- ! produces hydrogen
peroxide (H2O2), which, in turn, may be fully reduced to H2O
or partially reduced to hydroxyl radical (OH!), one of the
strongest oxidants. Although pyocyanin has been reported to
directly interact with 2¢,7¢-dichlorodihydrofluorescein and
dihydrorhodamine, which are commonly used to detect ROS
(22), it did not oxidize MitoSOX (not shown). Incubation of
cells with Mito-TEMPO, a mitochondria-targeted antioxi-
dant with superoxide and alkyl-scavenging properties, sig-
nificantly reduced pyocyanin-induced ROS production (Fig.
2C). These results suggest that a considerable portion of the
pyocyanin-induced ROS production occurs at the level of
mitochondria, although some pyocyanin-induced ROS pro-
duction may also take place in the cytosol, mediated by the
ability of pyocyanin to oxidize NADPH and to reduce cel-
lular oxygen concentrations (29).
The addition of pyocyanin to intact cells not only led to
ROS production but also resulted in a very rapid but in-
complete dissipation of the MMP, Dwm (Fig. 3A). This
change in Dwm was independent of the opening of the per-
meability transition pore (PTP) (34), because it also occurred
in the presence of cyclosporin A, a potent PTP inhibitor
(Fig. 3B). Next, we used an extracellular flux analyzer to
determine the effects of pyocyanin on respiration in in-
tact adherent mouse embryonic fibroblasts. The addition of
pyocyanin to these cells immediately increased oxygen
consumption (Fig. 3C). This apparent increase in respiration
was only partially reversible by oligomycin, which blocks
ATP synthase (Fig. 3C). The subsequent addition of the un-
coupler carbonylcyanide-p-trifluoromethoxyphenyl-hydrazone
(FCCP) did not restore respiration, whereas the addition of
antimycin A, an inhibitor of complex III, further reduced but
did not completely abolish oxygen consumption (Fig. 3C).
Antimycin A, by binding to the Qi site of cytochrome c re-
ductase, inhibits the oxidation of ubiquinol in the electron
transport chain of oxidative phosphorylation. The inhibition
of this reaction disrupts respiration and prevents the forma-
tion of the proton gradient across the inner membrane. Thus,
pyocyanin drastically reduced the respiratory response to the
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FIG. 1. Acid sphingomyelinase expression is required
for cell death and the release of cytochrome c from mi-
tochondria upon infection with Pseudomonas aeruginosa.
(A) HL-60 neutrophils or freshly isolated wild-type and
Asm-deficient peritoneal neutrophils were infected for 8 h
with P. aeruginosa strain ATCC 27853. Apoptosis was
determined by staining with FITC-annexin V. Displayed are
the means –SD, n = 4; *p < 0.05 compared with uninfected
and Dp < 0.05 compared with infected Asm-positive cells by
ANOVA. (B) Mitochondria were isolated from splenic
neutrophils expressing or lacking Asm. Isolated mitochon-
dria were infected with P. aeruginosa strain ATCC 27853 at
a MOI of 10 bacteria/1 mitochondrium for 15min. Ex-
pression of Asm is required for the release of Cyto c from
mitochondria by P. aeruginosa. Shown are representative
data from three independent experiments. Asm, acid
sphingomyelinase; Cyto c, cytochrome c; FITC, fluorescein
isothiocyanate; MOI, multiplicity of infection; SD, standard
deviation.
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subsequent addition of oligomycin and FCCP. Amassive loss
of cells because of death and detachment was excluded by
direct microscopic observation of the cells at the end of the
experiments. In contrast, if cellular respiration was depressed
byoligomycin, the addition of pyocyanin induced a recovery of
the respiratory rate (Fig. 3D). This recovery may be simply a
reflection of the loss ofDwm induced by pyocyanin:According
to the chemiosmotic model, depolarization with associated
respiratory stimulation is likely to reflect the appearance of a
Dwm-dissipating proton leak. Again, the subsequent addition
of FCCP had no effect, whereas antimycin A reduced respira-
tion (Fig. 3D). Similar effects were observed in both settings
with 25lM pyocyanin (not shown). These results suggest that
the pyocyanin-induced increase in oxygen consumption is only
partially caused by an increase in respiration, given the lack of
full reversal by antimycin A. Alternatively, respiration may be
increased bypassing complex III. Oxygen consumption is
probably also enhanced by the involvement of molecular ox-
ygen as an acceptor of electrons directly from pyocyanin, in-
dependent of the respiratory chain.
However, these experiments also point to a possible inter-
action between pyocyanin and the respiratory chain complexes.
One possible explanation of the generation of mitochondrial
superoxide by pyocyanin is the direct interference of the toxin
with respiration, diverting a part of the electron flow to super-
oxide production. To test this hypothesis, we used the well-
established method of alamethicin-permeabilized rat liver mi-
tochondria (RLM). We addressed the function of complexes I
and III, the main sites of ROS production, after the addition of
pyocyanin. Pyocyanin did not alter the function of complex I
(Fig. 4A).Weassessed the functionofcomplex III bymeasuring
the reduction of cytochrome c concentrations inmitochondria in
which the function of complex I was inhibited by rotenone. An
increase in absorbance measured at 550 nm corresponds with
the chemical reduction of this mobile electron carrier. On the
addition of decylubiquinol, cytochrome c reduction occurred;
this reduction was further stimulated by the addition of pyo-
cyanin. Reduced cytochrome c is then reoxidized by complex
IV. Adding the complex III inhibitor antimycinA during the re-
oxidation phase did not drastically change the rate of
FIG. 2. Pyocyanin-induced production of mitochondrial ROS in intact cells. (A) Production of mitochondrial ROS
was assayed with MitoSOX in intact Jurkat cells. Pyocyanin was added at the zero time point. (B) ROS production in
peritoneal neutrophils using MitoSOX. (C) Jurkat cells were preincubated with MitoTEMPO for 1 h before the addition of
pyocyanin. Shown are means –SD, n = 3. ROS, reactive oxygen species. To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/ars
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reoxidation. The subsequent addition of sodium azide (NaN3),
which inhibits complex IV activity, increased cytochrome c
reduction (Fig. 4B). These results indicate that pyocyanin ac-
cepts electrons from decylubiquinol and reduces cytochrome c,
thus replacing the function of complex III. Indeed, pyocyanin
reduced cytochrome c even in the presence of the complex III
inhibitor antimycin A (Fig. 4C). Reduction also occured when
all complexes were inhibited (Fig. 4D) and even in the absence
of mitochondria, provided an electron donor was present (Fig.
4E). The rate of cytochrome c reduction induced by pyocyanin
was slightly lowerwhenantimycinAwas addedafterNaN3 than
when NaN3 was used alone (Fig. 4F), a finding suggesting that
maximal reduction of cytochrome c by pyocyanin is partially
dependent on complex III activity.
ROS activate mitochondrial acid sphingomyelinase
Next, we tested whether the Asm/ceramide system func-
tions as a downstream target of pyocyanin and ROS, because
oxygen radicals have been shown to activate Asm (27), which,
in turn, releases ceramide, a proapoptotic molecule. To this
end, we purified mitochondria from freshly isolated peritoneal
neutrophils and determined the activity of Asm after treatment
with pyocyanin or H2O2. The results (Fig. 5A, B) demonstrate
a rapid activation of mitochondrial Asm activity by pyocyanin
or H2O2. The addition of Tiron, an antioxidant, to isolated
mitochondria prevented the activation of Asm by pyocyanin
(Fig. 5A), a finding demonstrating the crucial role of ROS in
Asm stimulation by pyocyanin in mitochondria.
Activation of Asm in isolated mitochondria on treatment
with pyocyanin or H2O2 resulted in a ceramide release that
was abrogated in Asm-deficient peritoneal neutrophils
(Fig. 5C). Confocal microscopy confirmed the increase in
ceramide concentrations in wild-type mitochondria after
treatment with pycoyanin; this increase did not occur in Asm-
deficient cells (Fig. 5D, E). This finding indicates that Asm is
necessary for the release of ceramide from isolated mito-
chondria after treatment with pyocyanin or H2O2.
FIG. 3. Short-term bioenergetic effects of pyocyanin in intact cells. (A) Mitochondrial membrane potential was
measured in Jurkat lymphocytes using TMRM under control conditions and on treatment with pyocyanin or uncoupler
FCCP. Mean values – SD are shown (n = 3). (B) As in (A), but after preincubation of the cells for 30min with CSA, an
inhibitor of the PTP. The arrows in panels (A) and (B) indicate addition of drugs as outlined. (C, D) OCR measured in intact
cells on addition of the indicated compounds. Results shown are representative of three independent experiments. CSA,
cyclosporine A; FCCP, carbonylcyanide-p-trifluoromethoxyphenyl-hydrazone; OCR, oxygen consumption rate; PTP, per-
meability transition pore; TMRM, tetramethylrhodamine, methyl ester. To see this illustration in color, the reader is referred
to the web version of this article at www.liebertpub.com/ars
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FIG. 4. Function of respiratory chain complexes in isolated mitochondria on addition of pyocyanin. (A) Complex I
activity was assayed as described in the Materials and Methods section, taking into account the direct oxidation of the
complex I substrate NADH by pyocyanin (n = 5). (B–D) Cytochrome c reduction after addition of the indicated substances
in the presence of permeabilized mitochondria. Pyocyanin was added in all experiments in its oxidized state as deduced
from the measured absorption spectra (not shown). In (B), only the complex I inhibitor rotenone was present; whereas in
(C), complex I and complex IV were inhibited with rotenone and NaN3. (D) Cytochrome c was reduced after the addition of
the indicated substances in the presence of permeabilized mitochondria, whereas complexes I, III, and IV were inhibited by
rotenone, antimycin, and NaN3, respectively. (E) Experiments were performed as in (B–D), but without addition of
mitochondria. Pyocyanin itself does not reduce cytochrome c unless the electron donor decylubiquinol is added. (F) The
experiment was performed as in (B). Results shown are representative of three experiments or conditions. NaN3, sodium
azide; NADH, nicotinamide adenine dinucleotide.
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Acid sphingomyelinase negatively regulates
pyocyanin-induced production of IL-8
Mitochondria have been shown to be crucial in the ac-
tivation of inflammasomes by recruiting and activating
proinflammatory caspases; they are also crucial in the
induction of cell death by the release of cytochrome c (6,
38). Therefore, we tested the effect of pyocyanin on the
release of IL-8 and on the induction of death in freshly
isolated neutrophils from wild-type and Asm-deficient
FIG. 5. Pseudomonas aeruginosa pyocyanin activates the acid sphingomyelinase/ceramide system in mitochondria.
(A–C) Mitochondria were isolated from wt or Asm-deficient neutrophils. Aliquots were stimulated with 50 lM pyocyanin
for 10 or 30min or with H2O2 for 10min or left unstimulated. They were then lysed, and Asm activity (A, B) or
mitochondrial ceramide concentrations (C) were determined. If indicated, 10mM Tiron was added during the stimulations.
Shown are the means – SD from four independent experiments; *p < 0.05 compared with untreated samples, Dp < 0.05
compared with treated wild-type cells, by ANOVA. (D, E)Wild-type or Asm-deficient peritoneal neutrophils were cultured
on glass cover slips for 15min, stimulated with 50lM pyocyanin for 10min, or left unstimulated. They were then fixed,
permeabilized, stained with Cy3-coupled anti-ceramide and Cy5-coupled anti-Tim 23 antibodies, and analyzed by confocal
microscopy. Shown are representative results from five independent experiments (D) and mean – SD (n= 5) (E) of the
fluorescence intensity in the Cy3 channel representing ceramide levels in mitochondria as defined by staining with Cy5-
coupled anti-Tim antibodies. Fluorescence was quantified in at least 100 mitochondria per group, that is, 500 mitochondria
total. The blue color represents Cy5, the red Cy3. *p < 0.05 compared with untreated samples, Dp< 0.05 compared with
treated wild-type cells, ANOVA. H2O2, hydrogen peroxide; wt, wild-type.
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neutrophils. The results demonstrate that pyocyanin in-
duces the release of a higher amount of IL-8 from Asm-
deficient neutrophils than from wild-type cells (Fig. 6).
Basal levels of IL-8 were also higher in Asm-deficient
neutrophils than in wild-type neutrophils. These findings
indicate a negative regulation of IL-8 release from neu-
trophils by Asm and ceramide.
Pyocyanin induces the death of neutrophils via
mitochondrial acid sphingomyelinase
Pyocyanin-induced cell death in wild-type neutrophils was
determined by fluorescein isothiocyanate (FITC)-annexin
V staining of intact peritoneal neutrophils. Asm-deficient
neutrophils resisted the toxin and exhibited significantly
less apoptosis than wild-type neutrophils after treatment
with pyocyanin (Fig. 7A). In accordance, only isolated mi-
tochondria from wild-type peritoneal neutrophils, not those
from Asm neutrophils, released cytochrome c after treatment
with pyocyanin (Fig. 7B). Similar results were obtained with
neutrophils isolated from the spleen and with HL-60 cells
(Fig. 7C).
These results indicate that pyocyanin requires the expres-
sion of Asm if it is to mediate the mitochondrial release of
cytochrome c and to trigger neutrophil death.
Discussion
Neutrophils are key elements of the host defense against
infection with P. aeruginosa (16). Neutropenia greatly sen-
sitizes mice to P. aeruginosa infections, with the result that
neutropenic mice cannot eliminate the pathogens from the
lung; they experience severe pneumonia and finally lethal
sepsis (16). It is therefore of great clinical importance to
understand the molecular mechanisms of the interaction be-
tween P. aeruginosa and neutrophils and, in particular, the
mechanisms that allow the pathogen to escape the neutrophil
attack.
Previous studies demonstrated that pyocyanin-induced
death of neutrophils is an important element in the strategies
used by P. aeruginosa as protection against the host defense
(3). On the other hand, it is important for the host immune
system to prevent overactivation, which may result in a very
harmful destruction of parenchyma or even a lethal cytokine
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FIG. 6. Pyocyanin-induced interleukin-8 is negatively
regulated by acid sphingomyelinase. Peritoneal neutrophils
were obtained from wt or Asm-deficient mice and stimulated
with 50lM Pyo for 8 h. Interleukin-8 levels were determined
by ELISA. Shown are the means–SD of four independent
experiments; *p< 0.05 compared with untreated, Dp< 0.05
compared with treated wild-type cells, by ANOVA. ELISA,
enzyme-linked immunosorbent assay; Pyo, pyocyanin.
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FIG. 7. Pyocyanin-induced cell death and mitochon-
drial cytochrome c release require mitochondrial acid
sphingomyelinase. (A, C) Peritoneal neutrophils or splenic
neutrophils were obtained from wt or Asm-deficient mice.
Cells were stimulated for 8 h with 50lM pyocyanin, and
apoptosis was analyzed by FITC-annexin V staining fol-
lowed by flow cytometry. Shown are mean – SD, n= 4;
*p < 0.05 compared with untreated, Dp< 0.05 compared
with treated wild-type cells, by ANOVA. (B) Wild-type or
Asm-deficient mitochondria were incubated with 50lM
pyocyanin for 15min and centrifuged. The pellets and the
supernatants were subjected to Western blot analysis for
cytochrome c. Cyochrome c in the pellet (P) of each sam-
ple represents mitochondrial cytochrome c; cytochrome c in
the supernatant (S) of the same sample represents cycto-
chrome c released from mitochondria on induction of apo-
ptosis. The sum equals total cytochrome c. Results are
representative of six independent experiments.
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storm. Thus, the induction of neutrophil apoptosis may also
contribute to the prevention of such an overactivation of the
immune system and may balance the proinflammatory re-
sponse. In this study, we tested this novel concept of a bal-
ance between immune activation and apoptosis.
We found that pyocyanin induces rapid death of wild-type
neutrophils and that this death depends on the activation of
Asm. We report a novel mechanism for this pyocyanin ac-
tion, that is, activation of Asm in mitochondria on the gen-
eration of ROS induced by pyocyanin in mitochondria. At
present, the function and regulation of mitochondrial Asm
have not been elucidated, athough previous studies clearly
showed mitochondrial expression of the enzyme and its as-
sociation with pro-caspase 3, a protein involved in the in-
duction of apoptosis on its release from mitochondria (21).
Our studies of isolated mitochondria indicate that the release
of cytochrome c as a prototypic event for the induction of
mitochondrial changes during apoptosis is induced by pyo-
cyanin via activation of Asm and is mediated by locally
produced ROS. At present, it is unknown how ceramide
mediates this proapoptotic effect. Several studies have shown
that ceramide can form large pores that may allow proteins
such as cytochrome c and proapoptotic caspases to be re-
leased from mitochondria (32). Ceramide may also interfere
with the binding of cytochrome c to cardiolipin and may
trigger the release of cytochrome c from this lipid (14, 24);
such a release is an initial and necessary event in the induc-
tion of mitochondrial changes during apoptosis. Furthermore,
ceramide has been shown to regulate several ion channels,
including Ca2 + and K + channels (2, 10, 20). C6 ceramide has
been recently suggested to trigger PTP opening (28), and it
may be possible that endogenous ceramide mediates death by
a similar effect. Furthermore, ceramide has been shown to
trigger the integration of Bax and Bak into mitochondrial
membranes (19). Therefore, the generation of ceramide may
allow these proteins, which are cytoplasmic or loosely as-
sociated with the outer mitochondrial membrane in viable
cells, to change their conformation, integrate into the mem-
brane, and cause apoptosis. It is certainly possible that cer-
amide activates several of these events that may act in
concert. Finally, it is possible that ceramide is converted to
proapoptotic sphingosine (for a recent review see Ref. 35),
which may also permeabilize mitochondrial membranes,
interfere with cytochrome c binding to cardiolipin, or both.
The molecular mechanisms of Asm activation have been
only partially characterized. In vitro studies used purified Asm
and demonstrated direct oxidation of Asm at cysteine resi-
due 629, resulting in enzyme dimerization and activation
(27). Our studies suggest a similar mechanism of mitochon-
drial Asm activation, because the effects of pyocyanin on Asm
in isolated mitochondria were prevented by preincubation
with the antioxidant Tiron. However, at present, it is unknown
whether Asm dimerization occurs in mitochondria after stim-
ulation. It is also possible that ROS regulate some yet unknown
intermediates that transmit the signal to Asm.
In addition, Asm has been shown to be regulated by the
lipid composition of membranes (23). Thus, anionic phos-
pholipids, as well as diacylglycerol, ceramide itself, and free
fatty acids, stimulate Asm activity (23). Whether pyocyanin
induces a change in mitochondrial membrane lipids, for in-
stance by oxidation, and thereby stimulates Asm has not yet
been determined.
Finally, Asm is a pH-sensitive enzyme, and the activation
of redox processes by pyocyanin may trigger a change in pH,
in particular an acidification of the matrix that increases the
activity of Asm and the generation of ceramide.
We found that pyocyanin increases the concentration of
IL-8 in neutrophils from wild-type mice. To understand
whether this increase depends on Asm, possibly by recruit-
ment of inflammasome proteins to mitochondria (38), we
tested whether an Asm deficiency impairs the release of IL-8
by neutrophils. Our findings demonstrate that Asm-deficient
neutrophils respond to pyocyanin by releasing IL-8, the
concentration of which is much higher in these neutrophils
than in wild-type cells. These findings suggest that the release
of IL-8 from neutrophils is negatively regulated by Asm. This
conclusion is consistent with the findings of Yu et al. (37),
who reported that a deletion of Asm results in an increase in
IL-8 concentrations on infection with P. aeruginosa. A
simple explanation for the enhanced production of IL-8 by
cells lacking Asm on treatment with pyocyanin is the resis-
tance of these cells to pyocyanin-induced death, whereas
wild-type cells die on treatment with pyocyanin. However, it
is also possible that mitochondrial ceramide serves to trap
proinflammatory molecules, downregulating their activity or
preventing them from their proper interactions with other
molecules of the respective inflammasome. In this scenario,
the absence of Asm and ceramide abrogates this inhibitory
effect, resulting in a marked overactivation of neutrophils.
Thus, the proinflammatory activity of neutrophils caused by
pyocyanin is regulated by the balance between stimulation
and ceramide-mediated death, downregulation of inflamma-
tion, or both. The observed form of death is most likely
classical apoptosis brought about by changes in mitochon-
drial functions and not caused by pyroptosis, because Asm-
deficient cells release massive amounts of cytokines but do
not die.
Finally, because ROS activates death and it may also
trigger the induction of cytokines, for instance by activation
of an inflammasome, on treatment of neutrophils with pyo-
cyanin, the absence of one pathway may shunt ROS to the
other, resulting in an overactivation of this pathway.
These findings suggest that the induction of apoptosis in
neutrophils is not only a part of the pathogen’s attack against
the host but also serves to balance the innate immune re-
sponse and prevent an overshooting reaction.
Our studies further demonstrate that pyocyanin directly
affects mitochondrial functions in intact cells. In particular,
pyocyanin seems to have multiple effects within the cells and
can provide an electron shunt pathway at various respiratory
chain sites. Pyocyanin can accept electrons from both nico-
tinamide adenine dinucleotide (NADH) and ubiquinol; its
measured electrochemical redox potential (0.045mV; not
shown) is higher than that of ubiquinol ( - 0.034mV; see also
results of experiments depicted in Fig. 4). In turn, pyocyanin
can donate electrons not only to cytochrome c, as shown in
this study, but also to molecular oxygen (29). As a redox
cycler, pyocyanin can oxidize mitochondrial NADH, thereby
decreasing proton export from the matrix through respiratory
complexes and causing a significant depolarization and pre-
sumably a decrease in the pH of the matrix. Indeed, such a
decrease in the MMP can be seen in intact cells within a few
minutes of pyocyanin treatment (25% decrease within
30min). Such a change is not related to the opening of the
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PTP, because this change also occurs in the presence of cy-
closporin A, an inhibitor of the PTP. A recent study obtained
a similar result with pancreatic acinar cells: 50lM of pyo-
cyanin decreased tetramethylrhodamine, methyl ester
(TMRM) fluorescence by 18% within 40min (4). The ob-
served depolarization explains the ATP depletion of the cells,
which has also been observed by several other groups (15,
22).
With regard to changes in the respiration of intact cells,
pyocyanin increased their oxygen consumption, which was
only partially sensitive to antimycin A, a finding suggesting
that increases in these parameters are independent of com-
plex III. Our interpretation is that this higher oxygen con-
sumption occurs because of the conversion of molecular
oxygen into superoxide radicals, a conversion that is not
detected by the extracellular flux analyzer used in this study.
Indeed, the addition of pyocyanin to intact cells immediately
induces a substantially increased production of mitochondrial
superoxide. The question arose as to whether mitochondrial
ROS production is linked to a direct effect of pyocyanin on
respiratory chain complexes. We found that pyocyanin does
not affect complex I function but can ‘‘replace’’ complex III
by draining electrons from ubiquinol and donating them to
cytochrome c. These results suggest, first, that pyocyanin-
induced superoxide production can be observed in mito-
chondria, primarily because NADH is the most concentrated
in mitochondria and, second, that pyocyanin can provide an
electron shunt pathway at various respiratory chain sites.
In summary, we found that the high concentrations of
P. aeruginosa pyocyanin that are present in the lungs of
patients infected with P. aeruginosa directly interfere with
mitochondrial functions. This interference results in depo-
larization, release of ROS, activation of Asm, and formation
of ceramide; this pathway triggers the release of cytochrome
c and, finally, causes cell death, whereas it negatively regu-
lates the induction of the proinflammatory cytokine IL-8.
This pathway constitutes a novel pathway of host-pathogen
interactions and serves to balance immune reactions.
Materials and Methods
Mice
Asm-deficient mice were in a C57BL/6 background,
and littermates were used as controls. Mice were housed
in isolated ventilated cages while providing a pathogen-
free environment. The mice were routinely tested for mi-
crobial infections by bacterial culturing and serology; test
results were negative before and during the study period.
The hygienic status of the mice was repeatedly tested by a
panel of common mouse pathogens according to the 2002
Federation of Laboratory Animal Science Associations
(FELASA) recommendations.
Cells
To obtain mature primary neutrophils, we infected mice
intraperitoneally for 3 h with 5 · 107 colony-forming units
(CFU) of the clinical P. aeruginosa strain 762 (9). We then
performed a lavage followed by Percoll purification of the
cells. The identity of neutrophils was determined by stain-
ing with FITC-coupled anti-Gr1 antibodies followed by
flow cytometric analysis. Isolated cells were cultured for 8 h
in RPMI 1640 medium supplemented with 10% fetal calf
serum (FCS), 10mM HEPES (pH 7.4), 2 mM l-glutamine,
1mM sodium pyruvate, 100 lM nonessential amino acids,
100 units/ml penicillin, 100 lg/ml streptomycin (all Life
Technologies), and 50 lM b-mercaptoethanol. The data
were confirmed by the use of primary splenic or peripheral
blood neutrophils. To this end, blood was taken or spleens
were homogenized, and cells were subjected to a discon-
tinuous density gradient composed of Histopaque 1077 and
1119 (Sigma-Aldrich). Samples were centrifuged for 30min
at 700 g at room temperature with no brake. Neutrophils
were collected from the interface of Histopaque 1077 and
1119, washed thrice, and resuspended in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10%
mouse serum.
Jurkat T cells and HL-60 neutrophils were grown in RPMI
1640 supplemented as described earlier. HL-60 cells were
differentiated for 36 h with 2 lM retinoic acid.
Mouse embryonic fibroblasts were grown in DMEM me-
dium supplemented as previously described (18).
Bacterial cultures
P. aeruginosa strains 762 or ATCC 27853 were grown on
tryptic soy agar plates (Becton Dickinson Biosciences).
Bacteria were removed from the plate and suspended in 40ml
of prewarmed, sterile tryptic soy broth (Becton Dickinson
Biosciences) in Erlenmeyer flasks. The optical density of the
bacterial culture was adjusted to 0.225, and the bacteria were
grown for 60min at 37!C with shaking at 125 rpm. This
procedure resulted in a culture in which the bacteria were in
the early log phase. The bacteria were pelleted by centrifu-
gation for 10min at 1600 g and were then resuspended in
prewarmed RPMI medium buffered with 10mM HEPES.
Aliquots were added to the cells or the mitochondria at a
multiplicity of infection (MOI) of 10 bacteria per cell or
mitochondrium.
Mice were infected by an intraperitoneal injection of
5 · 107 CFU P. aeruginosa strain 762 suspended in HEPES/
saline (H/S; 132mM NaCl, 20mM HEPES, pH 7.4; 5mM
KCl, 1mM CaCl2, 0.7mM MgCl2, and 0.8mM MgSO4) and
were put to death after 3 h so that we could obtain mature
peritoneal neutrophils.
Stimulations and infections
Cells or mitochondria were incubated with 50 lM pyo-
cyanin or 10 lMH2O2 or were infected with P. aeruginosa at
an MOI of 10 bacteria per cell for the indicated time.
Cell death
Cells were infected with P. aeruginosa at an MOI of 10
bacteria per cell or treated with 50lM pyocyanin for 8 h. Cell
death was determined by staining cells with FITC-coupled
annexin V, followed by FACS analysis or by trypan blue
staining and microscopic analysis of at least 200 cells per
sample.
Isolation of mitochondria
Cells were incubated for 30min at 4!C in buffer A, con-
sisting of 0.3 M sucrose, 10mM TES (pH 7.4), and 0.5mM
ethylene glycol tetraacetic acid (EGTA) (33). Cells were then
1106 MANAGO` ET AL.
disintegrated with a Dounce homogenizer with 40 strokes of
the tight pestle. Nuclei and unbroken cells were pelleted by
centrifugation for 5min at 600 g and 4!C. Mitochondria in
the supernatants were pelleted at 6000 g for 10min at 4!C and
resuspended in 50mM PIPES-KOH (pH 7.4), 50mM KCl,
2mMMgCl2, 2mMEGTA, 10lg/ml aprotinin/leupeptin (A/L),
2mM ATP, 10mM phosphocreatine, 5mM succinate, and
50 lg/ml creatine kinase. This buffer is slightly hyperosmotic
to protect the mitochondria from swelling. Mitochondria
were then incubated with the indicated doses of H2O2 or
pyocyanin. The purity of the mitochondrial preparations was
confirmed by Western blot analysis for the mitochondrial
marker proteins cytochrome c, Tom, and Tim 23 and for
proteins that are not present in mitochondria, in particular
LAMP-1 and cathepsin D.
Cytochrome c release from isolated mitochondria
Isolated mitochondria were incubated with 50 lM pyo-
cyanin for 15min or with 10 lM H2O2 for 10min. Stimu-
lation was terminated by centrifugation at 4!C, after which
supernatants were added to 5 · sodium dodecyl sulfate
(SDS) sample buffer. The pellets were resuspended in 1·SDS
sample buffer. Samples were boiled, and proteins were sepa-
rated on 12.5% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE), eletrophoretically trans-
ferred onto nitrocellulose membranes, incubated with anti-
cytochrome c antibodies (Becton Dickinson Biosciences),
and developed with the Tropix electrochemoluminescence
system.
Asm activity
Isolated mitochondria were stimulated with 50lM pyo-
cyanin for 10 or 30min or with 10lM H2O2 for 10min.
Samples were lysed in 250mM sodium acetate (pH 5.0) and
1% NP40 for 10min and homogenized by three rounds of
sonication (10 s each) with a tip sonicator. The lysates were
diluted to 250mM sodium acetate (pH 5.0) and 0.1% NP40
and incubated with 50 nCi per sample [14C]sphingomyelin
for 60min at 37!C. The substrate was dried before use and
resuspended in 250mM sodium acetate (pH 5.0) and 0.1%
NP40. Micelles were obtained by a 10-min bath sonica-
tion. The enzymatic reaction was stopped by the addition of
800 ll chloroform/methanol (2:1, v/v), phases were separated
by centrifugation, and radioactivity of an aliquot of the
aqueous phase was measured by liquid scintillation counting
to determine the release of [14C]phosphorylcholine from
[14C]sphingomyelin as a measure of acid sphingomyelinase
activity.
Ceramide measurements
Mitochondria were stimulated as described earlier. Sti-
mulation was terminated by lysis in 200ll H2O and extrac-
tion in CHCl3:CH3OH:1NHCl (100:100:1, v/v/v). The lower
phase was collected, dried, and resuspended in 20ll of a
detergent solution consisting of 7.5% (w/v) n-octyl glucopyr-
anoside and 5mM cardiolipin in 1mM diethylenetriamine-
pentaacetic acid (DTPA). Samples were sonicated for 10min,
and the kinase reaction was performed for 45min at room
temperature by the addition of 70ll of a reaction mixture
containing 10ll diacylglycerol kinase (GE Healthcare Europe),
0.1 M imidazole/HCl (pH 6.6), 0.2mM DTPA (pH 6.6),
70mM NaCl, 17mM MgCl2, 1.4mM EGTA, 2mM dithio-
threitol, 1 lM ATP, and 10 lCi [32P]cATP. The kinase re-
action was terminated by extraction of the samples in 1ml
CHCl3:CH3OH:1N HCl (100:100:1, v/v/v), 170 ll buff-
ered saline solution (135mM NaCl, 1.5mM CaCl2, 0.5 mM
MgCl2, 5.6mM glucose, 10mM HEPES [pH 7.2]), and
30ll of a 100mM EDTA solution. The lower phase was col-
lected and dried, and the samples were spotted onto Silica G60
thin-layer chromatography (TLC) plates and developed with
chloroform/acetone/methanol/acetic acid/H2O (50:20:15:10:5,
v/v/v/v/v). The TLC plates were exposed to radiography
films, the spots were removed from the plates, and the in-
corporation of [32P] into ceramide was measured with a phos-
phoimager (Fuji). Ceramide amounts were determined by
comparison with a standard curve with C16 to C24 ceramides
used as substrates.
Interleukin-8 measurements
IL-8 was measured by enzyme-linked immunosorbent
assay according to the manufacturer’s instructions (R&D).
Immunostaining of neutrophils
Neutrophils were cultured on glass cover slips and treated
with pyocyanin for 6 h, fixed for 15min in 1% paraformal-
dehyde, washed in phosphate-buffered saline (PBS), per-
meabilized for 10min in 0.1% Triton X-100 in PBS, washed,
blocked with 5% FCS and 0.025% Tween 20 in PBS, washed
again in PBS, and stained with anti-ceramide (clone MAB
011, diluted 1:250; Glycobiotech) and anti-Tim 23 (#611223,
diluted 1:200; Becton Dickinson Biosciences) for 45min in
H/S supplemented with 1% FCS. Cells were washed thrice
for 5min each with PBS plus 0.025% Tween 20 and once in
PBS; they were then stained for 45min at room temperature
with Cy3-coupled anti-mouse immunoglobulin M (1:250
dilution) and DyLight 649 goat anti-mouse IgG antibodies
(dilution, 1:500; all from Jackson ImmunoResearch). Cells
were washed again thrice for 5min each with PBS plus
0.025% Tween 20 and once in PBS; they were then embed-
ded in Mowiol and analyzed by confocal microscopy. Cy3-
fluorescence intensity, as a measurement for ceramide in
mitochondria, was quantified with Photoshop.
Mitochondrial membrane potential
and ROS production
MMP and ROS production were measured as reported
by Leanza et al. (18). Briefly, MMP was monitored with
TMRM (20 nM), whereas ROS production was measured
withMitoSOX (1 lM). Jurkat cells were incubated for 20min
at 37!C in Hank’s balanced saline solution. After incubation,
the indicated compounds were added, and the decrease in
TMRM fluorescence or the increase in MitoSOX fluores-
cence was measured by FACS.
Oxygen consumption assay
Oxygen consumption by adherent cells was measured with
an XF24 Extracellular Flux Analyzer (Seahorse Bioscience).
Wild-type mouse embryonic fibroblasts cells were seeded at
3 · 104 cells per well in 200ll of supplemented culture me-
dium (DMEM; Sigma-Aldrich). Oxygen consumption rate
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was measured at preset time intervals, and the instrument
automatically carried out the preprogrammed additions of the
various compounds (oligomycin, 1 lg/ml final concentration;
FCCP, 400 nM; antimycin A, 1 lM), added as a solution in
70 ll of DMEM.
Isolation of RLM
After rats were sacrificied, the liver was removed and
immediately immersed in an ice-cold isolation medium
(250mM sucrose, 5mM HEPES, 2mM EGTA; pH 7.5). The
liver tissue was minced, thoroughly rinsed several times with
ice-cold medium, and finally homogenized in the same so-
lution with a glass Teflon Potter homogenizer. Mitochondria
were then isolated by conventional differential centrifuga-
tion, as described by Schneider et al. (31). The protein con-
tent was measured by the biuret method, with bovine serum
albumin (BSA) as a standard.
Activity of mitochondrial respiratory chain complexes
Complex activity was extrapolated from the slope of ab-
sorbance decrease; data are expressed as a percentage of the
control (i.e., the activity without the addition of any derivative).
Complex I activity. TomeasureNADH-coenzymeQ (CoQ)
oxidoreductase (complex I) activity, we incubated RLMs (50lg
of protein per ml) with 10lM alamethicin, 3mg/ml BSA,
10mM Tris-HCl (pH 8.0), 2.5mMNaN3, and 65lMCoQ1. The
reaction was started by the addition of 100lMNADH. Changes
in absorbance (340nm) were monitored at 37!Cwith an Agilent
Technologies Cary 100UV-Vis spectrophotometer. Rotenone
2lM was added to assess the rotenone-independent (and thus
complex I-independent) activity to be subtracted.
Complex III activity. To measure CoQ cytochrome c ox-
idoreductase (complex III) activity, we added RLMs (10 lg
protein per ml) to a cuvette containing 50mM potassium
phosphate buffer, pH 7.5, supplemented with 10 lM ala-
methicin, 3mg/ml BSA, 2.5mM NaN3, 2lM rotenone,
0.025% Tween, and 75 lM oxidized cytochrome c. The re-
action was started by the addition of 75lM reduced decy-
lubiquinol (produced by reduction of decylubiquinone in
ethanol with NaBH4 shortly before use); changes in absor-
bance were monitored at 550 nm and 37!C.We added 2lg/ml
antimycin to assess the activity of the antimycin-dependent
complex III enzyme.
Statistical analysis
All data are displayed as mean – standard deviation. All
data were tested for normal distribution with the David–
Pearson–Stephens test. Statistical analysis was performed with
Student’s t-test for single comparisons and ANOVA for multi-
ple comparisons. The sample size planning was based on two-
sided Wilcoxon–Mann–Whitney tests using the free software
G*Power Version 3.1.7 of the University of Duesseldorf, Ger-
many. Statistical significance was set at the level of p< 0.05.
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Abstract: Pancreatic cancer is one of the most aggressive cancer entities, with an extremely 
poor 5-year survival rate. Therefore, novel therapeutic agents with specific modes of action 
are urgently needed. Marine organisms represent a promising source to identify new 
pharmacologically active substances. Secondary metabolites derived from marine algae are 
OPEN ACCESS
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of particular interest. The present work describes cellular and molecular mechanisms 
induced by an HPLC-fractionated, hydrophilic extract derived from the Baltic brown 
seaweed Fucus vesiculosus (Fv1). Treatment with Fv1 resulted in a strong inhibition of 
viability in various pancreatic cancer cell lines. This extract inhibited the cell cycle of 
proliferating cells due to the up-regulation of cell cycle inhibitors, shown on the mRNA 
(microarray data) and protein level. As a result, cells were dying in a caspase-independent 
manner. Experiments with non-dividing cells showed that proliferation is a prerequisite for 
the effectiveness of Fv1. Importantly, Fv1 showed low cytotoxic activity against non-malignant 
resting T cells and terminally differentiated cells like erythrocytes. Interestingly, accelerated 
killing effects were observed in combination with inhibitors of autophagy. Our in vitro data 
suggest that Fv1 may represent a promising new agent that deserves further development 
towards clinical application. 
Keywords: algae; Fucus vesiculosus; pancreatic; cancer; cell cycle inhibitors;  
autophagy; proliferation 
 
1. Introduction 
Pancreatic cancer has an overall five-year survival rate of 7.2% (in 2010) [1] and the only curative 
treatment option—being limited to less than 20% of the patients—is resection of the tumor by surgery. 
However, also patients with resection are dying because of tumor recurrence or metastasis development [2]. 
Pancreatic cancer is one of the few tumor entities for which the incidence and mortality rate is even 
predicted to increase in the next years [1,3]. Chemotherapeutic treatment regimens for pancreatic cancer 
have improved within the last years, but prolonged lifetime is limited to only a few months [2]. New 
therapeutic options are urgently needed. 
Brown algae might represent an invaluable source for identifying new therapy agents since they are 
rich in sulfated polysaccharides and secondary plant metabolites like fucoidans, fucoxanthin or 
phlorotannins [4–6]. Besides antioxidant activity and beneficial effects on cardiovascular disease, these 
substances were shown to exhibit anti-cancerous properties [4,5,7–10]. Fucoidans are known to inhibit 
proliferation in tumor cells [11,12]. For fucoxanthin and phlorotannins, anti-proliferative and apoptotic 
effects are known [13–16]. However, the particular mechanisms are not yet unraveled. 
In the present work, we systematically investigated the effect of a purified acetonic extract of the 
Baltic brown seaweed Fucus vesiculosus (called Fv1) on human cancer and non-malignant cell lines. 
We studied its effects on the gene expression and protein level and our analyses suggest cell cycle control 
mechanisms as the major mode of action. 
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2. Results 
2.1. Influence of Fv1 on Viability of Cancer Cells 
First, we analyzed the effect of Fv1 on the viability of tumor cells. Fv1 inhibited the growth of 
different tumor cell lines significantly (Figure 1). The EC50 (effective half maximal concentration) 
values of Fv1 range between 17.35 µg/mL for PancTU1 (95% CI: 16.74–17.99), 17.5 µg/mL for Panc89 
(95% CI: 17.24–17.77), 19.23 µg/mL for Panc1 (95% CI: 18.52–19.98) and 28.9 µg/mL for Colo357 
(95% CI: 22.71–32.11). Morphologically, Fv1-treated cells exhibited more spindle-like cells, observed 
with staining of actin and tubulin (Figure 2). Treated cells changed their microfilamental structures. 
Moreover, they rather grew in a solitary way and did not form dense epithelial structures like untreated 
cells do. Figure 2 shows one representative experiment with Panc89 pancreatic ductal adenocarcinoma 
(PDAC) cells. 
 
Figure 1. Inhibition of cell viability by Fucus vesiculosus (Fv1) in different cancer cell lines. 
5 × 103 cells were seeded in 96 well plates and treated with Fv1 or dimethyl sulfoxide 
(DMSO) as control (0.15%) after 24 h. After 72 h treatment, an AlamarBlue viability assay 
was performed. Values are presented as % of control; concentrations are shown using a 
logarithmic scale. Raw data are shown in Supplementary Table S1. n = 4. 
To get more insight into the time-dependent morphological changes induced by Fv1, live cell imaging 
was performed by taking microscopic images every 15 min. While untreated cells divided normally, we 
observed many Fv1-treated cells entering mitosis, showing a cleaving furrow but then the cells rounded 
up and died. Often, cell fragmentation was observed several hours later. Representative images of this 
process are given in Figure 3.  
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Figure 2. Fv1 leads to decreased cell numbers and to morphological alterations. Panc89 cells 
were seeded on coverslips and treated with Fv1 (10 µg/mL) or DMSO (0.125%)-containing 
cell culture medium. After 24 h, the cells were stained with an α-Tubulin antibody  
(2nd antibody: α-mouse, Alexa 488-coupled) and with phalloidin (Alexa 546-coupled) for  
actin cytoskeleton staining. The coverslips were mounted using a DAPI-containing  
mounting medium. Representative pictures were taken with a Zeiss CLSM. Two 
magnifications are shown.  
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Figure 3. Fv1 inhibits mitosis. Human pancreatic ductal epithelial (HPDE) cells were treated 
with Fv1 in a lethal dose (50 µg/mL) and observed using the JuLI Br Live Cell Analyzer. 
Pictures were taken every 15 min automatically for 24 h. Representative pictures show one 
single cell undergoing mitosis. 
2.2. Effect of Fv1 on Cell Cycle and Cell Cycle Inhibitors 
To elucidate the molecular mechanism mediated by Fv1 in more detail, we performed large scale 
gene expression profiling on over 40,000 transcripts using Agilent arrays, comparing Fv1-treated with 
untreated cells. The expression of many genes was significantly changed (Table 1A). Fv1 regulated 
about 10-fold less genes in Colo357 cells than in the cell lines Panc1, Panc89, PancTU1 and HPDE. 157 
genes were found to be commonly deregulated in the treated cell lines Panc89, Panc1 and PancTU1. 
Many of these genes are involved in cell cycle control, DNA repair and also in inflammation and  
cancer (Table 1B). Because of these findings, we focused on cell cycle regulating pathways. Interestingly, 
the cell cycle inhibitor p57 was induced in three cancer cell lines (Panc1, Panc89, PancTU1). Accordingly, 
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some downstream targets that are inhibited by p57 were suppressed (Cyclin E2, CDC45, CDC7, 
CDC25A, E2F1, PCNA, see Table 1C and Supplementary Figure S1 for the pathway graphic). 
Furthermore, the expression of the upstream regulator “tumor protein 53 inducible protein” TP53INP1 
was increased. In addition, the expression of cell division cycle protein 20 (CDC20) which activates the 
anaphase promoting complex (APC) [17], was decreased in three cell lines (Panc1, PancTU1, Panc89, 
see Table 1C). This led us to the suggestion that Fv1 induces a cell cycle arrest. 
Table 1. Fv1 regulates pathways involved in DNA-replication and cell cycle cells were 
cultured and incubated with Fv1 for 24 h. Whole cell lysates were produced by pooling 
attached cells and detached cells in the supernatant. RNA was isolated, reverse-transcribed 
and hybridized to Agilent 40K chips. After hybridization, data were normalized according 
to the analysis standards of SourceBioscience (Berlin). (A) Number of significantly 
regulated genes after Fv1 treatment. Criteria of significance were a p-value < 0.05 and a log 
fold change (lfc) >1 or <−1; (B) Collectively regulated genes of the cell lines Panc1, 
PancTU1 and Panc89 were analyzed using the DAVID (Database for Annotation, 
Visualization and Integrated Discovery) functional annotation clustering tool and KEGG 
(Kyoto Encyclopedia of Genes and Genomes) pathway. The most probable pathways, according 
to DAVID analysis, are shown. All experiments were performed in biological triplicates;  
(C) Gene expression data of single genes which are involved in the KEGG pathway of cell 
cycle regulation are shown with log fold changes (log 2) and bonferroni-corrected p-values. 
A 
Cell Line Number of Regulated Genes 
Panc1 3951 
Panc89 3909 
HPDE 2614 
Colo357 200 
PancTU1 6 h 340 
PancTU1 24 h 2930 
B 
Term Count % of Pathway Genes
p-Value  
(Benjamini-Hochberg-Corrected)
DNA replication 8 6.25 0.0000012 
Cell cycle 11 8.59 0.0000034 
Base excision repair 5 3.91 0.0045238 
Terpenoid backbone biosynthesis 4 3.13 0.0038877 
Oocyte meiosis 5 3.91 0.1670225 
Lysosome 5 3.91 0.1705743 
Pyrimidine metabolism 4 3.13 0.3412000 
Nucleotide excision repair 3 2.34 0.3292213 
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Table 1. Cont. 
C 
Target ID 
Panc1 PancTU1 Panc89 
Gene Symbol Gene Name 
Lfc p-Value Lfc p-Value Lfc p-Value 
NM_000076 2.0364 0.0326 1.0465 0.0261 2.7013 0.0347 CDKN1C 
cyclin-dependent kinase inhibitor 
1C (p57, Kip2) 
NM_057749 −1.9238 0.0470 −1.9484 0.0003 −4.3172 0.0050 CCNE2 cyclin E2 
NM_003504 −1.5647 0.0243 −1.3113 0.0054 −3.5616 0.0005 CDC45 
cell division cycle 45 homolog  
(S. cerevisiae) 
NM_003503 −1.3615 0.0132 −1.5369 0.0012 −3.7463 0.0081 CDC7 
cell division cycle 7 homolog  
(S. cerevisiae) 
NM_001789 −1.9897 0.0263 −1.8791 0.0001 −4.5741 0.0359 CDC25A 
cell division cycle 25 homolog A 
(S. pombe) 
NM_005225 −1.3352 0.0197 −1.3330 0.0004 −3.2981 0.0415 E2F1 E2F transcription factor 1 
NM_002592 −1.3851 0.0047 −1.1083 0.0018 −2.9858 0.0056 PCNA proliferating cell nuclear antigen 
NM_033285 2.2445 0.0023 3.9746 0.0052 5.6604 0.0427 TP53INP1 
tumor protein p53 inducible 
nuclear protein 1 
NM_001255 −1.1762 0.0036 −1.0547 0.0160 −3.2856 0.0221 CDC20 
cell division cycle 20 homolog  
(S. cerevisiae) 
To confirm this hypothesis, we examined changes in cell cycle by propidium iodide staining. 
Treatment with Fv1 led to an elevated number of cells in G2 phase and a decrease of cells in G1 and  
S phase (Figure 4). This suggests a cell cycle inhibition in the G2 phase, which was also observed in 
Panc89 cells (see Supplementary Figures S12 and S13). 
In addition, we analyzed some of the de-regulated genes on the protein level by Western blotting. The 
cell cycle inhibitors p21 and p27 were induced by Fv1 after 4 to 24 h as shown for the PDAC cell line 
Panc89 (Figure 5A). These findings support our hypothesis of a cell cycle affecting mechanism induced 
by Fv1. Analysis of cyclin D3, cyclin E1, p15 and p16 showed no differences compared to β-Actin or 
α-Tubulin as reference controls (see Supplementary Figures S2 and S3). 
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Figure 4. Fv1 induces a cell cycle arrest in pancreatic cancer cells. Colo357 cells were 
treated with Fv1 24 h after seeding and detached after 24 h of treatment. The detached cells 
were stained with hypotonic propidium iodide staining and measured by flow cytometry. 
The data were analyzed with Modfit and presented as percentage of cells for each cell cycle 
phase. One representative of two replicates is shown. See Supplementary Figures S11–S13 
for a 4 h time point and the corresponding experiments with the cell line Panc89. The  
sub-G1 peak was not considered, because only cells with a cell-like FSC and SSC were taken 
into account.  
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Figure 5. Effect of Fv1 on cell cycle regulating proteins. (A) Panc89 cells were grown for 
24 h in 6 well plates and treated with different concentrations of Fv1. At the indicated time 
points, cells were lysed and lysates were analyzed by Western blotting. Proteins were detected 
using fluorescence-labeled secondary antibodies and an infrared scanner (Odyssey, LICOR);  
(B) HCT 116 cells with wild-type p53 or loss of p53 were treated with different 
concentrations of Fv1 for 72 h. 5-Fluorouracil at 10 µg/mL was used as control. Viability 
was measured with AlamarBlue. The experiment was performed in biological triplicates. 
Significance was calculated using students t-test. Differences with a p-value <0.001 are 
indicated with **. One of 3 replicates is shown as representative experiment. 
The upstream regulator and one of the most important cell cycle regulators is p53. We analyzed its 
role in response to Fv1 using a p53 knockout model generated with the cell line HCT 116. The  
p53-inducing drug 5-Fluorouracil was used as control. The effect of Fv1 was significantly lower in the 
p53-lacking (−/−) cells than in the p53 wild-type variant (Figure 5B). 
2.3. Impact of Caspase Activity and Autophagy 
Analysis of PARP via Western blot showed a cleavage when high concentrations of Fv1 were  
applied (Figure 6A). Analysis of cell death via co-staining with Annexin V and propidium iodide showed 
no clear differentiation between apoptosis and necrosis, but a general dose-dependent cell death after 24 h 
of treatment (Figure 6B). Treated cells were larger in size (FSC) and more granulated (SSC) than normal 
cells. While the caspase inhibitor zVAD-fmk inhibited the cytotoxic effect of the prototypical member 
of the death ligand family, TRAIL, it had no impact on the Fv1 activity (Figure 6B). In addition,  
zVAD-fmk did not inhibit the anti-proliferative effect as observed by AlamarBlue assays  
(see Supplementary Figure S4). 
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Figure 6. Fv1 induces cleavage of Poly ADP ribose polymerase 1 (PARP), but cell death is 
not blocked by the caspase inhibitor zVAD-fmk. (A) 24 h after seeding, Panc89 cells were 
treated with Fv1. At the indicated time points, whole cell lysates were analyzed by Western 
blotting for the cleavage of PARP; (B) Panc89 cells were treated with Fv1 as described above, 
but in combination with zVAD-fmk for 24 h. Afterwards, cells were stained with Annexin 
V and propidium iodide and measured by flow cytometry. Viability of Panc89 cells treated 
with Fv1 and zVAD-fmk was observed by AlamarBlue staining after 72 h of treatment (see 
Supplementary Figure S4). 
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Cell death is often mediated through the mitochondrial pathway. The production of reactive oxygen 
species (ROS) and mitochondrial swelling were not induced when Colo357 cells were treated with Fv1 
for up to 60 min. Moreover, the membrane potential of isolated rat liver mitochondria was not influenced 
by Fv1 treatment (Supplementary Figures S5–S8). 
Another mechanism possibly involved in cell death is autophagy. The dependency of Fv1 on 
autophagy was analyzed using three different inhibitors of autophagy pathways (Figure 7). Interestingly, 
the effect of Fv1 was increased when autophagy was blocked by each of the three inhibitors. 
.  
Figure 7. Autophagy inhibitors increase the effect of Fv1. Colo357 cells were prestimulated 
23 h after seeding with chloroquine (50 µM), bafilomycin (10 nM, 50 nM) or 3-methyladenine 
(0.5 mM, 5 mM). One hour later, they were treated with Fv1 (15 µg/mL). After 24 h of Fv1 
treatment, cells were detached with accutase, stained with propidium iodide and measured 
by FACS. Single inhibitor treatments were subtracted from the combination treatments 
before calculating significances with t-tests. n = 2. 
2.4. Analysis of the Fv1 Effect on Non-Dividing Cells 
As many chemotherapeutics depend on cell proliferation, we analyzed the effect of Fv1 on  
non-proliferating cells. To do so, we used the PDAC A818-4 cell line model [18]. These cells can be 
transferred into a quiescent state by contact inhibition (previous unpublished data of our group). Panc89 
cells were used as a negative control, representing a common type of cancer cell line that is not 
influenced by contact inhibition. Accordingly, Panc89 cells incorporated more BrdU when they were 
seeded at higher numbers, while the incorporation of BrdU in A818-4 cells did not increase with the 
higher seeding density (Figure 8A). 
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Figure 8. Fv1 preferentially inhibits proliferating cells. (A) The PDAC cell lines A818-4 
and Panc89 were seeded at different densities. After 24 h, the cells were incubated with BrdU 
for 4 h. Subsequently, a BrdU ELISA was performed, and the BrdU incorporation was 
analyzed by measuring the absorbance at 450 nm. The slopes of the curves are significantly 
different (p = 0.000315); (B) A818-4 and Panc89 cells were seeded in a CIM 16 plates. After 
24 h, they were incubated with different concentrations of Fv1. For 72 h, the cell impedance 
was monitored in intervals of 15 min by the Roche XCelligence RTCA system. The cell 
number is represented by the area under the curve (AUC) which is presented as bar chart.  
n = 2. The experiment was validated with an AlamarBlue viability assay which shows the 
endpoint situation after 72 h of treatment (Supplementary Figure S9). n = 2. 
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To analyze the effect of Fv1 on these non-proliferating cells, we monitored them in real-time by the 
XCelligence RTCA system. Fv1 dose-dependently decreased the cell numbers of A818-4 cells when the 
seeding density was low. In contrast, Fv1 had no effect upon growth-arrested cells (Figure 8B). Cell 
numbers are represented as area under the curve (AUC).  
Panc89 cells, on the other hand, were inhibited at both seeding densities (Figure 8B). This finding 
was confirmed with a viability endpoint measurement after 72 h (Supplementary Figure S9). 
For toxicity analysis against sensitive non-malignant body cells, we tested the hemoglobin release of 
fresh red blood cells derived from healthy donors (Figure 9A). We did not see hemolysis in Fv1-treated 
red blood cells after 1–4 h of treatment, indicating that Fv1 does not destroy terminally differentiated, 
non-dividing cells (Supplementary Table S2). Quiescent peripheral blood mononuclear cells (PBMC) 
were also not affected, while activated proliferating PBMCs showed a reduced viability after 24 h of 
Fv1 treatment (Figure 9B).  
 
Figure 9. Cont. 
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Figure 9. Fv1 treatment does not lead to acute cytotoxicity but effects rapidly dividing  
non-malignant cells. (A) Freshly isolated red blood cells were seeded in 96 well plates and 
treated with different concentrations of Fv1. Absorbance of hemoglobin was measured in 
the supernatant at the given time points. 0.5% Triton X100 was used as maximum release 
control. Raw data are shown in Supplementary Table S2. Four technical replicates are shown;  
(B) Peripheral blood mononuclear cells (PBMCs) were isolated from freshly drawn human 
blood and activated. Resting or activated cells were treated with Fv1 or DMSO as solvent 
control. After 72 h, the viability was measured with an MTT assay. Data show raw OD-values. 
Data are presented as mean values ± standard deviation (SD) from three independent 
experiments; (C) For measurement of acute cytotoxicity, lactate dehydrogenase (LDH) 
release was measured in Panc89 cells after 1 and 24 h. Experiment performed at least twice with 
4 technical replicates each; (D) Three non-malignant (HUVEC, NHDF, KIF5eGFP, HPDE) and 
two PDAC cell lines (Panc89, A818-4) were seeded at different densities. After 24 h, they 
were treated with Fv1 for 72 h. Dose response curves and EC50 values were calculated using 
nonlinear regression (curve fit) with Prism (GraphPad). Experiments were performed at least 
twice with 4 technical replicates each. 
To characterize the anti-proliferative activity in more detail, we measured acute cytotoxicity by a 
lactatdehydrogenase (LDH) release assay (Figure 9D). Cancer cell lines did not release LDH after 1 h 
of treatment with Fv1, but after 24 h we detected a dose-dependent high LDH release (Figure 9C). This 
indicates a cytotoxic effect of Fv1 after 24 h, but argues against acute cytotoxicity. 
To test whether inhibition of proliferation was restricted to cancer cell lines, we tested the effects of 
Fv1 on different non-malignant cell lines and primary cells (human pancreatic ductal epithelial/HPDE 
cells, the fibroblast cell lines KIF5 and NHDF and freshly isolated endothelial HUVEC cells). Since these 
cells were rapidly dividing, we observed similar anti-proliferative effects as in cancer cell lines (Figure 9D). 
3. Discussion 
In this paper, we describe the anticancer effects of a Baltic brown seaweed extract. Fv1 inhibits 
proliferating cells and does not affect resting cells. This effect is comparable to clinically used 
chemotherapeutic drugs. Our findings show that the cell line A818-4 was only inhibited by Fv1 when 
proliferating. In other proliferating cells like Panc89 or Colo357, Fv1 led to an S/G2-phase arrest and to 
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an increase of the cell cycle inhibitors p21, p27 and p57. These findings were supported by the gene 
expression experiments. Large scale array experiments showed particularly regulation of genes involved 
in cell cycle regulation. Cell cycle inhibitors were upregulated after Fv1 treatment whereas the 
expression of downstream targets was decreased. Normally, this enforced form of cell cycle inhibition 
leads to apoptosis, necroptosis or other forms of programmed cell death [19,20]. Analyses of apoptosis 
via PARP cleavage showed, that in later stages of Fv1 treatment, a PARP-cleavage occurred, so 
eventually the cells undergo apoptosis. This hypothesis was supported by Annexin V/PI staining where 
events of early and late apoptosis/necrosis were observed. However, the cell death was not blocked by 
the caspase inhibitor zVAD-fmk. Therefore, we assume that it might only be a secondary effect of Fv1 
treatment. In addition, Fv1 did not cause mitochondrial swelling or destruction, thus Fv1 did not induce cell 
death by the mitochondrial pathways. Interestingly, Fv1 seems to be counteracted by autophagy mechanisms. 
Studies show that autophagy is not only involved in cell death [21,22]. Autophagy pathways also provide 
a rescue mechanism by stabilizing the cell metabolism [22]. A connection between cell cycle or DNA 
damage and autophagy is discussed in literature, but not fully understood, yet [23–25]. Further in vivo 
experiments with Fv1 could include the combination with inhibitors of autophagy. 
Interestingly, some of the described outcomes in the various test systems occur also when cells were 
treated with Gemcitabine. Gemcitabine is often described to induce apoptosis [26,27] but there is 
evidence that this could only be a side effect. Studies suggest that the effect of Gemcitabine alone  
is not influenced by inhibition of caspases [27,28]. This means, that Gemcitabine, Fv1 and other 
chemotherapeutics induce cell death, but the apoptotic pathway involving caspase activation and PARP 
cleavage only plays a secondary role. 
This supports the hypothesis that Fv1 is a strong inhibitor of the cell cycle like, e.g., Gemcitabine. 
Indeed, Fv1 led to a cell cycle arrest in G2 phase. This is in line with the microscopic observation that 
many cells entered the process of mitosis and duplicated their nuclei, but did not finish cytokinesis. The 
question is how this cell cycle arrest and cell death is mediated. The up-regulated proteins p21, p27 and 
p57 are all under the control of p53 [19]. Our experiment with p53 knockout cells showed, that there is 
an influence of p53 on the Fv1 effect. The difference we observed between p53 wild-type and deficient 
cells was comparable to the one observed for 5-FU. For this DNA-damaging chemotherapeutic agent, 
the p53 dependency has been described in literature [29]. However, in our other studied cancer cell lines 
except HCT116 and Colo357, p53 is mutated [18,30]. This is interesting, as Colo357 cells were more 
resistant to Fv1 than other PDAC cell lines. A connection might be the tumor protein 53 inducible  
protein 1 (TP53INP1). TP53INP1 is strongly induced by Fv1 on the gene expression level and it is able 
to play an autonomous role in cell cycle regulation and mediates several of its functions independently 
of p53 [31]. Another player might be CDC20. This gene was down-regulated by Fv1. It plays an 
important role in the spindle checkpoint. Eichhorn et al. showed that knockdown of CDC20 in HeLa 
cells induced mitotic arrest, similar to our observations [32]. Moreover, in Western blots, we observed 
a strong decrease of tubulin at later time points and higher Fv1 concentrations (data shown in 
Supplementary Figures S2 and S3). This might lead to a destruction of the spindle apparatus and 
activation of the spindle checkpoint. 
Combination experiments with chemotherapeutic drugs indicated that extracts of Fucus vesiculosus 
share completely additive effects with gemcitabine, paclitaxel and cisplatin (Supplementary Figure S10). 
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They neither inhibited nor synergistically enhanced the effects of the other drug. These findings support 
the assumption that a combination of chemotherapeutic drugs and Fv1 may be effective in vivo. 
Fv1 is a potent compound with strong anti-cancer activity as shown here under in vitro conditions. 
Subsequently, in vivo experiments in mice would be necessary to confirm the promising in vitro data 
and to assess potential side effects such as hepatotoxicity and nephrotoxicity of Fv1. Other compounds 
like fucoxanthin also show toxic effects on non-malignant cells in cell culture, but have no toxic effect 
in vivo [7]. Experiments in laboratory rodents would also reveal the uptake and bioavailability of Fv1 
when applied to complex organisms. Another way of further application would be the use of Fv1 for 
targeted therapy of cancer. To do so, Fv1 could be conjugated to cancer-specific target molecules or be 
wrapped by liposomes that can release their content specifically to cancer cells. However, structure and 
other chemical characteristics of Fv1 need to be elucidated prior clinical trials. In conclusion, Fv1 is a 
potent inhibitor of cancer cell growth. It does not induce apoptosis or necroptosis, nor does it induce 
mitochondrial swelling. However, Fv1 efficiently kills pancreatic cancer cells by inducing a cell cycle 
arrest by the induction of cell cycle inhibitors involving TP53INP1.  
4. Material and Methods 
4.1. Algae Extraction and Fractioning 
Freshly frozen parts of the central thallus of the alga Fucus vesiculosus, which were collected at 
spring time from coastal areas of Bülk, Kiel Fjord, Western Baltic Sea, were thawed and extracted with 
acetone at the rate of 1:2 (w/v). After further processing and drying, the extract was re-dissolved in 
dimethyl sulfoxide (DMSO) as preparation for normal phase high performance liquid chromatography 
(HPLC) on a Pharmprep60CC SiO2 column, followed by reversed-phase HPLC on an Amberlite® 
XAD7HP column. 67 fractions were generated, dried and dissolved in DMSO D6.  
Fv1 is represented by a pool of three successively eluted fractions within the hydrophilic sector of the 
applied gradient. According to their similar and most efficient anti-proliferative activity in the sequence 
of seven tested neighboring fractions and according to their characteristic 1H-NMR-profile showing four 
signals each at 5.82, 6.63, 7.89 and 8.98 ppm, the three nearby fractions were pooled to Fv1 in a 
concentration of 42 mg/mL in DMSO and stored at −60 °C for subsequent testing. 
4.2. Cell Lines, Cell Culture Maintenance and General Experiment Procedure 
PancTu1 cells were a kind gift of Dr. M. von Bülow (Mainz, Germany), Panc89 cells of Dr. T. Okabe 
(Tokyo, Japan), and Colo357 cells of Dr. R. Morgan (Denver, CO, USA) [33]. Panc1 cells were obtained 
from ATCC (LGC Standards, Wesel, Germany). These four pancreatic cancer cell lines were chosen in 
order to not depend too much on the particular genetic outfit of the cell lines. Most experiments have 
been done with 2 or more of the cell lines and representative experiments are shown. The E6/E7-HPV16-
immortalized human pancreatic ductal epithelial cell line HPDE was a gift of Dr. M. Tsao (MD, FRCPC, 
University Health Network, Toronto, ON, Canada) [34,35]. NHDF cells were purchased from Promocell 
(Heidelberg, Germany). Cell culture maintenance and experiments were performed in an incubator at  
37 °C with a 5% CO2 atmosphere and 5% humidity. HPDE cells were routinely cultured in HPDE 
medium (RPMI 1640 medium (Life Technologies, Darmstadt, Germany) supplemented with 10% FBS  
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(PAN Biotech, Aidenbach, Germany), 1% Glutamax (Life Technologies, Darmstadt, Germany) and 
mixed immediately before use 1:1 with keratinocyte medium SFM (Life Technologies, Darmstadt, 
Germany) supplemented with 0.025% bovine pituitary extract/2.5 µg/L epidermal growth factor  
(Life Technologies, Darmstadt, Germany)). NHDF cells were cultivated in fibroblast growth medium 
supplemented with supplement pack 2 (Promocell, Heidelberg, Germany). All other cell lines were 
cultured in RPMI 1640 medium (Life Technologies, Darmstadt, Germany) supplemented with 10% FBS 
(PAN Biotech, Aidenbach, Germany), 1% Glutamax and 1% sodium pyruvate ( both Life Technologies, 
Darmstadt, Germany). Red blood cells were isolated directly from fresh blood from healthy  
donors by centrifugation and maintained in PBS. Peripheral blood mononuclear cells (PBMC)  
were isolated and activated with a T cell activation/expansion kit (130-091-441, Miltenyi Biotec,  
Bergisch-Gladbach, Germany). 
4.3. Proliferation and Viability Experiments 
For proliferation experiments, cells were seeded in 96 well plates (5 × 103 cells per well if not noted 
otherwise) and treated after 24 h with serial dilutions of extracts premixed in cell culture medium. The 
algae extract stocks (42 mg/mL in DMSO) were thawed directly before use. Serial dilutions were done 
in DMSO to ensure a constant DMSO concentration of 0.15% in cell culture medium for each treatment. 
A DMSO concentration of 0.15% in cell culture medium was used as solvent control. TRAIL 
(PeproTech, Hamburg, Germany) was dissolved in PBS (0.5 µg/µL) and diluted in cell culture medium 
in a concentration of 200 ng/mL. zVAD-fmk (Promega, Mannheim, Germany) was dissolved in DMSO 
and diluted in cell culture medium using a concentration of 20 µM. After the indicated time points, the 
proliferation tests were performed as described below. Dose response curves were produced and EC50 
values calculated with Prism (GraphPad). 
4.4. Alamar Blue 
Ten microliters of AlamarBlue (Invitrogen, Carlsbad, CA, USA) reagent was added to each 96 well 
containing cells in 100 µL of medium and incubated for 4 h. Fluorescence of AlamarBlue was measured 
using an excitation wavelength of 545 nm and an emission wavelength of 595 nm (Tecan Spectrafluor 
Plus, Tecan, Maennedorf, Switzerland).  
4.5. BrdU ELISA 
For A818-4 cells, a BrdU ELISA was used to determine the optimal cell seeding concentration for 
contact-inhibited cell growth. Experiments were performed as described before and for the last 5 h, the 
BrdU labelling reagent was added to the cell culture at a final concentration of 10 µM. The following 
BrdU-staining was performed according to the manual (Roche, Cat. No. 11647229001). The BrdU-reaction 
was stopped with 25 µL 1 M H2SO4. Absorbance was measured using the Tecan Sunrise Reader  
(Tecan, Maennedorf, Germany) with a wavelength of 450 nm (Reference: 600 nm). 
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4.6. XCelligence Proliferation Measurement 
Cells were seeded in XCelligence CIM-plate 16 (AceaBio, San Diego, CA, USA) according to the 
manufacturer’s instructions in 10% FCS containing RPMI medium. After 24 h, cells were treated as 
described in the general experiment section for 96 well plates. Proliferation activity was measured every 
15 min for 72 h in a RTCA DP system (AceaBio, San Diego, CA, USA). 
4.7. Cytotoxicity LDH-Release 
LDH-release assays were performed using RPMI medium with 1% FCS, 0.5% GlutaMAX and 0.5% 
sodium-pyruvate for treatment, because these substances can interfere with the assay reagents. 1 × 104 
cells per well were seeded in 200 µL cell culture medium. After 24 h attachment, the cells were treated 
with extracts as described above. For each treatment, half of the wells were also treated with Triton-X100 
(1% final concentration in medium) as 100% control. After 1 or 24 h, LDH release was tested according 
to the manual (Takara Bio, Saint-Germain-en-Laye, France) and absorbance was measured in a Sunrise 
plate reader at 492 nm with a reference wavelength of 650 nm (Tecan, Maennedorf, Switzerland). 
4.8. Gene Expression Analysis 
For Agilent gene chip expression analysis, 1.07 × 106 cells were grown in 12 mL cell culture medium 
in T75 flasks for 24 h before treatment. Cells were treated with 30 µg/mL Fv1 or 0.15% DMSO as control. 
After an incubation time of 6 or 24 h, the supernatant was removed, the cells were washed with PBS and 
detached with Accutase and frozen at −80 °C. Then the RNA was extracted with the RNeasy Plus Mini 
Kit (Qiagen, Hilde, Germany), according to the manual. Quantity of the RNA was measured using 
NanoDrop (PeqLab). Experiments were performed in three independent replicates. RNA quality  
was controlled using a BioAnalyzer. Gene expression was measured using the “Sureprint G3  
Human GE 8 × 60K” (Agilent, Santa Clara, CA, USA) array which was processed according to the 
manufacturer’s instructions. For analysis, only genes were included that showed a p-value < 0.05 and a 
log fold change (lfc) >1 or <−1 and that were changed on at least three pancreatic cancer cell lines (Panc1, 
Panc89, PancTU1). The experiments were performed as three biological replicates with each cell line. 
4.9. Preparation of Cell Lysates and Western Blotting 
Cells were lysed with RIPA buffer and ultrasound. Protein concentration was measured with DC 
reagent (Bio-Rad Laboratories, Munich, Germany). Equal amounts of protein were loaded on a  
4%–20% tris-glycine gel (Novex, Life Technologies, Carlsbad, CA, USA) and separated by SDS-PAGE. 
Proteins were transferred by semi dry blot on a PVDF membrane (Immobilon-FL; Millipore/Merck, 
Darmstadt, Germany). For 2nd antibody, goat-anti-rabbit-IRDye800CW and goat-anti-mouse-IRDye680 
(LI-COR, Bad Homburg, Germany) were used. Blots were dried and scanned using an Odyssey  
infrared imager (LI-COR, Bad Homburg, Germany). Used antibodies: β-Actin (CS, A5441), α-Tubulin 
(Epitomics, 1878-1), PARP (CS, 9542S), p21 (CS, 2946), p27 (CS, 2552), p15 (CS, 4822). 
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4.10. FACS Cell Cycle Profiling—Annexin V/PI Staining 
For cell cycle profiling, experiments were performed as described above. Staining was performed in 
v-bottom shaped 96 well plates using a hypotonic propidium iodide (PI) staining solution (0.1% sodium 
citrate, 0.1% TritonX-100, 50 µg/mL PI, 5 µg/mL EDTA) [36]. Stained cells were measured 
immediately after staining using a FACS-Calibur (BD Biosciences, Heidelberg, Germany). Annexin 
V/PI staining was performed according to the manufacturer’s instructions (Miltenyi Biotec; 130-092-052). 
Immediately after adding the PI solution, the cells were measured in FACS-Calibur (BD Biosciences, 
Heidelberg, Germany). 
4.11. FACS PI Staining and Inhibitor Screening 
One hundred thousand (1 × 105) Colo357 cells were seeded in 12 well cell culture plates in 0.5 mL 
cell culture medium. After 23 h they were pretreated with Bafilomycin (10 nM, 50 nM), Chloroquine 
(50 µM), 3-Methyadenine (0.5 mM, 5 mM) or cell culture medium (control). One hour later, 15 µg/mL 
Fv1 or cell culture medium (control) was added. After 24 h, the cells were detached with Accutase 
(PAA), stained with propidium iodide and measured with a FACS-Calibur (BD, Heidelberg, Germany). 
The percentage of PI positive cells was determined for each treatment. 
4.12. Statistical Analysis 
Statistics were performed with Prism (GraphPad) and Excel (Microsoft) unless indicated otherwise. 
Significance was tested using students t-test. Differences with p-values <0.05 (*), <0.01 (**) or <0.001 
(***) were estimated as significant and indicated with asterisk. 
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Early effects of the antineoplastic agent salinomycin on
mitochondrial function
A Managò1, L Leanza1, L Carraretto1, N Sassi1,2, S Grancara2, R Quintana-Cabrera1,3, V Trimarco3, A Toninello2, L Scorrano1,3, L Trentin3,
G Semenzato3, E Gulbins4, M Zoratti2,5 and I Szabò*,1,5
Salinomycin, isolated from Streptomyces albus, displays antimicrobial activity. Recently, a large-scale screening approach
identified salinomycin and nigericin as selective apoptosis inducers of cancer stem cells. Growing evidence suggests that
salinomycin is able to kill different types of non-stem tumor cells that usually display resistance to common therapeutic
approaches, but the mechanism of action of this molecule is still poorly understood. Since salinomycin has been suggested to act
as a K+ ionophore, we explored its impact on mitochondrial bioenergetic performance at an early time point following drug
application. In contrast to the K+ ionophore valinomycin, salinomycin induced a rapid hyperpolarization. In addition, mitochondrial
matrix acidification and a significant decrease of respiration were observed in intact mouse embryonic fibroblasts (MEFs) and in
cancer stem cell-like HMLE cells within tens of minutes, while increased production of reactive oxygen species was not detected.
By comparing the chemical structures and cellular effects of this drug with those of valinomycin (K+ ionophore) and nigericin (K+/
H+ exchanger), we conclude that salinomycin mediates K+/H+ exchange across the inner mitochondrial membrane. Compatible
with its direct modulation of mitochondrial function, salinomycin was able to induce cell death also in Bax/Bak-less double-
knockout MEF cells. Since at the concentration range used in most studies (around 10 μM) salinomycin exerts its effect at the level
of mitochondria and alters bioenergetic performance, the specificity of its action on pathologic B cells isolated from patients with
chronic lymphocytic leukemia (CLL) versus B cells from healthy subjects was investigated. Mesenchymal stromal cells (MSCs),
proposed to mimic the tumor environment, attenuated the apoptotic effect of salinomycin on B-CLL cells. Apoptosis occurred to a
significant extent in healthy B cells as well as in MSCs and human primary fibroblasts. The results indicate that salinomycin, when
used above μM concentrations, exerts direct, mitochondrial effects, thus compromising cell survival.
Cell Death and Disease (2015) 6, e1930; doi:10.1038/cddis.2015.263; published online 22 October 2015
Salinomycin (SAL), an antibiotic that belongs to a large group
of polyether ionophores, is considered to be a potential
anticancer drug for cancer chemoprevention and therapy. SAL
has been proved to induce programmed cell death of cancer
stem cells (CSCs)1 as well as of various cancer cells including
chronic lymphocytic leukemia (CLL) cells, human colon,
breast, prostate, hepatocellular carcinoma and lung cancer
cells.2–4 On the other hand, the use of animal models revealed
that SAL has a narrow therapeutic index and SAL-induced
neuropathy occurs in vivo even at relatively low doses, which
do not give rise to systemic toxicity.5 Extensive research has
been undertaken to clarify the general mechanism(s) by which
SAL induces apoptosis and blocks tumor growth. Several
independent ways of action have been proposed to account for
the cancer cell-killing ability of SAL, including inhibition of
proximal Wnt/β-catenin signaling6 and induction of a marked
increase in the expression of the pro-apoptotic protein
NAG-1.7 Recent results point to SAL as a strong mTORC1
signaling antagonist in breast and prostate cancer cells8 and
as an initiator of autophagy in tumor cells.9,10 SAL however is
also able to suppress late stages of autophagy, leading to
accumulation of dysfunctional mitochondria with increased
production of reactive oxygen species (ROS).11
SAL is expected to impact mitochondrial function
thanks to its ability to act as an ionophore. However,
only few early studies addressed the direct effect of SAL on
isolated mitochondria;12 later works generally interpreted
mitochondria-related effects of SAL in intact cells presuming
that SAL acts similarly to valinomycin (VAL), a potassium
selective ionophore mediating potassium influx into the
mitochondria according to the electrochemical driving
force. For example, SAL-induced mitochondrial inner
membrane (IMM) depolarization and mitochondrial ROS
production have been proposed to be compatible with influx
of positively charged potassium ions.9,13,14 The chemical
structure of SAL is however more similar to nigericin (NIG)
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rather than to VAL (Supplementary Figure S1). We note the
presence of a carboxyl group, which can act as the H+ carrier.
NIG, similarly to monensin, acts as an ionophore with a
preference for potassium and mediates electroneutral
exchange of potassium ions with protons at the level of the
IMM. Notably, NIG and monensin have been shown to induce
apoptosis in human lung cancer and lymphoma cells,15,16
suggesting that the common mechanism of polyether iono-
phore antibiotics to altering potassium homeostasis in the
cytoplasm and mitochondria contributes to the induction of
apoptosis in cancer cells. In accordance, we have recently
demonstrated that pharmacological inhibition of a mitochon-
drial potassium channel (whose expression is upregulated in
many cancers17) and the consequent mitochondrial dysfunc-
tion might be exploited to selectively kill melanoma cells even
in vivo, as well as in ex vivo human leukemic cells.18,19
The mitochondrial effects of SAL have generally been
addressed 12–48 h following addition of the drug, even though
it is expected to reach quickly the IMM, as VAL and NIG do
when added to intact cells. The purpose of the present work
therefore was to reveal the early effects of SAL on
mitochondrial function as compared with VAL and NIG, in
primary human healthy cells, in cancer stem cell-like
immortalized human mammary epithelial cells expressing
Twist20 and in cancer cells. Our results reveal the short-term
effects of SAL and thus contribute to the elucidation of its
mechanism of action. In light of the fact that SAL is used in
screening studies on a small group of patients with invasive
carcinoma of the head, neck, breast and ovary,4 this point is
especially relevant.
Results
SAL affects the cell viability of many types of solid cancer and
leukemic cells. First we focused our attention on T leukemic
Jurkat cells, given that alteration of mitochondrial potassium
influx in these cells significantly impacts cell survival.21,22
Figure 1a shows a drastic reduction of cell survival,
as assessed using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay, by addition of sub-μM
concentration of NIG (IC50: 0.33 μM). Similarly, Jurkat cells
were sensitive to SAL and VAL in the μM range (IC50 SAL:
3.61 μM; IC50 VAL: 7.40 μM). Figure 1b proves, using Annexin
binding assay, that the decreased cell viability was due to
increased apoptosis. In all 10 μM of all three ionophores was
sufficient to kill more than 80% of the cells, while at 1 μM NIG
was most effective. Next, we tested the sensitivity of ex vivo
human cells to the above three ionophores. Human pathologic
B cells isolated from patients with CLL (B-CLL) have been
reported to be efficiently killed by 1 μM SAL, in contrast to
peripheral blood mononuclear cells from healthy subjects.6
In accordance, 1 and 10 μM SAL induced 60% and 94% B-CLL
death, respectively (Figure 1c). Similar data were obtained with
NIG and with VAL (Figure 1c and Supplementary Figure S2).
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Figure 1 Effect of salinomycin, nigericin and valinomycin on lymphocytes. Jurkat leukemic T cells (a and b) and human primary B-CLL cells (c) were incubated for 24 h with
different concentrations of the compounds, as indicated. Cell survival (a) was measured by MTTassay; values are expressed as the average percentage of cell survival compared
with untreated cells ± S.E.M. (n= 5). Cell death (b and c) was tested using FACS by the staining with FITC-Annexin V and propidium iodide. Staurosporine (Stauro or ST) was
used as positive control. Indicated values refer to the percentage of dead cells ± S.E.M. (n= 14). Statistically significant differences (Po0.05) are indicated by asterisks
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The above results confirm the ability of SAL and the other
two potassium ionophores to trigger apoptosis in lymphocytes.
The property of these ionophores to accumulate in the
mitochondria suggested that they might induce apoptosis by
altering organellar potassium homeostasis via direct action at
the level of the IMM. If this hypothesis were correct, death
induced by these agents ought to be independent of Bax and
Bak. These two pro-apoptotic proteins become inserted into
the outer mitochondrial membrane during apoptosis and
contribute to cytochrome c release from the intermembrane
space, which however occurs also via other pathways.23–25
Loss of cytochrome c has been shown to occur upon SAL
treatment at later stages of apoptosis. We used WT and
Bax/Bak double-knockout (DKO) mouse embryonic fibro-
blasts (MEFs) and observed that the absence of Bax and
Bak did not confer protection against SAL, NIG and VAL
(Figure 2a and Supplementary Figure S3). As expected, MEF
DKO cells were instead more resistant to staurosporine.
Altogether these data suggested that apoptosis induced by
these three ionophores might be, at least in part, due to their
direct effect on mitochondria. Therefore, we measured
acute changes of mitochondrial membrane potential (∆ψ),
production of ROS, matrix pH, swelling, mitochondrial
morphology and respiration upon addiction of SAL, NIG and
VAL. First, we observed that addition of 1 μM SAL, similarly to
NIG and in contrast to VAL, to isolated rat liver mitochondria
(RLM) resulted in hyperpolarization (Figure 2b). Also in intact
cells, only VAL caused depolarization (Figure 2c). Both
depolarization and hyperpolarization might trigger ROS
release (e.g. Zorov et al.26), and an increase in intracellular
ROS 30 h after SAL addition to intact cells was observed.13
In B-CLL cells, on a time scale of minutes, only VAL induced a
significant mitochondrial ROS release measured by MitoSOX;
even at 10 μMSAL, ROS production was comparable to that of
untreated cells (Figure 2d). The same result was obtained in
Jurkat lymphocytes (not shown), and in our study, preincuba-
tion with membrane-permeant ROS scavengers PEGylated
catalase and PEGylated superoxide dismutase did not affect
SAL-induced apoptosis, while it did reduce VAL-associated
death (Supplementary Figure S4).
Given the similar consequences of NIG and SAL addition,
we presumed that SAL mediates exchange of protons with
potassium. To directly prove this point, matrix pH was
measured in intact cells using mitochondria-targeted
SypHer.27 At 1 and 10 μM applied concentrations, both NIG
and SAL triggered an immediate matrix acidification in MEF
cells with a subsequent alkalinization that did not, however,
re-establish the original pH value (Figure 3a). As mentioned
above, SAL was shown to act on tumor stem cells as well, with
a lower IC50 than the one found here for Jurkat, MEF or B-CLL
cells.1 In particular, Gupta et al.1 showed (and we confirmed
(not shown)) that immortalized human mammary epithelial
cells (HMLE) ectopically expressing the transcription factor
Twist and therefore forced to undergo epithelial–mesenchymal
transition are sensitive to SAL, displaying an IC50 of around
1 μM regarding cell viability. Therefore, we asked whether SAL
shows the same effect on the mitochondria of cells with stem
cell-like features and used HMLE-Twist cells to measure
mitochondrial function. As Figure 3b illustrates, sustained
matrix acidification upon SAL and NIG addition could be
observed also in these cells. ROS release and changes in
membrane potential (Supplementary Figure S5 and S6)
occurred similarly to the other cells described above.
Matrix acidification is due to the entry of protons in exchange
for potassium ions leaving the matrix. VAL has also been
shown to cause acidification to some extent in the absence of
K+/H+ exchanger inhibitors.28 Given that acidification is known
to prevent activation of the permeability transition pore (PTP)
(e.g. Szabo et al.29 and Bernardi et al.30), which causes
swelling and might contribute to cytochrome c release,24 we
tested whether SAL prevents calcium-induced PTP opening.
A decrease of the absorbance, indicative of swelling, can be
detected in isolated mitochondria upon addition of 140 μM
calcium, sufficient to trigger the PTP opening (Figure 3c). In
contrast, SAL and NIG, as expected, completely abolish the
swelling due to calcium-induced PTP opening, at least on a
relatively short time scale, even though mitochondria are able
to take up calcium even in the presence of SAL as assessed by
calcium retention assay (not shown). Addition of VAL results in
incomplete swelling presumably due to entry of potassium and
to the subsequent compensating activation of the K+/H+
antiporter.31 Rapid changes in mitochondrial morphology
upon addition of VAL were observed also in intact cells using
mitochondria-targeted green fluorescence protein (Dimmer
et al.32 and Supplementary Figure S7). These experiments
indicated that although SAL and NIG affect to a small extent
the mitochondrial network, they do not have drastic early
effects similar to those induced by VAL (massive swelling;
Figure 3d and Supplementary Figure S7).
Althoughmitochondrial depolarization, ROS production and
swelling do not take place in the early phases following SAL
and NIG addition, the matrix acidification is expected to
severely impact on mitochondrial bioenergetics. Adenosine
triphosphate (ATP) depletion in cells upon SAL addition has
been described after 24 h,10 but whether it occurs as a direct
consequence of SAL action on mitochondrial respiration or as
a secondary independent effect is unclear. Figure 4 illustrates
that already 1 μM SAL and NIG significantly reduced basal
respiration in intact adherent MEFs as assessed by the
extracellular flux analyzer using a previously established
protocol.33 This decrease in respiration was further accentuated
by oligomycin, which blocks the ATP synthase. Subsequent
addition of the uncoupler carbonylcyanide-p-trifluoromethox-
yphenylhydrazone (FCCP) did not restore respiration,
whereas the addition of antimycin A, an inhibitor of complex
III, completely abolished oxygen consumption in both MEFs
(Figure 4a) and HMLE-Twist cells (Figure 4b). Antimycin A
inhibits the oxidation of ubiquinol in the electron transport
chain of oxidative phosphorylation (OxPhos), preventing
thereby the formation of the proton gradient across the IMM.
In summary, SAL and NIG drastically reduced the respiratory
response to the addition of FCCP. In contrast, VAL induced an
immediate increase in respiration and a loss of response to
oligomycin. When cellular respiration in MEFs was decreased
by oligomycin, the addition of VAL but not of SAL and NIG
induced a recovery of the respiratory rate (Figure 4c). This
recovery is a reflection of the loss of Δψm induced by VAL.
Subsequent addition of FCCP had no effect, whereas
antimycin A reduced respiration (Figure 4c). Similar changes
were observed in both settings with 10 μM SAL (Figure 4d),
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indicating that at least in MEF cells, 10 μM SAL was sufficient
to drastically reduce bioenergetic efficiency. These results
strongly suggest that matrix-pH-perturbing ionophores
significantly reduce respiratory efficiency, contributing to the
observed cell death.
In light of the above results we then compared B-CLL cells
directly with B lymphocytes isolated from healthy subjects as
previously described.19 Under the experimental conditions
used, SAL-induced apoptosis not only in B-CLL cells but also
in healthy B cells, although to a statistically significantly less
Figure 2 Salinomycin kills Bax/Bak-less mouse embryonic fibroblasts and alters mitochondrial membrane potential. (a) Cell survival in WT and Bax/Bak DKO MEFs was
measured by MTT assay (n= 4). Staurosporine was used as the classical apoptosis inducer. No significant differences were observed between WT and DKO cells.
(b) Mitochondrial membrane potential determined on rat liver isolated mitochondria (RLM) by measuring the distribution of the TPP+ ions across the mitochondrial membrane with
a selective TPP+ ion-sensitive electrode. Values are presented as variation of Δψ following addition of the indicated compounds. (c and d) Mitosox (c) and TMRM
(d) fluorescence on B-CLL cells, measured by FACS analysis after treatment with salinomycin, nigericin and valinomycin at the indicated concentrations; CCCP, antimycin and
staurosporine (ST) were used as positive controls. Average values ± S.D. are showed (n= 3 independent experiments)
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Figure 3 Salinomycin induces an instantaneous acidification of matrix pH in intact cells. (a and b) Measurement of transient variation of mitochondrial matrix pH in MEF
WT cells (a) and in HMLE-Twist cells (b) expressing mito-SypHer; changes in pH correspond to variations in the 535-nm fluorescence emission after alternative excitation at 405
and 488 nm. Results are expressed as mean 500/430 nm ratios ± S.E.M. of four different experiments. Addition of drugs is indicated by red arrow, while Na-acetate (NaAc) was
used as positive control (blue arrows). (c) Isolated rat liver mitochondria (RLM) swelling was measured as reduction of mitochondrial absorbance over time at 540 nm. CaCl2
(140 μM) was used to induce PTP opening and swelling. (d) MEF WT cells expressing mito-YFP were treated with SAL at the indicated concentrations and live images were
acquired over time to monitor changes in mitochondria morphology. Bars correspond to 25 μm. Magnified images are shown in the lower row. Results shown in (a)–(d) are
representative of three independent experiments
Salinomycin compromises mitochondrial function
A Managò et al
5
Cell Death and Disease
extent than in pathologic cells (Figure 5a). The same
experiments were performed on B-CLL cells co-cultured with
mesenchymal stromal cells (MSCs) from healthy donors,34
since MSCs of the bone marrowmicroenvironment have been
reported to protect B-CLL cells from apoptosis induced by
conventional chemotherapeutics.35 The apoptosis-inducing
effect of SAL was significantly reduced by the presence of
MSCs both for pathologic (Figure 5b) and for healthy B cells
(not shown) in agreement with the notion that adhesion of
B-CLLs on MSC favors survival36 and MSCs protect leukemia
cells from apoptosis induced by chemotherapeutic drugs.37
SAL was toxic to MSC after 24 h of treatment both when
co-culturing B-CLL with MSC (Figure 5c and Supplementary
Figure S8) and when culturing MSC alone (Supplementary
Figure S9). In order to test also another non-tumoral
system, cultured primary human skin fibroblasts were used
(Figure 5d). Again, these cells were sensitive to SAL and were
even more apoptotic with NIG applied at 10 μM concentration.
Figure 4 Salinomycin and nigericin affect respiration in a similar manner. (a–d) Oxygen consumption rate (OCR) of MEF WT cells (a, c and d) and of HMLE-Twist cells (b)
was measured in the presence of 1 μM salinomycin, nigericin and valinomycin (compounds). Representative experiments are shown. The compounds were added to the cells
either before (a and b) or after (c and d) inhibition of ATP synthase activity with oligomycin. The effect of 10 μM SAL in MEF cells was comparable to that of 1 μM, indicating that
already the lower concentration exerts the maximal effect
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Figure 5 Salinomycin, nigericin and valinomycin affect survival of leukemic B cells, mesenchymal stromal cells and fibroblasts. (a) Comparison of apoptosis in pathologic
B-CLL cells and B cells from healthy subjects (cells were incubated for 24 h in the presence of the indicated compounds and cell death was determined by FACS by staining with
FITC-Annexin Vand propidium iodide). Quantification of the cell death (all annexin-positive cells) ± S.E.M. (n= 14 for B-CLL cells and n= 6 for healthy B cells). (b) Apoptosis of
B-CLL (n= 14) cells compared with death occurring in the pathologic cells co-cultured with MSC (n= 4). Apoptotic cells were identified by FACS as in (a). (c) Mesenchymal
stromal cells were photographed after 24 h treatment with SAL and removal of co-cultured B-CLL cells by washing. Bars correspond to 75 μm. At higher concentrations of SAL the
number of cells decreased and the cells showed significant morphological alterations. (d) Human primary fibroblasts treated with the indicated substances for 24 h. Annexin-FITC
binding is shown. Results shown in (c) and (d) are representative of three independent experiments. Bars correspond to 50 μm
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Discussion
In the present work, by comparing the effects of three K+
ionophores on isolated mitochondria as well as in intact cells,
we demonstrate that SAL and NIG, two drugs identified as
promising chemotherapeutics, both act as K+/H+ exchangers
at the level of the IMM and contribute to the loss of
mitochondrial function in intact cells.
Our data clearly show that SAL action is comparable to that
of NIG while being distinct from the effects of VAL, and
demonstrates that in intact cells SAL mediates K+/H+
exchanger activity also at the level of the IMM. The
measurements in cells indicating IMM hyperpolarization,
mitochondrial matrix acidification and decrease of respiration
leave no doubt that, similarly to NIG, SAL reaches the
mitochondria within a few seconds upon addition. Indeed,
NIG has been reported also by other groups to cause IMM
hyperpolarization, without causing an acute effect on the
cytosolic pH or on the plasma membrane potential,38,39
and SAL was shown to cause extensive damage to the
mitochondria of Eimeria sporozoites.40 Our results suggest
that the reported ATP depletion uponSAL addition is a result of
the decreased respiration and that increase in mitochondrial
ROS release and mitochondrial depolarization detected 24 h
after addition are secondary effects occurring at a later time
point. These ionophores impact also cellular ion homeostasis,
that is, SAL suppresses autophagy flux and lysosomal
proteolytic activity.41 NIG and SAL may mediate the export
of potassium through the plasma membrane down its
concentration gradient in exchange for the uptake of protons,
and as a consequence cause acidification of the cytosol.
However, it has been shown that 0.5 μM NIG did not alter the
cytosolic pH under conditions that caused a pronounced
acidification of themitochondrial matrix within 15min.38 On the
other hand, on a longer time scale SAL treatment has been
shown to cause membrane scrambling.42
In mitochondria, NIG and SAL cause hyperpolarization, that
is, a shift of Δψ from the resting potential toward more negative
values, since by acting as H+/K+ exchangers, they adjust ΔpH
according to the K+ gradient across the IMM (depletion
of K+ during organelle isolation does not occur (e.g. Szabo and
Zoratti25 and Bernardi31): the equilibrium condition for K+/H+
electroneutral exchange is ∆μK=–∆μH. Since K+ is by far
more concentrated than H+, upon addition of NIG or SAL the
∆μH will essentially tend to the value set by the ∆μK (with the
opposite orientation).∆ψ increases tomaintain a constant∆μ̃H
in spite of the decrease (or inversion) of ∆μH.38,43 In other
words, proton influx being in exchange for K+, that is,
electroneutral, does not have by itself any effect on potential.
Hyperpolarization derives from the collapse of ∆pH, which the
mitochondrion compensates by increasing ∆ψ so as to keep
the overall electrochemical potential nearly constant. Neither
NIG nor SAL increasesmitochondrial ROS production in intact
cells, since these agents do not modify ∆μ̃H on short-term
scale; instead, they cause matrix acidification. These results
are in agreement with the study reporting that matrix
alkalinization favors ROS generation, whereas matrix
acidification induced by NIG strongly inhibits this process.44
The data presented here on VAL are also in line with the
findings described in the literature.31
Mitochondrial matrix pH is a factor that controls OxPhos in
intact cells. Matrix pH ranges from 7.7 to 8.2 in different cell
types, while the pH of the cytosol is around 7.0. This proton
gradient significantly contributes to the driving force on the
ATP synthase and impacts several transport processes
responsible for exchanging metabolites (e.g. pyruvate, gluta-
mate) or ions between mitochondria and the cytosol
(e.g. Greenbaum and Wilson45). Using a mitochondrial
pH-sensitive probe (mtAlpHi), Akhmedov et al.38 observed in
insulin-secreting cells a matrix acidification using 0.5 μM NIG,
which was partially recovered over the following 15 min,
similarly to our observations in MEF cells. Matrix realkaliniza-
tion depends on the operation of the H+ pumps and on the
electrogenic influx of cations and efflux of anions,46 but a ΔpH
of 0.4 unit persisted after the partial recovery in Akhmedov
et al.38. In addition, matrix acidification slowed down mito-
chondrial ATP synthesis by 20% over 20 min despite
hyperpolarization of the IMM, by regulating OxPhos down-
stream of Complex II. In the present study, a sustained
decrease of respiration by addition of NIG and SAL is
observed. This process might be compensated for a while
by ATP hydrolysis due to the ability of the ATP synthase to
work in the reversemode, which presumably contributes to the
ATP depletion observed (after 24 h) in several studies.
Sustained decrease of the respiration is expected to lead also
to loss of ΔΨm in the long term, which, in turn, might trigger
autophagy, mitophagy and ROS release. Indeed, depolariza-
tion induced by FCCP leads to ROS release (e.g. Sassi et al.47)
and is also known to trigger mitophagy (e.g. Lemasters48).
Thus, the initial changes observed here upon SAL addition
might well account for the published observations (mitochon-
drial depolarization, ATP depletion, ROS release and
mitophagy39) occurring after 424 h. Caspase activation and
cytochrome c release also occur at late time points.9 Whether
cytochrome c can be released upon depolarization-induced
PTP opening or due to accumulation of dysfunctional
mitochondria remains to be determined.
The relationship between mitochondrial respiratory inhibi-
tion, ATP depletion and cell death may be dependent on the
cell type as well as on specific conditions (e.g. Poltl et al.49).
Importantly, sensitivity of the cells to agents affecting
mitochondrial respiration depends on the metabolic state of
the cells, those relying mostly on mitochondrial respiration
rather than on glycolysis are more sensitive. Growing
evidence indicates that several types of cancer cells
(e.g. CSC-like surviving pancreatic ductal adenocarcinoma
cells (PDAC)50 and both normal and leukemic stem cells51)
are less glycolytic and more dependent on mitochondrial
respiration than others. PDAC cells are unable to increase
compensatory glycolytic fluxes following inhibition of OxPhos,
thereby showing large sensitivity to inhibition of mitochondrial
function. This may well explain the previously reported
selectivity of SAL towards CSCs. Thus, differences in the
sensitivity of the cell types used here and in other works
towards SAL can likely be ascribed to differences in metabolic
state. Healthy human fibroblasts and B lymphocytes have
been shown to principally rely on OxPhos for their
metabolism,52 possibly accounting for the SAL effect
observed here. In accordance with our findings, SAL was
found to be cytotoxic to healthy human peripheral blood
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lymphocytes at 10 μM concentration.53 In general, induction of
mitochondrial dysfunction and related energymetabolism54–56
and/or of substantial ROS release57,58 is considered a valid
strategy to fight malignant diseases. The question also arises
whether differences in sensitivity to SAL between CSCs and
non-CSCs might be ascribed to differences in the mitochon-
drial response to SAL. Our data suggest that this is not the
case, since the observed effects equally take place in the two
cell types. Instead, it has been reported that autophagy flux is
essential for maintaining proliferation of CSCs and that SAL
reduces the activity of cathepsins resulting in the inhibition of
lysosomal activity and autophagic flux to a greater extent in
CSCs with respect to non-CSC cells.41
In summary, in the present work we provide evidence that
SAL functions in intact cells as an K+/H+ antiporter and directly
impacts mitochondrial function in a fewminutes upon addition.
Our findings contribute to the understanding of themechanism
of action of this promising anticancer drug. The results
strengthen the hypothesis that polyether ionophore antibiotics
contribute to apoptosis induction by a common mechanism
andmight explain toxicity upon SAL treatment (e.g. Boehmerle
et al.,5 Scherzad et al.,53 and Ojo et al.59). Further studies will
be necessary to exactly delineate the factors contributing to
the moderate to high selectivity of SAL and NIG toward
tumoral cells as observed in several cases, given that these
ionophores a priori impact mitochondrial functions indepen-
dently of differences in signaling pathways (e.g. Wnt) and in
redox state and of the mitochondrial hyperpolarization typical
of tumoral cells. Therefore, the hypothesis that the apoptotic
effects of SAL and NIG depend on the ability of the cells to
compensate mitochondrial dysfunction, deserves to be tested
in future studies. For example, peroxisome proliferator-
activated receptor gamma coactivator 1-α, an important
regulator of mitochondrial biogenesis that is also involved in
the regulation of several stress programs and might integrate
mitochondrial biogenesis into cellular stress adaption, might
be involved in compensatory mechanisms (e.g. Hofer et al.60).
Materials and Methods
Reagents and cell lines. SAL, NIG and VAL and other commercial
chemicals were purchased from Sigma-Aldrich (Milan, Italy) unless otherwise
specified.
Mouse embryonic fibroblast (MEF), MEF WT, BAX/BAK-less (DKO) and mito-YFP
cells were grown in Dulbecco's modified Eagle's medium (DMEM) additionated with
10 mM HEPES buffer (pH 7.4), 10% (v/v) fetal bovine serum (FBS), 100 U/ml
penicillin G, 0.1 mg/ml streptomycin and 1% non-essential amino acids (100 ×
solution; Life Technologies, Thermo Fisher Scientific Inc, Waltham, MA, USA), in a
humidified atmosphere of 5% CO2 at 37 °C. Jurkat T lymphocytes were grown in
RPMI-1640 supplemented as above. B cells were isolated and maintained in culture
on a MSC layer as previously reported.34 Briefly, 2 × 105/well CLL MSCs were seeded
and incubated for a few days before the experiment at 37 °C in 5% CO2 up to
confluence. Then purified B-CLL cells (CD19+/CD5+) were added to the MSC layer at
a ratio of 2–5 : 1. Cells were then treated with SAL, NIG or VAL for 24 h to evaluate a
possible resistance to this agent due to the co-culture. Human skin fibroblasts, kindly
provided by Prof. V Bianchi (Padova), were cultured in DMEM supplemented with
10% FBS, L-glutamine and streptomycin.
HMLE TWIST cells were a kind gift of Prof. Weinberg and were grown in DMEM
F1/2 supplemented with insulin, hydrocortisone, bovine pituitary extract and
epidermal growth factor (all from Life Technologies, Thermo Fisher Scientific Inc).
Cells were grown and cultured as reported in Cordenonsi et al.61
Proliferation and cell death assays. To determine cell viability, tetrazolium
reduction (MTT) assay was used as reported previously.18 Briefly, 0.005 × 106 MEF
WT or DKO cells were seeded in standard 96-well plates in 200 μl of DMEM for
24 h. Then, the medium was replaced with DMEM without phenol red (PR) and FBS
and cells were treated as indicated in the figure legends. Suspension cells were
seeded and treated in DMEM without PR and FBS. After incubation, CellTiter
96 AQUEOUS One solution (Promega, Milan, Italy) was added to each well as
indicated by the supplier. Absorbance at 490 nm to detect formazan formation was
measured using a Packard Spectra Count 96-well plate reader (Life Technologies,
Thermo Fisher Scientific Inc).
Apoptosis for B-CLL and healthy cells was determined by FACS analysis (FACS
Canto II, BD BioSciences, Franklin Lakes, NJ, USA) using a double staining with
Annexin V-FLUOS (Roche, Basel, Switzlerland) and propidium iodide (PI; Sigma
Aldrich, St. Louis, MO, USA) as reported before.19 After incubation with the different
drugs, cells were incubated with PI (final concentration 1 μg/ml) and Annexin-V-
FLUOS (0.6 μl/sample) for 20´ at 37 °C in the dark, and were analyzed by FACS. For
human skin fibroblasts, cells were seeded in a 24-well plate and treated for 24 h as
indicated in 1 ml of DMEM without PR and FBS. After incubation, 2 μl/well of Annexin
V-FITC was added and cells were incubated for 20´ at 37 °C in the dark, and were
analyzed by a Leica DMI 4000 fluorescence microscope (Leica Microsystems,
Wetzlar, Germany).
Mitochondrial morphology. Mitochondrial network was studied by using
MEF mito-YFP cells seeded directly onto glass coverslips in six-well plates
(0.05 × 106) in DMEM. Then, coverslips were mounted onto holders, washed, filled
with 1 ml of DMEM without PR and FBS and compounds were added directly onto
the holder on the microscope stage of a Leica SP5 confocal system mounted on a
Leica DMI6000 microscope.
Determination of mitochondrial matrix pH in live cells. MEF
WT cells were seeded at a density of 50 × 103 cells/well onto glass coverslips. pH
measurements were performed in Ca2+/Mg2+ supplemented HEPES buffer
(HBSS, Invitrogen, Milan, Italy) 24 h after transfection with a mtSypHer expression
vector using Lipofectamine 2000 (Invitrogen). Coverslips were mounted onto the
holder and the different compounds were added directly and analyzed by a Leica
SP5 confocal system mounted on a Leica DMI6000 microscope. Ratiometric
sequential images of the 535 nm emission fluorescence were acquired every 3 min
during 30 min with a × 63 objective and the LAS-AF software after alternative
excitation at 430 nm and 500 nm. As a control of acidification, cells were treated with
30 mM NaAc at the end of each experiment. The multi-measure plug-in of Image J
software (NIH) was used to estimate mean fluorescence ratios of selected ROIs
matching the mitochondria in at least four experiments following background
subtraction; results are expressed as mtSypHer (500/430 nm) ratio.
Mitochondrial membrane potential and ROS production.
Mitochondrial membrane potential (MMP) and ROS production were measured
as in Leanza et al.19 Briefly, MMP was monitored using tetramethylrhodamine
methyl ester (TMRM; 20 nM), while ROS production was assayed using MitoSOX
(1 μM). B cells either from CLL patients or from healthy subjects were incubated for
20 min at 37 °C. After incubation, the indicated compounds were added and the
decrease in TMRM fluorescence or the increase in MitoSOX fluorescence was
measured by FACS. HMLE TWIST cells (0.07 × 106 cells/well) were seeded in a
12-well plate in 1 ml of their culture medium. The day after, cells were incubated
with TMRM 20 nM and MitoSOX 1μM in HBSS (Life Technologies, Thermo Fisher
Scientific Inc) for 20 min at 37 °C in the dark. After incubation, compounds were
added as indicated in the figure and the decrease in TMRM fluorescence or the
increase in MitoSOX fluorescence was measured by a Leica DMI 4000 fluorescence
microscope at the indicated time points.
Oxygen consumption assay. Oxygen consumption by adherent cells was
measured using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience, North
Billerica, MA, USA) as reported before.33,47 MEF WT cells were seeded at 3 × 104
cells/well in 200 μL of supplemented culture medium (DMEM; Sigma Aldrich).
Oxygen consumption rate (OCR) was measured at preset time intervals while the
instrument automatically carried out the preprogrammed additions of the various
compounds (oligomycin final concentration 1 μg/ml, FCCP 400 nM, antimycin A
1 μM), added as a solution in 70 μL of DMEM. HMLE TWIST cells were seeded at
6 × 104 cells/well in 200 μL of supplemented culture medium. As for MEF WT, OCR
was measured at preset time intervals upon the addition of the various compounds
(oligomycin final concentration 0.5 μg/ml, FCCP 1 μM, antimycin A 1 μM), added as
a solution in 70 μL of DMEM. A massive loss of cells because of death and
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detachment was excluded by direct microscopic observation of the cells at the end
of the experiments (not shown).
RLM isolation and determination of RLM membrane potential
and swelling. Rats were killed and the liver was removed and immediately
immerged in an ice-cold isolation medium (250 mM sucrose, 5 mM Hepes, 2 mM
EGTA, pH 7.5). The liver tissue was minced, thoroughly rinsed several times with
ice-cold medium and then homogenized in the same buffered solution using a glass/
Teflon Potter homogenizer. Mitochondria were then isolated by conventional
differential centrifugation and the protein content was measured by the biuret
method with bovine serum albumin as a standard.
Experiments were carried out with 1 mg of mitochondrial protein/ml suspended in a
standard incubation medium containing 200 mM sucrose, 10 mM HEPES (pH 7.4),
5 mM Na-succinate, 1.25 μM rotenone and 1 mM phosphate, additionated with
2 mM KCl.
Membrane potential (Δψ) was determined on the basis of the distribution of lipid-
soluble cation tetraphenylphosphonium (TPP+) across the mitochondrial membrane,
measured by a TPP+-specific electrode, as in Kamo et al.62
Mitochondrial swelling was determined by measuring light scattering at 90° with a
Perkin Elmer LS50B spectrofluorometer at 540 nm with a 5.5-nm slit width.
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Since the discovery of the participation of various ion channels in the regulation of cell proliferation and pro-
grammed cell death two decades ago, theﬁeld exploring ion channel function in relation to cancer has undergone
rapid development. Although the mechanisms accounting for the impact of ion channel modulators on cancer
growth have not been fully clariﬁed in all cases, numerous in vivo experiments targeting diverse ion channels
in various cancer models illustrate the great potentiality of this approach and promote ion channels to the
class of oncological targets. In the present reviewwe give an updated overview of the ﬁeld and critically discuss
the promising results obtained in pre-clinical models using speciﬁc pharmacological modulators of calcium, so-
dium, potassium and anion-permeable ion channels, whose expression is often altered in tumor cells and tissues.
Themost, especially critical issues are speciﬁcity of action and side-effects. Interestingly, some of themost potent
drugs are natural products, and several of the active compounds are already used in the clinic for other purposes.
In these latter cases involving drug repositioning we may expect a faster progression from preclinical to clinical
studies. This article is part of a Special Issue entitled: Calcium and Cell Fate. Guest Editors: Jacques Haiech, Claus
Heizmann, Joachim Krebs, Thierry Capiod and Olivier Mignen.
© 2015 Published by Elsevier B.V.
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1. Introduction
Plasma membrane ion channels are trans-membrane proteins that
selectively facilitate the permeation of speciﬁc ions between intracellular
and extracellular environments. By controlling ion ﬂuxes at multiple sites
within the cells and onmultiple time scales, ion channels shape rapid cell
signals in excitatory tissues but are involved also in slower processes,
such as proliferation (e.g. [1–3]), volume regulation (e.g. [4,5]), apoptosis
(e.g. [2,6–9]), migration (e.g. [10,11]) and cell adhesion (e.g. [12]) in
non-excitable cells. Since the ﬁrst reports linking ion channels to these
processes (e.g. [13–18]) the ﬁeld has undergone an exponential develop-
ment and by now the scientiﬁc community accepted the idea that regula-
tion of ion channel function during e.g. proliferation or apoptosis is not
merely a “side-effect”. Rather, channels play crucial modulating roles
and are able to determine the fate of the cells. Indeed, a role of ion chan-
nels in cancer development has been hypothesized already two decades
ago. Increasing evidence indicates that a variety of channel types not
only in the plasma membrane but also in intracellular organelles are
involved in neoplastic progression and importantly contribute to the
acquisition of the main characteristics of the cancer cells [19], including
metabolic re-programming [20,21], limitless proliferative potential
[22,23], apoptosis-resistance [8,24], stimulation of neo-angiogenesis [25]
as well as cell migration and invasiveness [12,26]. Thus, the channels
impacting cancer development and progression have been deﬁned as
“oncogenic channels”. Tumor progression leads to the acquisition of a
speciﬁc molecular proﬁle, giving rise to different malignant clones
which display altered genotypic and phenotypic characteristics. In this re-
spect, identiﬁcation of the “channelome”, i.e. of the type and expression
level of a certain set of ion channels, of different cancer types is especially
important, since ion channels not only contribute to malignant progres-
sion, but also offer a possibility of therapeutic intervention. Determination
of the “channelome” in pathologic tissues might help to set up strategies
to speciﬁcally target cancer cells but not healthy tissues, in contrast to the
most widely used chemotherapeutics which affect the most rapidly
proliferating cells.
Indeed, much convincing in vitro work by many different laborato-
ries has established that modulation of ion channels in cancer cells by
either altering their expression or using inhibitors/activators may im-
pair the growth and/or migration of these cells. On the other hand efﬁ-
cacy against cultured cancer cells is not necessarily maintained when
moving tomore complex in vivo systems, since, for example pharmaco-
kinetic properties of the anti-tumoral agents or effective drug delivery
to tumor tissues in the case of solid tumors might not be satisfactory.
Furthermore, the importance of the tumor microenvironment, with its
immunomodulatory, pro-inﬂammatory and anti-apoptotic roles, is
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coming into full focus (e.g. [27–29]). The tumor niche cannot be fully
reconstituted in vitro. Nonetheless, recent in vivo studies demonstrate
the efﬁcacy of ion channel targeting, consecrating this class of proteins
as promising pharmacological targets in oncology. Fig. 1. summarizes
the various types of ion channels present in different tumor tissues,
whose targeting yielded signiﬁcant inhibition of tumor growth in vivo
in animal models.
The primary scope of the present review is to give and updated over-
view of recent advances regarding pharmacological targeting; there-
fore, the speciﬁc mechanisms responsible for the tumor-reducing
effects will be only brieﬂy mentioned. For most of the channel proteins
we discuss, evidence has been gained of their altered expression in
tumor tissues with respect to healthy tissues, but for sake of simplicity
we do not refer to these data. In general, while convincing cases of
reduced tumor growth by application of channel inhibitors exist in the
literature, in a few instances the mechanism is likely to be unrelated
to their channel-inhibitory function, and/or, in several cases, the
demonstration that the drugs inhibits proliferation via its action on
ion channels is missing.
2. Calcium-permeable channels
Intracellular Ca2+ homeostasis impacts cell cycle checkpoints,
apoptosis, autophagy, migration and release of soluble modulators
such as neurotransmitters, hormones and growth factors in both normal
and neoplastic cells [30–33]. Major Ca2+ inﬂux pathways include
voltage-gated Ca2+ channels (VCC; L-type: CaV1.1–1.4; N-type:
CaV2.2; T-type: CaV3.1–3.3; R-type: CaV2.3; P/Q-type: CaV2.1), those
mediated by the Ca2+ permeable ion channels of the transient receptor
potential (TRP) family, purinergic receptors (e.g. P2X, forming Ca2+-
and Na+-permeable pores), and the store-operated calcium entry
(SOCE) pathway components Orai1 and STIM1 (or TRPC in combination
with STIM1). In addition, theNMDA class glutamate receptors expressed
in neurons and Piezo1 channels can also allow calcium inﬂux being non-
selective cation channels. At the intracellular level, activation of plasma
membrane (PM) localized G protein-coupled receptors (GPCRs) leads to
generation of inositol triphosphate (IP3) and subsequent stimulation of
IP3 receptors (IP3Rs) located on the endoplasmic reticulum (ER),
resulting in Ca2+ release from intracellular stores. Ca2+ from this
compartment can be released also via the ryanodine receptors (RYR).
Receptor-stimulated Ca2+ release from the ER stores serves as a signal
to activate Ca2+ inﬂux channels of the PM, the store-operated Ca2+
channels (SOCs). The two known SOCs are the Orai and TRPC channels.
Orai must be activated by STIM1, an ER-resident multi-domain protein
that functions as sensor of Ca2+ stored in the ER lumen and translocate
into ER-PM junctions to tether and activate Orai channels when ER Ca2+
concentration decreases, while TRPC can function also independently of
STIM1 [34,35]. The sarco/endoplasmic reticulum Ca2+ ATPase (SERCA),
the secretory pathway Ca2+ ATPase (SPCA) and themitochondrial calci-
um uniporter MCUwhichmediates uptake of this ion intomitochondria
actively sequester cytosolic calcium. The plasma membrane Ca2+ ATP-
ase (PMCA) and the PM-located Na+/Ca2+ exchanger (NCX) also play
Fig. 1. In vivo targeting of ion channels for cancer therapy. The ﬁgure lists all channels expressed in different organs whose expression is altered in the corresponding tumor tissues and
whose pharmacological targeting in vivo yielded signiﬁcant result in relation to tumor size or metastasis. See text for further details.
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a role in restoring resting Ca2+i by actively exporting calcium to the
extracellular millieau (for recent reviews see e.g. [30,36]). In addition,
acidic endogenous compartments such as lysosomes and lysosome-
related organelles harbor functionally active Ca2+-permeable TRP
channels (themain type is TRPML,mucolipin) and TPC twopore channels
as well as P2X receptors [37,38].
2.1. Voltage-gated calcium channels
Among the compounds targeting the Ca2+cyt-regulating systems
mentioned above, some ion channel antagonists have been shown to
impact on tumor size in various models. The expression of VCCs is a
characteristic of excitable cells, but some members (especially of the
CaV3 subfamily), are expressed in a number of cancer cell lines where
they modulate proliferation [39]. One of the ﬁrst in vivo studies has
been performed in 1992 using structurally unrelated L-type voltage-
gated calcium channel antagonists (CCA) amlodipine, diltiazem, and ve-
rapamil, all of which inhibit proliferation of HT-39 human breast cancer
cells with IC50 values ranging from 1.5 μM (for the dihydropyridine
amlodipine) to 10 μM (for the phenylalkylamine verapamil). Clinical
studies in humans showed that verapamil acts as a chemo-sensitizer,
overcoming multi-drug resistance (MDR) pump-mediated resistance
to anthracycline and increasing survival of patientswithmetastatic breast
carcinoma [40]. Its mechanism of action may thus be related more to
its interaction with other channels, such as those selective for sodium
(e.g. [41]) and potassium (e.g. [42,43], and with P-glycoprotein/MDR1
(e.g. [44]) than to Ca2+ channel inhibition. CCAs have been proposed to
be tested in clinical trials in adjuvant therapy for recurrent or unresectable
meningiomas [45,46]. In vivo in an animal model of breast cancer, oral
administration of amlodipine (0.35 mg/day), diltiazem (3.5 mg/day) or
verapamil (3.5mg/day) for 10 days inhibited HT-39 breast tumor growth
by 83.5 ± 20.1% (mean ± SE), 46.5 ± 6.6% and 68.2 ± 9.7%, respectively
[47]. However, the mechanism responsible for the in vitro and in vivo ef-
fects could not be clariﬁed, since HT39 cells were found not to express
VCCs. Interestingly, the dihydropyridine (DHP) amlodipine proved to be
the most efﬁcient drug in vivo but not all compounds in this class display
anti-proliferative effects in vitro. For example, while amlodipine,
nicardipine and nimodipine, inhibited the growth and DNA synthesis of
human epidermoid carcinoma A431 cells with IC50 values of 20–30 μM,
the structurally related nifedipine did not exert such an effect [48]. In ad-
dition, the L-type voltage-gated calciumchannel activator (F)-Bay K8644)
did not prevent the anti-proliferative effect of the above DHP inhibitors,
again pointing to a VCC-independent mechanism of action and in agree-
ment with the ﬁnding that these cells do not express L-type VCC [49].
Daily intraperitoneal administration of amlodipine (10 mg/kg) for
20 days into mice bearing A431 xenografts, retarded tumor growth and
prolonged the survival of mice: at day 23 post tumor inoculation, tumor
size was reduced by more than 55%. Furthermore, clinical trials for the
use of amlodipine in the treatment of hypertension suggest that long-
term treatment with these agents (at concentrations comparable to
those used in the above studies) does not cause signiﬁcant toxicities.
But what is the mechanism of action of amlodipine? In A431 cells
amlodipine has been shown to attenuate capacitive Ca2+ entry via intra-
cellular store-depletion activated calcium channels, ICRAC [48]. Recently,
the samegroup provided evidence that these cells express canonical tran-
sient receptor potential 1 (TRPC1) and TRPC5 which might mediate
calcium inﬂux and found that amlodipine arrested cell cycle progression
at the G1 phase by inducing a cyclin-dependent kinase inhibitor [50].
Finally, amlodipine was found to inhibit tyrosine phosphorylation of
EGFR both in vitro and in vivo, possibly by modulating cholesterol-rich,
caveolin-1-containing membrane microdomains and thus impacting on
EGFR-related mitogenic signaling [51]. At the same time, the effect of
this drug on rafts might also have an impact on the SOC channels
(especially TRPC) mediating ICRAC (e.g. [52], which in turn seem to be es-
sential components of a Ca2+-dependent signal ampliﬁcation required for
EGF-dependent cell proliferation [53]. To our knowledge a systematic
study unequivocally linking only the CCA drugs that inhibit cell prolifera-
tion to the above events has not beenperformedup tonow. Thiswouldbe
important in order to generalize the observed effects and to conﬁrm
amlodipine as promising, lead compound for the development of
derivatives as anti-tumor agents acting on mitogenic signaling.
Although in the above examples the CCA drugs presumably reduce
tumor growth independently of their direct inhibitory effect on L-type
calcium channels, targeting of the T-type VCCs by the selective inhibitor
KYS05047 (a 3,4-dihydroquinazoline derivative; IC50 for T-type
channels: ~0.2 μM) does so thanks to its ability to decrease intracellular
calcium concentration [54,55]. Growth of human lung adenocarcinoma
A549 cells was time and dose-dependently inhibited by KYS05047,
6–8 μM being the optimal, non-cytotoxic concentration. The authors
provided in vitro evidence that these drug concentrations induced a re-
duction of the cyclin-dependent protein kinases cdk2 and cdk4, a reduc-
tion of the phosphorylation of the tumor suppressor protein RB
(retinoblastoma) and of Akt and mTOR and as a consequence, an arrest
of the cell cycle in G1 phase. The authors proposed that these events
took place as a results of the reduction of cytosolic Ca2+ and of the
activation of Ca2+/calmodulin-dependent protein kinases (CaM-K),
whose downstream effectors (e.g. Rb and the Akt pathway) play a role
in the G1 to S transition [56]. Unfortunately, the speciﬁcity of the effect
has not been investigated, e.g. by downregulation of the channel protein
using siRNA, but oral administration of 10 mg/kg KYS05047 for 21 days
in a BALB/cnu/nu mouse A549 xenograft model reduced tumor volume
by approximately 50%. Whether this drug caused side effects and
whether it prolonged animal survival has not been investigated.
Another T-type calcium channel inhibitor, mibefradil, was also shown
to impact in vivo on tumor growth in a glioblastomamodel (C6 glioma).
This compound, also known as Ro 40-5967, was approved by FDA for
treating hypertension but it was then withdrawn by the producer
(Roche) due to dangerous drug-drug interactions. It inhibits T-type
channels with an IC50 of ~3 μM vs. ~18 μM for L-type channels [57].
The study involved administration of 30 mg/kg (intraperitoneally 3
times a day for 1 week) in combination with ionizing radiation [58].
The animals treated with mibefradil starting on postoperative day
(POD) 15 followed by radiosurgery on POD 22, survived twice as
much as the animals treated only with radiosurgery. In addition,
mibefradil (45 mg/kg PO four times daily) in co-administration with
temozolomide (an alkylating agent; 10 mg/kg/day IP) increased maxi-
mal survival from 20 days to 120 days in a D-54 MG xenograft model
for glioblastomamultiformae [59]. A clinical trial is therefore underway
to evaluate the effect ofmibefradil in patientswith progressive or recur-
rent glioblastoma following radiation therapy and the currently used
chemotherapeutic temozolomide. As mentioned, CCAs have been pro-
posed for testing in clinical trials as an adjuvant therapy for meningio-
mas [45,46]. Mibefradil, similarly to other VCC inhibitors, blocks cell
cycle progression beyond the G1/S interphase, but also induces apopto-
sis by causing PM depolarization and by decreasing integrin expression
and thus cell adhesion [60]. Interestingly, mibefradil and its derivative
NNC 55-0396 were recently identiﬁed in a large-scale screening as
down-regulators of mitochondrion-mediated hypoxia-inducible factor
(HIF)-1α protein stability and angiogenesis inhibitors [61]. Ca2+ signal-
ing has been shown to stimulate translation of HIF-1α during hypoxia
[62]. The activity of this transcription factor is related to tumor cell sur-
vival, proliferation, and angiogenesis, but how exactly these drugs affect
HIF-1α protein stability is still an openquestion. Theﬁnding that knock-
down of T-type Ca2+ channel also suppressed hypoxia-induced HIF-1α
protein stability speciﬁcally links this type of VCC to the effect of
mibefradil and NNC 55-0396. The question arises whether any
agent affecting intracellular Ca2+ homeostasis might affect HIF-1α sta-
bility. Calcium signaling has been shown to stimulate translation of
HIF-alpha during hypoxia (e.g. [62]) and for example artemisinin and
parthenolide, two SERCA inhibitors, induce phosphorylation of HIF-1α
[63]. The L-type calcium channel blocker cilnidipine selectively
suppressed HIF-1α activity in vascular cells [64] and expression of
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(HIF)-1/2α was signiﬁcantly reduced in a neuroblastoma cell line
expressing a dominant negative form of TRPM2 channel, the presence
ofwhich reduces calcium inﬂux into these tumor cells in response to ox-
idative stress [65]. Using a mouse tumor xenograft model into which
U87-MG human glioblastoma cells were injected, Kim and colleagues
demonstrated that intraperitoneal administration of 10 or 20 mg/kg
NNC 55-0396 was sufﬁcient to reduce tumor volume by more than
60%, aswell as angiogenesis,without inducing liver toxicity [61]. Finally,
the case of simvastatin can bementioned: this statin has been shown to
reduce tumor growth in colitis-associated colon cancer (CAC) model
in vivo by inducing apoptosis [66], and at the same time it has been re-
cently suggested to inhibit calcium inﬂux via L-type VCC [67]. However,
simvastatin is likely to exert pleiotropic effect and the relevance of its
action on L-type VCC in vivo has not been addressed up to now.
In summary, VCCs are potential oncological targets of demonstrated
importance. The advantage of using drugs targeting VCCs is that most of
these drugs have been approved by FDA for curing hypertension. The
major shortcoming of this ﬁeld is however that for most of the drugs
the speciﬁcity of the effect via VCCs and the exact mechanism of action
have not been fully demonstrated. As described above, some of themost
promising drugs, like mibefradil, have multiple effects which impact
tumor growth, therefore making these drugs good candidates for
co-adjuvant therapies [68].
2.2. Transient receptor potential channels
Beside VCCs, TRP proteins are emerging as promising oncological
targets [36,69]. TRP channels can be divided into subfamilies, namely
TRPV (TRP vanilloid), TRPA (TRP ankyrin), TRPM (TRP melastatin),
TRPC (TRP canonical) and TRPP (TRP polycystin). Mammalian TRP pro-
teins form homo- or hetero tetrameric non-selective Ca2+-permeable
cation channelswhich can be stimulated by a variety of different factors,
including change in temperature, mechanical stress, osmotic pressure,
change in pO2 and in pH, ROS, growth factors and cytokines. Therefore,
they are expected to play a crucial role in the tumor-microenvironment
cross-talk. TRPC channels are activated through pathways coupled to
phospholipase C (PLC), and can support receptor-operated Ca2+ entry;
TRPC1 and TRPC4 can also contribute to SOCE via relatively non-
selective cation currents.
Several investigations found evidence for a role of TRPC channels in
the regulation of hallmark cancer processes by using genetic modula-
tion of their expression (e.g. [53]). Thus, knockdownof TRPC1decreased
tumor volume by 40% in a xenograft model using human grade IV
glioma cell line D54MG [70]. However, a pharmacological agent
that speciﬁcally targets a TRPC subtype became only recently available
(e.g. [71,72]. A recent piece of work demonstrated that the sesquiter-
pene (−)–englerin A is a selective and potent activator of TRPC4 and
5 [73] and inhibits tumor cell growth by activating these ion channels,
thereby inducingmassive calcium inﬂux and consequent cell death. Un-
fortunately, the concentrations at which englerin A activates a calcium
inﬂux (around 250 nM) are in the range in which englerin A was lethal
within a few hours in rodents (132–544 nM) [74]. Interestingly, another
natural compound, 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol
(20-GPPD), ametabolite of ginseng saponin induced TRPC-mediated cal-
cium inﬂux into CT-26 colon cancer cells and AMPK kinase-dependent
apoptosis in vitro. In vivo, daily injection of 20-GPPD (1 mg/kg) for
4 weeks reduced tumor weight by 75% [75]. However, which TRPC
channel is targeted by this compound is unclear, as is themechanism ac-
counting for the selective effect of 20-GPPD on cancer cells.
Among TRPV channels, the highly calcium-selective channel TRPV6
(which allows however the passage of heavy metals zinc, manganese
and cadmium as well [76]) has been found to be expressed in a variety
of cancers including prostate and breast. Its expression correlates with
cancer progression, suggesting that it drives cancer cell growth. TRPV6
indeed acts as oncogenic ion channels [77,78]. A fewyears ago, a synthe-
sized derivative of TH-1177 was proven to be a speciﬁc inhibitor,
capable of distinguishing between TRPV5 and TRPV6 and to block the
proliferation of LNCaP human prostate cancer cells with and IC50 of
0.44 μM [79]. The same group has also achieved the synthesis of TRPV-
inhibiting drugs starting from 2-Aminoethyl-diphenylborinate
(2-APB), a known modulator of the IP3 receptor, of SERCA, of Orai and
of TRP channels. One of the analogs is more efﬁcient than 2-APB in
blocking TRP channels, but it also blocks SERCA [80]. To our knowledge
this study has not been followed up in vivo so far. Interestingly, two
short peptides that derive from Soricidin, a novel paralytic peptide
isolated from Blarina brevicaudawere shown to bind TRPV6 in ovarian
cancer cells with high afﬁnity and can be exploited via conjugation
with ﬂuorescent dye for in vivo imaging of human ovarian tumors in a
xenograft mouse model [81]. Whether these peptides show an anti-
tumor activity in vivo is still to be tested. The prototypical vanilloid
agonist capsaicin, the well-known ingredient of chili peppers, which
activates both TRPV6 and TRPV1, was shown to induce apoptosis by
its action on TRPV6 (as proven using siRNA) and downstreamactivation
of calpains at 50 μM concentration in human small cell lung cancer cells
(SCLC) in vitro while leaving unaffected normal human bronchial epi-
thelial cells [82]. Importantly, in vivo dietary administration of capsaicin
(50mgcapsaicin/kg food) almost completely blunted growth of DMS53
human SCLC tumors xenografted in nude mice [82]. In T24 bladder
cancer cells T24 200 μM Capsaicin caused signiﬁcant TRPV1-dependent
apoptosis by inducing ROS release and mitochondrial depolarization. In
vivo, subcutaneous injection of 5 mg/kg capsaicin every 3 days for
4weeks reduced the growth of T24 bladder cancer xenografts only slight-
ly, by 15% [83]. Mitochondrial depolarization but not increased ROS
release has been observed also in BON and QGP-1 NET pancreatic
neuroendocrine tumor cells in vitro upon capsaicin treatment at
high concentration [84]. In yet another study, the vanilloid receptor
TRPV antagonist capsazepine (CPZ) proved to be more cytotoxic
than capsaicin for some cell lines. ROS release by CPZ was related to
apoptosis in oral squamous cell carcinoma cells (OSCC), but was
found to be independent of TRPV1. Importantly, in three different
OSCC xenograft models, intra-tumoral injection of max. 40 μg CPZ
every other day for 18 days completely blunted tumor growth in
two out of the three models used [85]. In addition, the authors also
provided evidence that liver and kidney function had been preserved.
Survival of immortalized normal oral keratinocytes was not affected.
Mitochondrial Δψ loss and increased ROS release was associated
with apoptosis in PC-3 prostate cancer cell line as well and subcuta-
neous injection of either capsaicin or capsazepine (5 mg/kg body
weight) in nude mice signiﬁcantly suppressed PC-3 tumor growth
by inducing apoptosis of tumor cells [86]. Thus, capsaicinoids seem
to have a very promising in vivo effect in various tumor models and
most probably affect cell apoptosis via TRPV1 and/or TRPV6, in partic-
ular by inducing oxidative stress by still unknown mechanism. Most
cancer cells display an increased metabolic activity and are therefore
under oxidative stress. Increase in ROS by an external agent may
disrupt this delicate balance between ROS levels and the anti-oxidant ca-
pabilities of the cancer cells thereby triggering ROS-induced apoptosis,
without inducing the same impact on the healthy tissues [87].
Finally, it is of note that some cannabinoid compounds, in particular
cannabidiol (CBD), stimulate TRPV1 while the non-psychotropic
cannabigerol (CBG) is an antagonist of TRPM8 [88]. CBD displayed and
anti-invasive action which depended on the effect of CBD cannabinoid
receptor and TRPV1. In vivo, in a nude mice injected with human lung
carcinoma A549 cells, intraperitoneal application of 5 mg/kg body
weight CBD every 3 days for 28 days almost completely abolished the
appearance of metastatic nodules [89,90]. CBD was employed also in a
study with prostate carcinoma LNCaP cells, where the pro-apoptotic ef-
fect of CBDwas interpreted as partly due to TRPM8 antagonism andwas
accompanied by ROS release and p53 activation. In this case, in vivo, ap-
plication of 100 mg/kg CBD i.p. daily plus 5 mg/kg docetaxel, i.v. once a
week reduced tumor volume by approximately 60% when compared to
untreated animals [91]. Furthermore, CBG and other TRPM8 antagonists
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hampered colon cancer progression in xenograft tumors as well as
chemically induced colon carcinogenesis [92].
Altogether, these results point to the relevance of TRP channel
modulators for cancer treatment, especially in light of the fact that
both capsaicinoids and cannabinoids are natural substances. However,
given the pleiotropic effects of these drugs, a deﬁnitive proof demon-
strating the requirement for channel activation or inhibition in relation
to the anti-tumoral effects should ideally be provided for all cases.
2.3. Orai and STIM1
As mentioned above, SOCE, mediated by Orai and STIM1 proteins
has been linked to the proliferative potential of various cell types
[93–95] and to the resistance to apoptosis of cancer cells [96]. Ca2+ sig-
nalingmediated by TRP channels and byOrai/STIM1 directly or indirect-
ly inﬂuences cancer and stroma cell migration [11]. In patients with
esophageal squamous cell carcinoma (ESCC), high expression of Orai1
was associated with poor overall as well as recurrence-free survival
[97]. Orai1 sustained cell proliferation, migration and invasion of
KYSE-150 cells, an epithelial line derived from human ESCC tumor. In
a mouse model, treatment (10 μg/g body weight, three times weekly
i.p.) for four weeks with SKF96365, an inhibitor of SOCE (e.g. [98]), de-
creased tumor volume by approximately 50%. Although SKF96365, a
phenylethylimidazole, is not very speciﬁc and inhibits TRPC and VCCs
as well [71], an almost complete tumor-reducing effect was observed
in vivo by silencing Orai1, indicating that indeed this SOCE component
is fundamental for the development of ESCC [97]. In accordance with
the fundamental role of SOCE in the above example, STIM1 expression
was also found to be elevated in cervical cancer patient tissues and
correlated with tumor size. Overexpression or knockdown of STIM1 in
cervical cancer SiHa cells exacerbated or blunted tumor growth in
SCID mice, respectively. I.p. injection of these mice bearing tumor
xenograft of SiHa cells with SKF96365 (2.5 mg/kg), or 2-APB (2-
aminoethoxydiphenyl borate; 50 μg/kg) from the sixth day post-
inoculation for 9 days completely abolished tumor growth [99]. 2-APB
not only is used as a modiﬁer of SOCE but also acts on IP3Rs and TRPV
and TRPC channels [100,101]. Chen and coworkers [99] however proved
by genetic means that STIM1 overexpression enhanced invasive migra-
tion and VEGF secretion in vitro and, coherently, angiogenesis and local
invasion. Thus, even though the pharmacological agents used are not
speciﬁc, it seems clear that they targeted the STIM1/Orai1 complex.
Hopefully, thanks to the resolved crystal structure of Orai1 [102],
structure-based drug design strategy will provide more speciﬁc inhibi-
tors [103]. However, since STIM and ORAi proteins are ubiquitously
expressed, toxicity to normal cells should also be considered when
SOCE inhibitors are applied systemically. In the abovementioned papers
the question of toxicity has not been addressed in depth.
2.4. P2X receptors
The P2 family of receptors is comprised of P2Ymetabotropic and P2X
ionotropic receptors, the latter behaving as nonselective cation channels
permeable to calcium, sodium, and potassium ions. ATP-mediated inter-
cellular signaling is implicated in a wide range of physiological process-
es, including neurotransmission, neuromodulation, chemoattraction or
chemotaxis, and pain. One of the ﬁrst investigations linking P2X recep-
tors to cancer reported that statins - shown to reduce the risk of pancre-
atic cancer by 80% in humans according to a case control studywith half
a million veterans [104] and to reduce pancreatic tumor growth in
mouse models (see e.g. [105]) - probably act via P2X7 receptors [106].
In this in vitrowork, the authors showed, using genetic tools that the de-
crease in pAkt level, the inhibition of cell proliferation and apoptosis in-
duction by statins, in particular atorvastatin, was dependent on P2X7
expression. Following this lead, in vivo experiments in different tumor
models have been conducted to support a role of P2X7 receptors in
cancer progression. Tumor tissues contain much higher concentrations
of extracellular ATP (hundreds μM range) than healthy tissues, [107,
108]. ATP activates P2X receptors, among which P2X7 has been found
to be highly overexpressed in several cancer types. In a zebraﬁsh
model using the highly metastatic cancer line MDA-MB-435, 10 μM A-
438,079, a P2X7 antagonist halved the % of zebraﬁsh with metastasis
[109]. The same group later reported that emodin (1,3,8-trihydroxy-6-
methylanthraquinone), an anthraquinone derivative of Rheum ofﬁcinale
with known anticancer properties, speciﬁcally inhibited P2X7-
mediated currents with an IC50 of 3 μM [110]. In the same zebraﬁsh
model, in vivo invasiveness of the P2X7R-positive MDA-MB-435 cells
was reduced by 50% using 10 μM emodin. Two other studies indepen-
dently demonstrated that oxidized ATP (0.5 mg/mouse 3 times i.p.), a
selective antagonist of P2X7, signiﬁcantly reduced tumor volume in a
B16 melanoma-bearing mice model [111] as well as in a colon cancer
CT26 model (reduction by 90% with 3 intratumoral injections of
oxATP (600 mmol/L) [112]. The same authors also showed that
intratumoral injection of 300 nmol/L of the selective P2X7 inhibitor
AZ10606120 caused a strong inhibition ofmelanomaB16 tumor growth
as well. Interestingly, ATP was used also in a previous study against
A375 melanoma cells and similarly to oxATP, an N50% reduction of
tumor volume could be observed [113].
3. Potassium channels
As illustrated by the above examples, pharmacological targeting of
different calcium-permeable channels may have a dramatic impact on
tumor growth in vivo. Given the central role of calcium signaling in con-
tributing basically to all aspects of the cancer hallmarks, these successful
cases are not surprising. Beside calcium channels however, potassium
sodium and chloride channels can also be successfully targeted and in
some cases this strategy has already led to clinical trials in humans. In-
deed, these channels are equally important for tumor development
and progression as we know by now from numerous in vitro and
some in vivo experiments. The ﬁrst potassium channel with suggested
oncogenic potential was a member of the voltage-gated Kv family,
Kv11.1 (hERG) [114], shown to control the membrane resting-
potential of neuroblastoma cells whichwas related to their proliferative
abilities as described by Arcangeli and co-workers [115]. The ﬁrst ion
channel with proven oncogenic potential was Kv10.1 (EAG) [14],
which can be detected in approximately 70% of human tumor biopsies
of diverse origin [22]. In this seminal work, Stuhmer and colleagues
proved that expression of both EAG and of the voltage-dependent
Kv1.4 in non-tumoral Chinese hamster ovary cells conferred a trans-
formed phenotype and in vivo both channel-transfected lines favored
tumor progression when injected into the ﬂank of immune-depressed
mice. The size of the tumor obtained using the EAG-expressing line
was twice as much as that observed with Kv1.4, indicating the expres-
sion of EAG (expressed only in the brain in healthy subjects but in differ-
ent cancer cell types in cancer patients) gives rise to a more aggressive
behavior. Soon after the discovery that this speciﬁc channel is so impor-
tant for proliferation and tumor progression, several independent stud-
ies suggested that this is a general feature of potassium channels.
Indeed, K+ channels regulate cell cycle by affecting trans-membrane
potential across the PM [22] since they set the restingmembrane poten-
tial in both excitable and non-excitable cells: in general, the membrane
potential varies during cell cycle (with hyperpolarized value and high
permeability for K+ at the G1 to S transition) [116] and cell types with
a very hyperpolarized resting potential do not readily undergo mitotic
division. Membrane potential in turn impacts on calcium entry and cal-
cium signaling (for review see e.g. [23]). Furthermore, some K+ chan-
nels proved to play an important role for angiogenesis: for example
Eag1 was shown to increase HIF1α activity and angiogenesis [117].
Changes in channel expression, due to genomic, transcriptional,
post-translational or epigenetic alterations, often occur in cancer cells
(for recent review see e.g. [118]) and are correlated with increased pro-
liferative potential and/or altered apoptosis resistance (for review see
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e.g. [6]. A variety of K+ channels, such as voltage-gated K+ channels
(Kv), calcium-activated K+ channels (KCa) and ATP-sensitive K+ chan-
nels (KATP) show altered expression in tumor tissues (e.g. [118,119]).
Among the potassium channels, much attention has been dedicated
to the pharmacological targeting of Kv10.1 (EAG), Kv11.1 (hERG) and
the calcium-dependent potassium channel KCa3.1 for cancer treatment.
A monoclonal antibody speciﬁcally produced against Kv10.1 inhibited
the function of the channel, the colony forming ability of several differ-
ent types of cancer lines and the in vivo tumor growth of the highlymet-
astatic MDA-MB-435S cancer cells [120]. Furthermore, the open
channel blocker astemizole (50 mg/kg, administered orally, daily),
which does not cross the blood brain barrier and therefore does not af-
fect neuronal EAG activity and is already used in the clinic, inhibited
MDA-MB435S xenograft tumor growth by approximately 30% and
growth of EAG-expressing CHO by 50% [117]. In vivo application of a
combined therapy, using oral astemizole (50 mg/kg/day) and intraper-
itoneal injections of the active vitamin D calcitriol (0.03 μg/g body
weight twice a week for 3 weeks), in mice xenografted with the
human breast cancer cell line T-47D or with a primary breast cancer-
derived cell culture (MBCDF), resulted in 85% inhibition of tumor
volume. This treatment was more efﬁcient than application of either
drug alone [121].
Similarly to Kv10.1, Kv11.1 (hERG) is frequently overexpressed in
cancer cells (e.g. [122]) and it is implicated in tumor progression and
migration via regulation of HIF1α stability and of integrin function/
adhesion-dependent signaling [123]. In vivo experiments using hERG1
blockers demonstrate the importance of hERG function in various
systems: in a recent study, colorectal cancer cells (HCT116) were
injected into nude mice that were then treated with speciﬁc Kv11.1 in-
hibitors WAY123,398 and E4031 (both substances at 20 mg/kg, i.p. for
twoweeks daily). An approximately 50% reduction of the tumor volume
has been detected, butmost importantly these drugswere very effective
also using the same line that lacked p53 and inhibited both angiogenesis
and metastasis [124]. Similar results were obtained in azoxymethane-
induced colorectal carcinoma [125] and in a gastric cancer model
[126]: in the former case i.p. injections of E-4031 for 3 months caused
an 80% reduction in the number of colonic polyps, while in the latter
study combined application of 20 mg/kg E-4301 and of the anti-VEGF-
A antibody bevacizumab almost completely abolished tumor growth.
In addition, block of hERG in immune-deﬁcient mice decreased the
bone marrow engraftment and peripheral blood invasion of myeloid/
lymphoblastic leukemia cells and could overcomemesenchymal stroma
cell (MSC)-induced chemoresistance in vivo in leukemia mouse models
(E4031 administered daily at 20mg/kg formax. 4weeks) [127]. Howev-
er, most of the drugs that modulate Kv11.1 function are associated with
cardiotoxicity, either the long QT syndrome or fatal arrhythmias which
can be triggered by class III antiarrhythmic drugs such as E4031 and
Way 123,398. Given that tumor cells seem to preferentially express a
different splice variant of Kv11.1, i.e. hERG1B (e.g. [128]) with respect
to the cardiac tissue, drugs acting exclusively on the tumor-associated
variantmight be of great therapeutic utility. In this respect, it is interest-
ing to note, that ZC88, a novel 4-amino piperidine analog inhibited the
tumor growth in nude mice engrafted with SH-SY5Y neuroblastoma
cells by 60% at a dosage (50 mg/kg, i.p. application every 4 d for
16 days) that only slightly inﬂuenced the cardiac QT interval. A previous
study identiﬁed ZC88 as blocker of the N-type calcium channel (IC50
value of 0.45 μM), although the ZC88-mediated anti-proliferative effect
was not correlated with its effect on the calcium channel activity [129].
Recently, another, very promising molecule which is speciﬁc for the
hERG1B variant has been identiﬁed: CD-160,130, a novel pyrimido-
indole compound block this isoform with an IC50 value (1.8 μM) that
is ten-fold less with respect to that obtained for hERG1A. This drug
caused apoptosis in vitro and in vivo (10 mg/kg) reduced leukemia
burden by 90% in a preclinical SCID leukemia model using HL60 cells.
As expected, this compound did not induce any cardiotoxicity and
enhanced long-term survival [130].
Thus, numerous in vivomodels illustrate very convincingly that both
EAG and hERG are especially promising oncological targets. In vivo stud-
ies targeting other K+ channels also point to an important role of K+
channels in general to the tumor progression. As to other Kv channels,
recent in vitro data pointed out that selective blockers of voltage-gated
K+ (Kv) channels or ATP-sensitive K+ (KATP) channels signiﬁcantly
inhibited the proliferation of U87-MG human glioma cells, blocked the
cell cycle at the G0/G1 phase and induced apoptosis. In the U87-MG xe-
nograft model in nude mice, suspensions of the cells treated with 4-AP
(5 mmol/l), TEA (20 mmol/l) or glibenclamide (200 μmol/l) were
injected. The growth of the K+ channel inhibitor-treated cells was re-
duced by 50%, but the speciﬁcity of the effect has not been demonstrat-
ed nor the speciﬁc Kv channel responsible was identiﬁed [131].
In vivo evidence for the involvement of Kv1.3 in tumor growth has
been obtained in an A549 human lung adenocarcinoma model:
margatoxin (Mgtx), a selective blocker of Kv1.3 (IC50 2 nM) or short
hairpin RNA (shRNA) against Kv1.3, signiﬁcantly blocked cell prolifera-
tion and intra-tumoral injection of 1 nM Mgtx for seven days reduced
tumor volume in vivo by 75% [132]. Inhibition of Kv1.3 signiﬁcantly in-
creased expression level of p21Waf1/Cip1 and decreased the expression
level of Cdk4 and cyclin D3, altogether inhibiting G1 to S transition.
The in vivo anti-proliferative effect of Mgtx was conﬁrmed also in an
independent work, in an orthotopic melanoma model using B16F10
cells [133]. Furthermore, this study revealed for the ﬁrst time, that
membrane-permeant Kv1.3 inhibitors such as Psora-4, PAP-1 and
clofazimine, were able to induce apoptosis of different cancer cell
lines, via their action on the mitochondrial counterpart (mtKv1.3) of
the plasma membrane-located Kv1.3 [134]. Importantly, this effect
was observed exclusively with the membrane-permeant inhibitors
and genetic deﬁciency or siRNA-mediated downregulation of Kv1.3 ab-
rogated the effects of these drugs, which also killed cells in the absence
of Bax and Bak, in agreement with the following, experiment-based
model: block of mtKv1.3 inhibits depolarizing inﬂux into themitochon-
drial matrix with consequent hyperpolarization. This alteration leads to
signiﬁcant ROS production by mitochondria which in turn opens the
permeability transition pore (PTP), induce cytochrome c release inde-
pendently of the pro-apoptotic Bax and Bak molecules and ﬁnally
triggers apoptosis [21,135]. Since hyperpolarization also provides an in-
creased driving force for the mitochondrial calcium uptake system, the
calcium uniplex (MCU) [136,137] and a matrix calcium overload is
known to trigger opening of the PTP, we checked whether knockdown
of the channel formingMCU protein impacts signaling in the above sys-
tem. MCU itself might become a good oncological target, similarly to
other intracellular channels and to PTP [20,21], once speciﬁc activators
will be identiﬁed. As Fig. 2 illustrates, the mtKv1.3 inhibitors exerted
the apoptosis-inducing effect to the same extent, suggesting that an in-
terplay between mtKv1.3 and MCU does not play a role in our experi-
mental model. In vivo, intraperitoneal injection of clofazimine in an
orthotopic melanoma B16F10 mouse model reduced tumor size by
90%, without causing visible side-effects as assessed by histology
[133]. Expression of Kv1.3 in different cancer lines correlated with the
sensitivity of the cells toward the above inhibitors [138]. In accordance,
primary B cells obtained from patients suffering of chronic lymphocytic
leukemia that expressed high level of Kv1.3 also in their mitochondria,
readily underwent apoptosis upon treatment with the above Kv1.3 in-
hibitors while T cells from the same patients were resistant [139]. Co-
culturing with MSC did not reduce the ability of these drugs to kill the
pathologic B cells [140]. Using primary B cells from patients or healthy
subjects, it was possible to provide evidence that the selective cancer
cell-killing action of mtKv1.3 inhibitors can be ascribed to a synergistic
effect between altered redox state of cancer cells and the ability of
these drugs to induce drastic ROS increase, thereby forcing the cell to
cross the critical ROS threshold (see above). Because clofazimine is al-
ready used clinically to treat some autoimmune diseases and leprosy
and shows an excellent safety proﬁle [141], targetingmtKv1.3 is a feasi-
ble cancer therapy for at least some cancer types. In general, targeting of
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mitochondrial channels represents and interesting strategy since alter-
ation of mitochondrial bioenergetic efﬁciency and function which may
be achieved by changing ion channel function [142] can have a dramatic
consequence on cell fate (see e.g. [21,143–145].
In addition to Kvpotassium channels, calcium-dependent potassium
channels and the two pore TASK-3 channel have been identiﬁed as
oncological targets e.g. [146,147], but in vivo evidence by speciﬁc
pharmacological targeting of TASK is still missing to our knowledge.
As to KCa3.1, an important role for this channel in natural killer lympho-
cytes (NK), known to participate in the killing of cancerous cells. TRAM-
34 and NS6180, two speciﬁc inhibitors of KCa3.1 increased proliferation
of the NK cells as well as their ability to reduce in vivo tumor growth of
the leukemic K562 cells [148]. Block of PM-located KCa2.3 (SK channel)
has an impact on themigration of tumor cells: the edelfosine-like alkyl-
lipid inhibitor named Ohmline ((1-O-hexadecyl- 2-O-methyl-sn-
glycero-3-lactose) was shown to block SK channel with and IC50 of
300 nM [149] and was able to prevent bone metastasis of the
highly metastatic MDA-MB-435 cells [150]. Intravenous application of
15 mg/kg Ohmline 3 times a week for 15 weeks reduced by 50% lung
metastasis and completely blocked bone metastasis without impacting
on the primary tumor volume. Interestingly, the authors provided
evidence that Ohmline acted as a disrupting agent for lipid raft localiza-
tion of the SK3–Orai1 complex, this way the SK3–Orai1 complexmoved
away from lipid rafts, and SK3-dependent Ca2+ entry, migration, and
bone metastases were impaired.
In this respect it is interesting to note that several studies
demonstrated that sphingolipids are involved in the regulation of
SOCs [151–153]. These studies focused in particular on ceramide and
sphingosine. Cellular ceramide is either de novo synthesized or released
from sphingomyelin by the activity of neutral or acid sphingomyelinases.
Ceramide is then converted by acid or neutral ceramidase to sphingosine,
which can be phosphorylated to sphingosine 1-phosphate by the activity
of sphingosine kinase 1 and 2 [154]. Ceramide molecules dramatically
alter the biophysical properties of cell membranes, since they spontane-
ously associate with each other to form small, relatively rigid, gel-like
ceramide-enriched membrane domains. These small domains spontane-
ously fuse to highly hydrophobic, tightly packed, and gel-like large
ceramide-enriched membrane domains, also termed platforms, that
serve the organization of membranes and proteins within membranes
[155–157]. Ceramidemolecules also exclude cholesterol frommembrane
domains further promoting the unique properties of ceramide-enriched
membrane domains. Ceramide-enriched membrane platforms serve to
bind, trap and reorganize receptors, ion channels and intracellular signal-
ingmolecules and, thus, facilitate signal transduction. Consistentwith this
notion are the results of studies showing that receptors such as CD95
[156], CD40 [157], DR5 [158], and CFTR [159], or signaling molecules
such as NADPH-oxidase [160], caspase 8 [161], and Kv1.3 [162], are
concentrated and clustered within ceramide-enriched membrane do-
mains, a process that is crucial for signal transduction via thesemolecules.
This change of membrane properties might be also the mechanism
how ceramide acts on ion channel such as SOCs. Thus, it was shown
that overexpression of the acid sphingomyelinase releasing ceramide
from sphingomyelin or the addition of exogenous ceramide blocks the
activity of SOCs.Moreover, receptors such as CD95 that release ceramide
by activation of the acid sphingomyelinase also blocked SOCs via this
pathway as evidenced in experiments using acid sphingomyelinase-
deﬁcient cells that failed to inhibit SOCs after CD95 ligation [152].
However, ceramide can be converted to sphingosine that also inhibits
SOCs and triggers an increase of the membrane capacitance. Similar to
CD95, the p75 Nerve growth factor receptor that activates the acid
sphingomyelinase/ceramide also inhibited SOCs [151]. The cellular
effectors of sphingosine and the mechanisms how this lipid acts are
Fig. 2.Membrane-permeant inhibitors of the potassium channel Kv1.3 induce apoptosis independently ofMCU (mitochondrial calcium uniporter) activity. A) Cell death of Jurkat lympho-
cytes expressing Kv1.3 either expressing control scramble siRNA or siRNA against MCU, following 24 h-incubation with the indicated inhibitors. Concentrations were applied as indicated
in C). B)Western blot is shown to evaluate protein expression following transfection with siRNA (100 μg/lane of total extract). Kv1.3 migrates at 65 kDa. Anti-GAPDHwas used as loading
control. C) Cell death was analyzed as in A); values reported in the bar-graph indicate the mean percentage ± SD of dead cells calculated taking into account all annexin positive cells
(n ≥ 3). Differences between control and MCU-silenced cells are not statistically signiﬁcant.
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presently unknown. Itmight be possible that both lipids altermembrane
biophysics that result in inhibition of SOCs.
Consistent with the trappingmodel of ceramide functions described
above, ceramide was shown to also recruit TRPC6 channels to caveolae
[153]. However, in contrast to the inhibition of store-operated calcium
channels by ceramide, TRPC6 channels in endothelial cells were not
inhibited by ceramide and Ca2+-inﬂux even increased. This suggests
that the membrane composition, in particular an increase of ceramide
in membranes may have very different effects on different ion channels
depending on the interaction of the particular ion channel with the
membrane environment. Ceramide and sphingosine are very hydro-
phobic molecules and it seems highly unlikely that these lipids leave
the membrane to directly interact with the acqueous pore of an ion
channel. Ceramide has been shown to form small ceramide enriched-
membrane domains that spontaneously fuse to large ceramide-
enriched membrane platforms [156]. These domains and platforms
were shown to trap receptor and signaling molecules [163–165] and it
might be possible that these domains cluster Ca2+ channels. These do-
mains differ from other parts of the plasma membrane and it is very
likely that the rigidity and the hydrophobicity of ceramide-enriched
membrane domains is higher than that of other domains. Further, the
transmembrane diameter might be altered in these domains compared
to other parts of the membrane. The trapping of channels in such a
domainmay result in a conformational change of the protein to provide
an energetically more stable status. This conformational change then
may regulate the channels. Alternatively, it might be possible that
ceramide-enriched membrane domains cluster signaling molecules
that are integrated into the membrane via lipid anchors, for instance
Src-like tyrosine kinase [166]. Clustering of such kinases may result in
a transactivation of previously almost inactive kinases that then directly
or indirectly phosphorylate intracellular residues in ion channels and
thereby regulate these channels. This mechanisms was observed for
Kv1.3 channels, although these studies employed short chain ceramides
[166] and studies with physiologically more-relevant long chain
ceramides are not available at present to our knowledge.
4. Sodium channels
The expression of voltage-gated Na+ channels (VGSCs), especially
of Nav1.5, Nav1.6 and Nav1.7 and of their splicing variants was found
to be increased in many cancer types, including breast, prostate, lung
(both small-cell, SCLC, and non-small-cell, NSCLC), cervical cancer, leu-
kemia (for recent review see [167]). In breast cancer, the neonatal iso-
form of Nav1.5 (nNav1.5) would allow greater Na+ entry into the cell,
compared with the adult splice variant, with consequences of calcium
homeostasis and of the regulation of intra- and extracellular pH [167].
In breast, prostate and NSCLC tumor cells, VGSC activity was shown to
increase invasiveness by stimulating cysteine cathepsin activity [168].
Several independent preclinical studies demonstrated that pharmaco-
logical targeting of VGSC inhibits breast tumor growth and metastasis
formation.α-Hydroxy-α-phenylamides, a new class of small molecules
have potent inhibitory effect on voltage-gated sodium channels. Intra-
peritoneal injection of 10 mg/kg (every day for 24 days) of newly syn-
thesized enantiomers of 3-chlorophenyl-α-hydroxyamide into mice
bearing prostate cancer line PC3 xenografts resulted in a 60% decrease
in tumor volume [169]. Importantly, the inhibitory effect on hERG was
relatively small, up to 16% at the lowest dose used. In another study, ad-
ministration of the VGSC inhibitor RS100642 (intravenously 0.25mg/kg
for 4 weeks) to mice developing 7,12-dimethylbenz(a)anthracene
(DMBA)-induced breast cancer increased the survival of the animals
by 50 days [170]. In a prostate cancermodel usingMat-LyLu cells, injec-
tion of the general VGSC blocker tetrodotoxin at 200 nM concentration
decreased metastasis and prolonged survival [171]. Tumor growth of
orthotopic xenografts using the breast cancer line MDA-MB-231 ex-
pressing Nav1.5 could be reduced by 30% applying 60 mg/kg (daily for
four weeks) phenytoin, without affecting animal weight. Phenytoin
reduced cancer cell proliferation in vivo and metastasis to the liver,
lungs and spleen [172]. The important aspect of this study is that
it identiﬁes a drug that is already used at similar doses in the
clinic to treat epilepsy which is also able to reduce breast cancer
growth, although only partially. Another clinically used drug with
metastasis-inhibitory effect of breast cancer cells is ranolazine: when
injected into mice bearing MDA-MB-231 xenograft (50 mg/kg/day for
8 weeks), it signiﬁcantly reduced lung colonization by these Nav1.5-
expressing human breast cancer cells [173]. Importantly, both the
tumor volume, as assessed by bioluminescent imaging, and the number
of lung metastasis were reduced to a similar extent to what has been
obtained using the same cell line in which Nav1.5 expression was
abolished. Ranolazine is already used in the clinic as antianginal agent
with antiarrhythmic properties [174,175].
5. Anionic channels
A strategy involving anion channels that was recently applied with
success is targeting the ClC-3 channels, shown to be implicated in
human glioma spread [176]. Chlorotoxin, (ChlTx) puriﬁed from the
venom of the scorpion Leiurus quinquestriatus binds to matrix
metalloproteinase-2 (MMP-2), a key factor involved in the process of
tumor metastasis [177] and is also able to inhibit a voltage gated
chloride channel that is speciﬁcally expressed on human astrocytoma
and glioma cells [178]. This chloride channel was then identiﬁed as
ClC-3, a type of Cl−/H+ exchanger mainly expressed in endosomal/
lysosomal compartments (N95%). ChlTx has been reported to inhibit
the migration and invasion of glioma cells [179,180]. The facts that
these ClC-3 channels are highly expressed in glioblastoma and ChlTx
binds them as well as the observation that ChlTx preferentially binds
to a variety of human malignancies, but shows little or no binding to
normal human tissues that has allowed to exploit Chltx as a diagnostic
agent or as a vehicle for drug delivery [181]. Indeed, a synthetic version
of ChlTx, covalently linked to iodine 131 (131I-TM-601) was used in
Phase I clinical in patients with recurrent glioma [182]. TM601 has
been also shown to reduce angiogenesis in vivo [183]. Furthermore, a li-
posome system containing doxorubicin and modiﬁed with chlorotoxin
inhibited the growth of metastatic tumor by 85% and prevented the in-
cidence of lung metastasis in mice bearing 4T1 tumors, displaying only
low systemic toxicity [184].
ANO1/TMEM16A, initially identiﬁed from airway epithelial cells, is a
member of Ca2+-activated Cl− channels (CaCCs) that function to regu-
late epithelial secretion and cell volume for maintenance of ion and
tissue homeostasis. ANO1/TMEM16A has recently been shown to be
highly expressed in several epithelium originated carcinomas, gastroin-
testinal stromal tumor, ESCC and pancreatic cancer. Knockdown of
ANO1 breast cancer cell lines and other cancers inhibited proliferation,
induced apoptosis, and reduced tumor growth in established cancer xe-
nografts [185–187]. Compared with primary tumors, ANO1 expression
decreases in metastatic lymph nodes of patients with squamous cell
carcinoma of the head and neck. Stable reduction of ANO1 expression
enhanced cell motility and increased metastases while decreasing
tumor proliferation in an orthotopic mouse model [188]. The calcium-
activated chloride channel inhibitor (CaCCinh)-A01, a low molecular
weight inhibitor of ANO1 activity [189] and the recently identiﬁed
ANO1 inhibitors idebenone (short-chain analog of CoQ10), miconazole
and plumbagin [190]will hopefully be soon exploited for in vivo studies.
6. Conclusion and future direction
As illustrated in the above examples and in the summarizing Table 1,
this relatively new ﬁeld has already importantly contributed to the
identiﬁcation of possible therapeutic agents for several different cancer
types demonstrating the signiﬁcant efﬁcacy of ion-channel targeting
drugs mostly in preclinical models. Now, knowing the set of the
channels that contribute to the tumor development in a given tissue, a
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Table 1
Drugs targeting ion channels in vivo in cancer models. Please note that proof of speciﬁcity refers to evidence obtained by the lack of the observed pharmacological effect either in vitro or
in vivo following knockdownof the ion channel expression. Thereforewe do not considered as proof of speciﬁcity for this table thewell-demonstrated speciﬁc effect of the different drugs/
molecules on channel proteins (e.g. the actions of TTX aswell as that of anti-Kv10.1 antibodies are speciﬁc on the respective target proteins). For side-effects “n.d.” stays for not determined,
while “NO” refers to studies where the occurrence of side-effects was investigated at organ/tissue level or to the absence of apparent toxic effect. Please see for further details in the text.
Target channel Channel modulator Proof of
speciﬁcity
Type of cancer; % of reduction of tumor size Side
effects
References
Voltage-gated calcium channels
Cav channels Amlodipine, diltiazem, verapamil NO Breast cancer;
83.5 ± 20.1% (mean± SE), 46.5 ± 6.6% and 68.2 ± 9.7%, respectively
NO;
n.d.
[40,47]
Amlodipine NO Epidermoid carcinoma; 55% n.d. [48]
T-type Cav channels KYS05047 NO Lung adenocarcinoma; 50% n.d. [54]
Mibefradil NO Glioblastoma;
Reduction followed by radiosurgery
n.d. [58,59]
NNC 55-0396 NO Glioblastoma; 60% n.d. [61]
L-type
Cav
channels
Simvastatin NO Colon cancer;
57%
n.d. [66].
TRP channels
TRPC 20-GPPD NO Colon cancer; 75% n.d. [75]
SKF96365 NO Esophageal squamous cell carcinoma (ESCC);
50%
n.d. [71]
SKF96365 NO Cervical cancer; n.d. [99]
TRPV Capsazepine (CPZ) NO Oral squamous cell carcinoma cells (OSCC)
98,4%
NO [85]
TRPV1 Capsaicin NO Bladder;
15%
NO [83]
Cannabidiol NO Lung carcinoma;
83% (metastatic lesions)
n.d. [89,90]
TRPV6-TRPV1 Capsaicin siRNA vs TRPV6 Small cell lung cancer (SCLC);
91%
n.d. [82]
TRPM8 Cannabidiol NO Prostate carcinoma;
34%
n.d. [91]
P2X7 receptors
P2X7 Oxidized ATP NO Melanoma;
69%
n.d. [111]
Oxidized ATP NO Colon cancer; 90% n.d. [112]
AZ10606120 NO Melanoma;
58%
n.d. [112]
ATP NO Melanoma;
50%
n.d. [113]
Potassium channels
Kv10.1 (EAG) mAb56 (anti-EAG antibody) NO Breast cancer;
50%
n.d. [120]
Astemizole siRNA vs EAG1 Breast cancer;
30%
n.d. [117]
Astemizole + vitamin D calcitriol NO Breast cancer;
85%
NO [121]
Kv11.1 (hERG) WAY123,398 and E4031 siRNA vs hERG1 Colorectal cancer;
50%
n.d. [124]
E4031 NO Gastric cancer;
80%
n.d. [126]
Kv11.1
(hERG1B)
CD-160,130 NO Leukemia;
90%
NO [130]
Kv channels and KATP channels 4-AP, TEA and glibenclamide NO Glioma;
50%
NO [131]
Kv1.3 Margatoxin shRNA vs Kv1.3 Lung adenocarcinoma;
75%
Melanoma; 30%
n.d.;
NO
[132]
[133]
mtKv1.3 Clofazimine siRNA vs Kv1.3 Melanoma;
90%
NO [133]
KCa2.3 Ohmline NO Metastatic breast cancer;
50% reduction of lung metastasis, total block of bone metastasis
n.d. [150]
Sodium channels
Nav channels 3-Chlorophenyl-α-hydroxyamide NO Prostate cancer;
60%
n.d. [169]
RS100642 NO Breast cancer;
Survival increased by 50 days
n.d. [170]
Tetrodotoxin NO Prostate cancer;
45% reduction of metastasis
n.d. [171]
Nav1.5 Phenytoin Breast cancer;
36%
NO [172]
Ranolazine shRNA vs Nav1.5 Metastatic breast cancer; NO [173]
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combined therapy either using more than one channel inhibitors to-
gether or employing the drugs together with chemotherapeutics
seems to be a possible future therapeutic approach. However, the
main issue remains that in most cases the speciﬁcity of ion-channel
targeting drugs for the observed anti-proliferative, pro-apoptotic, anti-
angiogenic or anti-metastatic effects has not been proven using genetic
tools. While in several cases knock-down of the channel protein brings
to a similar behavior of the cancer cells to that observed upon inhibition
of the channels by pharmacologicalmeans, a clear-cut demonstration of
possible pleiotropic effects should be performed by proving that a cer-
tain drug is not efﬁcient anymore when the channel is not expressed.
For example, the natural compound curcumin with potent anti-
tumoral activity against various types of cancer (also in vivo), although
widely considered as safe, is not selective, as it acts by multiple mecha-
nisms. In fact, it inhibits KV11.1 (hERG1) in human leukemic cell lines
THP-1 [191] but also other channels, including Ora1 (ICRAC) [192].
Therefore it would be mandatory to perform an in-depth study to
understand whether its inhibitory effect of cancer growth is related to
ion channel inhibition and if yes, to which one.
Anothermain issue to be addressed in this ﬁeld is the question of the
possible side-effects. In many studied, this important point is not ad-
dresses at all. Independently of these issues, the reported studies point
to the possibility of repositioning already approved drugs (for recent
review see e.g. [193]), such as ranolazine, clofazimine, astemizole, phe-
nytoin,mibefradil, for which Phase II clinical trials for cancer studies can
be directly undertaken. This is an important achievement, and hopefully
future large-sale studies will clarify whether the use of these drugs in
patients confer any protective effect on long-term scale for the respec-
tive tumors.
Finally, it would be desirable to exploit the novel techniques that
might help drug delivery also for the modulators that target ion
channels. Indeed, tumor-speciﬁc delivery of anticancer therapeutics
could enhance the efﬁcacy of anticancer drugs and could limit side
effects associated with traditional chemotherapy. Various strategies
including employment of pro-apoptotic peptides, oligonucleotides,
liposomes, nanoparticles, radionuclides for delivery to the tumor
site might be useful in this respect [194–196]. In addition,
application of tumor-homing peptides is a very promising
possibility, based also on numerous preclinical and clinical trials
[194]. The so-far most successful strategy applies tumor-
penetrating peptides like iRGD, iNGR and tLyp-1, which activate a
transport pathway leading to the deep penetration of peptide/drug
complex into the tumor tissue. These peptides have a consensus
motif termed CendR which permits their binding to neurophilin-1
(NRP-1) receptors, shown to be over expressed in tumor tissues
and to allow entrance of the drugs to endothelial cells (for recent
review see [194]). This strategy thus helps to overcome the
limitation given by the fact that most of the drugs do not penetrate
the tumor tissue effectively.
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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) represents the most common form of pancreatic cancer with 
rising incidence in developing countries. Unfortunately, the overall 5-year survival rate is less than 5%. The most 
frequent oncogenic mutations in PDAC are loss-of function mutations in p53 and gain-of-function mutations in KRAS. 
Here we show that clofazimine (Lamprene), a drug already used in the clinic for autoimmune diseases and leprosy, is 
able to efficiently kill in vitro five different PDAC cell lines harboring p53 mutations. We provide evidence using 
siRNA, that clofazimine induces apoptosis in PDAC cells with an IC50 in the µM range via its specific inhibitory action 
on the potassium channel Kv1.3, known to regulate both proliferation and apoptosis in various cell types. We show 
that intraperitoneal injection of clofazimine results in accumulation of the substance in the pancreas of mice 8 hours 
after injection. In an orthotopic PDAC model employing SCID beige mouse clofazimine reduces the tumor weight by 
50% while does not significantly alter histology regarding tumor structure and angiogenesis and does not affect the 
number of liver metastases. In summary, our work identifies clofazimine as a promising therapeutic agent against 
PDAC and further highlights ion channels as possible oncological targets.  
 
Introduction 
 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive types of tumors, being the fourth 
leading cause of cancer mortality. Due to the poor prognostic factors, patients are diagnosed at a rather late stage of 
disease and their life expectancy is at most five years after diagnosis. In most cases, the only valid therapeutic 
approach is the radical surgical resection of the tumor, which however is feasible only in 20% of the cases, but 
recurrence of cancer lesions often occurs. Some other patients (30-40%) show unresectable locally advanced 
pancreatic cancer (LAPC) with a median survival of one year [1]. For the rest of the patients, who manifest 
metastasis at diagnosis, six months is the expected survival period (for a detailed review see e.g. [2]). Usually, in all 
cases palliative or curative systemic chemotherapy, sometimes associated to radiotherapy, is administered but 
unfortunately, a positive outcome cannot be guaranteed.  
For about 20 years, the only therapeutic option considered valid for the treatment of PDAC has been 5-
fluorouracile (5-FU). Nowadays, FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a 
promising first line therapy in patients [3], albeit the most diffused chemotherapy drug in clinical use is gemcitabine, 
administered alone or in combination with other chemotherapeutics such as 5-fluorouracile, capecitabine, platinum 
analogues and taxane [4]. The mechanism of action by which the cytotoxic effect is exerted by these molecules is the 
block of DNA synthesis; therefore considerable side effects occur in the healthy tissues by these therapies. Only 
recently, new molecules with aberrant expression in PDAC tissues have emerged as possible alternative targets in 
pancreatic tumor treatment. Among these are the epidermal growth factor receptor (EGFR)[5], human epidermal 
growth factor receptor type 2 (HER2) [6] and vascular endothelial growth factor (VEGF) [7]. For all of them a phase II 
or III clinical trial has been conducted but the improvement of outcome for PDAC patients is not satisfactory. 
Therefore, new therapeutic approaches are necessary.  
During the last decade, ion channels emerged as possible prognostic markers and therapeutic targets 
against various types of cancer as indicated also by in vivo studies in preclinical models [8, 9]. In particular, 
potassium (K+) channels have been shown to be crucially involved in many important physiological processes such 
as proliferation, migration, angiogenesis, cell volume regulation and apoptosis [10, 11] and to contribute to cancer 
progression [12]. The voltage-gated potassium channel Kv1.3 belongs to the Shaker family and is expressed in 
different tissues, such as brain, kidney, olfactory bulb, lymphocytes, skeletal muscle, adipose tissue [13]. Prevalent 
expression in healthy individuals occurs mainly in tissues of CNS and immune cells [14], but several types of cancer 
cells also display an altered expression of the protein [13]. Aberrant expression of Kv1.3 has indeed been observed 
in different types of tumors [15], such as melanoma [16], prostate [17], breast [18], B-cell lymphoma [19], chronic 
lymphocytic leukemia (B-CLL) [20, 21] gastric [22], pancreatic tumor [23] and in lung cancer [24]. Overexpression of 
Kv1.3 in cancer cells could give an advantage to cancer cells enhancing tumorigenic processes such as proliferation, 
cell migration and metastasis [10].  
Kv1.3 is expressed and active both in plasma membrane (PM) and in the inner mitochondrial membrane 
(IMM) of lymphocytes (mtKv1.3) [25], hippocampal neurons [26] and in various tumor cells [27, 28]. Expression of 
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Kv1.3 in the IMM seems to correlate with that in the PM e.g. [27]. Kv1.3 was located to cis-Golgi membranes as well 
[29] and, recently, to nuclear membrane [30] where it seems to be involved in regulation of transcription. While the 
plasma membrane Kv1.3 is required for cell proliferation, the mitochondrial channel regulates apoptosis. At the 
molecular level, mtKv1.3 is a target of the pro-apoptotic protein Bax, which inhibits the channel via a conserved 
positive amino acid residue, lysine 128, with a Kv1.3-inhibiting toxin like mechanism [31, 32]. Bax, or membrane 
permeant Kv1.3 inhibitors which can reach the mitochondrial channel, block the positive inward (toward the 
mitochondrial matrix) potassium current, thereby determining a transient hyperpolarization followed by the release of 
reactive oxygen species, the opening of the permeability transition pore with consequent loss of mitochondrial 
membrane potential and release of cytochrome c, finally leading to the activation of apoptotic cascade.   
We have previously shown that in vitro inhibition of mtKv1.3 using membrane-permeant Kv1.3 inhibitors 
such as Psora-4, PAP-1 and clofazimine results in apoptosis of various Kv1.3-expressing tumor cells [20, 28, 33]. 
These drugs were efficient even in the case of poor-prognosis tumors lacking Bax/Bak and bearing p53 mutations. 
Importantly, this effect was observed exclusively with the membrane-permeant inhibitors indicating the importance of 
the mtKv1.3 versus PM Kv1.3. Genetic deficiency or siRNA-mediated downregulation of Kv1.3 abrogated the effects 
of these drugs. The specific drugs, targeting mtKv1.3, were able to reduce tumor volume in vivo by 90% in a 
preclinical model of melanoma, without side effects [28] as well as to kill primary pathologic B cells from chronic 
lymphocytic leukemia patients, without affecting survival of healthy T cells of the same individual [20]. The 
mechanism of action has been clarified, pointing to a synergistic effect between the altered redox state, characteristic 
of tumor cells and the ability of these drugs to induce production of significant oxidative stress by inhibiting mtKv1.3, 
leading finally to ROS-induced cell death in the cancer cells, while leaving healthy cells alive.  
 Clofazimine blocks Kv1.3 with an IC50 of 300 nM, while it is much less effective on other potassium 
channels of the same family [34]. Clofazimine is a lipophilic riminophenazine antibiotic approved by the FDA and 
already in clinical use in human to treat pathologies like leprosy and psoriasis; its antibiotic, immunomodulatory and 
anti-inflammatory properties make it a versatile drug [35]. In light of the results obtained with clofazimine on B-CLL 
cells and in the orthotopic melanoma model, and of indication about expression of Kv1.3 in pancreatic tissues, we 
investigated whether this drug can be used against PDAC in an orthotopic xenograft model. 
 
Results 
 
Kv1.3 is expressed in different human PDAC cell lines  
 
Since our purpose was to understand whether clofazimine might be useful to induce apoptosis in PDAC 
cell lines via inhibition of the mitochondrial Kv1.3 channel, first we checked whether the widely used human PDAC 
lines of various origin express Kv1.3. To this end, we extracted information available in a previously reported 
Affymetrix U133 GeneChip set [36, 37]. Analysis of the microarray data shows that in 5 out of 8 lines expression of 
the KcnA gene encoding for Kv1.3 channel was relatively high (Figure 1A). To confirm these data in the cell lines 
used in our laboratories and to compare Kv1.3 expression with that of a non-tumoral pancreatic ductal epithelial line, 
we performed quantitative real time PCR using multiple reference genes of the non-tumoral HPDE line for 
normalization (Figure 1B). HPDE6-E6E7 (H6C7) is a non-tumoral, immortalized human pancreatic ductal epithelial 
cell line, generated by transformation with human papilloma virus 16 (HPV-16). Cultured HPDE cells express low 
levels of epidermal growth factor receptor (EGFR), erbB2, transforming growth factor (TGF)-alpha, Met/hepatocyte 
growth factor receptor (HGFR), vascular endothelial growth factor (VEGF), and keratinocyte growth factor (KGF). 
HPDE was shown to be non-tumorigenic when transplanted into SCID mice [38].   
The human tumor lines that were used have different origin and characteristics. All these lines have been 
characterized in detail in several previous works [39-41] and were found to be mutated in p53 and most of them, 
except BxPC3 are mutated also in K-RAS [41]. It is of note, that these cell lines, harboring mutation in p53, have 
been tested previously to be largely resistant to standard chemotherapeutics. Mutations in the p53 gene have been 
described in more than 50% of the patient samples and there is evidence that the p53 network is genetically altered 
in an even much higher proportion. AsPC1 is a human pancreatic tumor cell line that was derived from the metastatic 
site, an ascites, of a patient with adenocarcinoma in the head of the pancreas. Nude mice tumor model of AsPC1 
shows the similar characteristics of human PDAC with abundant mucin production and granular differentiation. 
BxPC3 is a primary human pancreatic tumor cells line from the body of the pancreas of a patient with 
adenocarcinoma. These cells are not prone to give metastasis and they are poorly differentiated. Nude mice tumor 
model of BxPC3 shows the similar characteristics of human PDAC with mucin production and displaying moderately 
differentiated adenocarcinomas with occasional lymphocytic infiltrations at the tumor peripheries. Colo357 cells 
originate from lymph node metastasis from a PDAC patient. They express low levels of Bcl-xL, are highly metastatic 
and are moderately differentiated. Capan1 PDAC line, originally obtained from liver metastasis, is highly resistant to 
different chemotherapeutic drugs, in particular to 5-FU. Tumor models using Capan1 show a well-differentiated 
adenocarcinoma with abundant mucin production. The poorly differentiated MiaPaCa2 cell line was initially delivered 
from the body and tail of the pancreas of a PDAC patient, while the metastatic Panc1 line was isolated from the head 
of the pancreas which invaded duodenal wall from a patient and expresses a high level of the anti-apoptotic Bcl-xL 
[42]. The relative quantity of Kv1.3 expression was higher in all these PDAC lines with respect to HPDE. To confirm 
that Kv1.3 was expressed also at protein level, we performed Western blot analysis on whole-cell extracts (Figure 
1C), revealing a similar level of expression in all cell lines (but it is to note that HPDE does not form tumors and thus 
does not have the typical characteristics of pathologic cells). Finally, in one of these lines, namely in Colo357 which 
was used for the in vivo studies in this paper (see below), we assessed mitochondrial expression of Kv1.3. The 
intensity of the channel protein band in progressively purer mitochondrial fractions was comparable, while the 
intensity of PM (PMCA) and ER (SERCA) markers decreased in contrast to the mitochondrial marker Bak (Figure 
1D). Altogether, these results indicate the presence of Kv1.3 in different PDAC cell lines.  
 
Clofazimine decreases cell survival in PDAC lines harbouring p53 mutations but spares non-tumoral lines 
 
Next, we studied the effect of clofazimine in the above PDAC lines in a previously used setting to induce 
apoptosis. Figure 2A shows that while HPDE and the epithelial cell line HUVEC were resistant to 10 µM clofazimine, 
basically all PDAC lines, even those that are resistant to 4 µM Staurosporine (PANC1, AsPC-1, Capan-1 and 
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MiaPaCa2), responded to this concentration of clofazimine with a significant reduction of cell survival. The efficiency 
of clofazimine, in accordance with data obtained with other cell lines [43], further increased when the drug was 
applied together with 4 µM Cyclosporin H, an inhibitor of multidrug resistance pumps, that is expected to decrease 
the export of clofazimine from the cells. EC50 was 1.5 µM for wt Colo357 cells. Although this value increased to 6 µM 
in Bcl-xL-overexpressing cells [44], there was still a significant impairment of cell survival at the highest concentration 
of clofazimine (Figure 2B). This result is in agreement with the action of clofazimine on the IMM-located mtKv1.3, i.e. 
downstream and independent of the OMM-located Bcl-2 family members.  
In order to prove that reduction of cell survival correlated with cell death and that clofazimine induced 
apoptosis via its action on Kv1.3, we followed Annexin binding in BxPC3 and AsPC1 cells transiently transfected 
either with scrambled RNA or with siRNA against Kv1.3 (Figure 2C-D). In both cell lines clofazimine-induced 
apoptosis and Annexin binding is evident after treatment with 10 µM clofazimine, even without addition of MDR 
inhibitors (in agreement with Fig 2A) when Kv1.3 is expressed, but upon silencing of the channel expression the drug 
is not effective anymore. Staurosporine was used as positive control, and in agreement with data of Fig 2A, this 
assay confirmed the resistance of AsPC-1 cells to this classical apoptosis-inducer, as well as the sensitivity of BxPC-
3 cells. PAP-1 without MDRi acts prevalently on the PMKv1.3 and was indeed unable to trigger apoptosis. Similar 
results were obtained also with Colo357 cells (Figure 2E).  
 
Clofazimine reduces tumor weight in vivo  
 
To further prove the relevance of our findings in vivo, we treated severe combined immunodeficient (SCID) 
beige mice bearing orthotopically xenotransplanted human Colo357 cells with intraperitoneally (i.p) injected 
clofazimine ten times, starting 10 days after tumor cell inoculation and continued every second day (Figure 3A). For 
the treatment regimen we followed a previously established inoculation protocol for Colo357 [45] and then analyzed 
tumor growth and metastasis. A statistically significant reduction of tumor weight occurred in the clofazimine-treated 
mice by more than 50% with respect to the control group treated with the same protocol but using only the solvent 
(Figure 3B). Instead, no difference in the number of liver metastasis occurred in the clofazimine-treated animals with 
respect to controls (Figure 3C). In order to prove that indeed clofazimine can reach the pancreatic tissue, we 
determined the clofazimine concentration in various tissues. Following i.p. administration of a single dose of 
clofazimine, it was found readily absorbed and metabolized. Low concentrations of the drug were detected in blood. 
HPLC−UV−ESI/MS analysis of whole tissues showed that clofazimine was basically absent in the brain indicating that 
it does not cross the blood brain barrier and was accumulated only to low extent in the heart. In the pancreas, kidney, 
liver and spleen, relatively high concentrations of clofazimine were found (Figure 4D).  
Next, we performed an immunohistochemical staining in order to characterize the orthotopic tumor tissues. 
We analysed the tumor area, proliferation and angiogenesis via staining with antibodies against KL1, Ki67 and CD31, 
respectively. The anti-KL1 antibody recognizes keratin and binds to cells with epithelial origin. Therefore, it stains 
neoplastic cells of epithelial origin and permits the detection of tumor area. Anti-Ki67 is against a nuclear protein 
which is highly expressed in proliferating cells, in particular during late G1-S-M and G2 phases of the cell cycle. 
Quiescent cells (G0 phase) are negative for this protein. Finally, anti CD31 or anti-PECAM-1 is against a protein 
which is constitutively expressed on the surface of embryonic and endothelial cells (also monocytes and neutrophils) 
and represents a marker of angiogenesis. Evaluation of the marker Ki67 showed a reduction in proliferation by 13% 
in the Clofazimine treated group. The other markers highlighted the presence of larger mucinous lobules in the 
clofazimine-treated pancreas tissues, but only minor differences regarding the tumor structure and the angiogenesis 
were observed between the control and drug-treated groups.  
 
Discussion 
 
In the present paper we report for the first time that clofazimine, a drug already used in the clinic is able to 
substantially reduce tumor weight in an orthotopic ductal pancreas adenocarcinoma model. Clofazimine is an FDA-
approved anti-mycobacterial agent recommended by the World Health Organization as part of the standard treatment 
of leprosy [35]. It has been in clinical use since the 1960s and is well-tolerated, although bioaccumulation of the drug 
can lead to visible (but reversible) changes in skin pigmentation. CFZ possesses anti-inflammatory and 
immunosuppressive activities, therefore it is used in various cutaneous, non-microbial, and chronic inflammatory 
disorders. In addition, clofazimine has recently been reported to exert potent antifungal activity by inducing a PKC1-
dependent stress [46]. More recent studies suggested  an expansion of  the clinical use  of CFZ to noncutaneous 
inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and type I diabetes mellitus [35]. Despite this 
known anti-inflammatory activity, the molecular and cellular mechanisms that underlie this property of CFZ have not 
been elucidated, but modulation of inflammation by clofazimine via its apoptosis-inducing effect on macrophages is a 
possibility [47, 48]. Indeed, clofazimine has been shown to cause mitochondrial membrane destabilization and 
activation of apoptosis in macrophages, at least in vitro [21, 49].  
We have previously shown that clofazimine is able to induce apoptosis in a cancer cell-selective way both 
in primary human tumor cells and in vivo in an orthotopic melanoma model by inducing ROS release from 
mitochondria due to its inhibitory effect on mtKv1.3. Experiments employing sub-lethal concentrations of a 
mitochondria-targeted pro-oxidant suggested a synergistic action between mtKv1.3-inhibition induced ROS release in 
mtKv1.3-expressing cancer cells and the elevated basal ROS level typical of cancer cells [50, 51] that drives 
prevalently the cancer cells to bypass a critical threshold of oxidative stress causing cells death [52, 53]. In addition, 
clofazimine might also act on the PM Kv1.3, known to be an important regulator of cell proliferation at least in some 
cell types [14, 24], and reduce tumor progression by decreasing proliferation. However the slight reduction of the 
Ki67 index indicative of proliferation and, in contrast, a larger reduction of the tumor weight suggests that the 
apoptosis-inducing effect of the applied drug was prevalent in the case of PDAC. Although in our studies, including 
the present work with PDAC cells, we obtained evidence using siRNA against Kv1.3 that this drug induced apoptosis 
prevalently due to its action on the channel, it must be mentioned that clofazimine is a drug with multiple targets and 
additional mechanisms accounting for its anti-tumoral effect have to be taken into account. For example, clofazimine 
has recently been identified in a large-scale screening as an inhibitor of Wnt signaling [54] and Wnt/β-catenin 
signaling plays important roles in PDAC tumor initiation and progression as well [55, 56]. Clofazimine was shown to 
decrease proliferation of HTB19 triple-negative breast cancer cells whose growth is Wnt pathway-dependent. The 
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authors also reported that clofazimine exerted a significantly smaller effect on non-cancerous mammary epithelial 
cells (HMEC) than on HTB19 cells, providing thus a further case of selective action on tumoral versus non-tumoral 
cells [54]. In addition, clofazimine has been shown to exert an inhibitory action on ABCB1/MDR1/P-glycoproteins 
(Pgp)[57], although this aspect is particularly relevant when applied together with chemotherapeutics to chemo-
resistant cells (e.g. [58]). Finally, clofazimine has been shown via bioinformatic screening to have the potential to 
inhibit p53–MDM2 interaction leading in turn to stabilization and activation of the tumor suppressor p53 [59, 60]. 
However, in our experimental setting clofazimine induced cell death independently of the p53 status in several cell 
lines. This finding is particularly relevant given that most PDACs display p53 mutation.  
Independently of the exact mechanism of action, in our experiments clofazimine reproducibly and 
substantially reduced PDAC tumor weight. This ability of clofazimine is in agreement with previous in vivo studies 
obtained in other type of cancers such as hepatocellular carcinoma [61] and melanoma [28]. In those works the effect 
of the drug on metastasis was not assessed, but the present report suggests that clofazimine might be taken into 
consideration for reduction of the primary tumor site only, since it did not reduce liver metastasis. The question arises 
why clofazimine was less effective in the PDAC model with respect to e.g. the melanoma model. We hypothesize that 
this result may reflect the well-known difficulty of drugs in general to reach PDAC tissues due to the stromal barrier, 
i.e. a dense extracellular matrix composed of hyaluronic acid, smooth muscle actin and collagen fibers [62, 63]. At 
the dosages used for the leprosy treatment, with oral administration, the plasma concentrations of the drug reaches 
0.5–1 µM [64]. However, a study on tissue concentrations found clofazimine ranging from 0.2 mg/g to 1.5 mg/g 
(approximately up to 500 µM) in the different organs of a human patient (a value of 0.4mg/g was obtained for 
pancreas) [65], which is in agreement with the finding that the drug is generally harmless for normal tissues of the 
organism. While in the present study a relatively high concentration of clofazimine was found in the pancreas of 
control animals, it is plausible to suppose that such high concentration could not be reached in PDAC pancreas 
because of the stromal barrier. Furthermore, clofazimine is a rather insoluble molecule: indeed it has been shown to 
form crystals in the kidney and to massively accumulate in macrophages during long-term oral dosing, where it forms 
insoluble, intracellular crystal-like drug inclusions (CLDIs). Recently, it has been reported that in vitro, soluble CFZ 
was cytotoxic because it depolarized mitochondria and induced apoptosis in macrophages [47] while in vivo, CLDIs 
did not induce macrophage apoptosis. Instead, CLDIs altered immune signaling response pathways downstream of 
Toll-like receptor (TLR) ligation, leading to decreased NF-κB activation and tissue necrosis factor alpha (TNFα) 
production and to enhanced interleukin-1 receptor antagonist (IL-1RA) production. Thus, the authors concluded that 
in vivo, macrophages detoxify soluble clofazimine by sequestering it in a biocompatible, insoluble form and this may 
contribute to the anti-inflammatory activity of the drug. Interestingly, we have recently demonstrated that the major 
pro-inflammatory cytokine tumor necrosis factor TNFα plays a major role in the malignancy of PDAC cells in vitro and 
in vivo. In vitro, TNFα strongly increased invasiveness of Colo357 cells while in vivo, TNFα treatment led to 
dramatically enhanced tumor growth and metastasis [66]. Furthermore, in severe combined immunodeficient mice 
with orthotopically growing PDAC tumors, the human-specific anti-TNF antibody infliximab reduced tumor growth and 
metastasis by about 30% and 50%, respectively. Thus, it is tempting to hypothesize that the observed tumor-
reducing effect of clofazimine is due to multiple factors, including apoptosis induction of PDAC cells but also to an 
indirect effect via modulation of macrophage function.  
In conclusion, our work provides evidence that clofazimine might be a useful agent against PDAC, possibly 
in combination with currently used chemotherapeutics or newly identified PDAC growth inhibitors such as infliximab. 
This possibility will have to be addressed in future studies. In addition, combination with other drugs targeting ion 
channels and/or ion transporters might be a strategy worthwhile to pursue. In fact, thanks to excellent recent works, 
several proteins mediating flux of ions have been identified as possible targets against PDAC. For example, hERG1 
potassium channels have been shown to drive PDAC tumor malignancy [67], the neurotransmitter GABA was 
identified as a promising agent for the prevention of PDAC in individuals at risk due to chronic alcohol consumption 
[68], the transient receptor potential melastatin-related 7 channel was found to regulate tumor migration [69], the 
store-operated calcium channels (SOCs) were shown to contribute to PDAC apoptosis resistance [70] while the 
P2X7 receptor regulates cell survival, migration and invasion [71]. Ion transporters which regulate pH are also 
relevant in this context [72, 73] - e.g. we have recently shown that the specific sodium-proton exchanger NHE1 
inhibitor cariporide reduced both three-dimensional growth and invasion and synergistically sensitized these 
behaviours to low doses of erlotinib [74]. Thus, in an ideal situation, a combined therapy bypassing basic 
mechanisms responsible for cancer progression and chemoresistance e.g. [75] might be particularly useful.  
  
 
Materials & Methods 
 
Cell lines and cell culture 
A panel of pancreatic cancer cell lines representing different phases of tumor progression were used. AsPC-1, 
BxPC3, Capan-1, MIA PaCa-2 and PANC-1 were provided by ATCC. AsPC1 and BxPC3 were cultured in RPMI-
1640 (Gibco/Life Technologies, Darmstadt, Germany) supplemented with 10% fetal bovine serum “GOLD” (FBS 
“GOLD”, PAA Laboratories/GE Healthcare Life Sciences), 1mM GlutaMAX and 1 mM sodium pyruvate 
(LifeTechnologies, Darmstadt, Germany). MIA PaCa-2 and PANC-1 were cultured in DMEM (4.5 g/l D-glucose) 
supplemented with 10% FBS “GOLD”, 1mM GlutaMAX and 1 mM sodium pyruvate. Capan-1 cells were grown in 
IMEM supplemented with 20% FBS “GOLD”, 1mM GlutaMAX and 1 mM sodium pyruvate. Human cell line of 
metastatic pancreas adenocarcinoma, Colo357, was obtained from Dr. R. Morgan (Denver, CO) [76]. The cells were 
cultured in a complete growth medium composed of RPMI-1640, 10% FCS (PAN-Biotech, Aidenbach, Germany), 
1mM GlutaMAX and 1 mM sodium pyruvate. The HPV16-E6E7 - immortalized human pancreatic duct epithelial cells 
(HPDE), kindly provided by Dr. Ming-Sound Tsao (Ontario Cancer Institute, Toronto, Ontario, Canada) [77] were 
used as a model for benign pancreatic ductal epithelium. The complete growth HPDE-medium was mixed with 50% 
RPMI 1640, supplemented with 10% FCS and 1mM GlutaMAX and 50% keratinocyte medium SFM (Gibco) 
supplemented with 0.025% bovine pituitary extract, 2.5 µg l-1 epidermal growth factor (Gibco). All cells were cultivated 
and maintained at 37°C in a humid atmosphere with 5% CO2. 
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Western blot 
Membrane enriched fraction proteins from different Pancreatic cell lines were obtained as previously reported [43]. 
Briefly, cells were washed in PBS and then resuspended in 300 μL of TES buffer (100 mM TES + 1 M sucrose, 100 
mM EGTA, 1X cocktail protease inhibitors) and lysed by an electronic pestle (Kontes, Sigma Aldrich) for 2 min on ice. 
Unbroken cells were separated by centrifugation at 500 g for 10 min at 4°C. The soluble cytosolic fraction was 
separated from the membrane-enriched fraction by centrifugation at 19,000 g for 10 min at 4°C. The pelleted 
membranes were suspended in TES buffer and separated by SDS-PAGE in a 10% polyacrylamide gel containing 6 
M Urea. To enhance protein separation, samples were solubilized for 1 h at RT in Sample Buffer (30% Glycerol + 
125 mM Tris/HCl pH 6.8 + 9% SDS + 0.1 M DTT+ Bromophenol blue). Protein concentration was determined using 
the BCA method in a 96 well plate (200 μL total volume for each well) incubating at 37°C in the dark for 30 min. 
Absorbance at 540 nm was measured by a Packard Spectra Count 96 well plate reader. After separation by 
electrophoresis, gels were blotted overnight at 4°C onto Polyvinylidene fluoride (PVDF) membranes. After blocking 
with a 10% solution of defatted milk, the membranes were incubated with the following primary antibodies overnight 
at 4°C: anti-Kv1.3 (1:200, rabbit polyclonal, Alamone Labs APC-101); anti-GAPDH (1:1000, mouse monoclonal, 
Millipore MAB374). After washing, the membranes were developed using corresponding anti-mouse or anti-rabbit 
secondary antibodies (Calbiochem). Antibody signal was detected with enhanced chemiluminescence substrate 
(SuperSignal West Pico Chemiluminescent Substrate, Thermo Scientific).  
 
MTT assay 
To determine cell growth/viability in PDAC cells, we employed the tetrazolium reduction (MTT) assay. To this end, 
10,000/well PDAC cells were seeded in standard 96-well plates and allowed to grow in the normally used medium for 
each line (200ml) for 24 h. The growth medium was then replaced with new fresh phenol red-free medium. Four wells 
were used for each condition. After 24 h incubation with the indicated drugs 10% CellTiter 96 AQUEOUS One 
solution (Promega) was added to each well. After 1-3 h of colour development at 37°C, absorbance at 490nm was 
measured using a Packard Spectra Count 96-well plate reader as in [78]. 
 
siRNA 
The sequences for the siRNA targeting human Kv1.3 were coupled to Alexa Fluo 555 (Qiagen). 80,000 cells/well 
(Colo357, BxPC-3, AsPC-1) were seeded into a 12 well plate in 1 mL of the growing medium. After 24 h cells were 
transiently transfected with 2 μg siRNA/well by Lipofectamine 2000, as suggested by the supplier. After 48 h from 
transfection, cells were treated for more 24 h with the different drugs as indicated. Cell death, evaluated by the 
binding of a FITC-labelled Annexin V, as well as siRNA transfection were determined using a DMI4000 Leica 
fluorescence microscope. 
 
Purification of mitochondria 
Mitochondria from Colo357 cells were purified by differential centrifugation as in [28]. Briefly, approximately 80% 
confluent cells from eight 150-cm2 flasks were washed once with PBS, detached by gentle scraping and spun down 
in a table centrifuge at room temperature. The pellet was resuspended in sucrose/N-[79]-2-aminoethanesulfonic acid 
(TES) buffer (300 mM sucrose, 10 mM TES, 0.5 mM EGTA, pH 7.4). After standing for 30 min on ice, cells were 
lysed in a Dounce homogenizer, and the lysate was centrifuged at 600 x g for 10min at 4°C. The pellet was again 
processed in the same way to maximize recovery. The combined supernatants were centrifuged once at 600 x g, and 
the pellet was discarded. The mitochondria-containing supernatant from the last step was centrifuged at 8000 x g for 
10 min at 4°C. The pellet was gently homogenized and suspended in a small volume of TES buffer. A further 
purification was obtained by centrifugation (8500 x g, 10min, 4°C) on a discontinuous Percoll gradient (60, 30 and 
18% Percoll in TES buffer). The floating material was discarded, and the fraction at the lower interface was collected 
and washed three times by centrifugation at 19,000 x g for 5 min. The final pellet was resuspended in TES buffer. 
 
Gene expression analysis 
Kv1.3 gene expression (KCNA3) was analyzed in a transcriptome microarray U133 A/B Affimetrix GeneChip set, 
including microdissected freshly frozen tissues specimen from pancreatic cancer and normal pancreatic tissue, a 
collection malignant pancreatic and benign stromal cell lines [37].  
 
Quantitative Real time PCR 
Total RNA was isolated from culture cells 24 hours after seeding. The total RNA was purified using peqGOLD Total 
RNA kit and treated with DNase I (PEQLAB Biotechnology GmbH) for removing residual DNA. RNA concentration 
was measured using Nanodrop spectrophotometer (PEQLAB Biotechnology GmbH) and the RNA-extracted quality 
was checked on 1% agarose gel. 1µg of RNA was reverse transcribed into cDNA with Maxima First Strand cDNA 
Synthesis kit (Thermo Fisher Scientific). Real- time PCR was performed in a total volume of 20µl using 50ng of the 
first-strand cDNA synthesis mixture as template. The assay was done with Double-dye (Taqman technology) probes; 
the exon-exon spanning primers sequence for kcnA3 (Kv1.3) was supplied by Primerdesign Ltd (Southampton, 
United Kingdom). The amplification reaction was run in StepOnePlus Real-time machine according to the follow 
conditions: Taqman enzyme activation at 95°, 10 min; denaturation at 95°, 15 sec, annealing at 50°C, 30 sec; 
extension at 72°C, 15 sec (50 cycles). The relative quantification of gene expression was calculated by the help of 
qBase Browser (Biogazelle NV, Zwijnaarde, Belgium) by applying  the comparative CT methods with a multiple 
reference gene normalization. Actb and Ywhaz were set as reference genes to normalize the gene expression; 
HPDE were used as reference sample to determine KcnA3 relative expression (fold change) in the panel of 
pancreatic cancer cell lines. 
 
 
Laboratory animals 
Four weeks old females SCID beige (C.B.-17.Cg-Prkdcscid Lystbb/Crl) mice weighting 14-19 g were obtained from 
Charles River (Sulzfeld, Germany). They were housed in a sterile environment and allowed to acclimatize for one 
week. The animal experiment and care were carried out in accordance with the guidelines of institutional authorities 
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and approved by local authorities (number V312-7224.121-7(123-10/11)). 
 
 
Orthotopic xenograft of human adenocarcinoma cells and treatment in a palliative setting 
The orthotopic injection was performed as previously described [80]. Human metastatic pancreas adenocarcinoma 
cells Colo357 were detached with Accutase solution (PAA Laboratories GmbH), resuspended at the concentration of 
106 cells ml-1 in 25 µl of Matrigel (BD-Biosciences) and stored on ice. After median laparotomy, 25µl of cell 
suspension were injected in tail of pancreas. For the palliative therapy, the animals were randomly designated to the 
treatment procedure: (1) no treatment, (2) Clofazimine treatment. The therapy was initiated ten days after the tumor 
inoculation and spanned over 20 days. Clofazimine was freshly dissolved at [2.5mM] in DMSO and sterile water for 
injection (Ampuwa, Fresenius-Kabi, Germany). For the therapy, it was administered in a dose of  5µl/g 
intraperitoneally. The control group was treated with a solution containing DMSO and physiological saline buffer. All 
animals were examined daily for general signs of distress and complications; tumor growth was monitored by 
ultrasound imaging. Thirty days after cell inoculation, the animals were sacrificed and tumor weight was determined 
after blood removal. Furthermore, several organs have been embedded in paraffin for histological staining and 
analysis. 
 
Immunohistochemistry 
Primary tumor samples from paraffin-embedded tissue were cut in 2µm sections and mounted onto slides. The 
specimen were tested for pan-cytokeratin (KL1, Beckman Coulter, mouse monoclonal 1:1500), Ki-67(SP6, 
ThermoScientific, rabbit monoclonal 1:300) and CD31 (SZ31, Dianova, rat monoclonal 1:30). The 
immunohistochemistry (IHC) was carried out according the following procedure: de-paraffinization with xylene, 
rehydration in descending concentrations of ethanol, followed by heat-induced epitope retrieval with sodium citrate 
buffer (pH 6.0). Washing steps were performed at room temperature with tris-buffered saline (TBS); to avoid non-
specific binding of the antibody to the tissues, all specimen were incubated with POD (Peroxidase-blocking solution, 
Dako) for fifteen minutes. The primary diluted antibodies (antibody diluent, DCS LabLine, Hamburg, Germany) were 
applied and the samples were kept in a humidified chamber for one hour. For the detection, the tissues were 
incubate with HPR-conjugate anti-rabbit/mouse (Dako) and Mouse-PO anti-rat for thirty minutes; subsequently, the 
substrate chromogen-DAB (Dako) was added and the staining developed for five minutes. Finally, the samples were 
counterstained with Hematoxylin (Dako) and dehydrated with ascending concentrations of ethanol and rinsed in 
xylene. 
 
Determination of clofazimine concentration in tissues  
Clofazimine (10 nmol/g) was injected into control mice every two days four times and after treatment the various 
tissues were collected, 100 mg were weighed, PBS (1 vol) was added, and the mixture containing tissues cut into 
small pieces was homogenized by use of electric pestle. The samples were vortexed (2 min) and then stabilized and 
extracted adding 0.43 M acetic acid (0.1 vol) + 100 uM 5-MOP as internal reference (0.1 vol) and acetone (10 vol), 
vortexed (2 min), sonicated (2 min), and centrifuged (12,000 g, 7 min, 4°C); the supernatant was collected, 
concentrated, and finally analyzed via HPLC-UV and LC-ESI/MS. according to previously established protocols for 
other drugs [81]. Blood samples were obtained by the tail bleeding technique: before drug administration, mice were 
anesthetized with isoflurane and the tip of the tail was cut off; blood samples (80−100 μL each) were then taken from 
the tail tip after 8 hours of drug administration. Blood was collected in heparinized tubes, kept in ice, and treated as 
described below within 10 min. 
 
 
 
Figure legends 
 
Figure 1. Expression of Kv1.3 potassium channel in different pancreatic ductal adenocarcinoma cell lines. A)  
Histogram of  the distribution  of  KcnA3 gene expression  in a panel of pancreatic cancer cell lines from Affymetrix 
U133 Gene Chip. Arbitrary intensity units of the probe ID (207237_at) for Kcna3; the intensity values were 
normalized with dCHIP2006 software (www.dchip.org) B) The Relative quantity of the gene expression as 
determined by quantitative RT-PCR was calculated by using qBase_Biogazelle software, which allows a multiple 
reference genes-normalization and performs inter-run calibration. Actb and Ywhaz of non-tumoral HPDE cells were 
set as reference genes (value 1) to normalize the gene expression. C) Whole cell extracts ( 50 µg/lane) from different 
PDAC cell lines were loaded on SDS-PAGE. Western blot revealed Kv1.3 bands (multiple bands are presumably due 
to glycosylation according to manufacturer or to degradation products) at around 65 kDa. These bands correlated 
with Kv1.3 expression since none of the bands were present in a cell line silenced for Kv1.3 (not shown). The same 
blot was developed with the antibody against GAPDH (45 kDa) as loading control.  D) Whole cell extract (Tot ext), 
enriched membranous fraction (Memb) and Percoll-purified mitochondria (Mito) fractions obtained from Colo357 were 
loaded at equal protein concentration ( 40 µg/lane). Enrichment in the mitochondrial marker Bak and decrease of the 
intensity of SERCA (ER marker) and PMCA (PM marker) indicates progressive purity during mitochondria isolation.   
 
Figure 2 Clofazimine induces apoptosis in PDAC lines with p53 mutation in a Kv1.3-dependent manner. A) 
MTT assay indicates decrease of cell survival at the higher concentration applied in seven independent PDAC lines, 
while two non-tumoral lines were largely resistant to clofazimine treatment. Staurosporine was used as positive 
control. B) Dose-response curve of the effect of clofazimine in wt Colo357 cells and in those stably overexpressing 
anti-apoptotic Bcl-xL. Higher than 10 µM clofazimine was not used due to the known crystal-forming ability of the 
drug above this concentration. C) - E) Effect of clofazimine on the indicated PDAC lines following transfection with 
scrambled RNA or siRNA against Kv1.3. Transfection efficiency is indicated by the red signal, since the siRNAs were 
labeled with Alexa568. Apoptotic cells are visualized by binding of FITC-labeled Annexin to phosphatidylserine, 
known to be translocated to the outer leaflet of the PM only during apoptosis. Staurosporine was used as positive 
control, while PAP-1 without MDRi as negative control.  
 
 
7  
Figure 3 Reduction of tumor weight  by clofazimine treatment in a SCID orthotopic PDAC model. A) SCID 
beige mice were treated with 5 µg/g body weight using the protocol indicated in the scheme. B) Tumor weight was 
determined for 6 mice each group at the end of the treatment as in (A). Statistical analysis shows significant 
difference (p<0.05)  between the two groups. C) mean number of liver metastasis ± SD. Difference is not statistically 
significant (p>0.05). D) Tissue accumulation of clofazimine determined as described in the materials and methods 
section. E) Percentage of Ki67 positive cells indicate the proliferative capacity of the cells. Samples from all six 
mice/group were evaluated revealing non-statistically significant difference (p-value=0.1433).  
 
 
Figure 4  Immunohistochemical analysis of PDAC tissues reveal no gross alterations regarding tumor 
structure and angiogenesis upon clofazimine treatment. Representative slides show tumoral tissues from 
control-treated group (left panels) and from the clofazimine-treated groups (right panels) stained with the indicated 
markers for proliferation (Ki67), epithelial cells (KL-1) angiogenesis marker (CD31) and with hematoxylin/eosin. 
Experiments are representative of three independent staining for each group of animals. notevole  non varrebbe la 
pena di mostrare solo quella??? 
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